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Abstract 
Several epidemiologic studies have established a strong and consistent link 
between cigarette smoking and increased cardiac morbidity and mortality. Other 
studies show that in addition to substantial increase in oxidative stress, certain other 
compounds of cigarette smoke, such as nicotine and carbon monoxide play a role in 
atherogenesis. Our results show that due to sustained free radical (>10'^ free radicals 
per puff) load during 4.6-4.9 years of cigarette smoking, young smokers (aged 23-25 
years) exhibited several proatherogenic actions, including a significant increase in 
atherogenic non-HDL-C, with a concomitant decline in the cholesterol concentrations 
of antiatherogenic HDL and its subtractions, HDL2 and HDL3. The data indicate a 
3.1-fold increase in blood nicotine and 2.3-fold increase in carboxyhemoglobin in 
young smokers. Eight-week Tocomin (150mg/day) treatment of smokers resulted in a 
significant reduction in nicotine and carboxyhemoglobin levels, which were reversed 
to 82 % and 50 % of respective control values of age-matched nonsmokers. These 
results indicate a strong protective effect of dietary tocotrienols, which may help 
lower risk of myocardial infarction in smokers. Our results show that in comparison 
to nonsmokers, a modest and significant increase in plasma total lipid (+42 %), TG 
(+15 %), FFA (+17 %), TC (+17 %), VLDL-C (+32 %), LDL-C (+52 %) and 
atherogenic non-HDL-C (+40 %) levels in smokers, which were significantly 
reversed to 89 - 101 % of nonsmokers value after 8 weeks of Tocomin 
supplementation. While antiatherogenic HDL and its subfractions HDL2 and HDL3 
were significantly lower (41-74 %) in smokers as compared to nonsmokers. Tocomin 
significantly blocked the reduction in HDL-C and HDL2-C levels and restored to 65 
% and 75 % of respective values in nonsmokers. However, cholesterol content of 
more antioxidative HDL3 was not affected during 8 weeks of Tocomin treatment. 
This may be due to markedly increased production of oxidants and significantly 
diminished antioxidant defense including a decline in total plasma antioxidants. 
Consistent with published reports that relative to Ib-LDL, the concentration of 
sd-LDL was substantially increased in patients with hyperLDLcholesterolemia, 
hypertriglyceridemia, combined hyperlipidemia, and hyperlipidemia with CHD; our 
results show a significantly greater increase in sd-LDL-C (75 %) than LDL-C (49 %) 
or Ib-LDL-C (36 %) of smokers as compared to nonsmokers. Thus, in smokers, >37 
% of LDL-C was recovered in sd-LDL subpopulation, which is >18 % higher than its 
percent share of total LDL-C in nonsmokers. On the other hand, although Ib-LDL-C 
in smokers was significantly increased (36 %), but its percent share of total LDL-C 
was not increased, instead decreased (9 %), indicating a preferential shift of LDL-C 
to more atherogenic sd-LDL subspecies due to oxidative stress induced 
hyperLDLcholesterolemia in smokers. Treatment of smokers with Tocomin 
Abstract 
significantly reduced both the cholesterol and apoB content of sd-LDL as well as 
their percent share of LDL close to corresponding control values in nonsmokers, 
indicating a shift from atherogenic sd-LDL to less atherogenic Ib-LDL and hence a 
strong antiatherogenic effect of Tocomin. It is interesting to mention that Tocomin 
mediated reduction in sd-LDL-C (39 %) was better than that of LDL-C (29 %). Since 
it has been established that LDL-C/HDL-C and HDL-C/TC ratios are good predictors 
for the presence and severity of CAD, intake of Tocomin by young smokers resulted 
in a normalization of these ratios. Consistent with the above results, we have initially 
included sd-LDL-C/HDL-C ratio, which was substantially increased from a ratio 
value of 0.576 in nonsmokers to 2.21 in placebo treated smokers. This sd-LDL-
C/HDL-C ratio was significantly reduced to 0.985 after Tocomin treatment. These 
results, which represent an initial demonstration, indicate that supplementation of 
young smokers with dietary tocotrienols for 8 weeks effectively ameliorated all the 
lipid parameters including highly atherogenic sd-LDL. 
The increase in plasma and lipoprotein lipid levels in young smokers is 
consistent with a significant increase of 54 % in hepatic HMG-CoA reductase activity 
of rats exposed to cigarette smoke for 4 weeks. Treatment of smoke exposed rats with 
dietary tocotrienols significantly blocked the increase in hepatic HMG-CoA reductase 
activity and reversed it to 84 % of normal control value, which may provide a 
mechanism for the reduction of plasma and lipoprotein lipids in smokers treated with 
Tocomin. Based on these results, it can be concluded that cholesterol lowering 
property of Tocomin in smoke exposed rats is due to the suppression of enzymatic 
activity of HMG-CoA reductase, the rate limiting enzyme in the biosynthetic pathway 
of cholesterol. 
In response to oxidative stress, evoked in dyslipidemic young smokers, 
plasma lipid peroxidation products, namely, conjugated diene, lipid hydroperoxide 
and malondialdehyde (MDA) were significantly increased, while plasma total 
antioxidants was significantly depleted. Tocomin administration significantly 
decreased the above plasma lipid peroxidation products with a concomitant and 
significant increase in plasma total antioxidants after 8 weeks of treatment. Similar to 
plasma, MDA content of erythrocytes in placebo treated smokers was significantly 
increased by 135 %. The intact erythrocytes isolated from smokers exhibited a further 
increase (>2-fold) in susceptibility to hydrogen peroxide induced MDA release, as 
compared to the basal MDA content in erythrocytes. The treatment of smokers with 
Tocomin effectively blocked the in vivo as well as in vitro susceptibility of 
erythrocytes to lipid peroxidation and significantly reduced MDA levels. However, 
this Tocomin mediated reversal of erythrocytes MDA content was only 68 % of 
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nonsmokers MDA value, while reversal of MDA release during H2O2 induced lipid 
peroxidation was complete (>100 %). Based on these results, its seems plausible that 
oxygen radicals formed over and above the detoxifying capacity of erythrocytes can 
cause peroxidative breakdown of phospholipid fatty acids and accumulation of MDA 
and hence membrane damage. In addition, our study suggests that due to constant 
availability of antioxidants, tocotrienols, in the plasma of treated smokers, the 
integrity of erythrocytes membrane is significantly improved as shown by substantial 
protection against in vivo as well as in vitro H2O2 induced lipid peroxidation. 
As discussed above, besides increase in the circulating levels of LDL-C 
during smoking, there is an appearance of high concentrations of sd-LDL 
subpopulation which is shown to be more atherogenic than LDL. An enhanced 
susceptibility to oxidative modification could contribute to the greater atherogenicity 
of sd-LDL. Our results show that in smokers, LDL, sd-LDL and Ib-LDL 
susceptibility to in vivo oxidation, measured as ex vivo base line diene conjugation 
(BDC), was significantly increased as compared to nonsmokers. However, the 
increase in ex vivo BDC level was greater in sd-LDL than LDL or Ib-LDL, indicating 
an enhanced in vivo oxidizability of sd-LDL in smokers. In nonsmokers, in 
comparison to a lag phase value of 80 min for both LDL and Ib-LDL, the lag time of 
sd-LDL was markedly reduced to 10 min, indicating an 8-fold shortening in the lag 
phase of Cu**-catalyzed sd-LDL oxidation. Consistent with these results, maximal 
conjugated diene as well as MDA formation in LDL and Ib-LDL was achieved after 
12 h of oxidation, while sd-LDL required only 30 min of Cu"^-catalyzed oxidation, 
indicating a substantially enhanced oxidative susceptibility of sd-LDL as compared to 
Ib-LDL or LDL. Tocomin supplementation of young smokers partially blocked the in 
vivo and in vitro LDL, sd-LDL and Ib-LDL oxidizability as seen by a decrease in ex 
vivo BDC levels and an increase in their lag phase values, which were restored to >80 
% lag phase values of nonsmokers. Similarly, ex vivo basal and Cu"^-induced 
maximal formation of MDA were markedly increased in circulating LDL, sd-LDL 
and Ib-LDL from smokers. Tocomin treatment of smokers caused a significant 
decrease and near normalization of both basal and maximal levels of MDA in LDL, 
sd-LDL and Ib-LDL. Relative to Ib-LDL, a markedly increased oxidizability of sd-
LDL subpopulation in smokers suggests that it may be more prone to further 
oxidation in the vessel wall of humans during smoking, as reported for sd-LDL 
phenotype. 
Several mechanisms could contribute to increased oxidative modification of LDL, sd-
LDL and Ib-LDL during smoking. Paraoxonase (PON) or arylesterase is a HDL-
associated enzyme that protects LDL as well as HDL from oxidative stress. Smoking 
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may be related to impaired PONl/arylesterase activity, thereby compromising 
antioxidant defense mechanisms. In the present study, we have demonstrated a 
significant decrease in the enzymatic activity of arylesterase in plasma (-41 %), HDL 
fraction (-56 %), HDL2 (-57 %) and HDL3 (-60 %) subfractions of placebo treated 
young smokers with respect to nonsmokers. Similarly, LDL-C/arylesterase activity 
ratio was substantially increased (160 %) in smokers vs. nonsmokers. Tocomin 
treatment significantly prevented the decrease in arylesterase activity in plasma (+18 
%), HDL (+23 %), HDL2 (+42 %) and HDL3 (+16 %) and partially restored these 
activity levels to 31 %, 54 %, 62 % and 46 % of corresponding values in nonsmokers. 
In addition, Tocomin supplementation was associated with a significant decline (40 
%) in LDL-C/arylesterase activity ratio and reversed it to 56 % of ratio value in 
nonsmokers. As PONl activity is thought to play an essential role in the prevention of 
LDL oxidation, depletion of the HDL-associated arylesterase activity, as seen above, 
may contribute to increased oxidizability of HDL, HDL2, HDL3, total LDL and 
highly atherogenic sd-LDL subfraction in smokers. Our results indicating an 
enhanced in vivo as well as in vitro oxidizability of LDL and more atherogenic sd-
LDL and less atherogenic Ib-LDL in conjunction with decreased plasma, HDL, HDL2 
and HDL3 linked arylesterase activity and substantially increased LDL-C/arylesterase 
ratio in young smokers is likely to be a potential mechanism for the increased 
oxidation of circulating LDL density subfractions. 
The present results have shown that plasma derived small dense, lipid poor 
HDL3 particles possess the more potent capacity than large, light, cholesteryl ester 
rich HDL2 to protect LDL from Cu^-catalyzed oxidation in normolipidemic 
nonsmokers. On the other hand, these results demonstrate that greater the reduction in 
HDL2-C or HDL3-C levels in dyslipidemic smokers, lower is their antioxidative 
activity as compared to their counterparts from normolipidemic nonsmokers. Thus, in 
smokers, a 74 % reduction in large, light HDL2-C was apparently responsible for a 
significantly lower antioxidative activity (19-23 %), while a reduction of only 41 % in 
small, dense HDL3-C showed a lower decrease (4-8 %) in the protection of LDL 
against oxidation. Consistent with the relationship between differential reductions in 
HDL2-C and HDL3-C and impairment of their antioxidative activity in dyslipidemic 
smokers, total protein content associated with HDL2 and HDL3 was also 
proportionally reduced by 64 % and 34 %. Our combined data clearly indicate that 
impairment of the antioxidative activity of HDL subfractions, particularly small, 
dense HDL3 in dyslipidemic smokers involving low antiatherogenic HDL-C levels, 
low HDL linked arylesterase activity, low HDL associated proteins, and high 
atherogenic non-HDL-C levels are intimately associated with elevated oxidative 
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stress- a newly recognized CVD risk factor, and may therefore contribute to enhanced 
atherogenesis. On the other hand, supplementation of young smokers with dietary 
tocotrienols mediated a significant therapeutic normalization of all the above 
parameters. In addition, Tocomin mediated a restoration of HDL2-C and HDL3-C 
levels by 75 % and 42 % of control value in nonsmokers, while arylesterase activity 
was increased by 62 % and 46 % in HDL2 and HDL3 particles, respectively. As a 
result, both HDL2 and HDL3 from Tocomin treated smokers were able to further 
reduce the maximal conjugated diene formation to a common level, 21 % lower than 
their normal counterparts in normolipidemic nonsmokers; thus exceeding the 
protection afforded against Cu"^-induced oxidation of LDL alone from Tocomin 
supplemented smokers. The combined results provide evidence that small, dense 
HDL3, relative to large, light HDL2, afford better potent protection of LDL against 
oxidative stress. Therapeutic normalization of HDL function, coupled with a strong 
hypolipidemic and antioxidant actions of dietary tocotrienols may therefore represent 
a novel therapeutic approach to attenuate dyslipidemia in young smokers as well as 
atherosclerosis in dyslipidemic chronic smokers. 
As indicated above, oxidative stress may be increased in smokers due to a 
higher production of reactive oxygen species (ROS), such as superoxide radical, 
hydroxy! radical, hydrogen peroxide and/or deficiency in the antioxidant defense 
systems. Therefore, as the balance between ROS production and antioxidant defenses 
is lost, the resultant oxidative stress through a series of events deregulates the cellular 
functions leading to various pathological conditions. An antioxidant compound might 
contribute partial or total alleviation of such damage. Our results show a significant 
increase of 45 % and 15 % in the erythrocytes activities of CAT and SOD of smokers, 
while Gpx and Gred activities were significantly decreased by 39 % and 35 %. 
Supplementation of Tocomin for 8 weeks were found to be therapeutically quite 
effective in reversing/normalizing the altered enzymatic antioxidant defense system 
in erythrocytes of young smokers. 
Since certain experiments such as mechanism (s) of lipid lowering action of 
tocotrienols and the extent of their protective effect on enzymatic and noenzymatic 
antioxidant defense systems including lipid peroxidation in various tissues etc. are 
unavailable from young smokers, male albino rats, exposed to cigarette smoke daily 
for 30 min for 4 weeks, have been used as an experimental model. In this animal 
model we investigated the efficacy of antioxidant and hypolipidemic agents Tocomin 
and Lovastatin by analyzing all the parameters in plasma and erjthrocytes, including 
blood nicotine and carboxyhemoglobin; plasma and lipoprotein lipids, erythrocytes 
lipid peroxides, arylesterase enzyme activity and differential in vivo and in vitro 
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oxidizability of highly atherogenic sd-LDL, less atherogenic Ib-LDL as well as LDL, 
as investigated in young smokers treated with and without Tocomin. It is interesting 
to mention that in general, the results obtained from the cigarette smoke exposed 
hyperlipidemic rats treated with dietary tocotrienols exhibited great similarities with 
the results in young smokers supplemented with Tocomin for 8 weeks. In addition, in 
this rat model, the hypolipidemic and antioxidative properties of Lovastatin are also 
comparable to Tocomin, used in both animal and human models. Here, we have 
summarized the dissimilarities between the results from two models. The results 
demonstrate that a 4-week cigarette smoke exposure induced a severe hyperlipidemia 
in S-C rats as compared to dyslipidemic young smokers. A much higher increase in 
plasma TG (102 % vs. 13 % in smokers) and atherogenic non-HDL-C (109 % vs. 46 
% in smokers) levels contributed to the increased degree of hyperlipidemia in S-C 
rats. On the other hand, in S-C rats, atherogenic HDL-C was decreased by only 11 %, 
in comparison to a decline of 51 % in smokers, indicating a very mild dyslipidemia in 
S-C rats. This markedly lower degree of dyslipidemia in S-C rats, versus young 
smokers, is apparently due to species difference, which is consistent with the known 
fact that rats are highly resistant to the initiation and development of atherosclerosis. 
These results in S-C rats are further supported by a 34 % reduction in cholesterol , 
content of large, light, cholesteryl ester rich HDL2, which is considered to be a strong 
predictor of presence and extent of CAD. In addition, cholesterol content of small, 
dense, lipid poor HDL3, which exerts potent protection of atherogenic LDL against 
oxidative stress, was reduced by only 5 % in S-C rats vs. N-C value, while in young 
smokers it was significantly reduced by 41 %. Together, these results suggest that 
dyslipidemic smokers may be more susceptible to atherogenesis than a 4-week 
cigarette smoke exposed animals. Highly increased plasma TG, TC, VLDL-C, LDL-
C and atherogenic non-HDL-C concentrations in S-C rats were significantly reduced 
to a level close to their counterparts in N-C rats, after 4 weeks of Tocomin or 
Lovastatin treatment, while similar reversal in the above parameters was seen in 
Tocomin supplemented young smokers. In complete contrast to young smokers, 
Tocomin treatment not only blocked the minimal decline of 11 % seen in HDL-C 
level of S-C rats but increased it to a level, 58 % higher than normal control value. 
Similarly, the decrease of 34 % in HDL2-C of S-C rats was blocked by Tocomin and 
increased to a level 98 % higher than HDL2-C value in N-C. Lovastatin treatment of 
S-C rats also increased the HDL-C (36 %) and HDL2-C (49 %) concentrations, but to 
a lesser extent than Tocomin. On the other hand, after 4 weeks of Tocomin or 
Lovastatin treatment, the cholesterol content of more antioxidative small, dense HDL3 
was increased, from a reduced value of only 5 % in S-C rats, to 39 % and 31 % higher 
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than normal control HDL3 value. These results are in agreement with published 
evidence indicating that Lovastatin treatment of hyperlipidemic subjects and animals 
was associated with a significant increase in HDL-C, while TRP has been shown to 
mediate an increase in HDL-C levels of hyperlipidemic rats as well as in a type II 
familial hypercholesterolemic subject. These results demonstrate that both dietary 
tocotrienols and Lovastatin exert a potent effect in normalizing the high levels of TG 
as well as atherogenic non-HDL-C in cigarette smoke-induced hyperlipidemia in rats. 
In addition, these agents exhibited a potent antiatherogenic effect by substantially 
increasing the concentrations of atheroprotective HDL. 
The comparison of the above results in cigarette smoke exposed rats versus 
young smokers, revealed that because of severe hyperlipidemia, coupled with a 
minimal decline in HDL-C (- 11 %) in S-C rats, there was a marked increase in 
plasma TG (+ 102 %), VLDL-C (+ 105 %) and LDL-C (+112 %). As a result, a 
substantial shift of cholesterol and apoB from less atherogenic Ib-LDL to more 
atherogenic sd-LDL had occurred, which significantly increased the sd-LDL-C (+ 
292 % vs. N-C value) and its percent share of LDL-C (85 % vs. 29 % in N-C). On the 
other hand, in dyslipidemic young smokers with mild hyperlipidemia, HDL-C level 
was significantly reduced (-51 %), while there was a modest increase in TG (+ 14 %), 
VLDL-C (+ 33 %) and LDL-C (+ 49 %); as a consequence of which, there was a 
proportional increase in sd-LDL-C (75 % vs. control value) and its percent share of 
LDL-C (37 % vs. 32 % in control). Both dietary Tocomin and Lovastatin effectively 
reduced and fully normalized the circulating TG, VLDL-C, LDL-C and more 
atherogenic sd-LDL-C, while cholesterol levels of antiatherogenic HDL were 
increased to a level significantly higher than N-C value. Consistent with these 
findings, LDL-C/HDL-C, HDL-CA'C, sd-LDL-C/HDL-C and Ib-LDL-C/HDL-C 
ratios were markedly altered (+ 125 %, - 48 %, + 314 % and + 44 %, respectively, vs. 
corresponding ratio values in N-C), in S-C rats, while treatment with Tocomin or 
Lovastatin fully normalized these altered ratios to a level, 15 % to 26 % better than 
their counterparts in N-C, indicating an excellent normalization of highly atherogenic 
sd-LDL-C and LDL-C levels. 
Consistent with the increase in plasma TG, FFA and TC levels of S-C rats, a 
significant increase in these lipids of liver, lung and kidney were also observed. 
While, Tocomin or Lovastatin treatment of S-C rats for 4 weeks was associated with 
a significant decreases in TG, FFA and TC of each tissue. These results demonstrate 
that sustained oxidative stress in S-C rats is also able to induce hyperlipidemia in the 
above tissues with a maximum increase in hepatic TC, while both Tocomin and 
Lovastatin effectively blocked these increases and restored the TG, FFA and TC 
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levels of liver, lung and kidney close to corresponding normal control values. The 
significant increase in plasma, liver, lung and kidney lipid levels is consistent with a 
significant increase (54 %) in liver HMG-CoA reductase activity of S-C rats. 
Treatment of S-C rats with dietary Tocomin or Lovastatin was associated with a 
significant decrease in plasma and tissue lipid levels as well as hepatic HMG-CoA 
reductase activity, which was restored to 84 % and 62 % of N-C value, which may 
provide a mechanism for the reduction of plasma and tissue lipids. These results 
indicate that both tocotrienols and Lovastatin may exert their hypocholesterolemic 
effect in hyperlipidemic rats and dyslipidemic young smokers in a similar manner as 
previously reported for hyperlipidemic animals and humans. 
In response to oxidative stress, evoked in cigarette smoke-induced 
hyperlipidemic rats, our data show a significant increase in lipid/lipoprotein 
peroxidation products. Conjugated diene, lipid hydroperoxide and MDA in plasma, 
liver, lung and kidney were significantly increased in S-C rats. The increase in plasma 
lipid peroxidation products is closely associated with a significant decline in total 
antioxidant capacity of plasma. The increase in lipid peroxidation products in plasma, 
liver, lung and kidney and decrease in plasma total antioxidants is consistent with the 
well known prooxidant effect of cigarette smoke in rats. Treatment of S-C rats with 
either 6.0 mg Tocomin or 0.50 mg Lovastatin/rat/day for 4 weeks was associated with 
a significant decline in lipid peroxidation products of plasma, liver, lung and kidney 
and a significant increase in plasma total antioxidants, indicating a potent antioxidant 
effect of Tocomin and Lovastatin. It is interesting to note that the changes observed in 
plasma total antioxidants, conjugated diene, hydroperoxide and MDA as well as 
erythrocytes MDA content and its release during in vitro H2O2 induced peroxidation 
from S-C rats is qualitatively similar to the changes seen in the young smokers. 
However, MDA release in intact erythrocytes from S-C rats was substantially higher, 
that is, >4-fold vs. >2-fold in young smokers, in comparison to their respective ex 
vivo basal MDA content in erythrocytes, indicating a massive oxidative stress in rats 
exposed to cigarette smoke , daily for 30 min, for 4 weeks. In addition, consistent 
with significantly higher free radical scavenging property of dietary tocotrienols than 
a-tocopherol, Tocomin offered much better protection against both in vivo and in 
vitro H2O2 induced lipid peroxidation in erythrocytes from S-C rats, than Lovastatin. 
As indicated earlier, severe hyperlipidemia in S-C rats was associated with an 
increase in LDL and appearance of high concentrations of sd-LDL subpopulation, 
which is shown to be rnore prone to oxidation than Ib-LDL or LDL and hence more 
proatherogenic. Conceptually, the differential in vivo and in vitro oxidizaibility of sd-
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LDL and Ib-LDL observed in hyperiipidemic S-C rats is consistent with the results 
obtained from dyslipidemic young smokers. 
Xanthine oxidase (XO) is a physiological source of superoxide anions in 
eukaryotic cells. Serum xanthine oxidase activity is known to be increased in various 
pathological disorders, such as carcinogenesis, hepatitis, inflammatory diseases, 
aging, hyperlipidemia and diabetes and that free radicals generated in the enzymatic 
processes are involved in the oxidative damage. Our results demonstrate that 
increased XO activity in plasma, liver, lung and kidney of cigarette smoke exposed 
rats was significantly blocked by Tocomin or Lovastatin and reduced to a level close 
to corresponding normal control values. These results show that dietary tocotrienols 
and Lovastatin, in addition to their potent hypolipidemic and antioxidant activity, has 
the ability to reduce XO activity in plasma, liver, lung and kidney, indicating an 
additional therapeutic benefit in the prevention and treatment of cigarette smoke 
induced dyslipidemia/hyperlipidemia and atherosclerosis. 
It is well known that cigarette smoking is associated with a substantial 
increase in oxidative stress, oxidant stress may be increased owing to a higher 
production of ROS, which are controlled by antioxidant enzymes, SOD, catalase, 
Gpx, Gred and GSH. An impaired radical scavenger function has been linked to 
decreased/increased activity of enzymatic and nonenzymatic antioxidants. Our results 
show a significant decrease in the activities of antiperoxidative enzymes, CAT, SOD, 
Gred, GST as well as GSH, in liver, lung and kidney of smoke exposed rats, except 
Gpx activity which was significantly increased. Treatment of cigarette smoke stressed 
hyperiipidemic rats with Tocomin or Lovastatin for 4 weeks, significantly 
reversed/restored the altered tissue activities of SOD, catalase, Gpx, Gred and GST 
including total, free and protein bound-SH contents of glutathione, to near normal 
control values, indicating an almost total alleviation of oxidative damage by these 
antioxidants. Both Tocomin and Lovastatin mediated a near normalization of 
peroxide levels and scavenging enzyme activities as well as GSH in liver, lung and 
kidney of cigarette smoke exposed rats, indicating a strong antilipid/lipoprotein 
peroxidative effect of these hypolipidemic agents. Based on these results in cigarette 
smoke induced hyperiipidemic rats in conjunction with the data in young smokers 
showing that supplementation of Tocomin for 8 weeks significantly improved the 
integrity of erythrocytes membrane as seen by improved protection against lipid 
peroxidation as well as reversal of enzymatic activities of CAT, SOD, Gpx and Gred 
to near normal levels, it is likely, that a similar Tocomin and Lovastatin mediated 
amelioration of overall antioxidant defense systems, as seen in different tissues of S-
C rats, may be operative in young smokers. Thus, it is possible, that supplementation 
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of young dyslipidemic smokers with dietary tocotrienols for 8 weeks would have 
been equally effective in the protection of cigarette smoke induced oxidative damage 
in hepatic, pulmonary and renal tissues. 
The combined results in dyslipidemic young smokers and cigarette smoke 
exposed hyperlipidemic rats, which represent an initial study, demonstrate that strong 
hypolipidemic impact of dietary tocotrienols and Lovastatin coupled with their potent 
antioxidative property can provide additional benefit in the suppression of oxidative 
stress, particularly in the oxidative resistance of highly atherogenic sd-LDL and LDL, 
and hence in the prevention and treatment of cigarette smoke induced 
dyslipidemia/hyperlipidemia and atherosclerosis. Although multiple atheroprotective 
effects of Tocomin and Lovastatin observed in cigarette smoke exposed rats were 
qualitatively comparable, but in view of the several toxic effects known to be 
exhibited by statins including Lovastatin in humans, use of dietary tocotrienols, 
which are vitamin E and have no toxicity, should be preferred. Taken together, daily 
intake of tocotrienols, by current young smokers as well as passive smokers, may be 
useful in the prevention and treatment of dyslipidemia/hyperlipidemia and 
atherosclerosis. Previously published reports clearly indicate that daily intake of 
routine dietary antioxidants by young, novice smokers, or heavy dose of antioxidant 
vitamin supplements by young smokers will not sufficiently alleviate the enormous in 
vivo oxidative stress/damage induced by cigarette smoke. However, since, dietary 
tocotrienols, because of their potent hypolipidemic/antiatherogenic and antioxidant 
actions, were able to substantially ameliorate/normalize all the altered parameters 
including atheroprotective function of HDL described in the thesis, we initially 
recommend daily supplementation of young smokers with dietary tocotrienols 
(Tocomin). In conclusion, based on Tocomin mediated multiple therapeutic benefits, 
described in the present study, daily intake of tocotrienols as a dietary supplement by 
novice/young/old moderate or heavy smokers as well as chronic smokers including 
passive smokers may be useful in the prevention and treatment of tobacco-induced 
dyslipidemia/hyperlipidemia and atherosclerosis. In addition, daily use of dietary 
tocotrienols will be efficacious, cost effective, and a good source of vitamin E. 
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A World Health Organization (WHO) survey projects that at least one billion 
people could die this century because of tobacco-related illnesses compared to 100 
million in the 20th century (WHO, 2007). In the year 2006, WHO reports that 47 % 
of men and 12 % of women are smokers, and smoking is responsible for the death of 
about 3.5 million subjects every year, meaning about 10,000 death cases per day. In 
the year 2000, 4.83 million premature deaths in the world were attributable to 
smoking; 2.40 million in developing countries and 2.43 million in industrialized 
countries (WHO, 2006). At present, approximately 5 million people die each year 
from tobacco-related illnesses, and if current trends continue, this figure will rise to 
about 10 million by 2025, most of the increase being in the Third World, where the 
annual number of deaths from smoking is predicted to rise to 7 million (UNS, 2004). 
A recent most exhaustive study of smoking, jointly conducted by scientists from 
India, Canada and the UK indicate that in India, tobacco fatalities could touch one 
million a year by 2010- of which 70 per cent would be young people-as against the 
current figure of 90,000 (Jha et al., 2008). 
In recent years, large household surveys have shown that in middle age, more 
than one third of men and a few percent of women smoke tobacco and that there are 
about 120 million smokers in India (Rani et al, 2003). Tobacco is commonly 
consumed in the form of bidis, which are smaller than cigarettes and typically contain 
only about a quarter as much tobacco, wrapped in the leaf of another plant. Anecdotal 
evidence suggests that many of those who smoke have been doing so for decades, so 
the hazards may already be substantial. However, smoking starts at somewhat older 
ages in India than it does in Europe and North America, and the average daily 
consumption per smoker is lower (Gupta, 1996; Gajalakshmi et al, 2003). The effects 
of prolonged smoking of bidis or cigarettes on mortality in India have been assessed 
reliably in only two specific localities (Gupta, 1996; Gajalakshmi et al, 2003; Gupta 
et al., 2000; Pednekar et al, 2007 and Gajalakshmi et al, 1996) in which the numbers 
of female smokers were too small to study. To assess the hazards of smoking in India 
nationwide among both women and men, Jha et al. (2008) conducted a case—control 
study that collected information on all adult deaths from 2001 to 2003 in a nationally 
representative sample of 1.1 million homes. In addition, the assignment of underlying 
causes of death is substantially more reliable for persons between the ages of 30 and 
69 years than for older persons, (Jha et al, 2006; Gajalakshmi et al, 2002; Kumar et 
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ai, 2006 and Joshi et ai, 2006) and the main effects of smoking on mortality occur 
after the age of 25 years (the approximate median age at which smoking begins 
among men in India (Rani et ai, 2003). Consumption of tobacco in any form -
cigarettes, bidis or gutkha - will be the primary cause behind one in five of all male 
deaths and one in 20 of all female deaths within the country. Shockingly, nearly 70% 
of these one million deaths - seven lakh people - will die young and in their prime. 
Over 50% of the tobacco deaths will occur in illiterate men or women, with 80% of 
them residing in rural India (Jha et ai, 2008). While men who smoke cigarettes will 
lose over 10 years of life, those who smoke bidis will lose about six years. Women 
bidi smokers, on the other hand, will lose eight years of their productive life. 
According to the study, smoking only a few (1-7) bidis a day raised mortality risks by 
25 % while an equal number of cigarettes a day doubled the risk. The study also 
found that among men, about 61% of those who smoke would die at ages 30-69 years 
compared with 41 % of otherwise similar nonsmokers. Among women, 62 % of those 
who smoke will die between 30-69 compared with only 38 % of nonsmokers. By 
2010, one in every 10 deaths in India will be due to smoking. While smoking related 
heart attacks was the main killer among urban Indians, TB was most prevalent among 
smokers in rural India (Jha et al, 2008). 
Cardiovascular diseases (CVD), as a group, are the leading cause of death in 
the world. Tobacco use is a major known risk factor for CVD and leads to a high 
burden of early death and disability. CVD is also the largest contributor to tobacco-
related deaths, in terms of absolute numbers. In many countries, deaths due to CVD 
considerably outnumber cancer-related deaths. CVD-related deaths, therefore, become 
the leading form of tobacco-related death in these countries. Cardiovascular diseases 
accounted for 16.7 million or 29.2 % of the total global deaths in 2002, according to 
the World health report 2003. Around 80 % of deaths due to CVD took place in low-
and middle-income countries. By 2010, CVD will be the leading cause of death in 
developing countries. (WHO, 2004) The contribution of developing countries to the 
global burden of CVD, in terms of disability-adjusted life-years (DALYs) lost, was 
2.8 times higher than that in developed countries (Reddy and Yusuf, 1998). India 
contributed to 17 % of the worldwide CVD mortality in 1990 (Reddy and Yusuf, 
1998). CVD-related deaths in India are expected to rise from about 3 million in 2000 
to 4.8 million in 2020 (Leeder et al, 2004). By 2020, about 42 % of the total deaths in 
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India are projected to be due to cardiovascular causes (Murray and Lopez, 1996). 
During the period 2000-2030, about 35 % of all deaths due to CVD in India are 
projected to occur in the age group of 35-64 years (Leeder et al., 2004). Tobacco, as a 
major cause of premature CVD, becomes especially relevant in this context. There is 
also increasing evidence that the lower-middle class and urban poor are becoming 
highly vulnerable to CVD as the epidemic advances in India (Reddy, 2004). The 
social gradient of tobacco consumption in India, which is characterized by higher 
consumption patterns among the poor, is also relevant to these social dimensions of 
CVD. Tobacco use, especially smoking, is associated with vascular diseases such as 
coronary heart disease (CHD, heart attack), angina (chest pain), sudden cardiac death 
(SCD, unheralded sudden death), arrhythmias (electrical disturbances), stroke (brain 
attack), peripheral artery disease (gangrene of the legs), abdominal aortic aneurysms 
(ballooning of the blood vessels), renal artery stenosis (decreased blood flow to the 
kidneys), cor pulmonale (poorly functioning lungs) and erectile sexual dysfunction 
(male impotence). Thus, smoking affects the entire vascular system. In a study done 
in 52 countries, smokers were found to be at 2.87 times increased risk of CHD 
compared to nonsmokers. The evidence was consistent across countries. The study 
also revealed a dose-response relationship. Individuals smoking more than 40 
cigarettes per day had a 9 times increased risk of CHD compared to never smokers. 
Smoking even 5 cigarettes per day was associated with an increased risk of CHD. 
Smoking accounted for about 35.7 % of the population-attributable risk of CHD 
worldwide (after adjusting for a range of cardiovascular risk factors) (Yusuf et al., 
2000). 
Second-hand smoke (SHS) or "environmental tobacco smoke" causes an 
estimated 35,000 to 40,000 deaths annually from cardiac and noncardiac arterial 
disease, according to the 2006 Surgeon General's report (USDH, 2006). A meta-
analysis on the cardiovascular effects of SHS in 2005 suggests that the pathologic 
effects of SHS are much larger than previously thought, possibly as high as 80 % to 
90 % of those of an active smoker (Bamoya and Glantz, 2005). Passive smoking is 
associated with ischaemic heart disease (IHD), with a 30 % excess risk of IHD in 
nonsmokers whose spouses smoke compared with nonsmokers whose spouses do not 
smoke (Law and Wald, 2003). Nonsmokers exposed to SHS had a 25 % excess risk of 
CHD compared with nonsmokers not exposed to smoke. There was a significant dose 
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response relationship (He et ai, 1999). Unlike the case with lung cancer, the risk of 
acute MI and CHD associated with exposure to tobacco smoke is non-linear at low 
doses, increasing rapidly with relatively small doses such as those received from SHS 
or actively smoking one or two cigarettes a day (Law and Wald, 2003; Benowitz, 
2003; Howard and Thun, 1999). However, there are as yet no Indian studies that have 
looked into the effects of SHS and chewing tobacco on C VD (Jha et ai, 2008). 
1.1 Pathogenesis of Smokers Complications 
Two of the approximately 5000 toxic compounds in cigarette smoke, nicotine and 
carbon monoxide (CO), have been studied extensively. Few of the other compounds, 
however, have been studied in isolation for their vascular effects. The gas phase of 
cigarette smoke contains more than 10^ ^ free radicals per puff, and the extent to which 
these compounds affect endothelial dysfunction and inflammation remains unclear 
(Ambrose and Barua, 2004, Fig. 1.1). In general, it is believed that both direct damage 
to vascular endothelium and disruption of natural endothelial repair mechanisms 
caused by smoking lead to increased vascular permeability and atherosclerosis 
(Bamoya and Glantz, 2005). Nicotine alone acutely increases endothelial dysfunction 
by means of impaired vascular reactivity (Neunteufl et ah, 2002). Coronary 
vasospasm caused by nicotine in cigarette smoke has been demonstrated in young 
women (Caralis et ai, 1992). The resulting hyperadrenergic state also leads to acute 
increases in blood pressure, heart rate, and myocardial oxygen demand following 
nicotine use. On the contrary, chronic nicotine exposure has been shown in several 
studies to result in lower blood pressure, likely due to biphasic actions on nicotinic 
receptors leading to a blockade in transmission with large, sustained nicotine doses. 
The effect of nicotine on lipoprotein metabolism was studied using rats as the 
experimental animal. There was a significant increase in the total cholesterol, 
phospholipids, and triglycerides as well as the amount of lipids associated with VLDL 
and LDL in sera of nicotine-treated rats. The incorporation of ^H labeled leucine into 
the apoB was found to be increased both in the medium and associated cells in the 
hepatocytes isolated from nicotine-treated rats indicating an increased synthesis and 
secretion of the apo B containing lipoproteins. This was further confirmed by the 
higher incorporation of '''C acetate into total and individual lipids of LDL and VLDL 
secreted into the medium as well as that associated with different lipids in the cell 
layer. The activity of lipoprotein lipase in extrahepatic tissues and plasma lecithin: 
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cholesterol acyltransferase (LCAT) activity were significantly lower in nicotine-
treated rats. These results indicate that nicotine exerts hyperlipidemic effects 
particularly by increasing the synthesis and secretion of TG rich lipoproteins. Since 
nicotine is one of the major hazardous components present in cigarette smoke and 
tobacco, one can extrapolate that the deleterious effect exerted by nicotine on rats 
extends to cigarette smokers and those who use other forms of tobacco (Ashakumary 
and Vijayamma, 1997). Carbon monoxide constitutes 4% of cigarette smoke and 
directly leads to high levels of carboxyhemoglobin. Through sustained exposure to 
high levels of CO, chronic hypoxia ensues, leading to increase exercise induced 
ischemia, ventricular dysfunction, and arrhythmias in patients with coronary artery 
disease (CAD) (Allred et al., 1989). The risk did not appear to vary according to the 
amount of nicotine or CO in the cigarette, and the mean amounts of both substances 
per cigarette were similar for the cases and controls. The results suggest that men who 
smoke the newer cigarettes with reduced amounts of nicotine and carbon monoxide 
do not have a lower risk of myocardial infarction (MI) than those who smoke 
cigarettes containing larger amounts of these substances (Kaufman et al., 1983). 
1.1.1 Changes in lipid and lipoprotein metabolism during smoking 
The burning of tobacco at temperature of 830-900 °C, leads to the production of 
about 5000 already identified toxic substances. This heterogeneous mixture consists 
of a gaseous phase containing noncondensed gases and vapors, like CO, nitrogen 
oxides, nitrosamine, etc., and a solid phase, consisting of the products of pyrolysis 
like the nicotine, phenols, organic acids, aldehydes, ketones and aromatic, polycyclic 
hydrocarbons. In addition, during cigarette smoking a considerable amount of free 
radicals are also liberated (Pryor et al, 1987), estimated as lO'"* and lO'^  free 
radicals/puff in the tar and gas phases (Church and Pryor, 1985). It is known that the 
oxidative stress derives from disequilibrium between the oxidant and antioxidant 
components, which may be of enzymatic and nonenzymatic type. Such disequilibrium 
may be due to an excessive increase of free radicals and/ or reduction of the defensive 
mechanisms. 
The smoke is able to cause tissue oxidative damage at various levels (Park et 
al., 1998), and contributes significantly to the appearance of endothelial dysfunctions 
(Nagy et al., 1997), and to the alterations which induce the arteriosclerotic process 
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(Lakier, 1992). As a matter of fact, one can observe in smokers an increase of lipid 
peroxidation products (Smith et ai, 1993), particularly important is the increase of 
oxidized LDL (Sanderson et al., 1995). Clinical studies also indicate that cigarette 
smoking alters plasma lipoprotein levels, which might help explain the increased 
incidence of CHD (Ambrose and Barua, 2004). However, data pertaining to changes 
in plasma and lipoprotein lipids of smokers are conflicting. Significant increase in 
plasma TG, TC, VLDL-C and LDL-C with a decrease in antiatherogenic HDL-C was 
reported (Brischetto et al., 1983; Cariqui et al., 1986; Neki et ai, 2002; Jaleel et ai, 
2007). Whereas, in other reports no significant alteration in the above lipid parameters 
of smokers were observed (Seppo et al., 2005; Neunteufl et al., 2000). The lower 
HDL-C concentrations in smokers compared with nonsmokers has been attributed to 
reduced HDL2-C (Moriguchi et al., 1990; Freeman et al., 1993; Shennan et al., 1985; 
Imamura et al., 2002) HDL3-C (Haffner et al., 1985), or to both subfractions (Ito et 
al., 1995). Some studies (Haffner et al., 1985; Albers et al., 1982) reported that 
plasma LCAT enzyme, which esterifies cholesterol on HDL (Franceschini et al., 
1991), was significantly reduced in smokers than nonsmokers, whereas others did not 
find significant differences in serum or plasma LCAT activity (Moriguchi et al., 1990; 
Ito et al., 1995; Dirican et al., 1999; Dullaart et al., 1994). 
Serum paraoxonase is a calcium dependent esterase that is known to catalyze 
hydrolysis of organophosphates, and is widely distributed among tissues such as liver, 
kidney, intestine, and also serum, where it is associated with HDL (Mackness et al., 
1996). PON specificity towards endogenous serum and tissue substrates is not well 
characterized and therefore synthetic substrates, such as paraoxon and phenyl acetate 
are used to monitor the enzyme's activity. Serum PON activity was shown to be 
reduced in patients after MI (Ayub et al., 1999), in patients with familial 
hypercholesterolemia (Mackness et al., 1991), and in patients with diabetes mellitus 
(Mackness et al., 1991; Abbott et al., 1995), diseases that are associated with 
accelerated atherogenesis. One of the mechanisms by which HDL may be 
antiatherogenic is its ability to protect LDL against oxidation. Several HDL-
associated proteins have these antioxidant effects, including PAF-AH, PON, 
ceruloplasmin and transferrin (Navab et al., 1998; Kunitake et al., 1992). Paraoxonase 
another HDL-associated protein protects LDL from oxidative stress. PON, an enzyme 
inhially known to hydrolyze organophosphate pesticides including paraoxon, was 
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later recognized as being able to hydrolyze biologically active phospholipids in 
oxidized LDL. Therefore, it may have antiatherogenic functions. In contrast to PAF-
AH, which is selective against phospholipids with short acyl chains, PON has a 
specific activity against oxidized phospholipids with longer acyl chains. DQipleiion of 
PON activity results in the loss of antioxidant function of HDL. Addition of PON to 
these HDL particles restores the protective function of HDL (Castellani et al., 1997). 
An increased susceptibility to atherosclerosis in PON-deficient mice further supports 
its important role in preventing lipoprotein oxidation and atherogenesis (Shih et al., 
1998). Under normal circumstances, circulating LDL as well as HDL is protected 
from oxidative stress by HDL-associated enzymes, particularly PON or arylesterase 
(Mackness et al, 1991; Watson et al, 1995). Smoking may be related to impaired 
PON 1/arylesterase activity, thereby compromising antioxidant defense mechanisms. 
In this respect, it has been previously reported (Blatter et al, 1993; Nishio et al, 
1997) that cigarette smoke extracts inhibited the enzymatic activity of PONl in 
healthy subjects, and this inhibition was time and dose dependent (Nishio et al, 
1997). James et al. (2000) have demonstrated that smoking was associated with 
reduced serum PONl activity and concentration in patients with CHD (James et al, 
2000; Mackness et al, 2001). Recently, Solak et al (2005) reported a significantly 
decreased PONl activity in heavy smokers with respect to never smokers, but the 
activity was indifferent in mild and moderate smokers. Boemi et al. (2001) have 
demonstrated that lower absolute PON concentrations and activities, higher LDL: 
PON concentration ratios and a lesser capacity to prevent LDL oxidation are 
consistent with the hypothesis that reduced serum PON in type 1 patients, similar to 
type 2 diabetics, could contribute to increased risk of vascular disease. 
Oxidative modification of LDL may be a key early step in the pathogenesis of 
atherosclerosis (Diaz et al, 1997). Evidence of oxidized LDL has been obtained from 
arterial walls of animal models of atherosclerosis and of CHD patients (Haberland et 
al., 1988; Yla"-Herttuala et al., 1989). Cigarette smoke contains numerous free radical 
species that can contribute to the oxidation of LDL in vitro (Church and Pryor, 1985; 
Yokode et al., 1988; Santanam et al, 1997), although data are conflicting (Chen and 
Loo, 1995). LDL isolated from smokers may be more susceptible to oxidation than 
LDL fi:om nonsmokers (Scheffler et al., 1990; Gouaze et al., 1998); however, others 
did not find any difference in LDL oxidizability between smokers and nonsmokers 
Introduction/Review of Literature 
(Siekmeier et al, 1996; Marangon et al, 1997). Aqueous extracts of cigarette smoke 
can produce oxidative modification of LDL in vitro (Yokode et al, 1988; Kagota et 
al, 1996) and in vivo (Yamaguchi et al, 2000; Yamaguchi et al, 2001; Yamaguchi 
et al, 2004) in animal models. In addition, peroxynitrite generated in the extracts of 
cigarette smoke is involved in oxidative modification of apoB of LDL in vitro 
(Yamaguchi et al, 2002). It is possible that increased atherogenecity of LDL in 
smokers is associated with a preponderance of small dense (sd-) LDL subpopulation, 
that is highly susceptible to oxidative modification than large buoyant (lb-) LDL 
(Tribble et al, 1992; Tribble et al, 1994; Tribble et al, 2001). Several studies have 
reported a 2- to 3-fold increase in CHD risk among patients with a predominance of 
sd-LDL particles (Austin et al, 1990; Austin et al, 1994). Similarly, Quebec 
cardiovascular study has confirmed that a predominance of sd-LDL is a strong and 
independent predictor of CHD in the first seven years of follow-up (St-Pierre et al, 
2005). Recently, Koba et al (2006) have reported that the progression of CHD was 
closely linked not to the LDL particle size, but to the concentrafion of sd-LDL. 
Therefore, sd-LDL has been highlighted as a new strong and useful marker for the 
risk of CHD. In the only published report, Mero et al (1995) have demonstrated that 
prevalence of sd-LDL is increased in smokers. In addition, prevalence as well as 
concentration of sd-LDL was significantly increased in type 2 diabetic hyperlipidemic 
subjects with CHD, as well as in subjects with various types of hyperlipidemia 
(Hirano et al, 2004). The involvement of increased oxidative stress in smokers is 
supported by an increased concentration of lipid peroxidation product, MDA, and 
decreased levels of antioxidants in the plasma of smokers (Solak et al, 2005; 
Bloomer, 2007; Lykkesfeldt, 2007; Bloomer et al, 2008). However, several studies 
showed a nonsignificant increase in MDA in smokers vs. nonsmokers (Nielsen et al, 
1997; Celec eM/., 2005). 
1.2 Oxidants, Nonenzymatic and Enzymatic Antioxidants 
Oxidative stress has been implicated in various pathological conditions involving 
cardiovascular disease, cancer, neurological disorders, diabetes, ischemia/reperflision, 
other diseases and ageing (Dalle-Donne et al, 2006; Dhalla et al, 2000; Jenner, 2003; 
Sayre et al, 2001). These diseases fall into two groups: (i) the first group involves 
diseases characterised by pro-oxidants shifting the thiol/disulphide redox state and 
impairing glucose tolerance-the so-called "mitochondrial oxidative stress" conditions 
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(cancer and diabetes mellitus); (ii) the second group involves disease characterised by 
"inflammatory oxidative conditions" and enhanced activity of either NAD(P)H 
oxidase (leading to atherosclerosis and chronic inflammation) or xanthine oxidase-
induced formation of ROS (implicated in ischemia and reperfusion injury) (Valko et 
al., 2007). Oxygen free radicals or, more generally, reactive oxygen species (ROS), as 
well as reactive nitrogen species (RNS), are products of normal cellular metabolism. 
ROS and RNS are well recognized for playing a dual role as both deleterious and 
beneficial species, since they can be either harmful or beneficial to living systems 
(Valko era/., 2006). 
Free radicals can be defined as molecules or molecular fragments containing 
one or more unpaired electrons in atomic or molecular orbitals (Halliwell & 
Gutteridge, 1999). The addition of one electron to dioxygen forms the superoxide 
anion radical (02—) (Miller et al., 1990). Superoxide anion, arising either through 
metabolic processes or following oxygen "activation" by physical irradiation, is 
considered the "primary" ROS, and can fiirther interact with other molecules to 
generate "secondary" ROS, either directly or prevalently through enzyme- or metal-
catalyzed processes (Valko et al., 2005). Various pathways of ROS formation are 
outlined in Fig. 1.2. The production of superoxide occurs mostly within the 
mitochondria of a cell (Cadenas and Sies, 1998). The hydroxy! radical, •OH, is the 
neutral form of the hydroxide ion. The hydroxyl radical has a high reactivity, making 
it a very dangerous radical with a very short in vivo half-life of approx. 10~^ s (Pastor 
et al., 2000). Thus when produced in vivo 'OH reacts close to its site of formation. 
Additional reactive radicals derived from oxygen that can be formed in living systems 
are peroxyl radicals (R00»). The simplest peroxyl radical is H00», which is the 
protonated form (conjugate acid; pA a^~4.8) of superoxide (02*") and is usually termed 
either hydroperoxyl radical or perhydroxyl radical. It has been demonstrated that 
hydroperoxyl radical initiates fatty acid peroxidation by two parallel pathways: fatty 
acid hydroperoxide (LOOH)-independent and LOOH-dependent. The LOOH-
dependent pathway of HO2'' initiated fatty acid peroxidation may be relevant to 
mechanisms of lipid peroxidation initiation in vivo (Valko et al., 2007). Peroxisomes 
are known to produce H2O2, but not O2—, under physiologic conditions (Valko et al., 
2004). Peroxisomes are major sites of oxygen consumption in the cell and participate 
in several metabolic functions that use oxygen. The organelle also contains catalase. 
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which decomposes hydrogen peroxide and presumably prevents accumulation of this 
toxic compound. Thus, the peroxisome maintains a delicate balance with respect to 
the relative concentrations or activities of these enzymes to ensure no net production 
of ROS. How the organelle maintains this equilibrium is unclear. When peroxisomes 
are damaged and their H2O2 consuming enzymes down regulated, H2O2 releases into 
the cytosol which is significantly contributing to oxidative stress. 
Nitric oxide (NO*) is a small molecule that contains one unpaired electron on 
the antibonding 2K*y orbital and is, therefore, a radical. Nitric oxide is generated in 
biological tissues by specific nitric oxide synthases (NOSs), which metabolise 
arginine to citrulline with the formation of NO* via a five electron oxidative reaction 
(Ghafourifar & Cadenas, 2005). Overproduction of RNS is called nitrosative stress 
(Valko et al., 2007). This may occur when the generation of RNS in a system exceeds 
the system's ability to neutralize and eliminate them. Cells of the immune system 
produce both the superoxide anion and nitric oxide during the oxidative burst 
triggered during inflammatory processes. Under these conditions, nitric oxide and the 
superoxide anion may react together to produce significant amounts of a much more 
oxidatively active molecule, peroxynitrite anion (0N00~), which is a potent 
oxidizing agent that can cause DNA fragmentation and lipid oxidation (Carr et al., 
2000). Thus, NO* toxicity is predominantly linked to its ability to combine with 
superoxide anions. 
At high concentrations, ROS can be important mediators of damage to cell 
structures, nucleic acids, lipids and proteins (Valko et al., 2007). It is known that 
metal-induced generation of ROS results in an attack not only on DNA, but also on 
other cellular components involving polyunsaturated fatty acid (PUFA) residues of 
phospholipids, which are extremely sensitive to oxidation (Siems et al, 1995). Once 
formed, peroxyl radicals (ROO*) can be rearranged via a cyclisation reaction to 
endoperoxides (precursors of malondialdehyde) with the final product of the 
peroxidation process being malondialdehyde (MDA) (Valko et a!., 2007). 
Prooxidative enzymes, including NADPH-oxidase (Babior, 1999), NO-synthase 
(Stuehr et al., 1990) or the cytochrome P-450 chain (Stief, 2000), can generate ROS. 
Lipoxygenase generates free radicals. Lipoxygenase needs free PUFA, which are not 
present in healthy tissue. Membrane-bound phospholipase produces PUFA and 
lysolecithins. Lysolecithins change the cell membrane structures, and free PUFA are 
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oxidized to form lipid hydroperoxides. Lipoxygenase with Fe^ "^  is inactivated status. 
Once Fe^ ^ oxidized to Fe^ "", lipoxygenase can convert PUFA in to hydroperoxides 
(Spiteller,2001). 
Xanthine oxidase (XO, EC 1.1.3.22) and xanthine dehydrogenase (XD, EC 
1.1.1.204) are interconvertible forms of the same enzyme, known as xanthine 
oxidoreductase (XOR) (Borges et al, 2002). In purine catabolism, XOR catalyzes the 
oxidative hydroxylation of hypoxanthine to xanthine and subsequently of xanthine to 
uric acid. Uric acid acts as a potent antioxidant and free radical scavenger. XOR has, 
therefore, important functions as a cellular defense enzyme against oxidative stress. 
With both XO and XD forms, but particularly with the XO form, numerous ROS and 
RNS are synthesized (Vorbach et al, 2003). Thus, the synthesis of both an 
antioxidant (uric acid) and numerous free radicals (ROS and RNS) makes XOR an 
important protective regulator of the cellular redox potential. XO generates O2' by 
catalyzing hypoxanthine and xanthine to uric acid. Under pathophysiologic 
conditions, this is another major source of vascular oxidative stress (Droge, 2002). 
XO exists in plasma, liver, kidney and endothelial cells but not in smooth muscle cells 
(Harrison et al., 2003). There is overwhelming evidence that serum XO levels are 
significantly increased in various pathological states, like hepatitis, inflammation, 
hypercholesterolemia, atherosclerosis, ischemia-reperfusion, carcinogenesis and aging 
and that free radicals generated in the enzymatic process are involved in oxidative 
damage (Borges, et al., 2002). Based on the above information, it may be possible 
that the inhibition of this enzymatic pathway by compounds that have both antiradical 
as well as XO inhibitory properties could provide additional therapeutic benefit. It has 
been reported that some flavonoids and structurally related antioxidants inhibit XO 
activity (Nagao et al., 1999; Khan and Sultana, 2004). 
The tripeptide y-glutamylcysteinylglycine or GSH is the major nonenzymatic 
regulator of intracellular redox homeostasis, ubiquitously present in all cell types at 
millimolar concentration (Meister, 1983), This cysteine-containing tripeptide exists 
either in reduced (GSH) or oxidized (GSSG) form, better referred to as glutathione 
disulfide, and participates in redox reactions by the reversible oxidation of its active 
thiol (Briviba et al., 1999). Under normal cellular redox conditions, the major portion 
of this regulator is in its reduced form and is distributed in nucleus, endoplasmic 
reticulum and mitochondria. In addition, GSH may be covalently bound to proteins 
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through a process called glutathionylation and acts as a coenzyme of numerous 
enzymes involved in cell defense (Pompella et al., 2003), Glutathione can thus 
directly scavenge free radicals or act as a substrate for glutathione peroxidase (Gpx) 
and glutathione-S-transferases (GSTs) during the detoxification of hydrogen peroxide, 
lipid hydroperoxides and electrophilic compounds. Glutathione peroxidases constitute 
a family of enzymes, which are capable of reducing a variety of organic and inorganic 
hydroperoxides to the corresponding hydroxy compounds, utilizing GSH and/or other 
reducing equivalents. There are several tissue specific Gpx's that exhibit also tissue-
specific functions. All of them are selenoproteins and their primary function is to 
counteract oxidative attack. During the catalytic cycle, selenium is oxidized by the 
hydroperoxide to a selenic acid derivative. This intermediate is subsequently reduced 
by the electron donor. When GSH is used, a seleno-disulfide is formed, which is 
cleaved by a second GSH molecule to yield the reduced Gpx. During catalysis, the 
oxidation state of the enzyme depends on the relative concentration of the reducing 
(GSH) and oxidized (hydroperoxides) substrates (Vari et al., 2005). Glutathione 
peroxidases are ubiquitously distributed. In the gastrointestinal tract the isoenzyme 
provides a barrier against hydroperoxides derived from the diet or from the 
metabolism of ingested xenobiotics. The phospholipid hydroperoxide Gpx-discovered 
as a factor preventing lipid peroxidation is considered to be involved in the protection 
of biomembranes against oxidative stress. Glutathione-S-transferases (GSTS) are 
three enzymes families-cytosolic, mitochondrial and microsomal-that detoxify 
noxious electrophilic xenobiotics, such as chemical carcinogens, environmental 
pollutants and antitumor agents. Moreover, they protect against reactive compounds 
produced in vivo during oxidative stress by inactivating endogenous unsaturated 
aldehydes, quinones, epoxides and hydroperoxides, all of which are produced 
intracellularly after the exposure to pollutants, or consumption of overcooked or 
mycotoxin-contaminated food, or polluted water (Hayes et al., 2000). Glutathione-S-
transferases exert those protective effects because they are able to catalyze the 
conjugation of GSH with oxidation end products and represent a second line of 
defense against the highly toxic spectrum of substances produced by ROS-mediated 
reaction. Both Gpx and GSTS activities can eventually lower the level of total 
intracellular GSH. During the course of the reaction catalyzed by Gpx, the 
exaggerated production of GSSG can lead to the formation of mixed disulfides in 
cellular proteins, or to the release of GSSG excess by the cell, to maintain the 
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intracellular GSH/GSSG ratio. Glutathione is synthesized in two sequential ATP-
dependent reactions catalyzed by y-glutamylcysteine synthetase (Y-GCS)-the rate-
limiting enzyme-and glutathione synthetase. Other factors in the regulation of the de 
novo GSH synthesis are the availability of cysteine and the concentration of GSH 
itself that inhibits, by a feedback mechanism, y-GCS activity. In the presence of 
oxidative stress, GSH concentration rapidly decreases while GSSG-potentially highly 
cytotoxic-increases because of the reduction of peroxides or as a resuh of free radical 
scavenging. Glutathione disulfide can also be reduced back to GSH by the action of 
glutathione reductase (Gred) utilizing NADPH as a reductant (Vari et al., 2005). 
Glutathione reductase is a flavoenzyme and is represented by a single-copy gene in 
humans. It has been observed that exposure to agents that lead to increased oxidative 
stress also leads to an increase in its mRNA content. Further experimental data have 
shown the importance of Gred activity in GSH metabolism, demonstrating that the 
enzymatic activity is regulated in response to stress, and that mutations affecting Gred 
activity would have deleterious consequences. The recycling pathway for GSH 
formation is thus fundamental in the metabolism of GSH dependent defense reactions. 
In conclusion, the presence of GSH is essential, but not in itself sufficient, to prevent 
the cytotoxicity of ROS, being of fundamental importance the functionality of the 
glutathione-dependent enzymes, which participate in the first and second lines of 
defense. Moreover, several experimental data indicate the tight interrelation between 
endogenous polyphenols, namely, GSH and its related enzymes, and dietary 
polyphenols (Vari et al, 2005). 
Superoxide dismutase (SOD) catalyzes the conversion of superoxide anion to 
hydrogen peroxide and oxygen. SOD activity was discovered by McCord and 
Fridovich in 1969; they later proved that the enzyme is required to sustain life in 
aerobic conditions (McCord et al., 1971). Several classes of the enzyme have since 
been specified, each containing a transition metal in its catalytic centre. In humans, 
mitochondrial MnSOD, and extra-and intracellular-CuZnSOD have been identified. 
Glutathione peroxidase is a selenium-dependent enzyme (selenoprotein). The 
substrate of the enzyme is reduced glutathione (GSH), and therefore it depends 
indirectly on the flavoprotein glutathione reductase (Gred) and cellular NADPH 
concentration. Catalase is a porphyrin containing enzyme of high molecular weight 
which destroys hydrogen peroxide in high concentration by catalyzing its two-
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electron dismutation into oxygen and water (Schonbaum and Chance, 1976). 
Alternatively, it can act as a peroxidase at low hydrogen peroxide concentration, using 
reducing co-substrates such as alcohols, including ascorbate and phenols. In 
mammalian cells, NADPH is bound to catalase and may protect the enzyme from 
inactivation by H2O2. In prokaryotes, the antioxidant function of catalase is well 
established. Unfortunately, in many animal cells, most of the enzyme is located in 
peroxisomes where the steady-state concentration of hydrogen peroxide is very high, 
that is, greater than 10"'' M. Even in erythrocytes which have a high content of non-
peroxisomal catalase, hydrogen peroxide is essentially degraded by Gpx. 
Interestingly, catalase is also present in significant, albeit small amounts, in the 
mitochondrial matrix, where its function remains controversial. The increased 
sensitivity of transfected CAT-enriched cells to some drugs and oxidants is attributed 
to the property of CAT in cells to prevent the drug-induced consumption of O2 either 
for destroying H2O2 to oxygen or for direct interaction with the drug. As a rule, 
however, further investigations are required to assess the antioxidant function of 
catalase in vivo (Chaudiere and Ferrari-Iliou, 1999). 
1.2.1 Enzymatic and Nonenzymatic antioxiodant alterations in smokers 
The effects of cigarette smoking on a variety of diseases, including cancer, 
emphysema, stroke, and cardiovascular disease, have been well documented (Aaron, 
1983; Abbott et al., 1986; Silverberg, 1984; Winniford, 1990; Lakier, 1992). Tobacco 
smoke contains numerous compounds emitted as gases and condensed tar particles. 
Both the particulate and gas phases of cigarette smoke contain free radicals and 
reactive oxygen species (ROS) (Church and Pryor, 1985). Oxidant stress may be 
increased in smokers owing to a higher production of ROS, such as superoxide 
radical, hydroxide radical, hydrogen peroxide and/or deficiency in the antioxidant 
defense systems. An impaired radical scavenger function has been linked to the 
increased or decreased activity of enzymatic and nonenzymatic scavengers of free 
radicals. Superoxide dismutase and CAT activities were reduced, while Gpx activity 
was unchanged in the erytherocytes from smokers (Murat et al, 1997). On the other 
hand, other reports indicate no change in the activityes of SOD and CAT (Harats et 
al, 1990; Duthie et al, 1991; Strain et a/., 1989), while a decline in Gpx activity was 
seen in erytherocytes from smokers (Harats et al., 1990; Ellis et al., 1984). Abou-Seif 
(1996) also observed that the activity of GPx was significantly decreased in the blood 
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of smokers. In addition, total blood GSH, GPx and GST activites were significantly 
increased in young smokers (Chin-San Liu and Yau-Huei Wei, 1999; Joshi et al, 
1988). On the other hand, xanthine oxidase has been shown to contribute to 
endothelial dysfunction of resistance vessels in cigarette smokers (Guthikonda et al., 
2003 and 2004). Inhibition of xanthine oxidase could have helped by decreasing the 
production of free radicals or by decreasing uric acid levels (Zweier et al, 1994; 
Kvietys et al., 1989). Smoking-induced endothelial dysfunction of resistance vessels 
was rapidly reversed with oral allopurinol. These data suggest that xanthine oxidase 
contributes importantly to endothelial dysfunction caused by cigarette smoking 
(Guthikonda et al., 2003). Recently, increased XO activity in plasma of young 
smokers vs. age matched nonsmokers has been reported (Bloomer et al., 2008). 
Alteration in the levels of glutathione (GSH) and related antioxidants has been 
demonstrated to be highly associated with the smoking-mediated ROS and free 
radicals (Travis, 1987). GSH has been known to be widely distributed in human 
tissues and participates in an array of cellular defense mechanisms (Meister, 1989). 
Cantin et al. (1987) reported that cigarette smokers have a significantly higher level of 
GSH in the epithelium lining fluid of the lower tracheal tract, whose alveolar surface 
suffers from enhanced oxidative stress elicited by smoking. Toth and co-workers 
(1986) found that the RBC of cigarette smokers has a higher content of GSH to 
protect the endothelial cells from damage by ROS than the RBC of the nonsmokers. 
Michelet et al. (1995) disclosed that the blood level of GSH in smokers is positively 
correlated with the number of cigarettes smoked per day. In an in vitro study, Eiserich 
et al. (1995) found that exposure of a GSH solution (0.1 mmol/liter) to three puffs of 
cigarette smoke resulted in complete GSH depletion and that cigarette smoke 
promoted the consumption of protein thiols and enhanced lipid peroxidation in blood 
plasma. These observations imply that the thiolgroup related antioxidants quickly 
respond to the smoking related prooxidants and are poorly regenerated in vitro (Al-
Turk et al., 1987). In smokers, GSH is important in reducing the susceptibility of 
tissues to the damage caused by these deleterious compounds (Habig et al., 1974; Bell 
et al., 1993; Grinberg-Funes et al., 1994; Alexandrie et al., 1994). In a previously 
published report, male albino rats exposed to cigarette smoke for 4 weeks exhibited a 
significant decrease in enzymatic activities of SOD, CAT, GPx and GST of liver, 
kidney, heart and lung (Bindu and Annamalai, 2004).. In another report (Helen and 
Vijayammal, 1997), activities of SOD, CAT and Gred were significantly reduced in 
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the liver of rats exposed to cigarette smoke for 90 days (Helen and Vijayammal, 
1997). 
1.3 Cholesterol Dynamics 
Cholesterol is present in tissues and in plasma either as free cholesterol or as a 
storage form, combined with a long-chain fatty acid as cholesteryl ester. In plasma, 
both forms are transported in lipoproteins. Cholesterol is an amphipathic lipid and as 
such is an essential structural component of membranes and of the outer layer of 
plasma lipoproteins. It is synthesized in many tissues from acetyl-CoA and is the 
precursor of all other steroids in the body such as corticosteroids, sex hormones, bile 
acids, and vitamin D. Cholesterol has many biological functions. For instance, the 
concentration of cholesterol influences the fluidity of cell membranes and thereby 
biological activities of the cell. The total body cholesterol is derived from two 
sources: (i) dietary and (ii) de novo biosynthesis. Cholesterogenesis mostly occurs in 
the liver, which also regulates the level of circulating plasma cholesterol and serum 
lipoproteins. The biosynthesis of cholesterol also occurs in the other organs like the 
intestines, adrenal cortex, reproductive organs and skin. Although other cells and 
tissues do not synthesize cholesterol, they have the genomic information for its 
synthesis. Under normal circumstances, these cells and tissues take up cholesterol 
from serum lipoproteins. 
Starting from the 2-carbon unit acetyl-CoA, the biosynthesis of the cholesterol 
proceeds to several intermediates, including mevalonate and isopentenyl 
pyrophosphate (Fig. 1.3). Isopentenyl pyrophosphate is further processed in a series of 
steps to two branched pathways, one leading to isopentenyl tRNA and isopentenyl 
adenine, and the other to famesyl pyrophosphate. Famesyl pyrophosphate is in turn 
channeled to synthesis of cholesterol, ubiquinone or dolichols (Brown and Goldstein, 
1983). Famesyl pyrophosphate was also converted to famesylated (Ras) proteins by 
famesyl-protein transferase. Hepatic level of cholesterol are maintained by a precised 
balance between reactions catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMG-CoA reductase, EC 1.1.1.34), cholesterol 7-a-hydroxylase, acyl 
CoA: cholesterol acyltransferase and cholesteryl ester hydrolase. The first two 
enzymes are the rate limiting enzymes for cholesterol and bile acid synthesis, 
respectively. Acyl CoA: cholesterol acyltransferase catalyzes esterification of free 
cholesterol, whereas cholesteryl ester hydrolase mediates release of free cholesterol 
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from stored cholesteryl esters. The primary feedback loop for regulation of cholesterol 
synthesis appears to be at the site where HMG-CoA is converted to mevalonic acid by 
the rate-limiting enzyme HMG-CoA reductase, cholesterol and other oxysterols 
inhibit the activity of HMG-CoA reductase. Isolation, purification, and 
characterization of rat hepatic HMG-CoA reductase have been well documented 
(Srikantaiah et al, \911\ Edwards et ai, 1979). HMG-CoA reductase has also been 
studied in several other species including chicken liver (Beg et al., 1978; Beg et ai, 
1979), human liver (Beg et al., 1982; Beg et al, 1984a) and human fibroblasts 
(Brown and Goldstein, 1983; Beg et al., 1987). Three basic control mechanisms for 
HMG-CoA reductase have been reported, (a) Long-term regulation, which involves 
the modulation of HMG-CoA reductase activity by changes in enzyme concentration 
through the regulation at transcriptional level and post-transcriptional regulatory 
mechanisms such as mRNA and enzyme protein degradation (Edwards et aL, 1983a; 
Edwards et al, 1983b; Liscum et al, 1983b; Clarke et al, 1983; Clarke et al, 1984) 
For instance, the product feedback regulation by mavalonate (Kita et al, 1987; Brown 
and Goldstein, 1980), in vivo inhibition of HMG-CoA reductase by cholesterol 
feeding (Arebalo et aL, 1981), cholesterylamine and mevinolin (Eisenberg and Levy, 
1975), and mevalonolactone (Beg et al, 1984b) has been reported. Tocotrienols, a 
natxirally occurring class of compounds of vitamin E family, have also been reported 
to regulate HMG-CoA reductase activity at the post-transcriptional level (Pearce et 
al, 1992; Parker et al, 1993). (b) Control of HMG-CoA reductase activity through 
changes in the membrane composition and membrane fluidity in the microsomal 
environment in the immediate vicinity of the enzyme (Siptal and Sabine, 1981; 
Richert et al, 1984). (c) Short-term regulation that involves reversible covalent 
modification (phosphorylation and dephosphorylation) of HMG-CoA reductase 
(Ingebritson and Gibson, 1980; Beg et al, 1981; Beg and Brewer, 1982). Three 
separate kinase systems for the regulation of HMG-CoA reductase involving short-
term covalent modification have been demonstrated (Ingebritson and Gibson, 1980, 
Beg et al, 1987). Studies involving incubation of rat hepatocytes with insulin and 
glucagon or administration of glucagon to rats have been shown to modulate the 
bicyclic cascade system involving phosphorylation of both HMG-CoA reductase and 
HMG-CoA reductase kinase (Ingebritson and Gibson, 1980; Gibson, 1985; Beg et al, 
1987; Gibson and Parker, 1987). 
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Although cholesterol is essential to life, excess or deficit of free cholesterol is 
known to be harmful. Several factors are known which cause an overall increase in 
cholesterol concentration in the liver (i) uptake of lipoproteins by receptor mediated 
endocytosis, (ii) non-receptor mediated intake of lipoproteins, (iii) uptake of free 
cholesterol from the cholesterol rich lipoproteins by cell membranes, (iv) de novo 
synthesis of cholesterol, and (v) hydrolysis of cholesterol esters by cholesteryl ester 
hydrolase. Under above situations, not only increased cholesterol levels inhibits its 
own synthesis by inhibiting HMG-CoA reductase and suppressing low density 
lipoprotein (LDL) receptors (Russel et al., 1983), but also by activating cholesterol 7-
a-hydroxylase and acyl CoA: cholesterol acyltransferase which utilize free 
cholesterol for bile acid synthesis and formation of cholesteryl esters, respectively. 
Conversely, some factors are involved in the decrease of hepatic cholesterol, they are 
(a) efflux of cholesterol from membrane to nascent high-density lipoproteins (HDL) 
and HDL3 which is catalyzed by lecithin: cholesterol acyltransferase, (b) esterification 
by acyl CoA: cholesterol acyltransferase and (c) utilization of cholesterol for 
synthesis of steroids and bile acids. Under these conditions, increase in cholesterol is 
achieved by activation of HMG-CoA reductase and cholesteryl ester hydrolase 
activities as well as induction in synthesis of LDL receptors in order to receive 
cholesterol from non-hepatic tissues by receptor mediated endocytosis. However, 
under normal conditions an intricate balance is maintained between the biosynthesis, 
utilization and transport of cholesterol, keeping its harmful effects to minimum. 
Lipids are transported through plasma compartment in lipoproteins, which are 
complex water soluble molecules consisting of a core of cholesteryl esters and TG 
covered by a surface monolayer of phospholipids, free cholesterol and 
apolipoproteins. In the last two decades, there have been major advances in our 
imderstanding of the role of plasma lipoproteins, apolipoproteins, lipolytic enzymes, 
and lipoprotein receptors in cholesterol and lipoprotein metabolism. This new 
information has provided major insights into the role of cholesterol and lipoproteins in 
the pathogenesis of premature atherosclerosis. There are six major classes of human 
plasma lipoproteins, these include chylomicrons, very low density lipoproteins 
(VLDL), intermediate density lipoprotein (IDL), low density lipoprotein (LDL), high 
density lipoprotein (HDL) and lipoprotein (a) [Lp(a)] (Gofman et al, 1954; Berg et 
al., 1974). Nuclear magnetic resonance subdivides the lipoproteins in plasma into the 
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following subclasses: (1) for VLDL, V6-V1 with V6 the largest and VI the smallest; 
(2) IDL; (3) for LDL, L3-L1 with LI being the smallest and denset. (Kwiterovich, 
2000). HDL can be further separated by hydrated density into HDL2a, HDL2b, 
HDL3a, HDL3b and HDL3c, (Kontush et ai, 2003). These lipoproteins are 
distinguished on the basis of their lipid content, ultracentrifugation size, 
electrophoretic mobility and surface proteins. Fifteen major human plasma 
apolipoproteins have been identified and their gene and protein structures determined 
(Brewer et ai, 1988). The six most clinically relevant apolipoproteins are A-I, B-lOO, 
B-48, C-II, E, J and M. The three major apolipoproteins on HDL are apoAI and 
apoAII, apoM (Suzuki et al, 1983; Xu and Dahlback, 1999). Apolipoprotein M is 
another apoprotein that is predominantly associated with HDL (Xu and Dahlback, 
1999). In human plasma apoB exist as two isoproteins designated apoB-100 and 
apoB-48, with molecular weights of 512 and 250 kDa, respectively (Kane et al., 1980; 
Kane, 1983). ApoB-48 and apoB-100 are the principal structural apolipoproteins on 
chylomicrons, VLDL, IDL and LDL. ApoB-100 is virtually the only apolipoprotein 
on LDL. 
The metabolic relationship of the major classes of lipoproteins containing 
apoB-48 and apoB-100 may be considered to consist of two major "apoB cascades". 
The first apoB cascade involves the stepwise delipidation of TG-rich chylomicrons 
secreted by the intestine. These lipoproteins transport dietary cholesterol and TG from 
the intestine to the liver and peripheral tissues. Shortly after secretion, chylomicrons 
acquire apolipoproteins C-II and E primarily from HDL. As already outlined, apoC-II 
activates lipoprotein lipase, which initiates TG hydrolysis and remodeling of the 
lipoprotein particles. With TG hydrolysis of the hydrated density the chylomicrons 
increases and chylomicron remnants are generated with a hydrated density of VLDL 
and then IDL. Chylomicron remnants are removed primarily by a hepatic remnant 
receptor. ApoE has been proposed to interact and initiate the hepatic uptake of the 
chylomicron remnants (Hertz et al, 1988). The second apoB cascade is a parallel 
cascade involving TG rich VLDL containing apoB-100 secreted by the liver. ApoC-II 
and apoE from HDL rapidly associate with the newly secreted hepatogenous VLDL. 
ApoC-II activates lipoprotein lipase, which hydrolyzes VLDL triglycerides, and the 
VLDL is serially converted to smaller VLDL remnants, IDL, and finally LDL. During 
the conversion of VLDL to LDL approximately 50 per cent of VLDL Temnmts and 
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IDL are removed directly from the plasma by interaction of apoE and apoB-100 with 
the remnant and LDL receptors. Another lipolytic enzyme, hepatic lipase and apoE 
have also been proposed to be necessary for the conversion of IDL to LDL. Hepatic 
lipase functions as both a triglyceryl hydrolase and phospholipase. LDL, the end 
product of the VLDL cascade, contains almost exclusively apoB-100 as its only 
protein constituent. ApoB-100 on LDL interacts with LDL receptor on the plasma 
membrane of cells in the liver, adrenal and peripheral cells, including smooth muscle 
cells and fibroblasts (Brown and Goldstein, 1986), where it supplies cholesterol to the 
intracellular cholesterol pool. The work of Brown and Goldstein (1979 and 1983) on 
the cellular metabolism of LDL elucidated the LDL Pathway. The high affinity 
receptors bind LDL particles and extract them from the fluid that bathes the cell. LDL 
is transported to lysosomes where the protein is degraded and the cholesterol is 
transferred to the intracellular cholesterol pool (Brown and Goldstein, 1986). The 
receptor displayed on the surface of the cells varies with the cellular demand for 
cholesterol. When the need is low, the cells make fewer receptors and take up LDL at 
a reduced rate, this protects the cells excess cholesterol but at a higher price, the 
reduction in the number of receptors decreases the rate of removal of LDL from the 
circulation, blood level of LDL rises and atherogenesis is accelerated. LDL receptor 
plays an important role in the maintenance of plasma LDL-cholesterol levels. The 
serum concentration of LDL, therefore, depends on the rate that liver removes IDL 
from the circulation, which in turn, depends on the number of functioning LDL 
receptors on the liver cell surface. High blood cholesterol which results from the 
ovexproduction and/or underutilization of LDL is known to be caused by two 
metabolic irregularities: (i) the genetic disease familial hypercholesterolemia; (ii) the 
consumption of high cholesterol diet. 
Cigarette smoke increased the production of cholesterol, through the induction 
of HMG- CoA reductase activity which is acting as a rate limiting step enzyme in 
cholesterol biosynthesis (Helen and Vijayammal, 1996). In addition, cigarette smoke 
exposure significantly increased the triglycerides levels (Yasue et al, 2006).The 
present study also observed increased concentration of TC and TG in young smokers 
and cigarette smoke exposed rats. This might be attributed to nicotine. Kavitharaj and 
Vijayammal also reported that chronic administration of nicotine was found to 
produce enhanced synthesis of triglycerides. Moreover, the present study observed 
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diminished ievel of HDL-C in smokers and cigarette smoke exposed rats. This result 
was reliable with earlier reports (Ramesh and Begum, 2006; Yasue et ai, 2006; 
Porkka and Ehnholm, 1996). Besides, Vella et al. (1994) also reported that HDL-C 
level was significantly decreased in cigarette smokers. This might be due to increased 
VLDL-C leads to decreased levels of HDL-C by the poorer availability of 
phospholipids remnants from VLDL-C to HDL-C formation and decreased activity of 
LCAT (Pugalendi and Ramakrishnan, 1991). Due to lipoproteins alteration, lipids 
might be accumulated in the tissues. Hence, in the present study, the total lipids level 
was significantly elevated in cigarette smoke exposed rats. 
1.4 Atherogenic Properties of Oxidized LDL and small dense LDL 
Oxidative modification of lipoproteins is believed to play a central role in the 
pathogenesis of atherosclerosis (Berliner and Heinecke, 1996; Steinberg, 1997). 
Because plasma contains several antioxidants (Frei, 1995) and lipoproteins with 
oxidative damage have been isolated from atherosclerotic lesions, (Berliner and 
Heinecke, 1996; Steinberg, 1997) lipoprotein oxidation generally is considered to 
occur in the vessel wall. Although lipid oxidation in the vessel wall is thought to 
occur as a result of a local deficiency of endogenous antioxidants or an excess of free 
metal ions, only limited data support these hypotheses. Research has shown that 
human atherosclerotic plaques contain massive amounts of lipid peroxidation 
products, despite the presence of large quantities of a-tocopherol (vitamin E) and 
ascorbate (Suama, 1995). Therefore, it is unclear whether oxidized lipoproteins 
originate in the arterial wall or are produced in the circulation and then enter the 
intimal space. Although LDL is a major risk factor for CAD, experiments have shown 
that incubation of macrophages with native LDL does not result in foam cell 
formation, a characteristic feature of atheromatous lesions (Brown and Goldstein, 
1983). However, after chemical modification of LDL, rapid uptake occurs, leading to 
cholesterol accumulation in the macrophage with subsequent foam cell formation, 
which suggests that LDL modification is a necessary step in atherogenesis. Oxidized 
LDL can induce foam cell formation, and oxidative modification of LDL is now 
recognized as an important process that occurs in vivo (Steinberg et al., 1989). Several 
lines of research support the occurrence of LDL oxidation in vivo (Steinberg, and 
Lewis, 1997). Oxidized apo B-lOO epitopes and increased levels of lipid peroxidation 
products can be detected in LDL extracted from both rabbit and human atherosclerotic 
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lesions (Yla"-Herttuala et al., 1989). Immunohistochemical staining of atherosclerotic 
lesions with specific monoclonal antibodies has demonstrated the presence of Ox 
LDL(Palinski era/., 1989). 
Many cell types are capable of oxidizing LDL, including monocytes, 
macrophages, neutrophils, endothelial cells, smooth muscle cells and fibroblasts. 
However, cell types that are involved in the atherosclerotic lesion in which OX LDL 
is found, i.e. macrophages, endothelial cells and smooth muscle cells, would seem to 
be the most likely to contribute to LDL oxidation in vivo. Once initiated, oxidation of 
LDL is a free radical driven lipid peroxidation chain reaction. Lipid peroxidation is 
initiated by free radical attack on double bond associated with a polyunsaturated fatty 
acid (PUFA). This results in the removal of a hydrogen atom from a methylene (CH2) 
group, the rate of which determines the rate of initiation, a key step in lipid 
peroxidation. Molecular rearrangement of the resulting unstable carbon radical results 
in a more stable configuration, a conjugated diene. The conjugated diene reacts very 
quickly with molecular oxygen, and the peroxyl radical thus formed is a crucial 
intermediate (Abuja and Esterbauer, 1995) (Fig. 1.4). A PUFA peroxyl radical in LDL 
may abstract a hydrogen atom from an adjacent PUFA to form a hydroperoxide and 
another lipid radical, a reaction which results in chain propagation. Removal of 
hydrogen atoms by the peroxyl radical from other lipids, including cholesterol, 
eventually yields oxysterols. Lipid hydroperoxides fragment to shorter-chain 
aldehydes, including malondialdehyde and 4-hydroxynonenal. These reactive 
aldehydes in turn may bind to e-aminogroups of apo B-100, giving the protein an 
increased net negative charge. The classical LDL receptor recognizes a specific 
domain of positive charges from lysine, arginine and histidine residues on apo B. 
Alteration of this domain results in failure of binding by the apo B/E receptor and an 
increase in negative surface charge on apo B-lOO results in increased recognition by 
the scavenger receptor. In vitro studies of LDL oxidation have verified the existence 
of "lag phase", during which significant oxidation of LDL can not be detected, prior 
to the onset of the "propagation phase", presumably after the endogenous antioxidants 
have been consumed. A steady increase in the detectable byproducts of oxidation 
continues, until the substrate, i.e. the PUFAs, has been depleted, and a plateau phase 
is reached. Assessment of resistance of LDL to oxidation has generally involved in 
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measurement of the duration of the lag phase including other variables, such as the 
rate of propagation, are also noted. 
The increased atherogenecity of LDL is associated with a preponderance of 
small dense (sd-) LDL subpopulation that is more prone to oxidative modification 
than Ib-LDL (Chancharme et al., 1999). It has been shown that not only the 
prevalence of sd-LDL but its concentration was substantially increased in healthy 
subjects with various types of hyperlipidemia such as hyperLDLcholesterolemia, 
hypertriglyceridemia, combined hyperlipidemia and chylomicronemia, 
hyperlipidimea with CHD, type 2 diabetic patients with and without CHD (Hirano et 
al., 2004). Lipoprotein profiles that are relatively rich in smaller, more dense LDL 
particles are associated with upto a 3-fold greater risk of myocardial infarction than 
those mainly consist of large buoyant (lb-) LDL particles (Austin et al., 1988; Austin 
et al., 1990; Stampfer et al., 1996). However, the mass of sd-LDL is independently 
associated with disease risk (Stampfer et al., 1996; Gardner et al., 1996; Lamarche et 
al., 1997; Austin et al., 1988), suggesting that these particles are more directly 
atherogenic than Ib-LDL. Similarly, Quebec cardiovascular study has confirmed that a 
predominance of sd-LDL is a strong and independent predictor of CHD in the first 
seven years of follow-up (St-Pierre et al., 2005). Recently, Koba et al. (2006) have 
reported that the progression of CHD was closely linked not to the LDL particle size, 
but to the concentration of sd-LDL. It has been suggested that in comparison to Ib-
LDL, sd-LDL are highly atherogenic as a result of their enhanced susceptibility to 
oxidative modification, higher penetration in the arterial wall, their lower binding 
affinity for the LDL-receptor, and prolonged plasma half life (Chapman et al., 1998; 
Bjomheded et al., 1996), Differences in oxidative susceptibility between Ib-LDL and 
sd-LDL have been attributed to differences in their physicochemical properties. 
Relative to Ib-LDL, sd-LDL has a reduced content of antioxidants (De Graaf et al., 
1991; Tribble et al., 1994; Tribble et al., 1995) and free cholesterol (De Graaf et al., 
1991; Tribble et al., 1992; Tribble et al., 1994), and is enriched with polyunsaturated 
fatty acids (De Graaf et al., 1991) and, possibly, hydroperoxides (Sevanian et al., 
1996). Antioxidant concentrations and free cholesterol content have been shown to 
predict differences in the oxidative susceptibility of LDL density subfraction (De 
Graaf ^/ al., 1991; Tribble et al., 1992; Tribble et al., 1994). Therefore, sd-LDL has 
been highlighted as a new powerful and useful marker for the risk of hyperlipidimea 
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with and without CHD, type 2 diabetic patients with and without CHD (Austin et al, 
1995; Hirano et al, 2004; Koba et al, 2006). 
1.4.1 High density lipoproteins and antioxidative mechanisms 
Epidemiological studies have identified low density lipoproteins and high 
density lipoproteins as independent risk factors that modulate CVD risk. The role of 
HDLs in protecting against the development of CHD has been demonstrated in 
numerous clinical studies. The studies show an inverse relationship between the 
concentration of HDL-C and the development of premature CHD (Gordon and 
Rifkind, 1989; Assmann et al, 2004), with a reduction in CHD risk of 2-4 % for each 
1 mg/dl increase in HDL-C. HDL is a class of heterogeneous lipoproteins containing 
approximately equal amounts of lipid and protein (Gordon and Rifkind, 1989). HDL 
particles are characterized by high density and small size. The various HDL 
subclasses vary in quantitative and qualitative content of lipids, apolipopropteins, 
enzymes, and lipid transfer proteins, resulting in differences in shape, density, size, 
charge, and antigenecity. Apo-Aj is the predominant HDL protein followed by apo-
A2. HDL fraction accounts for almost all of the cholesterol quantified as HDL-C. 
HDL can be further fractionated by density into HDL2 and HDL3, by size, or by 
apolipoprotein composition. The origin of HDL particles is not entirely clear. Several 
mechanisms have been proposed, including direct secretion in to plasma from 
hepatocytes or enterocytes; release during the interconversion of various HDL 
subpopulations by phospholipid transfer protein (PLTP), cholesteryl ester transfer 
protein (CETP), or hepatic lipase (HL); or direct interaction of free lipoproteins with 
cell membrane (Von Eckardstein et al, 2000). 
The reverse transport of cholesterol from peripheral cells to sites of 
catabolism, first described by Glomset and Norum in 1973, has been suggested to be 
the primary antiatherogenic mechanism of HDLs. Cholesterol efflux from 
macrophages to HDL can occur by passive diffusion (Yancey et al, 2003), by 
interaction with the SR-Bl receptor (Williams et al, 1999), or by binding to the 
ABCAl transporter (Rubin et al, 1991; Takahashi and Smith, 1999; Remaley et al, 
2001; Oram and Lawn, 2001; Liu et al, 2003). The preferred acceptor for the ABCAl 
transporter-mediated cholesterol efflux is poorly lipidated apo-Al (Castro and 
Fielding, 1988), which is converted to spherical a-HDL after esterification of free 
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cholesterol to cholesteryl esters by LCAT. Both the SR-Bl (Malerod et ai, 2002) and 
ABCAl transporter (Costet et al., 2000; Schwartz et al., 2000; Venkateswaran et ai, 
2000) pathways are modulated by the cellular content of oxysterols, which regulate 
the LXR pathway and expression of the SR-Bl and ABCAl transporter genes. After 
accepting excess cellular cholesterol from arterial macrophages and other peripheral 
tissues HDL transports the excess cholesterol to the liver for disposal. HDL is thus an 
integral component of the atheroprotective reverse cholesterol transport process, 
functioning as a carrier of excess cellular cholesterol from peripheral tissues to the 
liver, where it is excreted from the body as bile acids and cholesterol (Glomset, 1968). 
The second mechanism by which HDL may protect against CVD is the 
selective decrease of endothelial cell adhesion molecules, which facilitate the binding 
of mononuclear cells to the vessel wall and promote lesion development (Barter et al., 
2002). The HDL-induced increase in NO production may be an important 
atheroprotective feature of HDL, as diminishing bioavailability of endothelial-derived 
NO has a key role in the early pathogenesis of hypercholesterolemia-induced vascular 
disease and atherosclerosis (Cohen, 1995; Naruse et al., 1994; Cayatte et ai, 1994). 
Apoptosis of endothelial cells has been demonstrated in atherosclerosis. The ability of 
HDL to inhibit apoptosis has been shown in several studies (Nofer et al., 2001; 
Sugano et al., 2000). HDL exerts a protective effect by interfering with the apoptotic 
stimuli which endothelial cells are exposed. The mechanism is uncertain but this HDL 
function may contribute to longevity. The mechanism by which HDL decreases 
atherosclerosis is to protect LDL from oxidation. Oxidized or modified LDL, unlike 
normal LDL, is readily taken up by the scavenger receptor SR-A or CD36 on 
macrophages, resulting in cholesteryl ester accumulation with foam cell formation. 
The cholesterol-loaded macrophage produces a number of inflammatory cytokines 
and stimulates MCP-1 as well as endothelial cell adhesion molecules. Mechanisms of 
LDL oxidation in vivo involve concerted modification by chemically diverse oxidants, 
employing that any single low molecular weight antioxidants, such as vitamins E and 
C, even at physiologically relevant doses, may not provide complete oxidative 
protection of LDL in vivo (Witztum and Steinberg, 2001; Gaut and Heinecke, 2001). 
Plasma HDLs possess a spectrum of antiatherogenic actions, including potent 
antioxidant and anti-inflammatory activities (Van Lenten et al., 2001). Although 
HDLs can themselves undergo oxidative modification (Francis, 2000), several 
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enzymes that may cleave oxidized lipids and thereby inhibit LDL oxidation are 
associated with HDL particles; these include paraoxonase (PON) in its major isoforms 
PONl (Durrington et al., 2001), platelet-activating factor acetylhydrolase (PAF-AH) 
(Tselepis and Chapman, 2002s), LCAT (Goyal et al., 1997), and glutathione 
selenoperoxidase (Chen et al., 2000). In addition, apo-Ai, a major HDL 
apolipoprotein can remove oxidized lipids from LDL, suggesting that HDL can 
function as an acceptor of oxidized lipids (Navab et al., 2000). Apo-Ai was shown to 
reduce peroxides of both phospholipids and cholesteryl esters and to remove 
hydroperoxides, which are products of 12-lipoxygenase, from native LDL (Navab et 
al., 2000). Other HDL apolipoproteins, such as apo-AII, apo-AIV, apo-E, and apo-J, 
also function as antioxidants in vitro (Kontush and chapman, 2006). The diversity of 
antioxidative actions of HDL particles suggests that HDL provide efficient protection 
of LDL from oxidation in vivo. Plasma LDLs are heterogeneous in their physico-
chemical properties and consist of three major particle subclasses, Ib-LDL, 
intermediate LDL, and Sd-LDL; such LDL subfractions are distinct in their 
atherogenic and oxidative properties (Chapman et al., 1998; Kontush et al., 2003). 
Similarly, circulating HDL particles are heterogeneous in physico-chemical 
properties, intravascular metabolism, and biological activity (Lamarche et al., 1999). 
Ultracentrifugally isolated HDL3 exerts greater inhibition of adhesion protein 
expression in endothelial cells than HDL2 (Ashby et al., 1998). Isopycnic density 
gradient centrifugation allows reproducible isolation of 5 physicochemically defined, 
highly purified, major HDL subfractions, HDL2b, 2a, 3a, 3b, and 3c (Kontush and 
chapman, 2006). Indeed, HDL particle phenotypes are qualitatively and quantitatively 
altered in dyslipidemias associated with premature atherosclerosis, including 
hyperlipidemias of types IIA, IIB, and IV, and type 2 diabetes (Lamarche et al., 
1999). Significant differences between the HDL fractions derived from subjects with 
type 1 diabetes and those derived from control subjects has been reported (Valabhji et 
al., 2001). The greater values for HDL esterified cholesterol and phospholipid in the 
subjects with type 1 diabetes are attributable largely to increased concentrations of 
esterified cholesterol and phospholipid associated with larger, more buoyant HDL 
fractions (Valabhji et al., 2001). Paraoxonase catalyzes the break down of oxidized 
phospholipids in LDL. Studies have found that transgenic animals deficient in this 
enzyme are significantly more susceptible to the development of diet-induced 
atherosclerosis (Shih et al., 1998). On the other hand, PON transgene in mice 
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produces HDL resistant to oxidation (Oda et a!., 2002). Degradation of oxidized 
phospholipids has also been attributed to PAF-AH. Over expression of human apo-Ai 
in apo-E knockout mice increases PAF-AH activity and simultaneously reduces 
oxidative stress in plasma, decreases intracellular adhesion molecule (ICAM) and 
vascular cell adhesion molecule (VCAM) expression, and decreases monocyte 
recruitment in to the arterial wall (Kontush and chapman, 2006). 
Serum paraoxonase is a calcium-dependent esterase that is known to catalyze 
hydrolysis of organophosphates, and is widely distributed among tissues such as liver, 
kidney, intestine, and also serum, where it is associated with HDL (Mackness et aL, 
1996). PON specificity towards endogenous serum and tissue substrates is not well 
characterized and therefore synthetic substrates, such as paraoxon and phenyl acetate 
are used to monitor the enzyme's activity. Serum PON activity was shown to be 
reduced in patients after MI (Ayub et al., 1999), in patients with familial 
hypercholesterolemia (Mackness et al., 1991), and in patients with diabetes mellitus 
(Mackness et al., 1991; Abbott et al., 1995), diseases that are associated with 
accelerated atherogenesis. Genetic variations of PON correlated with HDL-
cholesterol and apo-Ai, suggesting antiatherogenic properties. Atherosclerosis occurs 
naturally in humans and rabbits but not in mice. Comparison of PON arylesterase 
activity revealed that in humans and rabbits, > 95 % is HDL associated. In mice, 
about 30 % of PON activity is lipid poor; in the absence of apo-Ai in mice, total PON 
arylesterase activity is reduced and > 60 % is lipid poor. It is striking that the rabbit 
has so much higher level of plasma PON activity than human and mice, especially in 
view of the fact that out of these three species, the rabbit is the most susceptible to 
cholesterol-induced atherosclerosis (Cabana et al., 2003). Smoking may enhance 
oxidative stress not only through the production of reactive oxygen radicals in smoke 
but also through weakening of the antioxidant defense mechanisms. In this context, a 
recent in vitro study showed that extracts of cigarette smoke inhibited the enzymatic 
activity of PON (Nishio and Watanabe, 1997). Given its hypothesized, antioxidant 
role, this could also contribute to the increased oxidation of LDL in smokers. The 
present study examined the hypothesis that smoking is associated with lower serum 
PON activity and examined the possible consequences of lower PON levels with 
respect to the protection of LDL from oxidation and the severity of vascular disease. 
Boemi et al. (2001) have demonstrated that lower absolute PON concentrations and 
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activities, higher LDL: PON concentration ratios and a lesser capacity to prevent LDL 
oxidation are consistent with the hypothesis that reduced serum PON in type 1 
patients, similar to type 2 diabetics, could contribute to increased risk of vascular 
disease. Although PON can offer protection against the toxicity of some 
organophosphates, its physiological role is still not clear; however, evidence exists for 
a protective effect of PON against oxidative damage (Mackness et ah, 1996). PON 
was suggested to contribute to the antioxidant protection conferred by HDL on LDL 
oxidation (Mackness et al., 1991; Navab et al., 1996; Kontush and chapman, 2006). 
The effect of HDL-associated PON or of purified PON on the LDL oxidation process, 
including its initiation (conjugated diene formation), propagation (peroxides 
formation), and decomposition (aldehydes formation) phases could be analyzed by 
using PON inhibitors. The inhibitory effect of HDL on LDL oxidation was suggested 
to be related to metal ion chelation, or to peroxidase, like activity. Under oxidative 
stress, not only LDL is susceptible to lipid peroxidation but all other serum-lipids, 
including those present in HDL, are also prone to oxidation. In fact, HDL has been 
shown to be the major carrier of lipid hydroperoxides in human serum (Hahn and 
Subbiah, 1994; Kontush and chapman, 2006). In this context it is interesting to 
mention that HDL-associated cholesteryl ester hydroperoxides are more rapidly 
reduced to their less reactive hydroxides than are those associated with LDL 
(Christison et al., 1995). Oxidative modification of HDL has also been shown to 
impair the ability of the lipoprotein to promote cholesterol efflux (Nagano et al., 
1991; Morel, 1994). Thus, inhibition of HDL oxidation by PON may preserve the 
antiatherogenic functions of HDL in reverse cholesterol transport, as well as its 
protection of LDL from oxidation. Kontush et al. (2003) have demonstrated that both 
serum and plasma-derived small, dense HDL particles possess the most potent 
capacity among HDL subspecies to protect LDL from both metal-dependent and 
metal-independent oxidation in normolipidemic subjects. The oxidative protection of 
LDL by ultracentrifugally isolated HDL subfractions (at equal cholesterol or protein 
concentration or equal particle number) increased in the order HDL2b <HDL2a 
<HDL3a <HDL3b < HDL3c. HDL subfractions efficiently protected not only total 
LDL but also intermediate LDL3 (typically the most abundant LDL subfraction in 
normolipidemic subjects) and small, dense LDL5 (a highly atherogenic LDL 
subfraction) (Chapman et al., 1998), thereby suggesting that HDL can attenuate 
oxidation of atherogenic LDL subclass. When HDL subfractions were subjected to 
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nonmetal or copper-induced oxidation in the absence of LDL, their oxidative 
resistance increased in the order HDL2b <HDL2a <HDL3a <HDL3b < HDL3c, 
thereby mirroring their antioxidative activity during LDL oxidation. Similarly, PONl 
activity with phenyl acetate or paraoxon as substrate increased in the order HDL2b 
<HDL2a <HDL3a <HDL3b< HDL3c. On a particle basis, contents of apo-Ai and 
apo-Aa were elevated in HDL3a and lowest in HDL3c. PAF-AH activity was 
significantly increased in small, dense HDL3c. LCAT activity was higher in HDL3 
relative to HDL2 subfractions (Kontush et al, 2003; Kontush and chapman, 2006). 
The present evidence for the differential antioxidative properties of HDL subfractions 
may have important consequences for our understanding of the protective 
antiatherogenic action of HDL in vivo. Thus, although small, dense HDL3c typically 
accounts for <15 % of total HDL, HDL3c may nonetheless play a pivotal role in the 
protection of LDL against oxidation, significantly exceeding the protection afforded 
by low molecular weight antioxidants. Indeed, it has been shown that HDL3, rather 
than HDL2, is strongly correlated with the antiatherogenic action of gemfibrozil in the 
VA-HIT Study (Robins et al, 2001). Considered together these findings identify that 
Small, dense HDL affords potent protection of LDL against oxidative stress, possess 
pronoimced anti-inflammatory properties, and display high cholesterol efflux 
capacity. The atheroprotective properties of HDL can, however, be compromised 
under conditions associated with accelerated development of atherosclerosis, such as 
in atherogenic low HDL-C dyslipidemias typical of metabolic diseases, including 
MetS and type-2 diabetes. A preferential increase in circulating concentrations of 
HDL particles possessing normalized antiatherogenic activity is therefore a promising 
therapeutic strategy for the treatment of common metabolic diseases featuring 
dyslipidemia, inflammation, and premature atherosclerosis (Kontush and chapman, 
2006). Solak et al. (2005) have reported a significantly reduced serum PONl activity 
in heavy smokers, while the activity was indifferent in mild and moderate smokers. 
James et al. (2000) have demonstrated the associated of smoking with reduced serum 
PON activity in patients with CAD. In addition, PONl and PAF-AH activities are 
consistently lower in all HDL subfractions fi^om type 2 diabetics (Nobecourt et al., 
2005). In type 2 diabetic, serum concentration of PONl are reduced to such as extent 
that diminished oxidative protection of LDL by HDL in vitro (Boemi aet al, 2001). 
HDL subfractions are deficient in antioxidative activity against LDL oxidation in 
atherogenic dyslipidemia involving low HDL levels (Hansel et al, 2004; Kontush et 
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ai, 2005; Nobecourt et al, 2005). In another study, HDL2 show decreased protection 
of LDL against oxidation mediated by THPI macrophages in poorly controlled type-2 
diabetes (Gowri et al, 1999). Our data clearly indicate that impairment of the 
antioxidative activity of HDL subfractions, particularly small, dense HDL in 
dyslipidemic smokers involving low antiatherogenic HDL-C levels, low HDL linked 
arylesterase activity, low HDL associated proteins, and high atherogenic non-HDL 
levels are intimately associated with elevated oxidative stress-a newly recognized 
CVD risk factor (Schwedhelm et al, 2004; Meisinger et al, 2005), and many 
therefore contribute to enhanced atherogenesis (Hansel et al, 2004; Kontush et al, 
2005; Nobecourt et al, 2005), 
1.5 Management of Cigarette Smoke Induced Hyperlipidemia, Dyslipidemia and 
Oxidative Stress 
It is now well established that tobacco smoking is an independent, modifiable risk 
factor for coronary, cerebral, and peripheral arterial diseases. Cigarette smoking 
increases the risk of myocardial infarction in both men and women (Fish III and 
Bartholomew, 2007). Cigarette smoke contains numerous free radical species that can 
contribute to the oxidation of LDL in vitro (Church and Pryor, 1985; Yokode et al, 
1988; Santanam et al, 1997). Oxidation of LDL may be a key early step in the 
pathogenesis of CHD. Supplementation of humans with antioxidant nutrients has also 
been shown to decrease the oxidizability of LDL in vitro (Fuller and Jialal, 1997) and 
reduce the recurrence of myocardial infarctions in CHD patients (Stephens and 
Parsons, 1996). Elsayed and Bendich, 2001 have demonstrate that dietary 
supplementation of smokers with antioxidants (vitamin C and E, P-carotene, 
ubiquinol, glutathione and a-lipoic acid) can reduced the over all oxidative burden 
that is increased by cigarette smoking. However, this supplementation can not 
substitute for the greater benefits of smoking cessation. On the other hand, in another 
initial report, Bloomer, (2007) has demonstrated that young, novice cigarette smokers 
have lower blood antioxidant capacity and higher lipid peroxidation levels compared 
to nonsmokers, despite having similar dietary intake. Based on these resuhs, Bloomer 
emphasized the importance of smoking abstinence to young, novice cigarette 
smokers. However, few scattered reports demonstrated that supplementation of 
smokers with vitamin E consistently reduced the LDL oxidizability (Princen et al, 
1992; Harats et al, 1990). On the other hand. Fuller et al (2000) initially 
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demonstrated that supplementation of young smokers with vitamin E showed a 
reduction in the lag phase of Cu"^ "^ -catalyzed LDL oxidation, whereas, vitamin C 
supplementation showed no effects on LDL oxidation. The combination of vitamins E 
and C did not provide any additional benefit to the smokers. Based on the results, 
Fuller et al. (2000) recommended that the only way for young smokers to reduce 
oxidative damage including premature CHD by tobacco is to quit smoking rather than 
to take antioxidant vitamin supplements. In only published report, Ismail et al. (2002) 
have demonstrated that daily supplementation of healthy male current smokers (25-45 
years; >5 smoking years) with 200 mg of Tocotrienol rich fraction (TRF) for 8 weeks 
significantly reduced the MDA release from intact erythrocytes, while, no change was 
observed in plasma MDA. On the other hand, TRF treatment to smokers caused a 
significant increase in erythrocytes associated SOD activity with a reduction in Gpx 
activity (Ismail et al., 2002). 
An encouraging development in the treatment and management of 
hyperlipidemia/dyslipidemia has been the introduction of a new class of ftingal-
derived compounds (statins) that are potent competitive inhibitors of HMG-CoA 
reductase, the rate controlling enzyme in the biosynthetic pathway for cholesterol. 
Statins have been widely used as the most potent class of drugs for the treatment of 
diabetes, CHD alone, diabetes with CHD, hypertriglyceridemia and combined 
hyperlipidemia (Maron et al, 2000; Vaughan et al., 2000; El-Swefy et al, 2000). 
Currently, statins including atorvastatin calcium (Lipitor) are quite effective lipid-
lowering agents and universally marketed and used by diabetic and nondiabetic 
dyslipidemic patients with or without CHD. However, statins as well as fibrates and 
bile acid sequesterants have been reported to exert a host of side effects (Haffner et 
at., 1998; Assmarm et al, 1998). In contrast, dietary tocotrienols have no toxicity and 
provide an effective lipid lowering property in addition to their potent antioxidant 
activity. Recently, our lab has demonstrated a strong hypoglycemic, antidiabetic, 
hypolipidemic and antioxidant effect of dietary tocotrienols (Tocomin) and lovastatin 
after a 14-week treatment of STZ-induced diabetic rats (Ali, 2007). The tocotrienol 
isomers (a-, P-, y- and 8-) are naturally occurring analogues of tocopherol isomers 
(Vitamin E) found mainly in cereal grains and palm oil. Tocotrienols differ from 
tocopherols by possessing three double bonds in the phytyl side chain (Fig. 1.5). 
Unlike tocopherols, tocotrienols have been shown to have an intrinsic 
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hypochlolesterolemic activity in animals and humans. The cholesterol lowering effect 
of tocotrienols was attributed mainly to their downregulation of HMG-CoA reductase-
the rate-limiting enzyme of the cholesterol biosynthetic pathway. The tocopherol 
isomers, on the other hand, do not inhibit cholesterol synthesis and thus do not lower 
serum cholesterol (Minhajuddin et al, 1999; Parker et al, 1993). Previously 
published reports indicate a strong hypolipidemic and antioxidant effect of tocotrienol 
rich fraction (TRF) or purified tocotrienols (Tocomin) in normolipidemic and 
hyperlipidemic rats (Beg et al, 1996; Minhajuddin et al, 1999; Minhajuddin et al, 
2005; Sharma and Rukmini, 1986 and 1987; Seetharamaiah and Chandrasekhara, 
1989; Watkins et al, 1993); normolipidemic and genetically hyperlipidemic swines 
and chickens (Qureshi et al, 1991c; Qureshi and Qureshi, 1993; Qureshi et al., 2000); 
hyperlipidemic rabbits (Tech et al., 1994); cholesterol/oxidized cholesterol-induced 
hyperlipidemic/atherosclerotic rabbits (Zainuddin, 2004; Zainuddin et al, 2006); and 
hyperlipidemic hamsters (Raederstroff et al, 2002). It has been earlier demonstrated 
that tocotrienols or TRF exhibits a strong hypolipidemic activity in normolipidemic 
and hyperlipidemic humans (Beg et al, 1995; Beg et al, 1996, Beg et al, 1997; 
Minhajuddin et al, 1999; Tan et al, 1991; Qureshi et al, 1991a, Qureshi et al, 1997; 
Qureshi et al, 2001b; Qureshi et al, 2002); and in a type II familial 
hypercholesterolemic patient with severe xanthomas (Beg et al, 1997). Our 
laboratory has demonstrated a strong hypolipidemic, antidiabetic and antioxidant 
impact of tocotrienols in type 2 diabetic patients with hyperlipidemia (Baliarsingh et 
al, 2005). Tomeo et al (1995) also reported that T3 significantly decreased plasma 
lipid peroxidation in patients with hyperlipidemia and carotid stenosis with no change 
in their lipid and lipoprotein parameters. It has been established that LDL-C/HDL-C 
and HDL-C/TC ratios are good predictors for the presence and severity of CAD 
(Drexel et al, 1992). Experiments involving the effects of T3 on apoB (LDL) and 
apoA-1 (HDL) and apoB/apoA-1 ratio have been reported in chickens, swine and 
humans. The apoB/apoA-1 ratio, considered being a better indicator than LDL-
C/HDL-C ratio, for assessment of CHD, was reduced in T3 treated subjects (Qureshi 
et al, 1991a). In addition, TRF treatment to hypercholesterolemic humans and type 2 
diabetic patients significantly improved the HDL/LDL and HDL-C/TC ratios 
(Qureshi et al, 2001a; Baliarsingh et al, 2005). Desmethyl tocotrienol and 
didesmethyl tocotrienol also mediated a significant decrease in serum TG, TC, LDL-
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C, apoB, Lp(a), platelet factor 4 and thromboxane B2 levels of hypercholesterolemic 
humans after a double blind, 12-week study (Qureshi et al, 1997). A dose-dependent 
effect of tocotrienol rich fraction containing mixture of the novel desmethyl- and 
didesmethyl tocotrienols (TRF25) has been investigated in hypercholesterolemic 
humans (Qureshi et al, 2002). The results showed that intake of a dose of 100 mg/day 
of TRF25 for 35 days caused maximum decrease in serum TC, LDL-C, apoB and TG 
levels when compared to baseline values (Qureshi et al, 2002). The synergistic effect 
of TRF25 has been reported in hypercholesterolemic humans. Administration of TRF 
in combination with lovastatin to hypercholesterolemic humans for 35 days exerted a 
synergistic lipid lowering effect, when compared to values obtained from subjects 
given TRF25 or lovastatin alone (Qureshi et al, 2001b). In hyperlipidemic patients 
with type 2 diabetes, low doses of pitavastatin (1 mg) and fenofibrate (100 mg) were 
both effective in decreasing sd-LDL-C concentration but via a different mechanisms: 
the former decreases total LDL including sd-LDL, while the latter decreased sd-LDL 
specifically (Tokuno et al, 2007). Recently, May et al (2008) demonstrates that, in 
diabetic patients with mixed dyslipidemia, combination therapy with simvastatin and 
fenofibrate had a greater positive effect on LDL cholesterol size profile, with a shift 
from more atherogenic sd-LDL-C to less atherogenic Ib-LDL-C, than either 
fenofibrate or simvastatin monotherapy. However, no one to date has studied a 
detailed and investigation pertaining to effect of cigarette smoke on cholesterol 
dynamics, overall oxidative status including the indices of free radical mediated 
lipid/lipoprotein peroxidation and status of enzymatic and nonenzymatic antioxidant 
defense system in plasma and erythrocytes, particularly, in vivo and in vitro 
oxidizability of more atherogenic sd-LDL, less atherogenic Ib-LDL, including LDL, 
and plasma HDL-associated arylesterase activity. We have thus investigated the 
hypolipidemic coupled with antioxidant property of tocotrienols (Tocomin) and 
Lovastatin in the alleviation of hyperlipidemia/ dyslipidemia and oxidative stress 
induced by cigarette smoke. 
38 
Scope of the Present Study 
1.6 Scope of the Present Study 
As discussed above, cigarette smoking is a major risk factor for tiie development 
of atherosclerosis, and is associated with coronary and peripheral vascular disease 
(Heitzer et al., 1996; Bamoya and Glantz, 2005; Neunteufl et a!., 2002). Cigarette 
smoke contains vast amount of both carbon-and oxygen-centered free radicals 
(10 per inhalation), which can directly and indirectly initiate and propagate the 
process of lipid peroxidation (Church et al, 1985). In addition, many compounds of 
cigarette smoke, such as nicotine and carbon monoxide have been reported to further 
increase the risk of CAD in chronic smokers (Caralis et al, 1992; Allred et al., 1989). 
Clinical studies also indicate that cigarette smoking alters plasma lipoprotein levels, 
which might help explain the increased incidence of CHD (Ambrose and Barua, 
2004). However, data pertaining to changes in plasma and lipoprotein lipids of 
smokers are conflicting. Significant increase m plasma TG, TC, VLDL-C and LDL-C 
with a decrease in antiatherogenic HDL-C was reported (Brischetto et al, 1983; 
Cariqui et al, 1986; Neki et al, 2002; Jaleel et al, 2007). Whereas, in other reports 
no significant alteration in the above lipid parameters of smokers were observed 
(Seppo et al, 2005; Neunteufl et al, 2000). The lower HDL-C concentrations in 
smokers compared with nonsmokers has been attributed to reduced HDL2-C 
(Moriguchi et al, 1990; Freeman et al, 1993; Shennan et al, 1985; Imamura et al, 
2002) HDL3-C (Haffner et al, 1985), or to both subfractions (Ito et al, 1995). Some 
studies (Haffher et al, 1985; Albers et al, 1982) reported that plasma 
lecithinxholesterol acyltransferase (LCAT) enzyme, which esterifies cholesterol on 
HDL (Franceschini et a/., 1991), was significantly reduced in smokers than 
nonsmokers, whereas others did not find significant differences in serum or plasma 
LCAT activity (Moriguchi et al, 1990; Ito et al, 1995; Dirican et al, 1999; DuUaart 
era/., 1994). 
Oxidative modification of LDL may be a key early step in the pathogenesis of 
atherosclerosis (Diaz et al, 1997). Evidence of oxidized LDL has been obtained from 
arterial walls of animal models of atherosclerosis and of CHD patients (Haberiand et 
al, 1988; Yla"-Herttuala et al, 1989). Cigarette smoke contains numerous free radical 
species that can contribute to the oxidation of LDL in vitro (Church and Pryor, 1985; 
Yokode et al, 1988; Santanam et al, 1997), although data are conflicting (Chen and 
Loo, 1995). LDL isolated from smokers may be more susceptible to oxidation than 
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LDL from nonsmokers (Scheffler et ai, 1990; Gouaze et ai, 1998), however, others 
did not find any difference in LDL oxidizability between smokers and nonsmokers 
(Siekmeier et al, 1996; Marangon et ai, 1997). Aqueous extracts of cigarette smoke 
can produce oxidative modification of LDL in vitro (Yokode et al., 1988; Kagota et 
al., 1996) and in vivo (Yamaguchi et al., 2000; Yamaguchi et al., 2001; Yamaguchi 
et al., 2004) in animal models. In addition, peroxynitrite generated in the extracts of 
cigarette smoke is involved in oxidative modification of apoB of LDL in vitro 
(Yamaguchi et al., 2002). It is possible that increased atherogenecity of LDL in 
smokers, as seen during diabetes, is associated with a preponderance of small dense 
(sd-) LDL subpopulation that is more susceptible to oxidative modification than large 
buoyant (lb-) LDL (Hirano et al., 2004; Tribble et ai, 1992; Tribble et al., 1994; 
Tribble et al., 2001). Several studies have reported a 2- to 3-fold increase in CHD 
risk among patients with a predominance of sd-LDL particles than those mainly 
consist of Ib-LDL particles (Austin et al., 1990; Austin et al., 1994). Similarly, 
Quebec cardiovascular study has confirmed that a predominance of sd-LDL is a 
strong and independent predictor of CHD in the first seven years of follow-up (St-
Pierre et al., 2005). Recently, Koba et al. (2006) have reported that the progression of 
CHD was closely linked not to the LDL particle size, but to the concentration of sd-
LDL. Therefore, sd-LDL has been highlighted as a new strong and useful marker for 
the risk of CHD. In the only published report, Mero et al. (1995) have demonstrated 
that prevalence of sd-LDL is increased in smokers. On the other hand, prevalence as 
well as concentration of sd-LDL was significantly increased in type 2 diabetic 
hyperlipidemic subjects with CHD, as well as in subjects with various types of 
hyperlipidemia with and vvithout CHD (Hirano et ai, 2004). However, considering 
the enhanced oxidizability and greater atherogenecity of sd-LDL subpopulation than 
Ib-LDL or LDL, its role in oxidative stress mediated dyslipidemia in young or chronic 
smokers has not yet been reported. Under normal circumstances, circulating LDL is 
protected from oxidative stress by HDL-associated enzymes, particularly paraoxonase 
(PON)/arylesterase acfivity, which destroys biologically active phospholipids 
(Mackness et ai, 1996). In vitro studies showed that extracts of cigarette smoke 
inhibited the enzymatic activity of PON (Blatter et al., 1993). In addition, other 
studies showed that smoking was independently associated with reduced serum 
PON/arylesterase activity (Solak et al., 2005) as well as it's concentration in patients 
with CHD, which increased the risk of CAD due to an apparently decreased capacity 
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to protect lipoproteins from oxidative stress (James et al, 2000). However, a detailed 
investigation pertaining to atheroprotective role of plasma HDL and its subfractions 
HDL2 and HDL3 on ex vivo and in vitro Cu'^ '^^ -mediated oxidizability of LDL from 
smokers has been lacking. The involvement of increased oxidative stress in smokers 
is supported by an increased concentration of lipid peroxidation product, 
malondialdehyde (MDA), and decreased levels of antioxidants in the plasma of 
smokers (Solak et al, 2005; Bloomer, 2007; Lykkesfeldt, 2007; Bloomer et al., 
2008). However, several studies showed a nonsignificant increase in MDA in smokers 
vs. nonsmokers (Nielsen et al., 1997; Celec et al., 2005). The levels of reactive 
oxygen species (ROS) are controlled by antioxidant enzymes, SOD, catalase, Gpx, 
Gred and nonenzymatic scavengers such as GSH. An impaired radical scavenger 
function has been linked to decreased activity of enzymatic and nonenzymatic 
scavengers of free radicals. Reports about the status of antioxidants and scavengers as 
defense mechanism in smokers are very contradictory (Church and Pryor, 1985), 
increase, decrease or no change in their levels in erythrocytes of smokers have been 
reported (Kocyigit et al., 2001; Solak et al., 2005; Ozguner et al., 2005; Sohn et al., 
1993; McCuster and Hoidal, 1990; Yokus et al., 2005; Sulochana et al., 2002). 
In the second part of the thesis, male albino rats exposed to cigarette smoke 
for 30 min on daily basis, for 4 weeks, have been used to define mechanism(s) and 
explore other proatherogenic changes that are unavailable from young smokers. In a 
previously published report, male albino rats exposed to cigarette smoke for 4 weeks 
exhibited a significant increase in lipid peroxidation products viz., conjugated diene, 
hydroperoxide and MDA of liver, kidney, heart and lung, while enzymatic activities 
of SOD, CAT, GPx and GST in the these tissues were significantly reduced 
(Binduand Annamalai, 2004). In another report (Helen and Vijayammal, 1997), 
conjugated diene, hydroperoxide, MDA and free fatty acid (FFA) levels were 
significantly increased in the liver of rats exposed to cigarette smoke for 90 days. 
Similarly, liver Gpx and GSH content was increased, while activities of scavenging 
enzymes, SOD, CAT and Gred were significantly reduced in smoke stressed rats 
(Helen and Vijayammal, 1997). 
Although lipid oxidation in the vessel wall is thought to occur as a result of 
local deficiency of endogenous antioxidants or excess of free metal ions, only limited 
data support these hypotheses (Fuller and Jialal, 1997; Stephens et al., 1996). 
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Research has also shown that human atherosclerotic plaques contain massive amounts 
of lipid peroxidation products, despite the presence of large quantities of a-tocopherol 
(vitamin E) and vitamin C (Suama et ai, 1995), Thus, it is unclear whether oxidized 
lipoprotein originate in the arterial wall or are produced in the circulation and then 
enter the intimal space. In smokers the risk of CHD would be exacerbated further by 
the presence of significantly lower plasma concentrations of antioxidant nutrients, 
which are destroyed by the free radicals present in cigarette smoke (Bridges et a!., 
1990; Handelman et al., 1996). Few scattered reports demonstrated that 
supplementation of smokers with vitamin E consistently reduced the LDL 
oxidizability (Princen et al, 1992; Harats et al, 1990). On the other hand. Fuller et al. 
(2000) initially demonstrated that supplementation of young smokers with vhamin E 
(400 lU/day) showed a reduction in the lag phase of Cu^-catalyzed LDL oxidation, 
whereas, vitamin C (1000 mg/day) supplementation showed no effects on LDL 
oxidation. The combination of vitamins E and C did not provide any additional 
benefit to the smokers. Based on their results Fuller et al. (2000) recommended that 
the only way for young smokers to reduce oxidative damage including premature 
CHD by tobacco is to quit smoking rather than to take heavy dose of antioxidant 
vitamin supplements. In an only published report, Ismail et al. (2002) have 
demonstrated that daily supplementation of healthy male current smokers (25-45 
years; >5 smoking years) with 200 mg of tocotrienol rich fraction (TRF) for 8 weeks 
significantly reduced the MDA release from intact erythrocytes, while no change was 
observed in plasma MDA. On the other hand, TRF treatment to smokers caused a 
significant increase in erythrocytes associated SOD activity with a reduction in Gpx 
activity (Ismail et al, 2002). 
Based on the above information, intervention trials involving nutrients/drugs 
having both hypolipidemic as well as antioxidant properties, such as dietary 
tocotrienols (Tocomin), have not been used to alleviate the multiple complications 
associated with oxidative stress and dyslipidemia in young smokers, that is, those 
who have been smoking for less then 5 years. In addition, no one to date has studied a 
detailed and coordinated investigation pertaining to effect of cigarette smoke on 
cholesterol dynamics, overall oxidative status including the indices of free radical 
mediated lipid/lipoprotein peroxidation and status of enzymatic and nonenzymatic 
antioxidant defense system in plasma and erythrocytes, particularly, in vivo and in 
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vitro oxidizability of more atherogenic sd-LDL, less atherogenic Ib-LDL, including 
LDL, and plasma HDL-associated arylesterase activity. We have thus investigated the 
hypolipidemic and antioxidant impacts of dietary tocotrienols (Tocomin) 
supplementation in young smokers and compared them w i^th placebo treated smokers. 
During the 8-week treatment phase, smokers, on daily basis, received three capsules, 
each containing 50 mg Tocomin, enriched with a-, P-, y- and 6-tocotrienols and 29.90 
lU of a-tocopherol. Smokers assigned to the placebo group received three capsules, 
each containing 29.90 lU of a-tocopherol. Protective effect of Tocomin on the 
concentrations of blood nicotine and carboxyhemoglobin was examined. The 
protective efficacy of Tocomin supplementation on plasma total lipid, TG, FFA, TC, 
VLDL-C, LDL-C, sd-LDL-C, Ib-LDL-C, HDL-C, and its subfractions, HDL2-C and 
HDL3-C, and non-HDL-C was investigated. In addition, quantification of cholesterol 
and apoB content in LDL and its subfractions, sd-LDL and Ib-LDL of smokers treated 
with and without Tocomin has been done. The effect of cigarette smoke on plasma 
total antioxidants; plasma, HDL-C, HDL2-C and HDL3-C associated arylesterase 
activity, erythrocytes and plasma lipid peroxidation products, that is, conjugated 
diene, lipid hydroperoxide and MDA as well as MDA release in intact erythrocytes 
was determined. In treated smokers, therapeutic role of Tocomin in the amelioration 
of the above parameters was investigated. Moreover, antioxidant impact of Tocomin 
on base line levels of ex vivo diene conjugation and lag phase time of in vitro Cu^-
induced oxidation of more atherogenic sd-LDL, Ib-LDL including LDL was 
undertaken. In addition, protective role of plasma HDL2 and HDL3 subfractions of 
HDL on in vitro Cu^^-mediated oxidizability of LDL isolated from plasma of normal 
subjects, smokers, placebo and Tocomin treated smokers was also determined. The 
efficacy of dietary tocotrienols in the protection and normalization of the altered 
enzymatic and nonenzymatic antioxidant defense system in erythrocytes of smokers 
was also investigated. 
In order to understand the mechanism(s) of lipid lowering action of dietary 
tocotrienols, at the level of hepatic HMG-CoA reductase as well as their protective 
effect on enzymatic and nonenzymatic antioxidant defense system including lipid 
peroxidation in liver, lung and kidney, we have used rats exposed to cigarette smoke 
for 4 weeks. For comparative purposes, smoke exposed rats were also administered 
Lovastatin, a widely used hypolipidemic drug with some known antioxidant property 
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(Chen et al, 1997; Singh et ai, 1997). In addition, in this animal model we 
investigated the efficacy of antioxidant and hypolipidemic agents Tocomin and 
Lovastatin by analyzing all the parameters in plasma and erythrocytes, including 
plasma and lipoprotein lipids, erythrocytes lipid peroxides and differential in vivo and 
in vitro oxidizability of highly atherogenic sd-LDL, less atherogenic Ib-LDL as well 
as LDL, as investigated in young smokers treated with and without Tocomin. 
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MATERIALS 
2.1.1 Chemicals 
The chemicals and reagents were obtained from various sources listed below. 
Chemical Source 
1- Chloro 2, 4-Dinitrobenzene 
1,1,3, 3-Tetra Methoxy Propane 
2, 2-Diphenyl-l-Picryl Hydrazyl 
2,4, 6-Tripyridyl-s-Triazine 
Bovine Serum Albumin 
Butylated Hydroxyl Toluene 
Cholesterol (Extra pure) 
Coommassie Brilliant Blue G 250 
Dextran Sulfate 
Digitonin 
5, 5'-Dithiobis (2-Nitrobezoic Acid) 
Glutathione Oxidized 
Glutathione Reduced 
Hemoglobin Assay Kit 
Hydroxylamine Hydrochloride 
NAD? 
NADPH 
Nitroblue Tetrazolium Salt 
Nicotine 
Palmitic Acid 
Phenazine Methosulfate 
Central drug house, Pvt. Ltd., India 
Sigma-Aldrich Inc., USA 
Sigma-Aldrich Inc., USA 
HiMedia Laboratories Pvt. Ltd., India 
Miles Ltd. Inc., USA 
HiMedia Laboratories Pvt. Ltd., India 
Sisco Research Laboratories Pvt. Ltd., India 
Ployscience Inc., USA 
Sigma-Aldrich Inc., USA 
Central drug house, Pvt. Ltd., India 
Sisco Research Laboratories Pvt. Ltd., India 
Sisco Research Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
Ranbaxy Diagnostics, India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
Acros Organics, USA 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
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Phenyl Acetate 
Phosphotungstic Acid 
Rat Chow 
Sodium Diethyl Dithiocarbamate 
Sodium Dithionate 
Sodium Dodecyl Sulfate 
Sodium pyrophosphate 
Thiobarbituric Acid 
Thiocyanate 
Triethanol amine 
Triphenyl Phosphine 
Triglyceride Assay Kit 
Xanthine 
Xylenoi Orange 
Sigma-Aldrich Inc., USA 
Loba Chemie, India 
Ashirwad Industries, Chandigarh, India 
HiMedia Laboratories Pvt. Ltd., India 
Central drug house, Pvt. Ltd., India 
Bio-Rad Laboratories, USA 
HiMedia Laboratories Pvt. Ltd., India 
Sigma-Aldrich Inc., USA 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
Recombigen Laboratories, India 
HiMedia Laboratories Pvt. Ltd., India 
HiMedia Laboratories Pvt. Ltd., India 
Twenty five percent palmvitae oil suspension of tocotrienols containing d-a-
tocopherol and purified individual d-a-tocotrienol (80 %), d-y-tocotrienol (90 %), d-5-
tocotrienol (60 %) and d-a-tocopherol (60 %) as well as RBD palm olein were 
supplied as a gift from CAROTECH BHD, Chemor, Malaysia. Tocomin*^ suspension 
(250 mg/g) contained 6.4 % d-a-tocotrienol, 1 % d-P-tocotrienol, 10.2 % d-y-
tocotrienol, 3.2 % d-5-tocotrienol and 5.7 % d-a-tocopherol. And also supplied softgel 
capsules (TOCOVID™ Supra Bio^^, with its new biooptimum absorption system, 
provides 200 % to 300 % higher absorption of its natural combination of 
phytonutrients in our body), each contains 50 % Tocomin" ,^ in which d-a-tocotrienol 
(15.38 mg), d-y-tocotrienol (28.20 mg), d-5-tocotrienol (6.42 mg) and d- a-tocopherol 
(15.32 mg or 29.90 lU). Cholesterol lowering drug, Lovastatin, was a gift from 
Saimira Innoform Pvt. Ltd., Chennai, India. 
All other chemicals and reagents used in this study were of analytical grade. 
46 
Experimental 
• 
2.1.2 Animals 
Male albino rats, weighing about 180-200 g were purchased from Indian 
Veterinary Research Institute, Barielly, India, were maintained to animal house 
environmental condition prior to the experiment. 
2.1.3 Diet/Exposure to cigarette smoke 
The rats were given pelleted rat chow and water ad libitum. Experimental rats 
from respective groups were administrated with Tocomin and Lovastatin. Both 
Tocomin (600 mg) and Lovastatin (50 mg) were solubilised in 5 ml ethanol and 
diluted to 100 ml in palmvitae oil. Tocomin and Lovastatin suspension was 
administrated through gastric intubation in two divided doses (morning and eveninig) 
of 0.5 ml each/rat/day. Exposure to cigarette smoke was done in morning by keeping 
two rats in bottomless metallic container (10 x 11 x 16 inch), having two holes of 3 
and 1.5 cm diameter, one on the either side. A burning cigarette was introduced 
through one hole (3 cm) and the other hole (1.5 cm) was used for ventilation. Animals 
were exposed to cigarette smoke for 30 min, daily for 4 weeks with interval of 10 min 
between each 10 min exposure, using 3 cigarettes/day/2 rats in each group. 
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2.2.1 Experimental Design 
2.2.1.1 Subjects and Study Design 
The study protocol was approved by the Board of Studies, Department of 
Biochemistry at J.N Medical College, A.M.U, Aligarh. Healthy male young smokers 
and nonsmokers were recruited from the university student body. Informed consent 
from study enrollment was obtained from each of the study subjects. The average age, 
body mass index (BMI), duration of smoking and number of cigarette smoked per day 
of 36 smokers was 23.22 ± 2.16 years, 20.74 ± 1.21BMI, 4.72 ± 0.931 years and 
12.82 ±2.16 per day, respectively. Twelve nonsmokers used in the study as a control, 
were not exposed to passive smoke at work or at home. The average age of 
nonsmokers was 22.92 ± 0.685 years, whereas average BMI was 23.82 ± 3.32. All the 
subjects in the study were healthy, with normal blood pressure (B.P) and had no 
reported systemic disease. All subjects declared in the questionnaire where ethnically 
homogenous, with similar nutritional habits, free from alcohol consumption, did not 
active exercise, and were drinking a maximum of 3-4 cups of tea a day. The study 
subjects declared no vitamin intake three month before the initiation of the study. 
During recruitment of the smokers and before the initiation of clinical trial, blood 
samples were drawn, from 6 smokers at a time, on weekly basis, in the morning after 
overnight fasting before any smoking. Ten ml of whole blood was withdrawn from an 
antecubital vein of each subject and was transferred into a heparinised glass tube. 
Plasma was collected by centrifiigation and used for the analysis of TG, TC, VLDL-
C, LDL-C, small dense (sd-) LDL-C, large buoyant (lb-) LDL-C and HDL-C. The 
average age, BMI, smoking index, and above plasma and lipoprotein lipid parameters 
are summarized in Table 1. Since, initial screening recruitment of smokers (n=36) and 
nonsmokers (n=12) and analysis of their lipid parameters consumed several months, 
baseline plasma and lipoprotein lipid were analyzed again before initiation of clinical 
trial. Based on the entry point plasma average TG, TC, VLDL-C, LDL-C, sd-LDL-C, 
Ib-LDL-C, HDL-C, HDL2-C, HDL3-C levels, 36 smokers participants were divided 
into two group of eighteen each. The 12 nonsmoker subjects were used as normal 
control (Table 2). The subjects were then randomly assigned to receive either one of 
the following treatment in a single-blind fashion: In placebo treated group, each 
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subject received three capsules daily for eight weeks, each containing a dose of 15.32 
mg (29.91 lU) d-a-Tocopherol, which is equivalent to the concentration d-a-
tocopherol present in Tocomin. In Tocomin treated group, 18 smokers received three 
Tocovid capsules daily for eight weeks. Each capsules containing 50 mg of Tocomin, 
which provided d-a-tocotrienol (15.38mg), d-y-tocotrienol (28.20mg), d-6-tocotrienol 
(6.42mg) and 29.91 lU (15.32 mg) d-a-tocopherol. The subjects in both the groups 
were instructed to take their supplements, thrice a day, with a meal to reduce any 
possible gastrointestinal side effects and to increase absorption of Tocotrienols/a-
tocopherol. The subjects followed their usual diet, activity and smoking habits, at the 
end of eight weeks, another fasting blood sample was drawn. Compliance was 
measured by pill counts on weekly basis and at the end of the study. 
2.2.1.2 Studies in rats 
For investigating the hypolipidemic and antioxidant effect of Tocomin and 
Lovastatin, rats were divided in the following groups as described below: 
=> Normal Control (N-C) 
Seven rats were given 1.0 ml palmvitae oil through gastric intubation for four weeks. 
=> Smoke Exposed Control (S-C) 
Seven rats in this group were administrated I.O ml palmvitae oil though gastric 
intubation for four weeks. 
=> Smoke Exposed Tocomin Treated (S-T3T) 
Seven rats in this group were given 6.0 mg Tocomin/rat/day, through gastric 
intubation for four weeks. 
=> Smoke Exposed Lovastatin Treated (S-LT) 
Seven rats in this group were given 0.50 mg Lovastatin/rat/day, through gastric 
intubation for four weeks. 
2.2.2 Analytical Procedures 
2.2.2.1 Collection of blood and packed erythrocytes 
At the end of the experiment treatment, overnight fasted rats in each group 
were anaesthetized and blood drawn from cardiac puncture. The blood from each rat 
in a given group was collected in heparinised tubes, mixed gently by inversion 2-3 
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times and incubated at 4*^ 0 for 2-3 h. Plasma was separated from blood by 
centrifiigation at 2,500 rpm for 30 min, aliquoted and either stored at 4°C or frozen at 
-IQpC for use in other experiments. 
Packed erythrocytes hemolysate was prepared as described by Lakshmi and 
Rajagopal (1998). After the separation of plasma and buffy coat, the packed 
erythrocytes obtained were washed thrice with physiological saline and a portion of 
washed erythrocytes was lysed in hypotonic (lOmM) sodium phosphate buffer, pH 
7.4. A portion of the washed packed erythrocytes was stored at 4°C for fiiture use. 
2.2.2.2 Preparation of liver, lung and kidney homogenate and post-mitochondrial 
supernatant 
At the end of the experiment, liver, lung and kidney from each rat were 
promptly excised and chilled in ice cold saline. After washing with saline, liver, lung 
and kidney were blotted and weighed. Each liver, lung and kidney were cut into 
pieces, mixed and 10 g of wet tissue was homogenized with 90 ml of chilled 0.1 M 
sodium phosphate buffer, pH 7.4, containing 1.17 % KCl in a waring blender. The 
volume of each homogenate was recorded and centrifuged at 1,000 rpm for 10 min at 
4°C. After centrifiigation, a portion of each homogenate fi-om liver, lung and kidney 
thus obtained was aliquoted and stored at -20*'C. The remaining portions of the liver, 
lung and kidney homogenates were centrifuged atl2, 000 rpm for 20 min at 4°C. The 
post-mitochondrial supernatant thus obtained was aliquoted and stored at -20°C for 
future use. 
2.2.2.3 Determination of nicotine contents in blood 
Nicotine content in blood samples was determined by the method of Varley 
and Gowenlock (1976). One ml fresh blood was collected in heparinised tubes; pH 
was adjusted to 9-10 by adding ammonium hydroxide (0.1 %) and then extracted 3 
times with 5 ml chloroform. The chloroform extract was washed once with 5 ml 
water, extracted with 5 ml dilute sulfiaric acid (0.5 M), pH was adjusted to 10 using 
ammonium hydroxide (0.1 %), then extracted 3 times with 5 ml chloroform, washed 
once with 5 ml water and dried by adding 1 gm anhydrous sodium sulphate. The 
solution was filtered and the optimal density of the filtrate was read at 260 nm. 
Nicotine standard was treated in the similar manner and used in the calculation of 
nicotine present in the blood samples. 
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2.2.2.4 Determination of carbon monoxide saturation in a mixture contain 
hemoglobin (Hb) and carboxy hemoglobin 
Carbon monoxide Satiiration in blood samples was determined by the method 
of Varley and Gowenlock (1976). 0.1 ml heparinised blood was mixed with 20 ml of 
0.1 % ammonia and 20 mg of sodium dithionate were added to convert Hb02 to Hb 
the optimal density was measured at 538 nm and 578 nm (isobestic wavelength) 
L=1.0 cm, slit width 0.02nm, the measurement was carried out within 10 min of the 
addition of sodium dithionate. The Carbon monoxide Saturation was calculated from 
the equation. 
SCO % = (2.44 D " V D " * - 2 . 6 8 ) 100 
The constants 2.44 and 2.68 have been calculated from a series of 30 measurements of 
Q538/ p578 Q^ Q o/„ HbCO (100 % Hb) and 100 % HbCO. The isobestic point was 
established at X= 578 ± 0.5 nm (n=100). 
2.2.2.5 Determination of free radical scavenging activity (antioxidant capacity) of 
Tocomin, a-tocotrienol, y-tocotrienol, 6-tocotrienoI and a-tocopherol 
The procedure of Mellors and Tappel (1966) as modified by Khanduja and 
Bhardwaj (2003) was used for determining the free radical scavenging activity of 
Tocomin, a-Ta, y-Ts, 6-T3, and a-T. The assay was carried out in a medium containing 
40 mM tris buffer, pH 7.4 and 125 ^M ethanolic solution of 2, 2-diphenyl-l-picryl 
hydrazyl (DPPH). The reaction was started by the addition of ethanolic solution of 
Tocomin, a-Ts, y-Ta, 5-T3, and a-T (25-200 i^ M) in a total volume of 2 ml. The 
samples were mixed thoroughly and the absorbance was recorded in dark at 517 nm 
(27 ± 2°C) at 1 min time interval up to 10 min against absolute ethanol. A control 
blank containing all the above ingredients except the test compounds was used in 
order to monitor the absorption of DPPH. The percent inhibition of the DPPH by the 
above antioxidants was calculated according to the formula reported by Yen and Duh 
(1994). 
2.2.2.6 Determination of plasma triglycerides 
Triglycerides were determined by using enzymatic kit. The method uses a 
modified Trinder color reaction to produce a fast, linear, end point reaction (Trinder, 
1969). The intensity of the color produced after incubation is directly proportional to 
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the concentration of the triglycerides in the plasma samples when measured at 500 
nm in a Beckman DU 640 spectrophotometer. Triglycerides in plasma samples were 
calculated by using a triolein standard. 
Plasma very low density lipoprotein-cholesterol (VLDL-C) was calculated by 
dividing plasma triglycerides values (mg/dl) by a factor of 5 as described by 
Friedewalde/a/. (1972). 
2.2.2.7 Determination of plasma free fatty acid 
Free fatty acid in plasma was estimated as described by Duncombe (1963). 
The procedure of Folch et al. (1957) was used for extracting free fatty acid from 
plasma lipids. Fifty microliter of plasma was mixed with 2.5 ml of chloroform: 
methanol (2:1), followed by centrifiigation at 1,000 rpm for 5 min to separate the 
phases, most of the upper layer was removed and 1.5 ml of the lower chloroform 
layer was recovered. Chloroform layer was placed in a test tube and incubated at 
45*'C till dryness. Lipid residue were dissolved in 500 \A of chloroform and to this 2.5 
ml of copper reagent, prepared by mixing 9 vol of aqueous 1 M triethanol amine, 1 
vol of IN acetic acid and 10 vol of 0.269 M copper nitrate was added. The tubes were 
vortexed for at least 2 min and centrifiiged at 3,000 rpm for 5 min to separate the 
phases clearly. The supernatant aqueous phase was removed and 0.1 ml of chloroform 
layer was taken in triplicate into clean dry tubes. Then, 1.0 ml of (0.05 % w/v) 
sodium diethyl dithiocarbonate, prepared in butanol and used within 7 days, was 
added to the chloroform solution and mixed. The absorbance was recorded at 440 rmi 
against a reagent blank in Beckman DU 640 spectrophotometer. The free fatty acid 
content was calculated by using palmitic acid as a standard, after subjecting it to the 
same procedure. 
2.2.2.8 Fractionation of plasma lipoproteins 
The precipitation method described by Wieland and Seidel (1989) was used 
for the isolation of plasma low density lipoprotein (LDL). The precipitation buffer 
consisted of 64 mM trisodium citrate adjusted to pH 5.05 with 5 N HCL, containing 
50,000 lU/L heparin. Before precipitation of LDL, plasma samples and precipitation 
reagent were allowed to equilibrate to room temperature. One ml of plasma sample 
was added to 7.0 ml of heparin-citrate buffer. After mixing with a vortex mixer, the 
suspension was allowed to stand for 10 min at 22°C. The insoluble LDLs were then 
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sedimented by centrifugation at 1,500 rpm for 10 min at 22°C. The pellet was 
resuspended in 1.0 ml of 0.1 M sodium phosphate buffer, pH 7.4, containing 0.9 % 
NaCl. 
The method for the isolation of small dense (sd-) LDL and large buoyant (lb-) 
LDL from isolated LDL is based on the two-step procedure of Hirano et al. (2004), 
which employs quantification of sd-LDL from senmi by heparin-Mg^* precipitation. 
In our modified method of sd-LDL and Ib-LDL isolation, 0.1 ml of precipitation 
reagent containing 15 lU of heparin and 90 mM MgCl2 was added to 0.1 ml of 
isolated LDL sample as described above. After mixing, the sample was incubated at 
37°C for 10 min. Then each sample was incubated in an ice-bath for 15 min and 
centrifiiged at 10.000 rpm for 15 min at 4°C. The supernatant containing sd-LDL was 
carefiilly removed and saved. The pellet containing Ib-LDL was dissolved in 0.1 M 
sodium phosphate buffer, pH 7.4, containing 0.9 % NaCI. Appropriate aliquots of 
LDL, sd-LDL and Ib-LDL fractions were used for the analysis of their cholesterol and 
apoB content. 
The dual precipitation method of Patsch et al. (1989) was used for the 
isolation of high density lipoprotein (HDL), HDL2 and HDL3 subtractions. According 
to this method 100 \i\ of reagent containing 1.0 g of dextran sulfate dissolved in 100 
ml of 0.5 mM MgC^ solution was added to 1.0 ml of plasma, and vortexed-mixed for 
3 sec. After an incubation period of 10 min at 22'^ C, the mixture was centrifiiged at 
1500 rpm for 15 min at 22°C and the supernatant containing HDL was removed. The 
clear supernatant was used for the analysis of HDL-C as well as for the isolation of 
HDL2 and HDL3 subtractions. For HDL fraction, 100 ^1 of reagent containing 1.0 g 
of dextran sulfate dissolved in 100 ml of 1.5 mM MgCl2 solution was added to i.O ml 
of HDL supernatant, and vertexed-mixed for 3 sec. Following an incubation of 10 
min at 22''C, the mixture was centrifiiged at 1500 rpm for 20 min at 22°C and the 
supernatant containing HDL3 fraction was removed, whereas the HDL2 precipitate 
was dissolved in 0.1 M sodium phosphate buffer, pH 7.4, containing 0.9 % NaCl. 
2.2.2.9 Determination of plasma cholesterol 
Total cholesterol in plasma, LDL, sd-LDL, Ib-LDL, HDL, HDL2 and HDL3 
subtractions was determined as described by Annino and Giese (1976), with a minor 
modification. For the determination of cholesterol in plasma and lipoproteins, 0.1 
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volume of plasma was mixed with 1 volume of isopropanol, allowed to stand for 5 
min and centrifuged at 3,000 rpm for 10 min. A suitable aliquot of isopropanol extract 
was used for cholesterol determination in a total volume of 0.75 ml. To each tube 
0.25 ml of 7.03 mM ferric chloride dissolved in glacial acetic acid, was added, mixed 
instantly, followed by the addition of 0.8 ml of sulphuric acid with thorough mixing. 
After 5 min, the absorbance was read at 550 nm in a Beckman DU 640 
spectrophotometer. The cholesterol content in the samples was determined by using a 
cholesterol standard. 
2.2.2.10 Measurement of ex vivo and in vitro Cu^-mediated susceptibility of 
LDL, sd-LDL and Ib-LDL to oxidation 
The ex vivo and in vitro Cu" -^mediated susceptibility of isolated LDL, sd-
LDL and Ib-LDL to oxidation was assessed by determining the lag phase of 
conjugated diene formation using the method of Esterbauer et al. (1989; 1992). Prior 
to oxidation studies LDL, sd-LDL and Ib-LDL samples were dialyzed against 5 mM 
phosphate buffer saline (PBS), pH 7.4, for 12 h. The incubation mixture contained 50 
\ig of LDL, sd-LDL or Ib-LDL in 1.0 ml of 10 mM PBS, pH 7.0. At time zero, before 
the initiation of Cu'^ -mediated oxidation, 1.0 ml aliquot of each sample was added to 
a tube containing 0.5 )JM EDTA, pH 7.4, for the assessment of ex vivo levels of 
conjugated diene. At zero time, another 600 \x\ (30 \ig) aliquot was added to a tube 
containing 0.6 ^M BHT and stored at 4°C, which were used for the determination of 
ex vivo level of lipid hydroperoxide. Then, lipoprotein samples were mixed with 
CUSO4 to a final concentration of 2.5 |iM and incubated at 37°C. In one series, at 
different time intervals of oxidation, 1.0 ml aliquots from LDL, sd-LDL and Ib-LDL 
incubation mixture were taken out, mixed with 0.5 mM EDTA, pH 7.4, stored at 4°C 
and used for the assessment of conjugated diene. The oxidation for LDL and Ib-LDL 
was carried out for 12 h, whereas for sd-LDL for 30 min. In another series, for the 
analysis of lipid hydroperoxide formation, 600 \i\ aliquots were added to tubes 
containing 0.6 ^M BHT, mixed and stored at 4''C. LDL, sd-LDL and Ib-LDL The 
formation of conjugated diene in each aliquot was measured by monitoring 
absorbance at 234 nm in a Beckman DU 640 spectrophotometer. Conjugated diene 
was calculated by using an extinction coefficient of 2.52 x lO'* M"' cm"' and 
expressed as nmole malondialdehyde (MDA) equivalent per mg LDL, sd-LDL or Ib-
LDL protein. 
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For the measurement of basal and Cu"'"'-induced generation of lipid hydroperoxide, 5 
volume of chloroform: methanol (2:1) was added to the samples, vortexed and 
centrifuged at 3,000 rpm for 10 min. Chloroform layer of each sample was taken out 
in a tube containing 0.6 jiM BHT, dried at 45°C and residues were dissolved in 
methanol. The assay was done according to the method of Nourooz-Zadeh et al. 
(1996) with minor modification. Ninety microliter of these samples in triplicate were 
transferred to microcentrifuge tubes, pre incubated for 5 min at 30^C, followed by the 
addition of 900 fal of a reagent containing 250 \xM ammonium sulphate, 100 \\M. 
xylenol orange, 25 mM sulphuric acid and 4 mM BHT in 90 % methanol. The 
samples were incubated either for 60 min at SO'^ C or, for 60 min at 4'^ C (used as 
control) and the absorbance was read at 560 nm in Beckman DU 640 
spectrophotometer. The levels of lipid hydroperoxide in lipoprotein samples were 
determined using the difference between mean absorbance of samples and control 
values. Hydroperoxide contents were determined using a molar absorption coefficient 
of 4.3 X 10" M"' cm''. The MDA in LDL, sd-LDL and Ib-LDL were assayed by the 
method of Niehaus and Samuelsson (1968). Briefly, 0.3 ml of LDL, sd-LDL and Ib-
LDL mixture in triplicate was thoroughly mixed with 2 ml of TCA-TBA-HCL 
reagent containing 15 % trichloroacetic acid, 0.375 % thiobarbituric acid and 0.25 N 
hydrochloric acid. The solution was heated for 15 min in a boiling water bath. After 
cooling, the flocculent precipitate was removed by centrifiagation at 1000 rpm for 10 
min. The absorbance of the samples was determined at 535 nm against a blank that 
contained all the reagents except the LDL, sd-LDL or Ib-LDL. The MDA 
concentration of the samples was calculated by using an extinc^on ,^qg)(sffi^ iwBft^ L56 x 
10^M"'cm"'). 
2.2.2.11 Measurement of m vitro Cu^*-mediated oxidatiob tlFLBL^ih the absl^nce 
or presence of HDL2 or HDL3 subfractions of Hti^L 
This was performed as described by Esterbauer et al. (1989iJ592is?Sife in 
vitro Cu'^ '^ -mediated susceptibility of isolated LDL to oxidation was assessed by 
determining the formation of conjugated diene. Prior to oxidafion studies LDL 
samples were dialyzed against 5 mM phosphate buffer saline (PBS), pH 7.4, for 24 h. 
The incubation mixture contained LDL (2.5 mg TC/dl) in the absence or presence of 
HDL2 (1.5 mg TC/dl), two concentrafion of HDL3 (1.5 mg TC/dl or 2.5 mg TC/dl), 
LDL in 1.0 ml of 10 mM PBS, pH 7.0. At time zero, before the initiation of Cu"^ "^ -
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mediated oxidation, 1.0 ml aliquot of each sample was added to a tube containing 0.5 
laM EDTA, pH 7.4, for the assessment of ex vivo levels of conjugated diene. Then, 
lipoprotein samples were mixed with CUSO4 to a final concentration of 2.5 ^M and 
incubated at ST^C. In one series, at different time intervals of oxidation, I.O ml 
aliquots from LDL incubation mixture were taken out, mixed with 0.5 mM EDTA, 
pH 7.4, stored at 4°C and used for the assessment of conjugated dienes. The oxidation 
for LDL was carried out for 12 h. The formation of conjugated dienes in each aliquot 
was measured by monitoring absorbance at 234 nm in a Beckman DU 640 
spectrophotometer. Conjugated dienes was calculated by using an extinction 
coefficient of 2.52 x 10'* M"' cm'' and expressed as nmole MDA equivalent per mg 
LDL protein. 
2.2.2.12 Measurement of plasma "total antioxidant power" (FRAP) 
The method of Benzie and Strain (1996) was used for measuring the ferric 
reducing ability of plasma, the FRAP assay, which estimate the "total antioxidant 
power", with minor modification. Ferric to ferrous ion reduction at low pH results in 
the formation of a colored ferrous-tripyridyl triazine complex. The assay was carried 
out in a total volume of 1.0 ml containing a suitable aliquot of plasma in 0.1 ml and 
900 |al of freshly prepared FRAP reagent, prepared by mixing 10.0 ml of 22.78 mM 
sodium acetate buffer, pH 3.6, 1.0 ml of 20 mM ferric chlorided and 1.0 ml of 10 mM 
2, 4, 6-tripyridyl-s-triazine solution prepared in 40 mM HCl. Before starting the 
reaction, both FRAP reagent and plasma samples were pre incubated for 5 min at 
30*^0. Incubation was done for 5 min at 30^0 and absorbance was recorded at 593 nm 
against a reagent blank in a Beckman DU 640 spectrophotometer. Ferrous sulphate 
was used as a standard for calculating the "total antioxidant power". 
2.2.2.13 Assay of arylesterase activity in plasma and HDL 
Plasma and HDL arylesterase activity was determined by the method of 
Ayub et al. (1999) by using phenyl acetate as the substrtate. The reaction mixture 
included 100 mM tris buffer, pH 8.0, 1 mM CaCli, suitable aliquots of plasma and 1 
mM phenyl acetate. After 5 min pre incubation at 25°C, the reaction was started by 
the addition of phenyl acetate and the samples were incubated for different time 
intervals at 25*^0. The initial rates of hydrolysis (within linear range) were determined 
spectrophotometrically at 270 nm against a reagent blank. Nonenzymatic hydrolysis 
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of phenyl acetate was substracted from the total rate of hydrolysis. Arylesterase 
activity in the above samples was calculated by using the molar extinction coefficient 
of 1.31 X 10^M"'cm''(LaDuandEckerson, 1984). 
2.2.2.14 Assay of xanthine oxidase activity 
Xanthine oxidase activity in plasma, liver, lung and kidney homogenate was 
assayed by the method described by Noro et al. (1983) with suitable modification. 
The reaction mixture consisted of 70 mM sodium phosphate buffer, pH 7.4, 10 )al of 
plasma or 100 ^l of 10 % liver, lung or kidney homogenate and 8 mM xanthine. 
After a 5 min preincubation, the reaction was started by the addition of xanthine and 
incubation was carried out for 15 min at 37*'C. The reaction was terminated by the 
addition of 0.5 ml ice-cold 10 % perchloric acid, followed by incubation for 10 min 
at room temperature. Samples were then centriftiged at 4,000 rpm for 10 min. The 
absorbance of the supernatant was recorded at 290 nm against a reagent blank in a 
Beckman DU 640 spectrophotometer. Xanthine oxidase activity was calculated by 
using a standard uric acid. 
2.2.2.15 Determination of hemoglobin content in blood 
Hemoglobin content in blood was determined quantitatively according to the 
procedure described in the instruction sheet enclosed with the reagent kit supplied by 
Ranbaxy Laboratories (Van Kampen and Zijistra 1961). The percent blood 
hemoglobin was determined by measuring the absorbance of cyanomethemoglobin at 
540 nm in a Beckman DU 640 spectrophotometer using a hemoglobin standard. 
2.2.2.16 Measurement of malondialdehyde release from intact erythrocytes 
The procedure of Cynamon et al. (1985) was employed for the determination 
of malondialdehyde (MDA) release from erythrocytes. Two aliquots of 0.22 ml of 
washed packed erythrocytes in duplicate were taken in two separate tubes. One 
series of aliquots were suspended in 4.18 ml of phosphate buffered saline, pH 7.4, 
and the second series of aliquots of erythrocytes were suspended in 4.18 ml of 
phosphate buffered saline, pH 7.4, containing 4 mM sodium azide. Both the 
suspensions were vortexed for 15 seconds. One ml of erythrocytes suspension of 
series one was taken in triplicate and mixed with 1.0 ml of freshly prepared 3 % 
hydrogen peroxide, whereas, 1.0 ml of 0.75 % hydrogen peroxide was added to the 
second series of erythrocytes suspension. The samples were mixed for 10 seconds 
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and incubated for 1 h at 37°C. At the end of incubation, 1.0 ml of 28 % TCA 
containing 100 mM sodium arsenite was added to each tube and centrifuged at 3,000 
rpm for 10 min. Two ml of the supernatant from each tube was taken in triplicate 
and mixed with 0.5 ml of 1 % thiobarbituric acid prepared in 50 mM NaOH. The 
samples were then boiled for 15 min at 95°C, cooled to room temperature and the 
absorbance was recorded at 535 nm against a reagent blank in a Beckman DU 640 
spectrophotometer. The concentration of MDA was calculated by using a standard 
MDAiLiu etal., 1982). 
2.2.2.17 Determination of malondialdehyde in erythrocytes 
The determination of MDA in erythrocytes was carried out according to the 
method of Stocks and Dormandy (1971). Briefly, 0.3 ml of packed erythrocytes in 
triplicate was made up to 1.0 ml in phosphate buffered saline, pH 7.4. To each tube, 
BHT in ethanol (0.75mM) was added, followed by the addition of 0.5 ml of 30 % 
TCA. Tubes were vortexed and allowed to stand in ice-bath for 2 h. Tubes were then 
centrifuged at 2,000 rpm for 15 min and 1.0 ml of the supernatant of each tube was 
transferred to another tube. To each tube, 75 ]xl of 100 mM EDT A and 250 fil of 1 
% thiobarbituric acid in 50 mM NaOH was added, mixed and kept in a boiling water 
bath for 15 min. After cooling the tubes to room temperature the absorbance of each 
sample was read against a reagent blank at 532 nm in a Beckman DU 640 
spectrophotometer. Malondialdehyde was used as a standard for the calculation of 
MDA concentration (Liu et ai, 1982). 
2.2.2.18 Estimation of lipid peroxides in plasma, liver, lung and kidney 
homogenates 
For the extraction of Lipid contents from plasma and tissues, the method 
of Folch et al. (1957) was employed. One volume of plasma or tissue homogenate 
was mixed with 5.0 volume of chloroform: methanol (2:1), followed by 
centrifligation at 1,000 rpm for 5 min to separate the phases. Most of the upper layer 
was removed; and 3.0 ml of the lower chloroform layer was recovered. The 
chloroform layer was placed in a test tube and incubated at 45°C till dryness. For 
the determination of conjugated dienes in plasma, liver, lung or kidney, 
corresponding lipid residues were dissolved in 1.5 ml of cyclohexane and the 
absorbance was recorded at 234 nm against a cyclohexane blank in a Beckman DU 
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640 spectrophotometer. The concentration of conjugated dienes formation was 
calculated by using a molar extinction coefficient of 2.52 x 1 0'* M"' cm''. 
In another experiment, quantification of lipid hydroperoxide was done 
according to the method Nourooz-Zadeh et al. (1996). The dried residues extracted 
from liver, lung and kidney homogenates were dissolved in methanol and 90 \i\ of 
the samples or plasma were transferred into 1.5 ml microcentrifuge tubes together 
with 10 |j,l of methanol (in triplicate) or 10 |al of 10 mM triphenyl phosphine (TPP) 
in methanol (in triplicate). The samples were then vortexed and incubated for 30 
min at 25°C, followed by the addition of 900 fil of a reagent containing 250 mM 
ammonium sulphate, 100 mM xylenol orange, 25 mM sulphuric acid and 4 mM 
BHT in 90 % methanol. The samples were incubated for additional 30 min at 25°C, 
and centrifuged at 12,000 rpm for 10 min prior to the determination of the 
absorbance of the supematants at 560 nm in a Beckman DU 640 
spectrophotometer. The levels of lipid hydroperoxide in tissue homogenates and 
plasma samples was then determined using the difference between the mean 
absorbance of samples with and without TPP pretreatment. Hydroperoxide contents 
were determined using a molar absorption coefficient of 4.3 x 10"* M"' cm"'. 
Lipid peroxide contents in plasma were assayed by the method of Yagi 
(1987). Plasma (25 pil) was mixed with 4.0 ml of 0.083 N H2SO4 followed by the 
addition of 0.5 ml of 10 % phosphotungstic acid. The samples were mixed and 
incubated for 5 min at room temperature and then centrifuged at 3,000 rpm for 10 
min. The supernatant was discarded and the sediment was mixed with 2.0 ml of 
0.083 N H2SO4 and 0.3 ml of 10 % phosphotungstic acid. The mixture was 
centrifuged at 3,000 rpm for 10 min, the sediment was suspended in 4.0 ml of water 
and 1.0 ml of thiobarbituric acid (TEA) reagent (a mixture containing equal 
volumes of 0.67 % aqueous TEA solution and glacial acetic acid) was added. The 
reaction mixture was heated for 60 min at 95 °C, cooled and the tubes were 
centrifuged at 3,000 rpm for 10 min. The absorbance of the supernatant was 
determined at 532 nm against a reagent blank in a Beckman DU 640 
spectrophotometer. The concentration of MDA was calculated by using a standard 
MDAiUuetal., 1982). 
The method of Ohkawa et al. (1979) was used for the determination of Lipid 
59 
Experimental 
peroxides in liver, lung and kidney homogenates. To 100 )al of 10 % liver, lung or 
kidney homogenate samples, 200 nl of 8.1 % SDS, 1.5 ml of 20 % acetic acid (pH 
3.5) and 1.5 ml of 0.8 % aqueous solution of TBA were added and mixed. The 
mixture was made up to 4.0 ml with water and heated in a water bath for 60 min at 
QS^ C. After cooling, the samples were centrifiiged at 3,000 rpm for 5 min and the 
supernatant of each sample was read at 532 nm against a reagent blank in a 
Beckman DU 640 spectrophotometer. Malondialdehyde was used as a standard for 
the calculation of MDA concentration (Liu et al, 1982). 
2.2.2.19 Determination of triglycerides, free fatty acid and total cholesterol in 
liver, lung and kidney homogenates 
The method of Folch et al. (1957) was employed for the extraction of Lipid 
contents from liver, lung and kidney homogenates. One ml of liver, lung and kidney 
homogenate was mixed with 5.0 ml of chloroform: methanol (2:1), followed by 
centrifiigation at 1,000 rpm for 5 min to separate the phases. Most of the upper layer 
was removed and 3.0 ml of the lower chloroform layer was recovered. The 
chloroform layer was placed in a test tube and incubated at 45°C till dryness. The 
lipid residues were dissolved in 1.0 ml of chloroform. One hundred microliter of 
samples (in triplicate) was taken for the determination of triglycerides in liver, lung 
and kidney, by using enzymatic kit. The method uses a modified Trinder color 
reaction to produce a fast, linear, end point reaction (Trinder, 1969). The intensity of 
the color produced after incubation is directly proportional to the concentration of the 
triglycerides in the samples when measured at 500 nm in a Beckman DU 640 
spectrophotometer. Triglycerides were calculated by using a triolein standard. 
Free fatty acid in plasma was estimated as described by Duncombe (1963). 
The above dissolved lipid residues (500 \x\) in chloroform was taken and to this 2.5 ml 
of copper reagent, prepared by mixing 9 vol of aqueous 1 M triethanol amine, 1 vol of 
1 N acetic acid and 10 vol of 0.269 M copper nitrate, was added. The tubes were 
vortexed for at least 2 min and centrifuged at 3,000 rpm for 5 min to separate the 
phases clearly. The supernatant aqueous phase was removed and 0.1 ml of chloroform 
layer was taken in triplicate into clean dry tubes. Then, 1.0 ml of (0.05 % w/v) sodium 
diethyl dithiocarbonate, prepared in butanol and used within 7 days, was added to the 
chloroform solution and mixed. The absorbance was recorded at 440 nm against a 
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reagent blank in Beckman DU 640 spectrophotometer. The Free fatty acid content 
was calculated by using palmitic acid as a standard, after subjecting it to the same 
procedure. 
For the determination of total cholesterol in liver, lung and kidney 
homogenates the method of Annino and Giese (1976) was used, with a minor 
modification. Fifty microliter of lipid residues in chloroform was mixed with 500 ^l 
of isopropanol, allowed to stand for 5 min and centrifijged at 3,000 rpm for 10 min. A 
suitable aliquot of isopropanol extract was used for cholesterol determination in a 
total volume of 0.75 ml. To each tube 0.25 ml of 7.03 mM ferric chloride dissolved in 
glacial acetic acid, was added, mixed instantly, followed by the addition of 0.8 ml of 
sulphuric acid with thorough mixing. After 5 min, the absorbance was read at 550 nm 
in a Beckman DU 640 spectrophotometer. The cholesterol content in the samples was 
determined by using a cholesterol standard. 
2.2.2.20 Assay of HMG-CoA reductase activity in liver homogenate 
HMG-CoA reductase enzyme activity in liver homogenate was estimated 
indirectly as described by Rao and Ramakrishnan (1975). Fresh 10 % tissue 
homogenate (1 g) were mixed with 9 ml of saline arsenat (0.1 % sodium arsenate in 
physiological saline) and 10 ml of 5 % perchloric acid was added, kept for 5 min at 
room temperature and centrifiiged at 2000 rpm for 10 min. One ml of the 
supernatant fi-om each tube was taken out and mixed with 0.5 ml of freshly 
prepared 1 M aqueous hydroxylamine hydrochloride, whereas for the assay of 
HMG-CoA, 0.5 ml of alkaline hydroxylamine hydrochloride were added and 
mixed. After an incubation of 5 min at room temperature, 1.5 ml of a 0.616 M ferric 
chloride reagent containing 5.2 % TCA, prepared in 0.65 N HCl was added, mixed 
and absorbance was read at 540 nm against a reagent blank in a Beckman DU 640 
spectrophotometer after 10 min of incubation at room temperature. 
2.2.2.21 Activities of antioxidant enzymes 
2.2.2.21.1 Determination ofcatalase activity in erythrocytes, liver, lung and kidney 
Enzymatic activity of catalase in erythrocytes hemolysate and post-
mitochondrial supernatant (PMS) of liver, lung and kidney was carried out according 
to the procedure described by Sinha (1972). The reaction was carried out in a total 
volume of 1.0 ml containing 10 mM phosphate buffer, pH 7.0 and erythrocytes 
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hemolysate equivalent to 22-36 |ig hemoglobin 1060-1074 ^g liver, 600-648 \ig lung 
and 721-657 |ag kidney of PMS protein. After a preincubation of 10 min at 30.C. the 
reaction was started by the addition of hydrogen peroxide resulting in a final 
concentration of 100 mM and the tubes were incubated for 5 or 10 min at 30°C. At 
the end of incubation, the reaction was terminated by the addition of 1.0 ml of 
potassium dichromate-acetic acid reagent, prepared by mixing 1 volume of 5 % 
aqueous solution of potassium dichromate with 3 volumes of glacial acetic acid. For 
zero time control, hydrogen peroxide was added after stopping the reaction. The 
tubes were heated in a boiling water bath for 15 min, cooled and the optical density 
was measured at 590 imi against a reagent blank in a Beckman DU 640 
spectrophotometer. Liver, lung, kidney and erythrocytes catalase activity was 
calculated by using a standard hydrogen peroxide calibration curve. 
2.2.2.21.2 Determination of superoxide dismutase activity in erythrocytes, liver, 
lung and kidney 
Enzymatic activity of superoxide dismutase (SOD) in erythrocytes 
hemolysate and PMS fraction of liver, lung and kidney was determined by the method 
as described by Kakkar et al. (1984). The assay mixture containing 52 mM sodium 
pyrrophosphate buffer, pH 8.3, 300 f^ M nitroblue tetrazolium, 186 fiM phenazine 
methosulphate and erythrocytes hemolysate equivalent to 29-50 i^ g hemoglobin 1060-
1074 \ig liver, 600-648 ^g lung and 721-657 |ig kidney PMS protein was 
preincubated for 5 min at 30''C and the reaction was initiated by the addition of 
NADH (780 |iM), by incubating the samples for different time intervals at 30°C. The 
reaction was stopped by the addition of 0.5 ml of glacial acetic acid at 1 min time 
interval up to 4 min. For zero time control, to the above incubation mixture, 0.5 ml of 
glacial acetic acid was added prior to the addition of NADH. To each tube including 
reagent blank 2.0 ml of n-butanol was added, rigorously extracted and centrifuged at 
3,000 rpm for 5 min, color intensity of the chromogen in the butanol extract was 
measured at 560 nm against a reagent blank in a Beckman DU 640 
spectrophotometer. SOD activity was calculated in terms of an arbitrary unit, which is 
defined as the enzyme concentration required inhibiting the chromogen formation by 
50 % in one min under the above assay conditions. 
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2.2.2.21.3 Determination of glutathione peroxidase activity in erythrocytes, liver, 
lung and kidney 
Glutathione peroxidase (Gpx) activity in erythrocytes hemolysate and liver 
lung and kidney homogenate was assayed by a modification of Mill's procedure 2 
(1959) as reported by Hafeman et at. (1974). The reaction mixture contained 80 mM 
sodium phosphate buffer, 80 ^M EDTA, pH 7.0, 1 mM sodium azide, 400 ^M GSH 
and erythrocytes hemolysate equivalent to 22-36 \xg hemoglobin, 715-751 |ag liver, 
381-455 \ig lung and 441-478 ^g kidney homogenate protein in a total volume of 0.5 
ml reaction mixture. After a 5 min preincubation at 37°C, the reaction was started by 
the addition of hydrogen peroxide (250 |aM) and the tubes were incubated for 2, 4, 6 
and 8 mins at 37°C. At the indicated time intervals, the reaction was terminated by the 
addition of 0.5 ml 10 % TCA. The tubes were centriftiged at 3,000 rpm for 10 min 
and 0.5 ml supernatant from each tube was added to tubes containing 2.0 ml of 0.4 M 
sodium phosphate buffer, 0.4 mM EDT A, pH 7.0 and 0.5 ml of 1 mM 5, 5'-
dithiobis(2-nitrobezoic acid, DTNB). The samples were mixed and optical density 
was recorded at 412 nm against a reagent blank within 2 min of DTNB addition in a 
Beckman DU 640 spectrophotometer. The erythrocytes, liver and kidney glutathione 
peroxidase activity was calculated after deducting the OD value of samples from the 
zero time control values by utilizing a standard glutathione. 
2.2.2.21.4 Assay of glutathione reductase activity in erythrocytes, liver, lung and 
kidney 
Glutathione reductase (Gred) activity was determined by the method of 
Carlberg and Mannervik (1975). The incubation mixture consisted of 82.5 mM 
soditmi phosphate buffer containing 25|aM EDTA, pH 7.6, 25 )iM oxidized 
glutathione and erythrocytes hemolysate equivalent to 22-36 )ag hemoglobin, 1060-
1074 ng liver, 600-648 (ig lung and 721-657 |xg kidney PMS protein. After a 5 min 
preincubation at 25''C, the reaction was started by the addition of NADPH (5|aM) and 
the tubes were incubated for 1-4 min at 25°C. The reaction was terminated at 1 min 
time interval by incubating the samples in an ice-bath. Zero time control tubes were 
prepared as above except 5 ^M NADPH was added after stopping the reaction. The 
absorbance of each sample was recorded at 340nm against a reagent blank in a 
Beckman DU640 spectrophotometer. By using the zero time control value the 
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enzyme activity was calculated on the basis of a molar extinction coefficient of 
NADPH(6.22xlO^M-'cm-'). 
2.2.2.21.5 Determination of glutathione-S-transferase activity in liver, lung and 
kidney 
The enzymatic activity of glutathione-S-transferase (GST) in liver, lung 
and kidney PMS fraction was carried out according to the procedure of Habig et al. 
(1974). The assay was carried out in a total volume of 1.0 ml containing 100 mM 
potassium phosphate buffer, pH 6.5, 1 mM GSH and 265-268^g liver, 180-164ng 
lung and 150-162 ^g kidney PMS protein. The samples were preincubated for 10 min 
at SO^C, the reaction was started by the addition of 1-chloro 2, 4-dinitrobenzene 
(CDNB) prepared in absolute ethanol (1 mM) followed by an incubation for 2 and 4 
min at 30°C. At the end of incubation the tubes were placed in an ice-bath for 15 min, 
after which the optical density was recorded at 340 nm against a reagent blank in a 
Beckman DU 640 spectrophotometer. The GST activity was calculated on the basis 
of molar extinction coefficient of CDNB (9.6 x 10'' M''cm'') after an appropriate 
deduction of zero time control values. 
2.2.2.22 Determination of total, free and protein-bound -sulfhydryl content of 
glutathione in liver, lung and kidney 
The total sulfhydryl content of glutathione in liver, lung and kidney 
homogenate was determined by the method of Ellman (1959) as modified by Sedlack 
and Lindsay (1968). The incubation mixture contained 60 mM tris buffer and 6 mM 
EDT A, pH 8.2, 3.50-3.75 mg liver, 1.90-2.27 mg lung and 2.20-2.39 mg kidney 
protein and 0.2 mM DTNB. The reaction mixture was mixed and made up to 5.0 ml 
by the addition of 3.2 ml absolute methanol. The tubes were centrifuged at 6,000 rpm 
for 5 min at 4°C and the absorbance of the clear supematants were read at 412 nm 
against a reagent blank in a Beckman DU 640 spectrophotometer. The total 
glutathione content was calculated by using a standard curve of reduced glutathione. 
For the determination of free sulfhydryl group of glutathione content in liver, 
lung and kidney homogenate, the method of Ellman (1959) as modified by Sedlack 
and Lindsay (1968) was employed. In order to assay free sulfhydryl content of 
glutathione, 0.5 ml of 10 % homogenate was precipitated by the addition of 0.5 ml of 
4 % sulphosalicylic acid (Jollow et al, 1974). The samples were incubated for 1 h at 
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4°C, centrifuged at 6,000 rpm for 5 min and 0.5 ml aliquots of the supernatant were 
used for the assay of free sulfhydryl group. The reaction mixture contained 267 mM 
tris buffer, 13 mM EDTA, pH 8.9 and 0.33 mM DTNB (prepared in absolute 
methanol). The absorbance of the sample was read against a reagent blank at 412 run 
within 2 minutes of DTNB addition. Free sulfhydryl content in the samples were 
calculated using a standard calibration curve of reduced glutathione. The protein 
bound sulfhydryl content of glutathione was calculated as the difference between total 
and free sulfhydryl content of glutathione. 
Free sulfhydryl group of glutathione content in packed erythrocytes was 
determined essentially by the method of EUman (1959) as modified by Sedlack and 
Lindsay (1968). Briefly, to 100 and 200 i^l of washed packed erythrocytes, 1.0 ml of 
10% TCA was added, mixed and incubated for 1 h at 4°C. At the end of incubation, 
the tubes were centrifuged at 1,200 rpm for 20 min at 4°C and 0.5 ml of the 
supernatant was used for the quantification of free sulfhydryl group. The free 
sulfhydryl group of erythrocytes was determined according to the procedures 
described above for liver and kidney homogenate, except 1.7 mM DTNB was used. 
2.2.2.23 Protein estimation 
The protein was determined by the method of Bradford (1976), using bovine 
serum albumin as standard. Aliquots of liver and kidney homogenates, PMS, LDL, 
sd-LDL, Ib-LDL, HDL, HDL2 and HDL3 were first precipitated with 10 % TCA. The 
protein pellets were dissolved in 0.5 N NaOH and suitable aliquots were used for 
protein determination. 
2.2.2.24 Statistical evaluation 
Statistical analysis of data was done by employing two-tailed Student t- test 
as described by Bennet and Franklin (1967). P values less than 0.02 were considered 
significant. 
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Results 
3.1 Antioxidative Activities of Tocomin, a-Tocotrienol, y-Tocotrienol, 6-
Tocotrienol and a-Tocopherol 
Antiradical activity or hydrogen donating ability of Tocomin, a-tocotrienol, y-
tocotrienol, 5-tocotrienol and a-tocopherol was measured by using DPPH, which 
reflects the antioxidative properties of these compounds. As shown in Fig. 3.1, the 
half quenching concentrations (IC50) were as follows: Tocomin, 50.85 |iM; a-
tocotrienol, 46.91 \iM; y-tocotrienol, 44.55 |aM; 6-tocotrienol, 38.12 |aM; and a-
tocopherol, 70.75 |iM. These findings indicate that as compared to a-tocopherol, y-, 
a-and 5-tocotrienols were more efficient scavengers of peroxyl radicals by 34 %, 37 
% and 46 %, respectively. Since Tocomin is a mixture of a-tocotrienol (25.6 %), y-
tocotrienol (40.8 %), 6-tocotrienol (12.8 %) and a-tocopherol (22.8 %), its efficiency 
as a scavenger of peroxyl radical was higher by 28 %, in comparison to a-
tocopherol. The reduction in the quenching efficiency of Tocomin in comparison to 
a-, y- and 8-tocotrienols is apparently due to the presence of 23 % a-tocopherol, 
which has a lowest peroxyl radical scavenging efficiency of 70.75fiM. 
3.2 Average Age, Body Weight, Body Mass Index (BMI) and Blood Pressure of 
Male Young Smokers after 8 Weeks of Tocomin Administration 
Data presented in Table 3 indicate the average age, body weight, BMI, and 
blood pressure of smokers after 8 weeks of placebo (containing 15.32 mg d- a-
tocopherol, equivalent to the amount present in Tocomin) or Tocomin administration. 
No significant changes in these parameters were observed when compared to their 
corresponding entry point values. 
3.3 Impact of Tocomin on Blood Carbon Monoxide Saturation and Nicotine in 
Young Smokers after 8 Weeks of Treatment 
As shown in Table 4, blood carbon monoxide saturation and blood nicotine 
levels were markedly increased from a normal control value of 5.99 SCO % and 
2.23 [ig/ml in nonsmokers to 13.75 SCO % (130 %) and 6.98 ^g/ml (203 %), 
respectively, in young smokers of placebo group. After 8 weeks of Tocomin 
treatment blood carbon monoxide saturation and blood nicotine levels showed a 
significant reduction of 44 % and 33 %, respectively, when compared to reflective 
values in placebo treated smokers. These result demonstrate that substantially 
increase in the levels of carbon monoxide and nicotine due to cigarette smoking may 
increase the risk of myocardial infarction in young men. 
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Fig. 3.1 Free radical scavenging activities of Tocomin, a-tocotrienol, y-tocotrienol, 6-
tocotrienol and a-tocopherol. The antioxidant activities of the above compounds at the 
indicated concentrations were carried out as described in methods. The assay is based 
on the reduction of 2, 2-diphenyl, 1-picrylhydrazyl (DPPH), which gives strong 
absorption maxima at 517rmi. Values represent the mean of triplicate determinations. 
The average error in the data points in these assay were mean ± less than 3 %. The 
average absolute absorbance value of 100 % DPPH was 0.00786 ± 0.00029. 
TABLE 1 
AVERAGE AGE, BODY WEIGHT, BODY MASS INDEX, SMOKING INDEX 
AND LIPID PARAMETERS OF THE STUDY SUBJECTS 
Parameters Nonsmokers Smokers (n=12) (n=36) 
Age (years) 22.9210.685 23.22±2.16 
Body weight (Kg) 63.08±0.792 62.14±5.11 
BMI (kg/m )^ 23.82±3.32 20.741L21 
Duration of smoking (years) - 4.72± 0.931 
Cigarette smoked per day 12.82±2.16 
Smoking index""" 60.51± 5.23 
Triglycerides (mg/dl) 105.81+1.47 J+f^^ls lf)« 
Total cholesterol (mg/dl) 148.64±6.04 
VLDL- C (mg/dl) 22.48±2.19 
LDL- C (mg/dl) 73.36±3.54 
Sd-LDL-C (mg/dl) 22.09±1.93 
Lb-LDL- C (mg/dl) 50.51±2.59 
HDL-C (mg/dl) 53.0712.49 
171.68±4.43 
(+15.50 %)" 
31.92±3.13 
(+41.94 %)' 
117.65±4.80 
(+60.37 %)" 
51.00±4.36 
(+130.08%)" 
66.22± 2.74 
(+31.10 %)" 
22.2514.82 
(-58.07 %)" 
Values are mean ± SD from individual subjects in each group. 
Significantly different from nonsmoker at *p<0.001 and p<0.05. 
Number of cigarettes smoked per day x years of smoking. 
TABLE 2 
AVERAGE AGE, BODY WEIGHT, BODY MASS INDEX, SMOKING INDEX 
AND LIPID PARAMETERS OF THE STUDY SUBJECTS AT ENTRY POINT 
Parameters 
Age (years) 
Body weight (Kg) 
BMI (kg/m )^ 
Smoking index^ ^ 
Triglycerides 
(rag/dl) 
Total cholesterol 
(mg/dl) 
VLDL-C 
(mg/dl) 
LDL-C 
(mg/dl) 
Sd-LDL-C 
(mg/dl) 
Lb-LDL-C 
(mg/dl) 
HDL-C 
(mg/dl) 
HDL2-C 
(mg/dl) 
HDL3 -C 
(mg/dl) 
Nonsmokers 
(n=12) 
23.83±0.686' 
64.70±1.14 
24.61±3.32 
-
104.77±1.01 
106.19±1.60 
23.41±0.368 
82.98±0.278 
26.22±0.590 
55.17±0.801 
45.49±4.17 
14.17±0.162 
30.08±0.057 
Smokers 
(n=36, Entry 
point values) 
24.30±2.ir 
63.91±4.10 
21.1911.01 
64.7214.92 
121.2211.67 
(+15.70 %)" 
181.9819.39 
(+17.58 %)' 
31.1911.40 
(+33.23%)" 
123.4412.67 
(+48.75%)" 
45.8514.10 
(+74.86%)" 
75.0616.06 
(+36.05 %)" 
22.4411.43 
(-50.67 %)" 
3.7610.299 
(-73.46 %)" 
17.7610.894 
(-40.96 %)" 
Placebo 
(0-week 
baseline) 
(n=18) 
25.3013.23* 
64.9115.24 
22.1012.31 
64.6214.32 
120.4811.96 
(+15 %)" 
182.0815.90 
(+17.64 %)" 
31.1911.40 
(+33.23 %)" 
123.4412.67 
(+48.75%)" 
45.8514.10 
(+74.86%)" 
75.0616.06 
(+36.05 %)" 
22.4411.43 
(-50.67 %)" 
3.7610.299 
(-73.46 %)" 
17.7610.894 
(-40.96 %)" 
Tocomin 
(0-week 
baseline) 
(n=18) 
23.3012.65* 
63.5112.98 
21.2311.69 
63.2315.26 
121.9611.67 
(+16.40%)" 
181.8017.79 
(+17.46 %)" 
32.1910.402 
(+37.40%)" 
122.8513.09 
(+48.04%)" 
43.012.93 
(+63.99 %)" 
75.6511.85 
(+37.12 %)" 
22.1811.62 
(-51.24 %)" 
3.7710.358 
(-73.39 %)" 
17.7611.12 
(-40.95 %)" 
Values are mean ± SD from individual subjects in each group. 
Significantly different from nonsmoker at "p<0.001. 
'^ ''^ Number of cigarettes smoked per day x years of smoking 
TABLE 3 
AVERAGE AGE, BODY WEIGHT, BODY MASS INDEX AND BLOOD 
PRESSURE OF MALE YOUNG SMOKERS AFTER 8 WEEKS OF 
TOCOMIN ADMINISTRATION 
Parameters Nonsmokers (n=12) 
Smokers 
(n=36, Entry 
point values) 
Placebo 
(8-week) 
(n=18) 
Tocomin 
(8-week) 
(n=I8) 
Age (years) 23.83±0.686* 24.30±2.ir 25.50±1.73* 23.5012.21* 
Body weight 64.70±L14 63.9114.10 64.6113.98 63.8314.51 
(Kg) 
BMI (kg/mO 24.6113.32 21.1911.01 21.3611.03 21.2211.05 
Duration of 
smoking 
(years) 
Cigarette 
smoked per 
day 
Smoking 
index*^ 
Systolic Blood 
pressure 
(mm Hg) 
Diastolic 
Blood 
pressure 
(mm Hg) 
83.9112.67 
4.8310.529 4.6410.463 4.9610.511 
13.4012.18 13.8313.16 
64.7214.92 64.1715.32 
135.5013.70 137.7113.50 140.16l3.13 
12.8212.26 
63.8914.76 
134.3813.20 
84.6912.81 83.5012.45 83.0512.29 
Values are mean ± SD from all groups of subjects. 
*^Number of cigarettes smoked per day x years of smoking. 
TABLE 4 
IMPACT OF TOCOMIN ON BLOOD CARBON MONOXIDE SATURATION 
AND NICOTINE IN YOUNG SMOKERS AFTER 8 WEEKS OF 
TREATMENT 
Carbon monoxide 
P /T t t saturation (SCO %) or Nicotine 
^ (Carboxyhemoglobin) (M^ g/ml) 
Nonsmokers 5.99±0.056 2.23±0.065 
Placebo 13.75±0.436 6.98±0.030 
(8-week) (+129.54 %)' (+202.69 %)' 
Tocomin 7.25*0.021* 4.49±0.035 
(8-week) (-43.88 %)" (-33.48 %)" 
Values are mean ± SD from pooled blood of 12 nonsmoker subjects. 
"Values are mean ± SD from pooled blood or plasma of 18 smokers in 
placebo or Tocomin treated group. 
Significantly different from nonsmoker at ''p<0.001. 
Significantly different from placebo at 'p<0.001. 
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3.4 Impact of Tocomin on Plasma Lipids, Plasma Lipoprotein Lipids, Lipid 
Peroxidation Status in Plasma and Erythrocytes in Male Young Smokers 
after 8 Weeks of Treatment 
3.4.1 Effect on plasma lipids 
As depicted in Table 5, all the plasma lipid parameters were significantly 
increased in young smokers, when compared to normal control values. Total lipid 
(TL), triglycerides (TG), free fatty acid (FFA) and total cholesterol (TC) 
concentrations were significantly increased from 460, 106, 126 and 155 mg/dl in 
nonsmokers to 629, 122, 143 and 182 mg/dl, respectively, in smokers before the 
initiation of Tocomin treatment (0-week baseline). After 8 weeks of Tocomin 
treatment, levels of TL, TG, FFA and TC were significantly decreased to 475 mg/dl 
(27 %), 106 mg/dl (13 %), 131 mg/dl (11 %) and 152 mg/dl (16 %) respectively, 
when compared to corresponding values of 8-week placebo treated smokers. 
Whereas, after 8-week of placebo intake, the above plasma lipids levels were not 
affected and remained similar to 0-week placebo baseline values. 
3.4.2 Effect on plasma lipoprotein lipids 
As shown in Table 6, plasma VLDL-C, LDL-C and antiatherogenic non-HDL-
cholesterol (non-HDL-C) levels were significantly increased from 23, 83, 109 mg/dl 
in nonsmokers to a 0-week baseline value of 31 mg/dl (33 %), 123 mg/dl (49 %) and 
160 mg/dl (46 %) respectively, in placebo treated smokers. After 8 weeks of 
Tocomin treatment, VLDL-C, LDL-C and non-HDL-C levels showed a significant 
reduction by 16 %, 29 % and 20 % respectively, in comparison to corresponding 8-
week placebo treated values in smokers. In contrast, cigarette smoking by young men 
was associated with a substantial decline in HDL and its subfractions, HDL2-C and 
HDL3-C levels by 51 %, 73 % and 41 %, respectively, when compared to 
corresponding values in nonsmokers group. Tocomin treatment of smokers for 8 
weeks caused a significant increase of 36 % and 188 %, in HDL-C and HDL2-C 
levels, respectively, in comparison to 8-week placebo treated corresponding values in 
smokers. In addition, total protein content associated with HDL, HDL2 and HDL3 
subfractions was also significantly reduced in smokers by 42 %, 62 % and 30 %, 
respectively, when compared to corresponding nonsmokers values. Tocomin 
treatment caused a significantly increased in HDL and HDL2 total protein by 28 % 
72 
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Results 
and 106 %, respectively, after 8 weeks of treatment, in comparison to corresponding 
placebo treated values. As expected, 8-week intake of placebo capsules, containing 
15.32 mg d-a-Tocopherol, did not influence the plasma VLDL-C, LDL-C, HDL-C, 
HDL2-C, HDL3-C and total protein of HDL, HDL2 and HDL3 levels, when compared 
to respective 0-week baseline values in smokers. 
3.4.3 Effect on plasma LDL, small dense LDL and large buoyant LDL sub fractions 
Table 7 shows cholesterol and apoB concentrations of plasma LDL-C, small 
dense (sd-) LDL-C and large buoyant (lb-) LDL-C. In nonsmokers, LDL-C and its 
apoB content were 83 and 141 mg/dl, respectively. The cholesterol and apoB content 
of sd-LDL subspecies was 26 and 43 mg/dl, respectively, whereas, amount of 
cholesterol and apoB associated with Ib-LDL was 55 and 93 mg/dl. In comparison to 
values in nonsmokers, smokers showed an increase in LDL-C from 83 to 123 mg/dl 
(49 %) and LDL-apoB content from 141 to 167 mg/dl (19 %), whereas, cholesterol 
content in sd-LDL was increased from 26 to 46 mg/dl (75 %) and its apoB levels was 
increased from 43 to 54 mg/dl (25 %). On the other hand, cholesterol and apoB 
contents in Ib-LDL were increased by 36 % and 16 %, respectively, when compared 
to respective values in nonsmokers. Following 8 weeks of Tocomin treatment to 
smokers, cholesterol and apoB levels of LDL were significantly reduced to a level 
similar to normal values in nonsmokers. The cholesterol and apoB associated with 
sd-LDL decreased from 46 and 54 mg/dl to 29 mg/dl (39 %) and 46 mg/dl (17 %), 
respectively, in Tocomin treated smokers, indicating a restoration by 90-93 % 
normal cholesterol and apoB values in sd-LDL subspecies. On the other hand, in 
Tocomin treated smokers, both cholesterol and apoB associated with Ib-LDL fraction 
were significantly reduced to 59 and 98 mg/dl, respectively, which are similar to 
corresponding values of 55 and 93 mg/dl in nonsmokers. As expected, after 8 weeks 
of placebo intake, cholesterol and apoB associated with LDL, sd-LDL and Ib-LDL 
were not affected in comparison to 0- week baseline placebo values. 
In normolipidemic subjects, the percent wise distribution of cholesterol and 
apoB from LDL particle to sd-LDL and Ib-LDL subpopulation were 32 %, 30 %, 66 
% and 66 %, respectively. In young smokers, the percent sd-LDL-C and sd-LDLapoB 
was significantly increased by 37 % and 32 %, respectively, whereas percent share of 
LDL-C and LDL-apoB in Ib-LDL was 61 % and 64 %, respectively, indicating a 
75 
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small change in comparison to percent values in nonsmokers. The percent increase in 
sd-LDL-C and sd-LDL-apoB registered in smokers were reduced by 33 % and 30 %, 
respectively, after 8 weeks of Tocomin treatment. In contrast, percent Ib-LDL-C in 
Tocomin treated group was significantly increased by 66 %, whereas, no change in 
percent Ib-LDL-apoB was seen, when compared to the corresponding percent values 
of smokers. As expected, placebo treated smokers did not registered significant 
change, when compared to values of 0-week base line smokers. These results 
demonstrate that a homogeneous preparation of sd-LDL and Ib-LDL subspecies can 
be obtained by employing heparin-Mg'^ -mediated precipitation of purified plasma 
LDL. In addition, the results also show that the concentration of sd-LDL, which is 
considered more atherogenic than LDL, was significantly increased in smokers. In 
smokers treated with Tocomin for 8 weeks, the sd-LDL or Ib-LDL concentration was 
significantly reduced to a level similar to normal control values in nonsmokers. 
3.4.4 Impact on the ratios of LDL-C/HDL-C, HDL-C/TC, sd-LDL-C/HDL-C and 
Ib-LDL-C/HDL-C 
As shown in Table 8, LDL-C/HDL-C, HDL-C/TC, sd-LDL-C/HDL-C and Ib-
LDL-C/HDL-C ratios were calculated from the data presented in Table 5, 6 and 7. 
LDL-C/HDL-C ratio was significantly increased fi-om 1.82 in nonsmokers to 5.30 
(191 %) in smokers, when compared to ratio in nonsmokers. After 8 weeks of 
Tocomin treatment, the increase in LDL-C/HDL-C ratio was significantly prevented 
and decreased to 3.01 (48 %). On the other hand, HDL-C/TC ratio was significantly 
decreased from 0.293 in nonsmokers to 0.120 (59 %) in smokers group. Tocomin 
treatment to these smokers significantly increase in HDL-C/TC ratios and restored it 
to 0.194 (60 %). In nonsmokers, when sd-LDL-C values were divided by HDL-C, a 
ratio of 0.576 was obtained, which'is substantially lower than LDL-C/HDL-C ratio of 
1.82. In smokers, sd-LDL-C/HDL-C ratio was substantially increased to a ratio value 
of 1.91 (232 %), when compared to nonsmokers value. As expected, sd-LDL-
C/HDL-C ratio in Tocomin treated smokers were significantly reduced to a value of 
0.985 (55 %), in comparison to ratio value of placebo treated smokers. In comparison 
to sd-LDL-C/HDL-C, the ratio of Ib-LDL-C/HDL-C in smokers was increased by 169 
%, from a nonsmokers value of 1.21 to 3.26. Consistent with these results, the Ib-
LDL-C/HDL-C ratios in treated groups were significantly reduced to a value of\.%\ 
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(44 %), in comparison to ratio value of placebo treated smokers. As expected, in 
placebo (equivalent to the concentration, 23 % present in Tocomin) treated smokers 
did not registered significant change in LDL-C/HDL-C, HDL-C/TC, sd-LDL-
C/HDL-C and Ib-LDL-C/HDL-C ratios, when compared to values of 0-week base 
line smokers. These results indicate that sd-LDL-C/HDL-C ratio may be considered 
as a better and novel predictor for coronary artery disease (CAD) risks than LDL-
C/HDL-C ratios. In addition, the ratios related to sd-LDL-C and HDL-C in treated 
smokers were positively modulated and restored similar to nonsmokers values, 
indicating normalization of cholesterol levels associated with the above lipoproteins. 
3,4.5 Impact on plasma total antioxidants and lipid peroxidation products 
Table 9 shows the antioxidant impact of Tocomin on plasma concentrations of 
total antioxidants, conjugated diene, lipid hydroperoxide and malondialdehyde 
(MDA) in smokers. In placebo treated smokers, total plasma antioxidants level was 
reduced from 82 |imole/dl in nonsmokers to 40 (52 %) |amole/dl. Treatment of 
smokers w t^h Tocomin for 8 weeks caused an increase of 26 % in total antioxidants 
level, in comparison to value in placebo smokers. Formation of conjugated diene, 
hydroperoxide and MDA in plasma were increased from 11.93, 1.11 and 2.90 
^mole/dl in nonsmokers to 18.19 (52 %), 1.83 (66 %) and 5.51 (90 %) fxmole/dl, 
respectively, in smokers of placebo group. After 8 weeks of Tocomin treatment levels 
of conjugated diene, hydroperoxide and MDA were significantly decrease by 26 %. 
25 % and 27 %, respectively, when compared to corresponding values of placebo 
treated smokers. These results demonstrate that, in smokers, due to increase in 
oxidative stress, plasma total antioxidants concentration was reduced, whereas, 
formation of above lipid peroxidation, conjugated diene, lipid hydroperoxide and 
MDA products were significantly increased. Treatment of smokers with dietary 
tocotrienols (Tocomin) in the formation of conjugated diene, lipid hydroperoxide and 
MDA were significantly reduced to respective near normal values in nonsmokers, 
indicating a strong in vivo antioxidant effect of Tocomin. 
3.4.6 Effect on membrane lipid peroxidation in erythrocytes 
As seen in Table 10, erythrocytes from smokers of placebo group showed a 
greater susceptibility to hydrogen peroxide-induced lipid peroxidation than those 
from nonsmokers group. Malondialdehyde content of erythrocytes hemolysate was 
increased from 12.21 nmol/gHb in nonsmokers to 28.68 (135 %) nmol/gHb in 
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TABLE 9 
ANTIOXIDANT IMPACT OF TOCOMIN ON PLASMA TOTAL 
ANTIOXIDANTS POWER, CONJUGATED DIENE, LIPID 
HYDROPEROXIDE AND MALONDIALDEHYDE CONTENT IN YOUNG 
SMOKERS AFTER 8 WEEKS OF TREATMENT 
Group/Treatment Total Conjugated Lipid MDA 
antioxidants diene liydro peroxide 
Nonsmokers 8L52±0.324 11.93±0.023 L105±0.075 2.90±0.432 
Placebo 
(8-week) 
39.51±0.796" 18.19±0.014 1.832±0.216 5.51±0.723 
(-5L53%)" (+52.47%)" (+65.79%)" (+90.0%)" 
Tocomin 
(8-week) 49.77±0.988** 13.50±0.013 L374±0.084 4.01±0.626 (+25.96%)" (-25.78%)" (-25.12%)" (-27.22%)" 
Values are mean (^mole/dl) ± SD from pooled plasma of 12 nonsmoker subjects. 
**Values are mean ± SD from pooled plasma of 18 smokers in placebo or 
Tocomin treated group. 
Significantly different from nonsmoker at "p<0.001. 
Significantly different from placebo at "p<0.001 and "p<0.05. 
TABLE 10 
MALONDIALDEHYDE CONTENTS AND IN VITRO MDA RELEASE IN 
ERYTHROCYTES OF YOUNG SMOKERS AFTER 8 WEEKS OF TOCOMIN 
TREATMENT 
Group/Treatment MDA 
(nmole/g Hb) 
Erythrocyte MDA 
release (percent) 
Nonsmokers 12.21±0.218 26.50±0.497 
Placebo (8-week) 
28.68±L07 
(+134.88%)* 
59.53±0.526 
(+124.64%)" 
Tocomin (8-week) 
18.06±0.217 
(-35.31 %)" 
23.00±0.427 
(-60.00 %)" 
Values are mean ± SD from pooled packed erythrocytes of 12 nonsmoker 
subjects. 
**Values are mean ± SD from pooled packed erythrocytes of 18 smokers in 
placebo or Tocomin treated group. 
Significantly different from nonsmoker at "p<0.001. 
Significantly different from placebo at *p<0.001. 
Results 
smokers of placebo group. A significant decrease of 35 % in MDA content was seen 
in smokers after treatment of Tocomin, when compared to placebo treated smokers 
value. Similarly, the release of MDA in smokers of placebo group was markedly 
increased by 125 %, when compared to nonsmokers value. Formation of MDA was 
decreased by 60 %, after 8 weeks of Tocomin treatment. These results demonstrate 
that the young smokers are associated with a significant increase in erythrocytes 
membrane lipid peroxidation, which is significantly prevented by the treatment of 
Tocomin. 
3.5 Regulatory Effect of Tocomin on Antioxidant Defense System in Young 
Smokers after 8 Weeks of Treatment 
It is known that, oxidative stress may be increased in smokers to a higher 
production of reactive oxygen species (ROS), such as superoxide radical, hydroxyl 
radical, hydrogen peroxide and/or deficiency in the antioxidant defense systems. An 
impaired radical scavenger ftinction has been linked to the decreased activity of 
enzymatic and nonenzymatic scavengers of free radicals. Therefore, the status of 
antioxidant enzymes, such as catalase, superoxide dismutase (SOD), glutathione 
peroxidase (Gpx), glutathione-S-transferase (GST) and glutathione reductase (Gred) 
including reduced glutathione (GSH) concentrations in erythrocytes are highly 
important. 
3.5.1 Impact on erythrocytes catalase, superoxide dismutase, glutathione 
peroxidase and glutathione reductase activities 
As seen in Table 11, the erythrocytes catalase activity in smokers was 
substantially increased by 145 %, in comparison to the activity level in nonsmokers. 
Treatment of smokers with Tocomin significantly prevented this increase by 52 %, 
when compared to the catalase activity of smokers in placebo group. On the other 
hand, the increase in the erythrocytes enzymatic activity of SOD in smokers was 15 
% in comparison to the value in nonsmokers. This increase in SOD activity in 
smokers was decreased by 8 %, following 8 weeks of intake of Tocomin. 
The data summarized in Table 11 showed a significant decrease of 39 % in the 
activity of Gpx from 15.26 units in nonsmokers to 9.29 units in smokers of placebo 
group. Treatment of smokers with Tocomin significantly blocked this decrease and 
increased the Gpx activity close to the level in nonsmokers. Similarly, Gred activity 
was significantly decreased by 35 % from a normal control value 146 units in 
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TABLE 11 
REGULATORY EFFECT OF TOCOMIN ON ERYTHROCYTES CATALASE, 
SUPEROXIDE DISMUTASE, GLUTATHIONE PEROXIDASE AND 
GLUTATHIONE REDUCTASE ACTIVITIES IN YOUNG 
SMOKERS AFTER 8 WEEKS OF TREATMENT 
Group/Treatment Catalase* Superoxide Glutathione Glutatliione 
dismutase^ peroxidase* reductase*"^  
Nonsmokers 828.82±8.95 1.531±0.0275 15.26±0.199 146.04±4.91 
Placebo 
(8-week) 
2033.29±18.10 
(+145.02 %)" 
1.768±0.0161 9.29±0.176 94.70±5.63 
(+15.48 %)" (-39.12%)" (-35.15%)* 
Tocomin 
(8-week) 
968.51±6.34 
(-52.36 %)" 
1.621±0J09 13.78±0.216 137.73±4.48 
(-8.25%)" (+48.33%)" (+45.43%)" 
^One unit (U/gHb) of enzyme activity is defined as the ^moles of H2O2 
decomposed/min/g Hb. 
^One unit (KU/gHb) of enzyme activity is defined as the amount of enzyme 
required to inhibit O.D. at 560 nm of chromogen production by 50 % in one min. 
'''One unit (U/gHb) of enzyme activity is defined as the fimoles of oxidized 
glutathione formed/min/g Hb. 
**One unit (U/gHb) of enzyme activity is defined as the ^moles of NADPH 
oxidized/min/g Hb. 
Values are mean ± SD from pooled erythrocytes hemolysate of 12 nonsmoker 
subjects. 
Values are mean ± SD from pooled erythrocytes hemolysate of 18 smokers in 
placebo or Tocomin treated group. 
Significantly different from nonsmokers at "p<0.001. 
Significantly different from placebo at "p<0.001. 
Results 
nonsmokers. After 8 weeks of Tocomin treatment of smokers, this decrease in Gred 
was by 45 %, when compared to the activity in placebo group. This decrease or 
increase in enzyme activities was prevented by Tocomin, demonstrating their potent 
antioxidant property. 
3.6 Ex vivo and Copper-Mediated In vitro Oxidative Modification of LDL, Sd-
LDL and Lb-LDL in Young Smokers after 8 Weeks of Tocomin Treatment 
3.6.1 Antioxidant effect on basal levels of conjugated diene formation and lag 
phase in LDL, sd-LDL and Ib-LDL 
As depicted in Table 12, the ex vivo base line diene conjugation (BDC) levels 
of LDL, sd-LDL and Ib-LDL in young smokers were increased by 31 %, 60 % and 
54 %, respectively, in comparison to the corresponding normal control values. 
Treatment of Tocomin to smokers partially blocked the in vivo oxidation of LDL, sd-
LDL and Ib-LDL and reduced their BDC levels by 15 %, 23 % and 19 %, 
respectively. As expected, the lag phase time of LDL oxidation was reduced from 80 
min in normal control to 40 min in smokers, whereas, for Ib-LDL oxidation, it was 
reduced from 80 min in normal control to 40 min in smokers. Treatment of smokers 
with Tocomin increased the lag phase time of LDL oxidation to 66 min, respectively, 
whereas, lag phase time of Ib-LDL oxidation in the treated group was increased to 66 
min. In comparison to lag phase time of LDL or Ib-LDL oxidation in normal control, 
sd-LDL oxidation resulted in a strikingly lower lag phase time of 10 min, which was 
reduced to 5 min in smokers. Following treatment with Tocomin the lag phase time 
of sd-LDL oxidation was increased to 8 min. These result demonstrate that relative to 
Ib-LDL, ex vivo conjugated diene formation in sd-LDL were increased in smokers, 
resulting in a strikingly lower lag phase time, indicating a substantially enhanced 
susceptibility of sd-LDL to in vivo oxidation. 
3.6.2 Antioxidant impact on basal levels ofMDA in LDL, sd-LDL and Ib-LDL 
As evident from the data in Table 13, the ex vivo base line levels of MDA in 
LDL, sd-LDL and Ib-LDL were significantly increased by 54 %, 54 % and 49 %, 
respectively, in smokers, when compared to corresponding values in nonsmokers. 
Supplementation of Tocomin significantly blocked the in vivo increase in the 
formation of MDA of LDL, sd-LDL and Ib-LDL in smokers and reduced their levels 
by 31 %, 26 % and 30 %, respectively, in comparison to corresponding basal values 
in placebo treated smokers. On the other hand, placebo treated smoker, did not 
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TABLE 13 
EX VIVO GENERATION OF MALONDIALDEHYDE CONTENTS IN 
OXIDATION OF LDL, Sd-LDL AND Lb-LDL, IN YOUNG SMOKERS 
AFTER 8 WEEKS OF TOCOMIN TREATMENT 
Group/ 
Treatment 
MDA 
LDL Oxidation Sd-LDLOxidation Lb-LDL Oxidation 
Basal Basal Basal 
Nonsmokers 
(n=12) ^4.95±0.851 *4.54±0.063 *4.71±0.103 
Smokers (n=36) 
(Entry point 
values) 
^7.64*0.163" 
(+54.34%)* 
^6.98*0.136" 
(+53.74%)* 
*7.00±0.131" 
(+48.61%)* 
Placebo (n=18) 
(8-week) *7.17±0.130 ^6.79±0.131 ^6.85±0.124 
Tocomin (n=18) 
(8-week) 
^5.29±0.097'' 
(-30.74%)^ ^ 
*5.14±0.132'' 
(-26.36%)^ ^ 
*4.93±0.133" 
(-29.57%)^ ^ 
The MDA contents are expressed as nmole malondialdehyde/mg protein. 
Basal MDA represent the status of oxidized LDL, sd-LDL and Ib-LDL in vivo. 
^Values are mean ± SD from LDL, sd-LDL and Ib-LDL subpopulation, isolated 
from pooled plasma of each group. 
*Percent increase with respect to basal value in nonsmokers. 
^^Percent decrease with respect to basal value in smokers. 
Significantly different from normal control at ''p<0.001 and ''p<0.01. 
Significantly different from placebo at ''p<0.001. 
Results 
significantly affect the formation of basal MDA in LDL, sd-LDL and Ib-LDL. These 
combined results indicated that similar to ex vivo conjugated diene and MDA 
formation in LDL, sd-LDL and Ib-LDL, are also increased in smokers, which were 
significantly blocked following Tocomin treatment. 
3.7 Copper-Mediated In Vitro Oxidative Modification of LDL in Absence or 
Presence of HDL subfractions HDL2 or HDL3 in Young Smokers after 8 
Weeks of Tocomin Treatment 
3.7.1 Antioxidant effect of HDL subfractions HDL 2 or HDL 3 on maximal levels of 
conjugated diene formation in LDL oxidation 
It is known that plasma HDL and its subfractions HDL2 and HDL3 possess a 
spectrum of antiatherogenic action, including potent antioxidant and 
antiinflammatory activities. Although HDL and its subfi-actions HDL2 and HDL3 can 
themselves undergo oxidative modification, several enzymes that may cleave 
oxidized lipids and thereby inhibit LDL oxidation are associated with HDL and its 
subfractions HDL2 and HDL3; these included paraoxonase (PON) in its major 
isoforms, platelet-activating factor acetylhydrolase (PAF-AH), lecithin cholesterol 
acyl transferase (LCAT), and glutathione selenoperoxidase. Based on above finding 
in normolipidemic subjects, we have investigated the differential antioxidative action 
of HDL subfractions, HDL2 and HDL3 on Cu '^^ -induced oxidation of LDL by 
measuring the generation of conjugated diene. For this purpose LDL, HDL2 and 
HDL3 were isolated from plasma of normolipidemic nonsmokers and young smokers 
either supplemented with placebo or Tocomin. When HDL2 or HDL3 subfractions 
were added to LDL at LDL-total cholesterol (TC) to HDL2-TC or HDL3-TC ratio 
(1.66:1.0 or 1.0:1.0 for HDL3) directly before the addition of CUSO4, time course of 
LDL oxidation was significantly delayed. Antioxidative protection of LDL by HDL2 
or HDL3 was highly pronounced in each group at late stages of oxidation as shown for 
conjugated diene formation in figures 3.2, 3.3, 3.4, 3.5 for nonsmokers, smokers, 
placebo treated smokers and Tocomin treated smokers, respectively. Throughout the 
time course of Cu^-induced LDL oxidation from normolipidemic nonsmokers, 
smokers, placebo treated or Tocomin treated smokers, small, dense HDL3 exhibited 
more potent protection effect than large, light HDL2 subfraction. As shown in Table 
14, in nonsmokers, addition of HDL2 or HDL3 during LDL oxidation decreased the 
maximal amount of conjugated diene by 28 % and 32 %, respectively, as compared 
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levels of HDLa subtractions and mixtures containing LDL, HDL2 or two levels of 
HDL3 from plasma of smokers (n=36). HDL2 (1.5mg TC/dl), two levels of HDL3 
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indicated time intervals conjugated diene was measured at 234 nm. The ex vivo 
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Fig. 3.4. Copper-mediated oxidation kinetics of LDL, HDL2 subtractions, or two 
levels of HDL3 subtractions and mixtures containing LDL, HDLj or two levels of 
HDLa from plasma of placebo treated smokers (n=18). HDL2 (1.5mg TC/dl), two 
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Fig. 3.5. Copper-mediated oxidation kinetics of LDL, HDLi subtractions, or two 
levels of HDL3 subtractions and mixtures containing LDL, HDL2 or two levels of 
HDL3 from plasma of Tocomin treated smokers (n=18). HDL2 (L5mg TC/dl), 
two levels of HDL3 (1.5mg TC/dl or 2.5mg TC/dl) subtractions and LDL (2.5mg 
TC/dl) were incubated with CUSO4 in the absences or presence of HDL 
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and at the indicated time intervals conjugated diene was measured at 234 nm. 
The ex vivo baseline conjugated diene values of HDLj, HDL3, LDL, LDL+HDL2, 
LDL+HDL3 and LDL+HDL3 samples were deducted from the corresponding 
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Results 
to maximal conjugated diene value of LDL oxidation. In smokers, the maximal diene 
conjugation of LDL was increased from 1059 units in nonsmokers to 1452 units (+37 
%) in smokers. Addition of HDL2 (1.5mgTC/dl) or two levels of HDL3 (1.5mgTC/dl 
or 2.5mgTC/dl) decreased the maximal amount of conjugated diene formed on 
oxidation by 35 %, 47 % and 53 % respectively. Treatment of smokers with Tocomin 
for 8 weeks decreased the maximal conjugated diene value of LDL to from a placebo 
treated value of 1449 units to 1013 units, which is identical to control value in 
nonsmokers. Whereas, oxidation of LDL from Tocomin treated group in presence of 
HDL2 or two levels of HDL3 resulted in further decrease from a conjugated diene 
value of 1013 units to 606 units (40 %), 566 units (44 %) and 520 units (49 %), 
respectively, which are lower (21 %) than corresponding maximal conjugated diene 
values in nonsmokers. These results indicate a strong antioxidative protection of LDL 
by HDL2 or HDL3 in young smokers supplemented with dietary tocotrienols. It is 
worth mentioning that maximal conjugated diene formation after oxidation of LDL, 
LDL+ HDL2 or LDL + two levels of HDL3 in 8-week placebo treated smokers was 
similar to corresponding entry point conjugated diene values in smokers, indicating 
that smokers supplemented with placebo capsules containing 15.32 mg d-a-
tocopherol (which is equivalent to the amount present in Tocomin) did not exhibit 
any additional effect. These results demonstrate that in each group, both large, light, 
cholesteryl ester rich HDL2 and small, dense, lipid poor HDL3 potently inhibited LDL 
oxidation. However, antioxidative effect of HDL3 was higher than HDL2. 
3.8 Regulatory Effect of Tocomin on Plasma, HDL, HDL2, HDL3 Arylesterase 
Activity and LDL-C: Arylesterase Activity Ratio in Young Smokers after 8 
Weeks of Treatment 
It is known that arylesterase (paraoxonase) activity is associated with plasma 
HDL, which is involved in the protection of LDL and HDL from oxidative 
modification. Arylesterase activity is known to be reduced in hypercholesterolemia, 
diabetes and vascular cardiac diseases in smokers. The arylesterase activity was 
shown to be regulated both genetically and by diet, indicating that adequate dietary 
intake of antioxidants such as vitamin E is essential. Therefore, we have also 
investigated the impact of Tocomin on arylesterase activity in plasma, HDL, HDL2 
and HDL3 subfractions in smokers of placebo group. As shown in Table 15, due to 
excessive increase in free radicals in smokers of placebo group, arylesterase activity 
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Results 
in plasma, HDL and its subfractions HDL2 and HDL3 of smokers was significantly 
reduced by 2050, 1866, 648 and 1193 units in nonsmokers to 1202 (41 %), 817 (56 
%), 281 (57 %) and 477 (60 %) units, respectively, in placebo group. The distribution 
of arylesterase activity in HDL and its subfractions, HDL2 and HDL3, was 91 %, 35 
% and 64 %, respectively, of plasma arylesterase activity in nonsmokers. Treatment 
of smokers with dietary Tocotrienols (Tocomin) significantly increased this decrease 
in arylesterase activity by 18 %, 23 %, 42 %, and 16 %, respectively, when compared 
to corresponding values in placebo smokers. Consistent with the above results, the 
ratio of LDL-C to arylesterase activity in smokers was markedly increased from 4.03 
X 10"^  in nonsmokers to 10.48 x 10"^  (160 %) in smokers of placebo group. This 
increase in the ratio of LDL-C to arylesterase activity in smokers was significantly 
reduced to a value of 6.28 x 10"^  (40 %) after treatment with Tocomin for 8 weeks. 
These results suggest that treatment of smokers with dietary Tocomin significantly 
prevented the increase in LDL-C: arylesterase activity ratio and decreased it to a 
level, which is 64 % of ratio value of nonsmokers indicating a potent antioxidant 
effect of Tocomin. 
3.9 Average Body Weight and Diet Consumption in each Group of Rats before 
and after 4 Weeks of Treatment 
As shown in Table 16, the average body weight (g) of smoke exposed control 
rats (S-C), Tocomin treated (S-T3T) and Lovastatin treated (S-LT) rats was 178, 184 
and 179 (g), respectively, whereas for normal control (N-C) rats the average body 
weight was 177 g, whereas, the average body weight of N-C, S-T3T and S-LT rats 
showed a significant gain of 31 %, 49 % and 22 % respectively after 4 weeks of 
treatment. On the other hand, average diet consumption/group/day (g) of S-C, S-T3T 
and S-LT was 155, 172 and 172 (g), respectively, whereas, the average diet 
consumption of N-C, S-T3T and S-LT rats showed a significant gain of 4 %, 17 % 
and 6 % respectively after 4 weeks of treatment. In addition, there was no significant 
change on average diet consumption of S-C rats, in comparison to their initial diet 
consumption (before treatment). These results demonstrate that in smoke exposed 
Tocomin treated rats the average diet consumption and the gain in body weight after 
4 weeks was significantly higher than rats in N-C and S-LT groups. 
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TABLE 16 
AVERAGE BODY WEIGHT AND DIET CONSUMPTION IN EACH GROUP 
OF RATS BEFORE AND AFTER 4 WEEKS OF TOCOMIN AND 
LOVASTATIN TREATMENT 
Group 
Average body weight/rat (g) 
Before 
treatment 
Average diet 
consumption/group/day (g) 
After 
treatment 
Before 
treatment 
After 
treatment 
N-C 
177.14±2.67 232.85±15.63 
(+31.44%) 0A\» 
165±5.00 171.66±10.40 
(+4.03%) 
S-C 177.85±3.93 210.12±18.14 155±5.00 150±5.00 
(+18.14%)' (-3.22%) 
S-T3T 184.28±7.86* 274.28±13.14 171.66±7.63 200±10 
(+48.83%)" (+16.50%)" 
S-LT 179.28±6.07* 218.57±13.45 171.66±7.63 181.66±2.88 
(+21.91%)" (+5.82%)" 
Values are mean ± SD from 7 rats in each group. 
N-C, normal control; S-C, smoke exposed control; S-T3T, fed 6 mg 
Tocomin/rat/day and S-LT, given 0.50 mg Lovastatin/rat/day for 4 weeks. 
Significantly different from N-C at "p<0.001. 
Significantly different from S-C at 'p<0.001. 
Results 
3.10 Impact of Tocomin and Lovastatin on Hemoglobin, Blood Carbon 
monoxide Saturation and Blood Nicotine in Smoke Exposed Rats Treated 
for 4 Weeks 
Data presented in Table 17, indicated the hemoglobin (Hb), blood carbon 
monoxide saturation (carboxyhemoglobin) and blood nicotine. Hemoglobin a level 
was significantly reduced by 20 %, in smoke exposed (S-C) rats, when compared to 
N-C value. However, a highly significant increase in Hb concentration was observed 
in smoke exposed rats treated with Tocomin (21 %) and Lovastatin (17 %) for 4 
weeks when compared to S-C rats. Both Tocomin and Lovs^tatin administration to 
smoke exposed rats mediated an increase in Hb levels close to normal value. 
Whereas, blood carbon monoxide saturation and blood nicotine levels were increased 
from 6.1 (SCO %) and 1.2 ^g/ml in N-C to 10.6 SCO % (73 %) and 4.6 ^g/ml (299 
%)\ respectively, in S-C rats. After 4 weeks of Tocomin and Lovastatin treatment 
blood carbon monoxide saturation and blood nicotine levels showed a significant 
reduction of 30 % and 70 % in S-T3T respectively, whereas in S-LT, blood carbon 
monoxide saturation and blood nicotine levels were reduced by 26 %, and 50 % 
respectively, in comparison to values in S-C rats. 
3.11 Impact of Tocomin and Lovastatin on Plasma Lipids, Plasma Lipoprotein 
Lipids, Hepatic HMG-CoA Reductase Activity and Lipid Peroxidation 
Status in Plasma, Liver, Lung and Kidney and Erythrocytes in Smoke 
Exposed Rats Treated for 4 Weeks 
In the experiments described below the efficacy of Tocomin (6mg/rat/day) and 
Lovastatin (0.50mg/rat/day), in preventing the increase in lipid parameters, lipid 
peroxidation and oxidative stress was investigated in smoke exposed rats, after 4 
weeks of administration. 
3.11.1 Effect on plasma lipids 
As seen in Table 18, all the plasma lipids parameters were significantly 
increased in smoke exposed control (S-C) rats, when compared to N-C values. Total 
lipids (TL), triglycerides (TG), free fatty acids (FFA) and total cholesterol (TC) 
significantly increased from 393, 50, 123 and 82 mg/dl in N-C to 507, 101,145 and 
149 mg/dl, respectively, in S-C group. After 4 weeks of Tocomin treatment, levels of 
TL, TG, FFA and TC were significantly decreased by 9 %, 40 %, 11% and 29 %, 
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TABLE 17 
IMPACT OF TOCOMES AND LOVASTATIN ON BLOOD HEMOGLOBIN, 
CARBON MONOXIDE SATURATION AND NICOTINE IN CIGARETTE 
SMOKE EXPOSED RATS AFTER 4 WEEKS OF TREATMENT 
Group Hemoglobin 
(g/dl) 
Carbon monoxide 
Saturation (SCO %) 
or 
(Carboxyliemoglobin) 
Nicotine 
(^ g/mI) 
N-C 14.3810.264 6.11±0.034 1.16±0.033 
S-C 11.51±0.015* 10.58±0.271 4.63±0.042 
(-19.96%)" (+73.15 %)" (+299.13 %)" 
S-T3T 13.98±0.017' 7.37±0.023 1.37±0.043 
(+21.45%)" (-30.34 %)" (-70.41 %)" 
S-LT 13.5110.021* 7.86±0.064 2.33±0.035 
(+17.37%)" (-25.75 %)" (-49.67 %)" 
'Values are mean ± SD from pooled blood of 7 rats in each group. 
N-C, normal control; S-C, smoke exposed control; S-T3T, fed 6 mg Tocomin/ 
rat/ day and S-LT, given 0.50 mg Lovastatin/rat/day for 4 weeks. 
Significantly different from N-C at "p<0.001. 
Significantly different from S-C at "p<0.001. 
TABLE 18 
IMPACT OF TOCOMIN AND LOVASTATIN ON PLASMA TOTAL LIPID, 
TRIGLYCERIDES, FREE FATTY ACID AND TOTAL CHOLESTEROL IN 
CIGARETTE SMOKE EXPOSED RATS AFTER 
4 WEEKS OF TREATMENT 
Group Total lipid Triglycerides Free fatty acid Total 
cholesterol 
N-C 393.34±1.60 50.08±0.831 123.41+0.432 81.79±2.81 
S-C 506.9712.25 101.29±2.67 145.19±0.513 148.81±4.36 
(+28.89%)" (+102.25%)" (+17.64%)" (+81.94%)" 
S-TjT 462.43±1.60 61.23±1.93 129.49±0.393 104.92±2.85 
(-8.78%)" (-39.54%)" (-10.81%)" (-29.49%)" 
S-LT 470.21+1.15 60.78±1.85 126.61+0.372 96.87±2.65 
(-7.25%)" (-40.0%)" (-12.79%)" (-34.90%)" 
Values are mean (mg/dl) ± SD from pooled plasma of 7 rats in each group. 
N-C, normal control; S-C, smoke exposed control; S-T3T, fed 6 mg 
Tocomin/rat/day and S-LT, given 0.50 mg Lovastatin/rat/day for 4 weeks. 
Significantly different from N-C at "p < 0.001. 
Significantly different from S-C at •p<0.00l and "p<0.05. 
Results 
respectively, when compared to corresponding S-C values. Whereas, in Lovastatin 
treated rats, TL, TG, FFA and TC levels were significantly reduced by 7 %, 40 %, 13 
% and 35 % respectively, in comparison to corresponding values in S-C group. 
These results demonstrate that 4-week treatment of smoke exposed rats with 6 mg 
Tocomin or 0.50 mg Lovastatin mediated a similar and significant reduction in above 
lipid parameters. 
3.11.2 Effect on plasma lipoprotein lipids 
As seen in Table 19, plasma VLDL-C, LDL-C and non-HDL-cholesterol (non-
HDL-C) levels were significantly increased from 10, 52 and 63 mg/dl in N-C to 21 
mg/dl (105 %), 110 mg/dl (112 %) and 131 mg/dl (109 %) respectively, in S-C. After 
4 weeks of Tocomin or Lovastatin treatment, both VLDL-C, LDL-C and non-HDL-C 
levels showed a significant reduction 41 %, 44 % and 43 %, respectively, in S-T3T, 
whereas, in S-LT, VLDL-C, LDL-C and non-HDL-C were significantly reduced of 
41 %, 48 % and 46 %, respectively, in comparison to corresponding values in S-C 
rats. HDL-C, HDL2-C and HDL3-C levels were decreased from 19, 6 and 13 mg/dl in 
N-C to 17 mg/dl (11 %), 4 mg/dl (34 %) and 12 mg/dl (5 %), respectively, in S-C 
values. After 4 weeks of Tocomin treatment (S-T3T) HDL-C, HDL2-C and HDL3-C 
levels showed a significant increase of 77 %, 200 % and 45 %, respectively, when 
compared to corresponding values in S-C, whereas, in S-LT, HDL-C, HDL2-C and 
HDL3-C levels were increased by 53 %, 125 % and 37 %, respectively. These results 
demonstrate that both Tocomin and Lovastatin are equally effective in reducing 
VLDL-C and LDL-C levels. On the other hand, in comparison to N-C values, 
treatment of smoke exposed rats with Tocomin mediated a significantly higher 
increase in HDL-C, HDL2-C and HDL3-C concentration than the increase seen in 
Lovastatin treated rats. 
3.11.3 Effect on plasma LDL, small dense LDL and large buoyant LDL 
subfractions 
Data presented in Table 20 depict levels of plasma LDL-C, LDL-apoB, small 
dense (sd-) LDL-C, sd-LDL-apoB, large buoyant (lb-) LDL-C and Ib-LDL-apoB. In 
normal rats, LDL-C and its apoB content were 52 and 121mg/dl, respectively, in N-
C, the cholesterol and apoB content of sd-LDL subpopulation was 15 and 39 mg/dl, 
respectively, whereas, cholesterol and apoB concentrations associated with Ib-LDL 
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TABLE 19 
IMPACT OF TOCOMIN AND LOVASTATIN ON PLASMA VLDL-C, LDL-C, 
HDL-C, HDL2-C AND HDL3-C SUBFRACTIONS AND NON-HDL-C IN 
CIGARETTE SMOKE EXPOSED RATS AFTER 
4 WTEEKS OF TREATMENT 
Parameters N-C S-C S-T3T S-LT 
VLDL- C 10.01±0.056 
LDL-C 52.00±0.231 
HDL- C 19.06±0.081 
HDL2- C 6.0610.015 
HDL3- C 12.98±0.052 
. 20.54±0.262 12.11±0.195 12.20±0.216 
Non-HDL- C 62.73±3.63 
(+105.19 %)" (-41.04 %)" (-40.60 %)" 
110.22±0.295 61.5210.404 56.9810.292 
(+111.96%)" (-44.18%)" (-48.30%)" 
17.0110.063 30.0510.216 25.9910.196 
(-10.75 %)• (+76.77%)" (+52.79 %)" 
4.0010.011 12.0010.031 9.0010.024 
(-33.99%)" (+200.0 %)" (+125.00%)" 
12.3610.063 17.9810.081 16.9510.073 
(-4.77 %)' (+45.46 %)" (+37.13 %)" 
130.8014.79 74.8713.25 70.8813.83 
(+108.51 %)" (-42.75 %)" (-45.81 %)" 
Tor the calculation of non-HDL-C, TC and HDL-C data is taken from Table 18 
and 19. 
Values are mean (mg/dl) ± SD from pooled plasma of 7 rats in each group. 
N-C, normal control; S-C, smoke exposed control; S-T3T, fed 6 mg 
Tocomin/rat/day and S-LT, given 0.50 mg Lovastatin/rat/day for 4 weeks. 
Significantly different from N-C at "p<0.001 and '^ p<0.02. 
Significantly different from S-C at "p<0.001. 
TABLE 20 
IMPACT OF TOCOMIN AND LOVASTATIN ON PLASMA LDL, SMALL 
DENSE AND LARGE BUOYANT LDL SUBPOPULATION IN CIGARETTE 
SMOKE EXPOSED RATS AFTER 4 WEEKS OF TREATMENT 
Parameters N-C S-C S-T3T S-LT 
LDL-C 52.00±0.231* 110.22±0.295* 61.52±0.404* 56.98±0.292* 
(+111.96%)" {-44.18%)* (-48.30 %)• 
LDL-apoB 120.84±0.921 138.87±0.523 125.0710.823 128.8210.725 
(+14.92 %)" (-9.93 %)" (-7.23 %)' 
Sd-LDL-C 15.3010.042 59.9210.096 18.9910.071 16.9810.054 
(+291.63 % ) ' (-68J0 % ) " (-71.66 % ) " 
% LDL-C 29.4010.321 543611.26 30.86i0.624 29.7510.462 
(+84.89 %)" (-43.23 %)" (-45.27 %)' 
Sd-LDL-apoB 39.07+0.814 71.25+1.021 40.0310.716 38.5211.190' 
(+82.36 %)" (-43.81 %)* (-45.93 %)" 
% LDL-apoB 32.3110.832 51.3011.62 32.0110.605 29.9010.531 
(+58.77 %)* (-37.60 %)' (-41.71 %)" 
Lb-LDL-C 36.9710.056 50.0110.154 42.9810.044 39.9510.085 
(+35.27 % ) " (-14.05 % ) ' (-20.11 % ) " 
% LDL-C 71.0311.213 45.3510.962 69.8110.943 70.1011.129 
(-36.15 %)" (+53.93 %)" (+54.57 %)" 
Lb-LDL-apoB 80.5411.191 67.6511.120 82.1711.10 82.1010.624 
(-16.00 %)" (+21.46 %)' (+21.35 %)" 
% LDL-apoB 66.6210.926 48.7010.835 65.6210.859 63.7010.825 
(-26.89 %)" (+34.74 %)' (+30.80 %)' 
'Values are mean (mg/dl) ± SD from LDL, sd-LDL and Ib-LDL subpopulation, 
isolated from pooled plasma of 7 rats in each group. 
N-C, normal control; S-C, smoke exposed control; S-T3T, fed 6 mg Tocomin/ rat/ 
day and S-LT, given 0.50 mg Lovastatin/rat/day for 4 weeks. 
Significantly different from N-C at ''p<0.001. 
Significantly different from S-C at "p<0.001, ''p<0.01 and 'p<0.02 
Results 
were 37 and 81 mg/dl. In comparison to control values, smoke exposed rats showed 
an increase in plasma LDL-C from 52 to 110 mg/dl (112 %) and LDL-apoB from 
121 to 139 mg/dl (15 %), whereas sd-LDL-C was increased from 15 to 60 mg/dl 
(292 %) sd-LDL-apoB was increased from 39 to 71 mg/dl (82 %). In comparison to 
sd-LDL, the increase in ib-LDL-C of S-C rats was only 35 %, whereas, Ib-LDL-
apoB level was reduced by 16 % when compared to corresponding values in N-C. 
Following 4 weeks of Tocomin or Lovastatin treatment to smoke exposed rats, LDL-
C levels were significantly reduced by 44 % and 48 %, respectively, and restored 
these values close to the N-C value. Consistent with a small increase in LDL-apoB 
content of S-C rats, after 4 weeks of Tocomin or Lovastatin treatment, the decline in 
LDL-apoB was also minimal. The cholesterol and apoB associated with sd-LDL 
decreased from 60 and 71 mg/dl to 19 mg/dl (68 %) and 40 mg/dl (44 %), 
respectively, in S-T3T, whereas, sd-LDL-C and its apoB content in S-LT was 
reduced to 17 mg/dl (72 %) and 39 mg/dl (46 %), respectively. On the other hand, 
the cholesterol level of Ib-LDL subfraction in both the treated groups was 43 and 40 
mg/dl, which is close to a value of 37 mg/dl in N-C. As indicated above, apoB 
associated with Ib-LDL fraction was reduced from an N-C value of 81 to 67 mg/dl in 
S-C, whereas, a significant increase to a similar value of 82 mg/dl (21 %) indicating 
a fiill restoration of Ib-LDL-apoB levels and similar to value in N-C. 
In normolipidemic rats, the percent wise distribution of cholesterol and apoB 
from LDL particle to sd-LDL and Ib-LDL fractions were 29 %, 32 %, 71 % and 67 
%, respectively, in smoke exposed rats the percent sd-LDL-C and sd-LDL-apoB was 
significantly increased by 85 % and 59 %, when compared to the corresponding 
percent values fi-om normal rats. Similarly, the percent Ib-LDL-C and Ib-LDL-apoB 
in S-C rats was increased by 36 % and 27 %, in comparison to corresponding percent 
values of N-C rats. The percent increase in sd-LDL-C and sd-LDL-apoB registered in 
smoke exposed rats, was significantly reduced by 38-45 % after 4 weeks of Tocomin 
or Lovastatin treatment. In contrast, percent Ib-LDL-C and Ib-LDL-apoB values in 
both the treated groups were significantly increased by 31-55 %, when compared to 
the corresponding percent values of smoke exposed rats. These results demonstrate 
that a homogeneous preparation of sd-LDL and Ib-LDL can be obtained by 
employing heparin-Mg'^ -mediated precipitation of purified plasma LDL. In addition, 
the results also show that the prevalence and concentration of sd-LDL, which is 
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considered more atherogenic than LDL or Ib-LDL was substantially increased in 
smoke exposed rats. In smoke exposed rats treated with Tocomin or Lovastatin for 4 
weeks, the sd-LDL concentration was significantly reduced to a level similar to 
control value (N-C). 
3.11.4 Impact on the ratios of LDL-C/HDL-C, HDL-C/TQ sd-LDL-C/HDL-C and 
Ib-LDL-C/HDL-C 
As shown in Table 21, LDL-C/HDL-C, HDL-C/TC, sd-LDL-C/HDL-C and Ib-
LDL-C/HDL-C ratios were calculated from the data presented in Table 18, 19 and 20. 
LDL-C/HDL-C ratio was significantly increased from 2.72 in N-C to 6.11 (125 %) in 
S-C group, when compared to ratio in N-C. After 4 weeks of treatment, the increase 
in LDL-C/HDL-C ratio was significantly prevented and decreased to 2.04 and 2.19 in 
S-T3T and S-LT, respectively, which is close to normal control value. On the other 
« 
hand, HDL-C/TC ratio was significantly decreased from 0.233 in N-C to 0.121 (48 
%) in S-C group. Tocomin or Lovastatin treatment to these rats significantly 
prevented the increase in HDL-C/TC ratios and fiilly restored them to a ratio value 
similar to N-C. In N-C, when sd-LDL-C values were divided by HDL-C, a ratio of 
0.802 was obtained, which is substantially lower than LDL-C/HDL-C ratio of 2.72. In 
smoke exposed rats, sd-LDL-C/HDL-C ratio was substantially increased to a ratio 
value of 3.32 (314 %), when compared to N-C value. As expected, sd-LDL-C/HDL-
C ratio in Tocomin and Lovastatin treated rats were substantially reduced to a value 
of 0.632 (81 %) and 0.653 (80 %), respectively, these ratio values in S-T3T and S-LT 
are significantly lower than a ratio of 0.802 in N-C. In comparison to sd-LDL-
C/HDL-C, the ratio of Ib-LDL-C/HDL-C in S-C rats was increased by 44 %, from an 
N-C value of 1.93 to 2.77. Consistent with these results, the Ib-LDL-C/HDL-C ratios 
in treated groups where only partially (21-26 %) restored, in comparison to ratio 
value of N-C rats. These results indicate that sd-LDL-C/HDL-C ratio may be 
considered as a better and novel predictor for CAD risks than LDL-C/HDL-C ratios. 
In addition, the ratios related to sd-LDL-C and HDL-C in Tocomin or Lovastatin 
treated rats were positively modulated and restored similar to normal control value, 
indicating normalization of cholesterol levels associated with the above lipoproteins. 
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TABLE 21 
EFFECT OF TOCOMIN AND LOVASTATIN ON THE RATIOS OF LDL-
C/HDL-C, HDL-C/TC, Sd-LDL-C/HDL-C AND Lb-LDL-C/HDL-C IN 
CIGARETTE SMOKE EXPOSED RATS AFTER 
4 WEEKS OF TREATMENT 
Ratio^ 
Group 
N-C s-c S-TjT S-LT 
LDL-C/HDL-C 2.7210.021 6.1110.036 
(+124.63 %)" 
2.0410.026 
(-66.61 %)• 
2.1910.021 
(-64.15 %)' 
HDL-C/TC 0.23310.032 0.12110.003 0.28610.077 0.26810.036 (-48.06 %)" (+136.36 %)" (+121.48 %)" 
Sd-LDL-C/HDL-C 0.80210.008 3.3210.031 0.63210.006 0.65310.005 
(+313.96 % ) " (-80.96 % ) ' (-80.33 % ) " 
Lb-LDL-C/HDL-C 1.9310.021 2.77+0.31 1.4310.012 1.5310.016 (+43.52 % ) " (-25.90 % ) ' (-20.72 % ) o/.\« 
F^or the calculation of ratios, data is taken from Table 18,19 and 20. 
Values are mean ± SD from pooled plasma of 7 rats in each group. 
N-C, normal control; S-C, smoke exposed control; S-T3T, fed 6 mg Tocomin/ rat/ 
day and S-LT, given 0.50 mg Lovastatin/rat/day for 4 weeks. 
Significantly different from N-C at "p<0.001 and ''p<0.01. 
Significantly different from S-C at 'p<0.001, ''p<0.05 and ''p<0.01. 
Results 
3.11.5 Lipid Lowering Effect on liver, lung and kidney triglycerides, total 
cholesterol and free fatty acids 
As seen in Table 22, hepatic levels of triglyceride (TG), total cholesterol (TC) 
and free fatty acids (FFA) were significantly increased in smoke exposed rats (S-C) 
by 32 % 131 % and 38 %, respectively, when compared to corresponding values in 
N-C. Similarly, in lung, TG and TC levels were significantly increased by 20 % and 
49 % respectively, whereas, FFA level was not affected, while, TG, TC and FFA 
levels, in kidney of S-C rats were significantly increased by 31 %, 40 % and 58 %, 
respectively, when compared to respective values in N-C. Feeding of Tocomin or 
Lovastatin to smoke exposed rats for 4 weeks was associated with a significant 
decline in liver TG, TC and FFA levels by 15 %, 37 % and 19 % respectively, in S-
T3T, whereas, in S-LT group, TG, TC and FFA levels were reduced by 7 %, 40 % 
and 15 % respectively, when compared to corresponding values in S-C group. 
Similarly, in lung, TG, TC and FFA levels were reduced by 10 %, 32 % and 8 % 
respectively, in S-T3T. Whereas, in S-LT a decline of 13 %, 27 % and 9 % in TG, TC 
and FFA levels, respectively was seen. In kidney, Tocomin mediated a decline of 
22 %, 18 % and 25 % in TG, TC and FFA, whereas, these lipid parameters were 
reduced by 17 %, 21 % and 17 %, respectively, in S-LT, when compared to 
corresponding values in S-C group. These results demonstrate that similar to plasma 
TG, TC and FFA levels in liver, lung and kidney were significantly increased in 
smoke exposed rats. In addition, feeding of Tocomin or Lovastatin to smoke exposed 
rats resulted in a significant decline of TG, TC and FFA to a level similar to 
corresponding values in N-C. The combined results demonstrate that levels of TG, 
TC and FFA in plasma, liver, lung and kidney lipids were significantly increased in 
smoke exposed rats. Treatment of these stressed rats v^ ath 6 mg Tocomin/rat/day or 
0.50 mg Lovastatin/rat/day mediated a significantly decline in the above lipid 
parameters, similar to corresponding values in N-C rats. 
3.11.6 Regulation ofeniymatic activity of hepatic HMG-CoA reductase 
As shown in Table 23, hepatic HMG-CoA reductase activity in smoke exposed 
rats (S-C) was significantly increased by 54 % when compared to N-C value. Feeding 
of tocotrienols (Tocomin) or Lovastatin to these rats resulted in a significant decrease 
in HMG-CoA reductase activity by 81 %, and 35 %, respectively. These results 
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TABLE 23 
IN VIVO MODULATION OF HEPATIC HMG-CoA REDUCTASE ACTIVITY 
IN CIGARETTE SMOKE EXPOSED RATS TREATED WITH TOCOMIN 
AND LOVASTATIN FOR 4 WEEKS OF TREATMENT 
Group HMG-CoA reductase activity^ 
N-C 4.59±0.092 
S-C 2.12±0.034* 
(+53.81 %)• 
ST3T 3.8410.087' 
(-81.32 %)' 
S-LT 2.8610.027* 
(-34.90 %)' 
^Expressed as ratio of HMG-CoA to Mevelonate; lower the ratio higher the 
enzyme activity. 
Values are mean 1SD from pooled liver homogenate of 7 rats in each group. 
N-C, normal control; S-C, smoke exposed control; S-T3T, fed 6 mg Tocomin/ 
rat/day and S-LT, given 0.50 mg Lovastatin/rat/day for 4 weeks. 
Significantly different from N-C at •p<0.001. 
Significantly different from S-C at •p<0.001. 
Results 
demonstrate that Tocomin and Lovastatin mediated decrease in cholesterol levels of 
smoke exposed rats, is apparently due to decline in the enzymatic activity of hepatic 
HMG-CoA reductase, the rate limiting enzyme in the biosynthetic pathway of 
cholesterol. 
3.11.7 Impact on plasma total antioxidants and lipid peroxidation products 
As seen in Table 24 depicts the antioxidant impact of Tocomin or Lovastatin on 
plasma concentrations of total antioxidants, conjugated diene, lipid hydroperoxide 
and MDA in smoke exposed (S-C) rats. In S-C rats, plasma total antioxidants level 
was reduced from a control value of 54 to 40 (25 %) ^mole/dl. Treatment of S-C rats 
with Tocomin or Lovastatin for 4 weeks resulted in a significant increase of total 
antioxidants levels by 24 % and 11 %, when compared to N-C value. The oxidative 
stress induced in S-C rats significantly enhanced plasma lipid peroxidation products, 
such as conjugated diene, lipid hydroperoxide and MDA. Formation of conjugated 
diene, lipid hydroperoxide and MDA in plasma was increased from 9.51, 1.19 and 
1.44 in N-C to 14.10 (48 %), 1.95 (64 %) and 3.23 (124 %) ^mole/dI, respectively, in 
S-C. After Tocomin treatment, in S-T3T, a significant decrease of 18 %, 33 % and 37 
% was seen in the formation of conjugated diene, lipid hydroperoxide and MDA, 
respectively, when compared to corresponding values in S-C rats. Similarly in S-LT, 
conjugated diene, lipid hydroperoxide and MDA in plasma were also significantly 
decreased by 11%, 29 % and 32 %, respectively, when compared to corresponding 
values in S-C rats. These results demonstrate that in S-C rats, due to increase in 
oxidative stress, total antioxidants level was decreased, whereas, concentration of 
plasma conjugated diene, lipid hydroperoxide and MDA were significantly increased. 
Tocomin (tocotrienols) or Lovastatin treatment significantly restored the total 
antioxidants level and blocked the increase in plasma conjugated diene, lipid 
hydroperoxide and MDA to a level close to corresponding normal values. 
3.11.8 Effect on membrane lipid peroxidation in erythrocytes 
As seen in Table 25, erythrocytes from smoke exposed rats (S-C) group showed 
a greater susceptibility to hydrogen peroxide-induced lipid peroxidation than those 
from N-C group. A substantial increase of 147 % in the MDA content in S-C was 
observed, when compared to N-C value. Formation of MDA was markedly decreased 
by 54 % and 33 %, after the administration of Tocomin or Lovastatin, respectively. 
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TABLE 24 
ANTIOXIDANT IMPACT OF TOCOMIN AND LOVASTATIN ON PLASMA 
TOTAL ANTIOXIDANTS, CONJUGATED DIENE, LIPID 
HYDROPEROXIDE AND MALONDIALDEHYDE CONTENTS IN 
CIGARETTE SMOKE EXPOSED RATS AFTER 
4 WEEKS OF TREATMENT 
„ Total Conjugated Lipid . , _ . 
Group X- -J * J- u J .J MDA 
'^  antioxidants diene hydroperoxide 
N-C 53.67±0.063 9.51±0.013 1.19±0.005 1.44±0.041 
S-C 39.99±0.134 14.10±0.011 1.95±0.051 3.23±0.112 
(-25.48%)" (+48.26%)" (+63.86%)" (+124.3%)" 
S-T3T 49.44±0.064 11.54±0.015 1.30±0.005 2.02±0.041 
(+23.63%)" (-18.15%)" (-33.34%)" (-37.46%)" 
S-LT 44.4010.875 12.51±0.023 1.38±0.024 2.1910.065 
(+11.02%)" (-11.27%)" (-29.23%)" (-32.19%)" 
'Values are mean (fimole/dl) ± SD from pooled plasma of 7 rats in each group. 
N-C, normal control; S-C, smoke exposed control; S-T3T, fed 6 mg Tocomin/ rat/ 
day and S-LT, given 0.50 mg Lovastatin/rat/day for 4 weeks. 
Significantly different from N-C at "p<0.001. 
Significantly different from S-C at "p<0.001 and ''p<0.05. 
TABLE 25 
MALONDIALDEHYDE CONTENTS AND IN VITRO MDA RELEASE IN 
ERYTHROCYTES OF CIGARETTE SMOKE EXPOSED RATS AFTER 4 
WEEKS OF TOCOMIN AND LOVASTATIN TREATMENT 
Group MDA Erythrocytes MDA release 
(nmole/g Hb) (percent 
N-C 23.1310.1018 6.92±0.107 
S-C 57.06±1.103 13.33±0.122 
(+146.69 %)• (+92.63 %)* 
S-T3T 26.34±0.264 7.11±0.140 
(-53.83%)' (-46.66%)" 
S-LT 38.50±0.283 9.47±0.057 
(-32.52 %)' (-28.95 %)" 
'Values are mean ± SD from pooled packed erythrocytes of 7 rats in each group. 
N-C, normal control; S-C, smoke exposed control; S-T3T, fed 6 mg Tocomin/ 
rat/day and S-LT, given 0.50 mg Lovastatin/rat/day for 4 weeks. 
Significantly different from N-C at ''p<0.001. 
Significantly different from S-C at ''p<0.001. 
Results 
• 
when compared to the corresponding values in S-C. Similarly, release of MDA 
erythrocytes was increased from 6.92 in N-C tol3.33 nmol/gHb (93 %) in S-C. A 
highly significantly decrease of 47 % and 29 % in MDA release was seen in smoke 
exposed rats treated with 6 mg/rat/day Tocomin or 0.50 mg/rat/day Lovastatin, 
respectively, when compared to corresponding values in S-C rats. These results 
demonstrate that exposure of cigarette smoke to rats for 4 weeks was associated with 
a significant increase in both ex vivo and in vivo erythrocytes membrane lipid 
peroxidation product and MDA, which was significantly prevented by the 
administration of Tocomin or Lovastatin. 
3.11.9 Impact on liver, lung and kidney lipid peroxidation products 
As seen in Table 26, the formation of conjugated diene, lipid hydroperoxide and 
MDA in liver of smoke exposed rats were significantly increased by 46 %, 35 % and 
37 %, respectively, whereas in lung, these levels were significantly increased by 44 
%, 54% and 46 %, respectively. Similarly, in kidney formation of conjugated diene, 
lipid hydroperoxide and MDA were significantly increased by 68 %, 71 % and 42 %, 
respectively, when compared to corresponding values in N-C. Feeding of Tocomin 
or Lovastatin to smoke exposed rats for 4 weeks, was associated with a significant 
decline in the formation of liver conjugated diene, lipid hydroperoxide and MDA by 
27 %, 22 % and 28 % respectively, in S-T3T rats whereas, in S-LT, these levels were 
reduced by 26 %, 21 % and 10 %, respectively, when compared to corresponding 
values in S-C group. Similarly, in lung, conjugated diene, lipid hydroperoxide and 
MDA were significantly reduced by 19 %, 27 % and 21% respectively, in S-T3T and 
in Lovastatin treated rats; these values were decreased by 21 %, 24 % and 22 %, 
respectively, when compared to corresponding values in S-C rats. In addition, 
formation of conjugated diene, lipid hydroperoxide and MDA in kidney was 
significantly reduced by 24 %, 35 % and 11 % respectively, in S-T3T. Similarly, the 
above three lipid peroxidation products in kidney were significantly decreased by 23 
%, 31 % and 14 %, respectively, in S-LT group, when compared to corresponding 
values in S-C group. These results demonstrate that increased levels of conjugated 
diene, lipid hydroperoxide and MDA in liver, lung and kidney of smoke exposed rats 
were significantly reduced after 4 weeks of Tocomin or Lovastatin treatment. 
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Results 
3.12 Ex vivo and Cu**-Mediated In vitro Oxidation of LDL, Sd-LDL and Lb-
LDL in Smoke Exposed Rats after 4 Weeks of Tocomin and Lovastatin 
Treatment 
3.12,1 Antioxidant effect on basal levels of conjugated diene formation and lag 
phase in LDL, sd-LDL and Ib-LDL 
As depicted in Table 27, the ex vivo base line diene conjugation (BDC) levels of 
LDL, sd-LDL and Ib-LDL in smoke exposed rats were increased by 60 %, 62 % and 
15 %, respectively, in comparison to the corresponding N-C values. Feeding of 
Tocomin to smoke exposed rats partially blocked the in vivo oxidation of LDL, sd-
LDL and Ib-LDL and reduced their BDC levels by 27 %, 31 % and 11 %, 
respectively. Similarly, after Lovastatin treatment (S-LT), BDC levels in LDL, sd-
LDL and Ib-LDL were reduced by 20 %, 19 % and 9 %, respectively, in comparison 
to the corresponding N-C values. As expected, the lag phase time of LDL oxidation 
was reduced from 95 min in N-C to 62 min in S-C, whereas, for Ib-LDL oxidation, it 
was reduced from 54 min in N-C to 41 min in S-C. Treatment of smoke exposed rats 
with Tocomin or Lovastatin restored the lag phase time of LDL oxidation to 83 min 
and 71 min, respectively, whereas, lag phase time of Ib-LDL oxidation in both the 
treated groups was restored to 50 min and 45 min, respectively. In comparison to lag 
phase time of LDL or Ib-LDL oxidation in N-C, sd-LDL oxidation resulted in a 
strikingly lower lag phase time of 16.40 min, which was significantly reduced to 12 
min in S-C. Following treatment with Tocomin or Lovastatin the lag phase time of 
sd-LDL oxidation was increased to 16 min and 14 min, respectively. These result 
demonstrate that relative to Ib-LDL, both ex vivo and in vitro conjugated diene 
formation in sd-LDL were markedly increased in smoke exposed rats, resulting in a 
strikingly lower lag phase time, indicating a substantially enhanced susceptibility of 
sd-LDL to in vivo oxidation. Similarly, treatment of smoke exposed rats with dietary 
Tocotrienols (Tocomin) or Lovastatin mediated an antioxidant effect by 
preferentially and significantly blocking the ex vivo formation of conjugated diene of 
more atherogenic sd-LDL, when compared to Ib-LDL or LDL. 
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Results 
3.13 Regulatory Effect of Tocomin and Lovastatin on Plasma, HDL and its 
Subfractions HDL2 and HDL3 Arylesterase Activity and LDL-C: 
Arylesterase Activity Ratio in smoke exposed Rats after 4 Weeks of 
Treatment 
It is well known that enzyme arylesterase, also known as paraoxonase, is 
associated with plasma HDL. The antioxidant activity of HDL is believed to reside in 
its enzymes, particularly arylesterase. Several reports indicated that HDL-associated 
arylesterase enzyme protects against LDL oxidative modification. The arylesterase 
activity was shown to be regulated both genetically and by diet, indicating that 
adequate dietary intake of antioxidants such as vitamin E is essential. Therefore, we 
have also investigated the impact of Tocomin or Lovastatin on plasma, HDL and its 
subfractions HDL2 and HDL3, isolated from plasma of each group by dextran sulfate 
precipitation method. As shown in Table 28, arylesterase activity in plasma, HDL and 
its subtractions HDL2 and HDL3 of smoke exposed rats was significantly reduced 
from 643, 551, 160 and 371 units in N-C rats to 536 (17 %), 464 (16 %), 139 (13 %) 
and 317 (15 %) units in S-C rats. Treatment of smoke exposed rats with Tocomin 
significantly blocked the decrease in arylesterase activity and increased it by 28 %, 12 
%, 11 % and 13 %, respectively, in S-T3T, whereas, in S-LT rats, arylesterase activity 
was increased only by 7 %, 7 %, 5 %, and 8 %, respectively, when compared to 
corresponding values in S-C group. The distribution of arylesterase activity in HDL 
and its subfi^ctions, HDL2 and HDL3, was 86 %, 29 % and 67 %, respectively, of 
plasma arylesterase activity in normal control. These resuhs indicate that feeding of 6 
mg Tocomin/rat/day was more efficient in terms of increase in HDL-associated 
arylesterase activity in comparison to S-LT rats, which were fed 0.50 mg 
Lovastatin/rat/day. Consistent with above results, the ratio of LDL-C to arylesterase 
activity in S-C rats was significantly increased from 0.807 x 10'^  in N-C to 2.03 x 10'^  
(151 %) in S-C rats. This increase in the ratio of LDL-C to arylesterase activity in S-
C rats was significantly reduced to a value of 0.996 x 10'^  (51 %), after Tocomin 
treatment (S-T3T). Similarly, in S-LT rats, ratio value was significantly reduced by 
0.969 X 10"^  (52 %), after 4 weeks of Lovastatin treatment. These results suggest that 
treatment of smoke exposed rats with dietary Tocomin or Lovastatin significantly 
prevented the increase in LDL-C/arylesterase activity ratio and decreased it to a level, 
which is 81 % or 83 %, respectively, of ratio value of normal control rats indicating a 
potent antioxidant effect of Tocomin or Lovastatin. 
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Results 
3.14 Effect of Tocomin and Lovastatin on Plasma, Hepatic, Lung and Kidney 
Xanthine Oxidase Activity in Smoke Exposed Rats after 4 Weeks of 
Treatment 
Xanthine oxidase is known to be an important biological source of free radicals. 
There is overwhelming evidence to suggest that serum xanthine oxidase activity is 
significantly increased in various pathological disorders, like hepatitis, inflammatory 
diseases, hypercholesterolemia, atherosclerosis, ischemia-reperfusion, carcinogenesis, 
aging and diabetes and that free radicals generated in the enzymatic processes are 
involved in oxidative damage. Thus, it may be possible that the inhibition of this 
enzymatic pathway by the compounds that have both antiradical and xanthine oxidase 
inhibitory properties may have additional therapeutic importance in the treatment of 
the above diseases. Therefore, we have investigated the possible inhibitory effect of 
Tocomin or Lovastatin on plasma, hepatic, lung and kidney xanthine oxidase activity 
in smoke exposed rats. As seen in Table 29, plasma, hepatic, lung and kidney 
xanthine oxidase activity was significantly increased from 5.31, 0.514, 0.381 and 
1.77 units in N-C to 9.05 (70 %), 0.752 (46%), 0.464 (21 %) and 0.347 (96 %) units 
in smoke exposed rats (S-C). Tocomin had a significant effect in preventing this 
increase in xanthine oxidase activity of plasma, hepatic, lung and kidney and reduced 
them by 34 %, 28 %, 10 % and 48 %, respectively, when compared to the 
corresponding values in S-C. Similarly, treatment of smoke exposed rats with 
Lovastatin was associated with a significant decline of 28 %, 20 %, 11 % and 48 %, 
respectively, in plasma, hepatic, lung and kidney xanthine oxidase activity, when 
compared to the corresponding values of S-C rats. These results demonstrate that 
both Tocomin and Lovastatin, in addition to their potent antioxidant activity also 
significantly inhibited the elevated levels of xanthine oxidase associated with plasma, 
liver, lung and kidney of smoke exposed rats, indicating a dual therapeutic benefit in 
the treatment of these disorders. 
3.15 Regulatory Effect of Tocomin and Lovastatin on Antioxidant Defense 
System in Smoke Exposed Rats after 4 Weeks of Treatment 
Oxidative stress may be increased in smoke exposed rats due to a higher 
production of reactive oxygen species (ROS), such as superoxide radical, hydroxyl 
radical, hydrogen peroxide and/or deficiency in the antioxidant defense systems. An 
impaired radical scavenger function has been linked to the decreased activity of 
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TABLE 29 
EFFECT OF TOCOMIN AND LOVASTATIN ON PLASMA, LIVER, LUNG 
AND KIDNEY XANTHINE OXIDASE ACTIVITY IN CIGARETTE SMOKE 
EXPOSED RATS AFTER 4 WEEKS OF TREATMENT 
Group 
Xanthine oxidase activity 
Plasma Liver Lung Kidney 
(U/ml)^  (U/mg protein)* (U/mg protein)* (U/mg protein)* 
N-C 5.3110.031 0.51410.0023 0.38110.0011 0.17710.0011 
S-C 9.0510.138 
(+70.43%)" 
0.75210.0027 
(+46.30%)" 
0.46410.0010 
(+21.18%)" 
0.34710.0011 
(+96.04%)" 
S-TjT 6.0110.119 0.53810.0018 0.41710.0012 0.18010.0052 
(-33.59%)" (-28.45%)" (-10.12%)" (-48.12%)" 
S-LT 6.5410.162 0.60110.0014 0.41310.0023 0.17910.0070 
(-27.73%)" (-20.07%)" (-10.99%)" (-48.41%)" 
^One unit of enzyme activity is defined as nmole of uric acid formed/min/ml. 
*One unit of enzyme activity is defined as nmole of uric acid formed/min/mg 
protein. 
^Values are mean 1 SD homogenate of pooled liver, lung or kidney of 7 rats in 
each group. 
N-C, normal control; S-C, smoke exposed control; S-T3T, fed 6 mg 
Tocomin/rat/day and S-LT, given 0.50 mg Lovastatin/rat/day for 4 weeks. 
Significantly different from N-C at "p<0.001. 
Significantly different from S-C at "p<0.001. 
Results 
enzymatic and nonenzymatic scavengers of free radicals. Therefore, the status of 
antioxidant enzymes, such as catalase, superoxide dismutase (SOD), glutathione 
peroxidase (Gpx), glutathione-S-transferase (GST) and glutathione reductase (Gred) 
including reduced glutathione (GSH) concentrations in liver, lung and kidney of 
experimental smoke exposed rats are highly important. 
3.15.1 Impact on the regulation of hepatic, lung and kidney catalase, superoxide 
dismutase, glutathione peroxidase, glutathione reductase and glutathione-S-
transferase activities 
As seen in Table 30, catalase activity in liver, lung and kidney were 
significantly decreased from a value of 3.79, 1.62 and 2.56 units in N-C to 2.43 (36 
%), 1.38 (15 %) and 1.34 (48 %) units, in S-C, respectively. Administration of 
Tocomin to smoke exposed rats (S-T3T) resulted in a significant increase in liver and 
kidney catalase activities by 3.33 (37 %) and 2.60 (94 %) units, respectively, whereas, 
catalase activity in lung was increased by only 9 %, when compared to corresponding 
tissue values of S-C rats. In Lovastatin treated (S-LT) group, liver catalase activity 
was significantly increased by 33 %, whereas, lung and kidney catalase activity were 
significantly increased and fully restored to normal level. However, in comparison to 
corresponding tissue values of normal control rats (N-C), the decline in hepatic, lung 
and kidney SOD activity of smoke exposed rats was 26 %, 11 % and 16 %, 
respectively. Treatment of Tocomin or Lovastatin smoke exposed rats resulted in a 
significant increase in hepatic SOD activity by 24 % and 20 %, respectively, whereas, 
SOD activities in lung and kidney was fully restored to respective normal values. 
Table 32 summarizes the results of Gpx, Gred and GST activities in liver, lung 
and kidney of smoke exposed rats after 4 weeks of Tocomin or Lovastatin treatment. 
In smoke exposed rats, Gpx activity in liver, lung and kidney were significantly 
increased from a value of 58, 104 and 61 units in N-C to 71 (23 %), 116 (11%) and 
92 (50 %) units, respectively, in S-C rats. As evident, after 4 weeks of treatment with 
Tocomin, Gpx activity in liver and lung was significantly decreased by 25 % and 21 
%, whereas, kidney Gpx activity was fully normalized after Tocomin or Lovastatin 
treatment. In S-LT rats, the Gpx activity in liver, lung and kidney were decreased by 
24 % and 21 %, respectively, when compared to corresponding tissue values in S-C 
group. On the other hand, in smoke exposed rats, the enzymatic activities of hepatic 
Gred and GST were decreased significantly by 32 % and 25 %, respectively, when 
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compared to corresponding values of N-C rats. Feeding of Tocomin or Lovastatin to 
smoke exposed rats significantly blocked the decrease in hepatic Gred and GST 
activities and increased them to a similar value of 29 % and 20 %, respectively, 
Compared to corresponding values of lung Gred and GST activities in N-C, the 
enzymatic activities of Gred and GST in S-C group were significantly decreased by 
37 % and 40 %, respectively, whereas, the enzyme activities in kidney were reduced 
by 8 % and 40 %, respectively, when compared to corresponding values of N-C. 
Administration of Tocomin or Lovastatin to smoke exposed rats significantly 
prevented the decrease in Gred activity and increased to a level, which is similar to 
normal value, whereas, GST activity in kidney was increased by only 48 % and 37 %, 
respectively, when compared to respective values in S-C rats. In simimary, hepatic, 
lung and kidney catalase, SOD, Gpx, Gred and GST enzymes, which constitute a 
mutually supportive team of defense against ROS, are significantly decreased in 
smoke exposed rats. However, feeding of Tocomin or Lovastatin substantially 
quenches these free radicals (ROS), thus positively normalizing the above enzyme 
levels. 
3.15.2 Impact on hepatic, lung and kidney total, free and protein-bound-sulfhydryl 
contents of glutathione 
Reduced glutathione, a major non-protein thiol plays a crucial role in 
coordinating the antioxidant defense processes in the body. Perturbation of GSH 
status of a biological system can lead to serious consequences. As evident from Table 
31, hepatic total, fi-ee and protein-bound-SH contents of glutathione were 
significantiy reduced fi"om a value of 75, 12 and 63 units in N-C to 34 (54 %), 11 (11 
%) and 24 (61 %) units in smoke exposed rats, respectively. Feeding of Tocomin or 
Lovastatin to smoke exposed rats significantly increased the hepatic total and protein-
bound-SH levels of glutathione by 104 % and 139 % in S-T3T and by 100 % and 135 
%, in S-LT respectively, in comparison to the corresponding values in S-C. Whereas, 
fi-ee-SH content in Tocomin or Lovastatin treated group was increased and restored to 
a value similar to N-C rats. Total, fi-ee and protein-bound-SH contents of glutathione 
in lung were significantly decreased in smoke exposed rats by 55 %, 19 % and 62 %, 
respectively, in comparison to the corresponding values in N-C. Administration of 
Tocomin to smoke exposed rats prevented this decrease and increased the lung total 
and protein-bound-SH levels of glutathione by 110 % and 129 %, respectively, in 
121 
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comparison to the corresponding values in S-C, whereas, free-SH level was fully 
normalized. Similarly, in S-LT rats, an increase of 72 % and 144 %, respectively, in 
total and protein-bound-SH levels of glutathione was seen, when compared to the 
corresponding values in S-C, while no effect was seen on free glutathione. Whereas, 
kidney total, free and protein-bound-SH contents of glutathione were significantly 
reduced by 63 %, 16 % and 70 %, respectively, in smoke exposed rats, when 
compared to the corresponding values in N-C. Tocomin treatment to smoke exposed 
rats substantially increased the kidney total and protein-bound-SH levels of 
glutathione by 161 % and 212 %, respectively, whereas, in S-LT rats, a significant 
increase of 139 % and 182 %, respectively, was observed in both treated groups, 
which were restored similar to normal value in N-C rats. These results indicate that in 
general decline in liver, lung and kidney GSH contents of smoke exposed rats was 
significantly blocked after Tocomin or Lovastatin treatment, indicating an antioxidant 
effect of dietary tocotrienols (Tocomin) and Lovastatin. 
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Discussion 
Cigarette smoking is firmly established as a primary risk factor for atherosclerotic 
cardiovascular disease. Increased oxidative stress is one of the principal mechanisms 
by which it may exert its pathological influence. This study is the first to examine the 
effect of dietary tocotrienols (Tocomin) supplementation on overall proatherogenic 
actions of cigarette smoke. Results presented in the thesis demonstrate that young 
(aged 23-25 years) cigarette smokers (smoking history, 13 cigarettes/day for 4.6-4.9 
years) experience an exaggerated oxidative stress when compared with age-matched 
nonsmokers. The cigarette smoke induced extensive proatherogenic changes, that 
occurred in young smokers, were reflected on a variety of parameters, such as, blood 
nicotine, carboxyhemoglobin, plasma and lipoprotein lipids including cholesterol and 
apoB content of LDL and its subfractions, small dense (sd-) LDL and large buoyant 
(lb-) LDL, plasma lipid peroxidation products including ex vivo and in vitro 
oxidizability of LDL, sd-LDL and Ib-LDL, plasma total antioxidants and HDL-
associated arylesterase activity; malondialdehyde (MDA) release and antioxidant 
enzymes in erythrocytes. Supplementation of young smokers with dietary tocotrienols 
(Tocomin, 150 mg/day) for 8 weeks, significantly reduced the overall oxidative 
burden and effectively ameliorated the above altered parameters, thus, indicating a 
strong hypolipidemic/antiatherogenic and antioxidant effect of Tocomin. 
For many years, a-tocopherol (a-T) was generally considered the most potent 
chain breaking antioxidant in the vitamin E family (Burton et al., 1983). However, 
several reports have shown tocotrienols (T3S) to be more potent than tocopherols 
(Suama et al., 1993; Kamat and Devasagayan, 1995; Kamat et al., 1997). 
Tocotrienols have been shown to exhibit greater free radical scavenging properties as 
cell membrane constituents than tocopherols (Yamaoka and Carrillo, 1990; Serbinova 
et al., 1991). They quench free radicals in cell membranes and protect them against 
lipid peroxidation. The higher antioxidant potency of a-T3 as compared to a-T is 
attributed to the combined effects of three properties: it's higher recycling efficiency 
fi-om chromanoxyl radical, its more uniform distribution in membrane bilayer, and its 
stronger disordering of membrane lipids which makes interaction of chromanols with 
lipid radicals more efficient. Since, Tocomin used in the present study is a mixture of 
a-T3, y-T3, 5-T3 and a-T; we have examined the efficacy of individual T3S, a-T and 
Tocomin as a scavenger of peroxyl radical. Our result showed that, by using DPPH, 
the order of antiradical activity or hydrogen donating ability, expressed in terms of 
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half quenching concentration (IC50) was 5-T3> a-T3> Y-T3> Tocomin> a-T. Our 
results are in agreement with earlier reports (Qureshi et al, 2000) indicating that in 
intact membranes, including LDL particles, tocotrienols may have a significantly 
greater antioxidant effect than a-T and they may provide greater protection against 
coronary artery disease (CAD). The possible mechanism for this superior efficacy of 
tocotrienols compared to a-T has been reported elsewhere (Packer, 1995). The 
reduction in the free radical quenching efficiency of Tocomin (50.83 \iM) in 
comparison to 5-T3, a-T3, y-T3 is apparently due to the presence of 23 % a-T, which 
has a lowest peroxyl radical scavenging efficiency of 70.75 |iM. These results are 
consistent with a previous report indicating the presence of higher percentage (20 %) 
of a-T in tocotrienol rich fraction (TRF), reduces the antioxidant activity (Qureshi et 
al.. 2000). 
It is now well established that tobacco smoking is an independent, modifiable 
risk factor for coronary, cerebral, and peripheral arterial diseases. Cigarette smoking 
increases the risk of myocardial infarction in both men and women (Fish III and 
Bartholomew, 2007). The gas phase of cigarette smoke contains more than lO'^  free 
radicals per puff, and the extent to which these compounds affect endothelial 
dysfunction and inflammation remains unclear (Ambrose and Barua, 2004). Several 
studies show that in addition to increase in oxidative stress, certain other compounds 
of cigarette smoke, such as nicotine and carbon monoxide (CO) play a role in 
atherogenesis. Nicotine alone acutely increases endothelial dysfunction by means of 
impaired vascular reactivity (Neunteufl et al, 2002). Coronary vasospasm caused by 
nicotine in cigarette smoke has been demonstrated in young women (Caralis et al., 
1992). Nicotine also increase the diurnal secretion of Cortisol (Hill, 1975), which may 
contribute to cardiac arrhythmias (Moss et al, 1971; Oliver and Yates, 1971), and it 
may lead to increased platelet adhesiveness (Hawkins, 1972). Carbon monoxide 
constitutes 4% of cigarette smoke and directly leads to high levels of 
carboxyhemoglobin. Through sustained exposure to high levels of CO, chronic 
hypoxia ensues, leading to increased exercise-induced ischemia, ventricular 
dysfunction, and arrhythmias in patients with CAD (Allred et al, 1989). In addition, 
in one cross-sectional study in Britain, carboxyhemoglobin levels appeared to be 
better predictor of atherosclerotic disease than smoking histories (Hammond et al, 
1976). Consistent with earlier reports (Jarvis et al, 1987; Choen et al, 1980), our 
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results show a 3.1-fold increase in blood nicotine and 2.3-fold increase in 
carboxyhemoglobin in young smokers. Eight-week Tocomin treatment of these 
smokers caused a significant reduction in nicotine and carboxyhemoglobin levels, 
which were reversed to 82 % and 50 % of respective control values of nonsmokers. 
These results indicate a strong protective effect of dietary tocotrienols, which may 
help lower the risk of myocardial infarction in smokers. Oxidative stress mediated by 
free radicals present in the gas phase and tar of cigarettes has been hypothesized to be 
central to the pathogenesis of smoking-related atherosclerosis (Fuster et al, 1996). 
The exact toxic components of cigarette smoke and the mechanisms involved in 
cigarette smoke related cardiovascular dysfunction are largely unknown, but cigarette 
smoke increases inflammation, thrombosis, and oxidation of LDL-C. Recent 
experimental and clinical data support the hypothesis that cigarette smoke exposure 
increases oxidative stress as a potential mechanism for initiating cardiovascular 
dysfunction (Ambrose and Barua, 2004). Our results indicate a modest and significant 
increase in plasma total lipid, TG, free fatty acid (FFA) and TC in smokers. The 
increase in plasma TG levels is apparently due to an increase in VLDL which can be 
the result of either increased VLDL production or decreased VLDL clearance. It is 
possible that massive free radical load in smokers may stimulate VLDL production by 
increasing adipose tissue lipolysis, increasing hepatic de novo fatty acid synthesis, 
and decreasing hepatic fatty acid oxidation, all of which provide fatty acid substrate 
for esterification into TG and assembly into VLDL particles in the liver as well as 
increase in plasma FFA. Tocomin effectively blocked the increase in the above lipid 
parameters and reversed them to a level similar to their respective control values of 
nonsmokers. As expected, plasma levels of VLDL-C, LDL-C and atherogenic non-
HDL-C were significantly increased (33-49 %) in smokers, which were significantly 
reversed to 89-93 % of nonsmokers value after 8 weeks of Tocomin treatment. In 
contrast to atherogenic LDL, cholesterol associated with antiatherogenic HDL was 
significantly lower (51 %) in young smokers as compared to nonsmokers. However, 
the cholesterol content of large, light, cholesteryl ester-rich HDL2, which is 
considered to be a strong predictor of presence and extent of CAD (Drexel et al., 
1992), was preferentially and markedly reduced by 74 %, while small, dense, lipid-
poor HDL3, which exerts potent protection of atherogenic LDL against oxidative 
stress, was significantly reduced by 41 % in placebo treated smokers. Tocomin 
supplementation of young smokers blocked the reduction in HDL-C and restored to 
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65 % of HDL-C value in nonsmokers. Consistent with the substantial decline (74 %) 
in HDL2-C of smokers, Tocomin effectively restored this decrease to 75 % of HDL2-
C value in nonsmokers. However, cholesterol content of more antioxidative HDL3 
was not reversed during 8 weeks of Tocomin treatment. This may be due to markedly 
increased production of oxidants and significantly diminished antioxidant defense 
including a decline in total plasma antioxidants (Table 9). 
Low density lipoproteins are composed of distinct subclasses that differ in 
size, density, chemical composition, and their association with cardiovascular disease 
(Gardner et al, 1996; Griffin et ai, 1994; Lamarche etai, 1997). Lipoprotein profiles 
that are relatively rich in small dense (sd-) LDL particles are associated with upto a 3-
fold greater risk of myocardial infarction than those mainly consist of large buoyant 
(lb-) LDL particles (Austin et al. 1988; Austin et al. 1990; Stampfer et al, 1996). 
Compared with Ib-LDL particles, sd-LDL is more susceptible to oxidation (Tribble et 
al. 1992; Chait et al. 1993; Tribble et al, 1995; Tribble et al. 2001). Furthermore, 
sd-LDL has poorer binding affinity to the LDL receptor, resulting in increased plasma 
half-life in the circulation and decreased clearance (Nigon et al, 1991). In addition, 
because of the smaller size, sd-LDL can efficiently penetrate the endothelial barrier 
into the arterial intima and interact with intima proteoglycans, leading to retention in 
the arterial wall (Hurt-Camejo et al, 1990). Therefore, sd-LDL particles are 
considered more atherogenic than Ib-LDL. It has been shown that not only the 
prevalence of sd-LDL but its concentration was significantly increased in healthy 
subjects with various types of hyperlipidemia, such as hyperLDLcholesterolemia, 
hypertriglyceridemia, combined hyperlipidemia and chylomicronemia, 
hyperlipidemia with CHD and type 2 diabetic hyperlipidemic patients with CHD 
(Hirano et al, 2004). Similarly, Quebec cardiovascular study has confirmed that a 
predominance of sd-LDL is a strong and independent predictor of CHD in the first 
seven years of follow-up (St-Pierre et al, 2005). Recently, Koba et al (2006) have 
reported that the progression of CHD was closely linked not to the LDL particle size, 
but to the concentration of sd-LDL. Therefore, sd-LDL has been highlighted as a new 
potent and useful marker for the risk of CHD (Austin et al, 1995; Hirano et al, 2004; 
Koba et al, 2006). In response to proatherogenic action of cigarette smoke, our 
results show a significantly greater increase in sd-LDL-C (75 %) than LDL-C (49 %) 
or Ib-LDL-C (36 %) of smokers as compared to nonsmokers. Thus, in smokers, >37 
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% of LDL-C was recovered in sd-LDL subpopulation, which is >18 % higher than its 
percent share of total LDL-C in nonsmolcers. On the other hand, although Ib-LDL-C 
in smokers was significantly increased (36 %), but its percent share of total LDL-C 
was not increased, instead decreased (9 %), indicating a preferential shift of LDL-C to 
more atherogenic sd-LDL subspecies due to oxidative stress induced 
hyperLDLcholesterolemia in smokers. Treatment of smokers with Tocomin 
significantly reduced both the cholesterol and apoB content of sd-LDL as well as their 
percent share of LDL close to corresponding control values in nonsmokers, indicating 
a shift from atherogenic sd-LDL to less atherogenic Ib-LDL and hence a strong 
antiatherogenic effect of Tocomin. It is interesting to mention that Tocomin mediated 
reduction in sd-LDL-C was better than that of LDL-C (39 % vs. 29 % in LDL-C). The 
preferential increase in cholesterol and apoB content of sd-LDL in smokers is 
consistent with previous finding indicating that sd-LDL particles have poorer binding 
affinity to the LDL receptor, resulting in increased plasma half life in the circulation 
and decreased clearance (Nigon et al, 1991). Our results are consistent with a recent 
report (Tokuno et al, 2007), where administration of 1 mg pitavastatin to type 2 
diabetic hyperlipidemic patients for 3 months significantly reduced both LDL and sd-
LDL. Mechanism wise, similar to pitavastatin (Saito et al, 2001; Sone et al, 2002), 
induction of LDL receptors by dietary tocotrienols may stimulate the uptake of LDL 
and sd-LDL particles with a minimum effect on Ib-LDL particles. Alternatively, 
similar to potent induction of LDL receptors by 2 mg pitavastatin, high dose of 
tocotrienols may preferentially facilitate the removal of sd-LDL particles (Sone et al, 
2002). The efficient and preferential removal of sd-LDL than Ib-LDL in Tocomin 
treated smokers may also be related to precursor-product relationship. In humans, TG 
rich large VLDL (VLDLl) is proposed to be a precursor of sd-LDL, while smaller 
VLDL (VLDL2) is proposed to be a precursor of Ib-LDL (Packard and Shepherd, 
1997; Tribble et al, 2001). As shown for fibrate (Milosavljevic et al, 2001), dietary 
tocotrienols may also reduce sd-LDL particles by suppressing the production of 
VLDLl and stimulating the transfer from VLDLl to VLDL2 via the activation of 
lipoprotein lipase. Consistent with these reports, our results show a concomitant 
decline of both plasma TG and sd-LDL levels after 8 weeks of Tocomin 
supplementation of young smokers. Thus, the specific decrease in sd-LDL implied 
significant increases in LDL buoyancy. Based on our results, the primary target of 
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therapy in hyperLDLcholesterolemic subjects with and without CHD should be the 
preferential lowering of highly atherogenic sd-LDL subpopulation along with LDL. 
It has previously been established that LDL-C/HDL-C and HDL-C/TC ratios 
are good predictors for the presence and severity of CAD (Drexel et al, 1992). A 
LDL-C/HDL-C ratio of 1.82 in nonsmokers is better than the normal ratio range of 
3.2 to 3.6 or preferably lower designated for normocholesterolemic humans. This ratio 
of 1.82 was increased to a much higher LDL-C/HDL-C ratio value of 5.30 in 
smokers. Tocomin treatment of smokers significantly reduced this ratio to a normal 
value of 3.01. Similarly, in nonsmokers, HDL-C/TC ratio of 0.293 was observed, 
which is well within normal ratio range of 0.20 or preferably higher. This ratio of 
0.293 in nonsmokers was significantly reduced to a ratio value of 0.119 in placebo 
treated smokers, which was significantly increased to near normal ratio of 0.194 after 
Tocomin treatment. Consistent with the above results, we have initially included sd-
LDL-C/HDL-C ratio, which was substantially increased from a ratio value of 0.576 in 
nonsmokers to 2.21 in placebo treated smokers. This sd-LDL-C/HDL-C ratio was 
significantly reduced to 0.985 after Tocomin treatment. These results, which represent 
an initial demonstration, indicate that supplementation of young smokers with dietary 
tocotrienols for 8 weeks effectively ameliorated all the lipid parameters including 
highly atherogenic sd-LDL. This Tocomin mediated decrease of significantly elevated 
sd-LDL in smokers could have major clinical implications because of known 
quantitative changes in LDL profile are associated with an improvement of prognosis 
of CAD patients. 
The significant increase in plasma and lipoprotein lipid levels in young 
smokers is consistent with a significant increase (54 %) in hepatic HMG-CoA 
reductase activity of rats exposed to cigarette smoke for 4 weeks (Table 23). 
Treatment of smoke exposed rats with dietary tocotrienols significantly blocked the 
increase in hepatic HMG-CoA reductase activity and reversed it to 84 % of normal 
control value, which may provide a mechanism for the reduction of plasma and 
lipoprotein lipids in smokers treated with Tocomin. Therefore, Tocomin enriched in 
tocotrienols may exert their cholesterol lowering effect in dyslipidemic smokers and 
hyperlipidemic rats exposed with cigarette smoke in a similar manner as previously 
reported for hyperlipidemic animals (Minhajuddin et al, 1999; Qureshi et al, 2001; 
Beg et al, 2000) and humans (Qureshi et al, 1991; Qureshi et al, 1997; Qureshi et 
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al, 1995). Mechanism wise, as previously shown in HepG2 cells, as well as in 
normolipidemic and hyperlipidemic rats, tocotrienols reduce cholesterol synthesis by 
suppressing HMG-CoA reductase activity, which in turn is reduced by a decline in its 
protein mass (Minhajuddin et al., 1999; Parker et al., 1993). The decline in protein 
mass may be achieved by inhibition of HMG-CoA reductase synthesis and/or 
enhanced degradation. Consistent with in vivo results in rats (Minhajuddin et al., 
1999), y-tocotrienol has been shown to mediate the suppression of enzymatic activity 
and protein mass of HMG-CoA reductase in HepG2 cells through decreased synthesis 
(57 % of control) and enhanced degradation (2.4-fold versus control) of the enzyme 
(Parker et al., 1993). In addition, y-tocotrienol was shown to upregulate LDL receptor 
in mammalian cells and may be implicated in part for the reduction of apoB-
lipoprotein in vivo (Parker et al., 1993). Thus, tocotrienols reduce cholesterol 
formation in mammalian cells by suppressing HMG-CoA reductase activity through 
two actions: decreasing the efficiency of translation of HMG-CoA reductase mRNA 
and increasing the controlled degradation of HMG-CoA reductase protein, 
posttranscriptionally (Parker et al., 1993). In addition, another report indicates that y-
tocotrienol influences apoB secretion by both cotranslational and posttranslational 
processes involving a decreased rate of apoB translocation and accelerated 
degradation of apoB in HepG2 cells. This activity correlated with a decrease in free 
and esterified cholesterol (Theriault et al., 1999). Taken together, the information 
indicates an association between the suppression of hepatic cholesterol synthesis and 
apoB secretion, and the observed lowering of apoB and LDL-C levels in animal and 
human models (Theriault et al., 1999). However, elucidation of precise in vivo 
mechanism(s) of Tocomin-mediated inhibition of HMG-CoA reductase at molecular 
level remains to be investigated. 
Oxidative modification of lipoproteins is believed to play a central role in the 
pathogenesis of atherosclerosis (Berliner and Heinecke, 1996; Steinberg, 1997). 
Because plasma contains several antioxidants (Frei, 1995) and lipoproteins with 
oxidative damage have been isolated from atherosclerotic lesions (Berliner and 
Heinecke, 1996; Steinberg, 1997), lipoprotein oxidation generally is considered to 
occur in the vessel wall. Although lipid oxidation in the vessel wall is thought to 
occur as a result of a local deficiency of endogenous antioxidants or an excess of free 
metal ions, only limited data support these hypotheses. Research has shown that 
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human atherosclerotic plaques contain massive amounts of lipid peroxidation 
products, despite the presence of large quantities of a-tocopherol (vitamin E) and 
ascorbate (Suama, 1995). Therefore, it is unclear whether oxidized lipoproteins 
originate in the arterial wall or are produced in the circulation and then enter the 
intimal space. Our data show that due to sustained free radical load in smokers, 
oxidation of lipid/lipoprotein particles is considerably enhanced. Conjugated diene 
(which measure the initial phase of lipid peroxidation), lipid hydroperoxide 
(intermediate product of lipid peroxidation) and MDA (which measure the 
degradation phase of lipid peroxidation) in plasma are significantly increased in 
smokers. The increase in plasma lipid peroxidation products is associated with a 
significant decline in plasma total antioxidants. The former suggests increased 
production of oxidants while later indicates diminished antioxidant defense. Both the 
changes indicate an existence of profound oxidative stress. These results are 
consistent with the well known prooxidant effect of cigarette smoke. Recently, 
Bloomer (2007) has shown that young novice smokers (pack-year history of 3±2) 
have a lower plasma antioxidant capacity and exhibited a greater degree of lipid 
peroxidation compared to nonsmokers. Our results indicate a significant decrease in 
plasma lipid peroxidation products with a concomitant and significant increase in 
plasma total antioxidants in Tocomin treated smokers. Therefore, cigarette smoke 
induced oxidative stress was not only attenuated but significantly reversed after 
Tocomin treatment. Similar to plasma, MDA content of erythrocytes in placebo 
treated smokers was significantly increased by 135 %. The intact erythrocytes isolated 
from smokers exhibited a further increase (>2-fold) in susceptibility to hydrogen 
peroxide induced MDA release, as compared to the basal MDA content in 
erythrocytes. The treatment of smokers with Tocomin effectively blocked the in vivo 
as well as in vitro susceptibility of erythrocytes to lipid peroxidation and significantly 
reduced MDA levels. However, this Tocomin mediated reversal of erythrocytes MDA 
content was only 68 % of nonsmokers MDA value, while reversal of MDA release 
during H2O2 induced lipid peroxidation was complete (>100 %). Based on these 
results, its seems plausible that oxygen radicals formed over and above the 
detoxifying capacity of erythrocytes can cause peroxidative breakdown of 
phospholipid fatty acids and accumulation of MDA and hence membrane damage. In 
addition, our results suggest that due to constant availability of antioxidants, 
tocotrienols, in the plasma of treated smokers, the integrity of erythrocytes membrane 
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is significantly improved as shown by substantial protection against in vivo as well as 
in vitro H2O2 induced lipid peroxidation. A similar increase in erythrocytes MDA 
release of intact erythrocytes from placebo treated young smokers (25-45 years; >5 
smoking years) has been reported (Ismail et al, 2002), which was significantly 
reduced in TRF treated smokers. However, TRP supplementation of young smokers 
failed to influence plasma MDA levels (Ismail et al., 2002). 
Although LDL is a major risk factor for CAD, experiments have shown that 
incubation of macrophages with native LDL does not result in foam cell formation, a 
characteristic feature of atheromatous lesions (Brown and Goldstein, 1983). However, 
after chemical modification of LDL, rapid uptake occurs, leading to cholesterol 
accumulation in the macrophage with subsequent foam cell formation, which suggests 
that LDL modification is a necessary step in atherogenesis. Oxidized LDL can induce 
foam cell formation, and oxidative modification of LDL is now recognized as an 
important process that occurs in vivo (Steinberg et al., 1989). Different subclasses of 
LDL have been isolated based on size or density. As discussed earlier on page 131, 
besides increase in the circulating levels of LDL-C during smoking, there is an 
appearance of high concentrations of sd-LDL subpopulation which is shown to be 
more atherogenic than LDL. An enhanced susceptibility to oxidative modification 
could contribute to the greater atherogenicity of sd-LDL (De Graaf et al, 1991; 
Tribble et al., 1992; Dejager et al, 1993; Chait et al, 1993; Tribble et al, 1994; 
Tribble et al, 1995; Tribble et al, 2001). In contrast with native LDL, oxidized LDL 
particles initiate a series of events, including vascular inflammation and macrophage 
foam cell formation that are central to the atherogenic process (Tribble et al, 1999). 
LDL particles with a greater tendency to become oxidized might thus be more likely 
to participate in proatherogenic events. In an only report. Fuller et al. (2000) have 
initially demonstrated a reduction in the lag phase of Cu'^-catalyzed LDL oxidation 
from young smokers, which was significantly increased in subjects, received 
antioxidant vitamin E (a-tocopherol). However, no one to date has studied the 
protective effect of dietary tocotrienols, a known hypolipidemic agent with a strong 
antioxidant property, on the in vivo and in vitro Cu'^-induced oxidizability of LDL, 
more atherogenic sd-LDL and less atherogenic Ib-LDL from young smokers. Our 
results show that in smokers, LDL, sd-LDL and Ib-LDL susceptibility to in vivo 
oxidation, measured as ex vivo base line diene conjugation (BDC), was significantly 
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increased as compared to nonsmokers. However, the increase in ex vivo BDC level 
was greater in sd-LDL than LDL or Ib-LDL, indicating an enhanced in vivo 
oxidizability of sd-LDL in smokers. In nonsmokers, in comparison to a lag phase 
value of 80 min for both LDL and Ib-LDL, the lag time of sd-LDL was markedly 
reduced to 10 min, indicating an 8-fold shortening in the lag phase of Cu'^-catalyzed 
sd-LDL oxidation. This substantial difference in the oxidative susceptibility between 
sd-LDL and Ib-LDL of nonsmokers is consistent with the previous reports indicating 
an inherently reduced content of antioxidant and free cholesterol, increased amount of 
more oxidizable polyunsaturated fatty acids and preformed hydroperoxide in sd-LDL 
particles (DeGraaf era/., 1991; Thomas e/a/., 1994; Sevanian e/a/., 1996; Tribblee/ 
al., 2001). 
Consistent with these results, maximal conjugated diene as well as MDA formation in 
LDL and Ib-LDL was achieved after 12 h of oxidation, while sd-LDL required only 
30 min of Cu'^-catalyzed oxidation, indicating a substantially enhanced oxidative 
susceptibility of sd-LDL as compared to Ib-LDL or LDL. Tocomin supplementation 
of young smokers partially blocked the in vivo and in vitro LDL, sd-LDL and Ib-LDL 
oxidizability as seen by a decrease in ex vivo BEXT levels and an increase in their lag 
phase values, which were restored to >80 % lag phase values of nonsmokers. 
Similarly, ex vivo basal and Cu'^ -induced maximal formation of MDA were markedly 
increased in circulating LDL, sd-LDL and Ib-LDL from smokers. The significant 
increase in conjugated diene and MDA in LDL and sd-LDL persists when expressed 
as nanomoles per milligram protein or cholesterol, which suggests that increased 
oxidation of LDL density subfractions, was not merely a result of change in the 
composition of LDL and sd-LDL during smoking. Tocomin treatment of smokers 
caused a significant decrease and near normalization of both basal and maximal levels 
of MDA in LDL, sd-LDL and Ib-LDL. Relative to Ib-LDL, a markedly increased 
oxidizability of sd-LDL subpopulation in smokers suggests that it may be more prone 
to further oxidation in the vessel wall of humans during smoking, as reported for sd-
LDL phenotype by Chait et al. (1993). 
Several mechanisms could contribute to increased oxidative modification of 
LDL, sd-LDL and Ib-LDL during smoking. Paraoxonase (PON) or arylesterase is a 
HDL-associated enzyme that protects LDL as well as HDL fi-om oxidative stress 
(Mackness el al., 1991; Watson et al., 1995). This enzyme destroys oxidized 
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phospholipids that are biologically active and thereby prevents the toxic 
proatherogenic effects induced by oxidized LDL (Watson et al, 1995) and preserves 
HDL modification by lipid peroxides (Shih et al., 1998; Oda et al, 2002; Solak et al, 
2005). Smoking may be related to impaired PONl/arylesterase activity, thereby 
compromising antioxidant defense mechanisms. In this respect, it has been previously 
reported (Blatter et al, 1993; Nishio et al, 1997) that cigarette smoke extracts 
inhibited the enzymatic activity of PON 1 in healthy subjects, and this inhibition was 
time and dose dependent (Nishio et al, 1997). James et ah (2000) have demonstrated 
that smoking was associated with reduced serum PONl activity and concentration in 
patients with CHD (James et al, 2000; Mackness et al, 2001). Recently, Solak et al 
(2005) reported a significantly decreased PONl activity in heavy smokers with 
respect to never smokers, but the activity was indifferent in mild and moderate 
smokers. However, in those studies protective effect of any antioxidants or a 
hypolipidemic drug with antioxidant property was not investigated. In the present 
study, we have demonstrated a significant decrease in the enzymatic activity of 
arylesterase in plasma (-41 %), HDL fraction (-56 %), HDL2 (-57 %) and HDL3 (-60 
%) subfractions of placebo treated young smokers with respect to nonsmokers. 
Similarly, LDL-C/arylesterase activity ratio was substantially increased (160 %) in 
smokers vs. nonsmokers. Tocomin treatment significantly prevented the decrease in 
arylesterase activity in plasma (+18 %), HDL (+23 %), HDL2 (+42 %) and HDL3(+16 
%) and partially restored these activity levels to 31 %, 54 %, 62 % and 46 % of 
corresponding values in nonsmokers. In addition, Tocomin supplementation was 
associated with a significant decline (40 %) in LDL-C/arylesterase activity ratio and 
reversed it to 56 % of ratio value in nonsmokers. As PONl activity is thought to play 
an essential role in the prevention of LDL oxidation, depletion of the HDL-associated 
arylesterase activity, as seen above, may contribute to increased oxidizability of HDL, 
HDL2, HDL3, total LDL and highly atherogenic sd-LDL subfraction in smokers. An 
earlier report has shown that in normolipidemic subjects, degree of oxidizability, 
potency in protecting LDL against oxidation and PONl activity was far greater in 
small, dense, lipid poor HDL3 than large, light, cholesteryl ester rich HDL2 
subfraction (Kontush et al, 2003). Our results show that in normolipidemic 
nonsmokers 65 % of HDL-associated arylesterase activity was recognized in HDL3, 
while only 35 % in HDL2, indicating a more potent antioxidative property of HDL3 
than HDL2. However, due to sustained oxidative stress in smokers, HDL, HDL2 and 
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HDL3 linked arylesterase activity was almost equally reduced. However, Tocomin 
supplementation of young smokers was associated with a maximum reversal and 
increase in arylesterase activity linked with HDL2 (42 %), along with an increase of 
only 16 % in more antioxidative HDL3 subfraction, indicating only a partial 
restoration of antioxidant function of HDL. These results are consistent with a 
previous report indicating that depletion of PON results in the loss of the antioxidant 
function of HDL, and addition of PON to HDL restores the protective function of 
HDL (Castellani el al, 1997). In addition, Aviram et al. (1998) also reported that 
purified PON is a potent inhibitor of in vitro LDL and HDL oxidation. Additionally, 
lipoproteins isolated from PON knockout mice were more susceptible to oxidation 
than lipoprotein isolated from their wild-type littermates (Shih et al., 1998), and PON 
knock out mice on a high fat-high cholesterol diet are more susceptible to 
atherosclerosis (Shih et al., 1998). These studies strongly suggest an important role 
for PON in preventing the oxidation of LDL and in the protection of atherosclerosis. 
Our results indicating an enhanced in vivo as well as in vitro oxidizability of LDL and 
more atherogenic sd-LDL and less atherogenic Ib-LDL in conjunction with decreased 
plasma, HDL, HDL2 and HDL3 linked arylesterase activity and substantially increased 
LDL-C/arylesterase ratio in young smokers is likely to be a potential mechanism for 
the increased oxidation of circulating LDL density subfractions. In this context, our 
data provide suggestive evidence for the increased CVD risk observed in smokers. In 
addition, daily intake of tocotrienols as a dietary supplement will be useful in the 
prevention and treatment of smoking induced dyslipidemia and atherosclerosis. 
It is now established that oxidation of LDL constitutes a key event in 
inflammation and atherogenesis (Witztum and Steinberg, 2001). Mechanisms of LDL 
oxidation in vivo involve concerted modification by oxidants produced by arterial 
wall cells, such as reactive nitrogen species, reactive chlorine species, hydroxyl 
radicals, and lipid-soluble free radicals (Gaut and Heinecke, 2001). Plasma HDLs 
possess a spectrum of antiatherogenic actions, including potent antioxidant and 
antiinflammatory activities (Van Lenten et al, 2001). Although HDLs can themselves 
undergo oxidative modification (Francis, 2000), several enzymes that may cleave 
oxidized lipids and thereby inhibit LDL oxidation are associated with HDL particles; 
these include paraoxonase (PON) in its major isoform, PONl (Durrington et al, 
2001), platelet-activating factor acetylhydrolase (PAF-AH) (Tselepis and Chapman, 
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2002), lecithin-cholesterol acyltransferase (LCAT) (Goyal et al, 1997), and 
glutathione selenoperoxidase (Chen et al., 2000). In addition, apolipoprotein A-I 
(apoA-I), a major HDL apolipoprotein, can remove oxidized lipids from LDL, 
suggesting that HDL can function as an acceptor of oxidized lipids (Navab et al., 
2000). Other HDL apolipoproteins, such as apoA-II (Boisfer et al., 2002), apoA-IV 
(Ostos et al., 2001), apoE (Miyata and Smith, 1996), apoJ (Kelso et al., 1994), and 
apo M (Feingold et al., 2008) also function as antioxidants in vitro. The diversity of 
antioxidative actions of HDL particles suggests that HDL provide efficient protection 
of LDL from oxidation in vivo. The inhibitory effect of HDL on LDL oxidation was 
suggested to be related to metal ion chelation, or to peroxidase like activity. Under 
oxidative stress, not only LDL is susceptible to lipid peroxidation but all other serum-
lipids, including those present in HDL, are also prone to oxidation. In fact, HDL has 
been shown to be the major carrier of lipid hydroperoxides in human serum (Hahn 
and Subbiah, 1994; Kontush and Chapman, 2006). In this context it is interesting to 
mention that HDL-associated cholesteryl ester hydroperoxides are more rapidly 
reduced to their less reactive hydroxides than are those associated with LDL 
(Christison et al., 1995). Oxidative modification of HDL has also been shown to 
impair the ability of the lipoprotein to promote cholesterol efflux (Nagano et al., 
1991; Morel, 1994). Kontush et al. (2003) have demonstrated that both serum and 
plasma-derived small, dense HDL particles possess the most potent capacity among 
HDL subspecies to protect LDL from both metal-dependent and metal-independent 
oxidation in normolipidemic subjects. The oxidative protection of LDL by 
ultracentrifugally isolated HDL subfractions (at equal cholesterol or protein 
concentration or equal particle number) increased in the order HDL2b <HDL2a 
<HDL3a <HDL3b < HDL3c. HDL subfractions efficiently protected not only total 
LDL but also intermediate LDL3 (typically the most abundant LDL subfraction in 
normolipidemic subjects) and small, dense LDL5 (a highly atherogenic LDL 
subfraction) (Chapman et al., 1998), thereby suggesting that HDL can attenuate 
oxidation of atherogenic LDL subclass. When HDL subfractions were subjected to 
nonmetal or copper-induced oxidation in the absence of LDL, their oxidative 
resistance increased in the order HDL2b <HDL2a <HDL3a <HDL3b < HDL3c, 
thereby mirroring their antioxidative activity during LDL oxidation. 
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The present results have shown that plasma derived small dense, lipid poor 
HDL3 particles possess the more potent capacity than large, light, cholesteryl ester 
rich HDL2 to protect LDL from Cu^^-catalyzed oxidation in normolipidemic 
nonsmokers. These results are consistent with earlier reports in normolipidemic 
subjects showing a more potent antioxidative effect of HDL3 subfractions than HDL2 
subfractions (Kontush et a!., 2003; Yoshikawa el ai, 1997; Huang et ai, 1998). In 
both the groups of smokers, that is, entry point and 8-week placebo treated, due to 
atherogenic dyslipidemia (Table 6), the in vitro oxidation of LDL was enhanced as 
shown by an increase in maximal conjugated diene formation (Table 14). On the other 
hand, dyslipidemia involving low HDL-C, HDL2-C and HDL3-C levels (Table 6) is 
apparently responsible for the impaired antioxidative activity of HDL subfractions 
against LDL oxidation. These results demonstrate that greater the reduction in HDL2-
C or HDL3-C levels in dyslipidemic smokers, lower is their antioxidative activity as 
compared to their counterparts from normolipidemic nonsmokers. Thus, in smokers, a 
74 % reduction in large, light HDL2-C (Table 6) was apparently responsible for a 
significantly lower antioxidative activity (19-23 %), while a reduction of only 41 % in 
small, dense HDL3-C showed a lower decrease (4-8 %) in the protection of LDL 
against oxidation (Table 14). Our results are consistent with recent reports indicating 
that HDL subfractions are deficient in antioxidative activity against LDL oxidation in 
atherogenic dyslipidemias involving low HDL-C levels (Hansel et ai, 2004; Kontush 
et ai, 2005; Nobecourt et ai, 2005). In another study, HDL2 show decreased 
protection of LDL against oxidation mediated by THPI macrophages in poorly 
controlled type 2 diabetes (Gowri et ai, 1999). Consistent with the relationship 
between differential reductions in HDL2-C and HDL3-C and impairment of their 
antioxidative activity in dyslipidemic smokers, total protein content associated with 
HDL2 and HDL3 was also proportionally reduced by 64 % and 34 %. Similarly, 
Tocomin treatment was associated with a restoration of HDL2 and HDL3 associated 
proteins by 80 % and 67 % of control values in nonsmokers (Table 6). Our combined 
data clearly indicate that impairment of the antioxidative activity of HDL 
subfractions, particularly small, dense HDL3 in dyslipidemic smokers involving low 
antiatherogenic HDL-C levels, low HDL linked arylesterase activity, low HDL 
associated proteins, and high atherogenic non'HDL-C levels are intimately associated 
with elevated oxidative stress- a newly recognized CVD risk factor (Schwedhelm et 
ai, 2004; Meisinger et ai, 2005), and may therefore contribute to enhanced 
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atherogenesis (Hansel et al, 2004; Kontush et al, 2005; Nobecourt et al, 2005). On 
the other hand, supplementation of young smokers with dietary tocotrienols mediated 
a significant therapeutic normalization of all the above parameters (Table 6 & 15), 
improving the antioxidative/antiatherogenic function of HDL subfractions (Table 14). 
Altered enzymatic activities may also contribute to the antioxidative deficiency of 
HDL subfractions. Solak et al. (2005) have reported a significantly reduced serum 
PONl activity in heavy smokers, while the activity was indifferent in mild and 
moderate smokers. James et al. (2000) have demonstrated the association of smoking 
with reduced serum PON activity in patients with CAD. In addition, PONl and PAF-
AH activities are consistently lower in all HDL subfractions from type 2 diabetics 
(Nobecourt et al., 2005). In type 1 diabetes, serum concentrations of PONl are 
reduced to such an extent that diminished oxidative protection of LDL by HDL in 
vitro (Boemi et al, 2001). Consistent with these reports, our results also show a 
significantly decreased arylesterase activity in HDL and its subfractions HDL2 and 
HDL3 as well as high LDL-C: arylesterase activity ratio in dyslipidemic smokers 
(Table 15), implying a role of arylesterase enzyme in the antioxidative deficiency of 
HDL subfractions. Tocomin supplementation of smokers markedly protected LDL 
from oxidative stress and fully reduced the formation of maximal conjugated diene to 
a level similar to control value in nonsmokers. In contrast to dyslipidemic smokers, 
Tocomin mediated a restoration of HDL2-C and HDL3-C levels by 75 % and 42 % of 
control value in nonsmokers (Table 6), while arylesterase activity was increased by 62 
% and 46 % in HDL2 and HDL3 particles, respectively (Table 15). As a result, both 
HDL2 and HDL3 from Tocomin treated smokers were able to further reduce the 
maximal conjugated diene formation to a common level, 21 % lower than their 
normal counterparts in normolipidemic nonsmokers; thus exceeding the protection 
afforded against Cu^-induced oxidation of LDL alone from Tocomin supplemented 
smokers. The combined results provide evidence that small, dense HDL3, relative to 
large, light HDL2, afford better potent protection of LDL against oxidative stress. 
However, the atheroprotective properties of HDL can be compromised under 
conditions associated with accelerated development of atherosclerosis, such as in 
atherogenic low HDL-C dyslipidemias. Persistent deficiency of HDL function along 
with an increase in non-HDL-C and TG levels may result in accelerated 
atherosclerosis in chronic smokers. Therapeutic normalization of HDL function, 
coupled with a strong hypolipidemic and antioxidant actions of dietary tocotrienols 
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may therefore represent a novel therapeutic approach to attenuate dyslipidemia in 
young smokers as well as atherosclerosis in dyslipidemic chronic smokers. 
The levels of reactive oxygen species (ROS) are controlled by antioxidant 
enzymes, superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (Gpx), 
glutathione reductase (Gred) and nonenzymatic scavengers such as glutathione 
(GSH). An impaired radical scavenger function has been linked to decreased activity 
of enzymatic and nonenzymatic scavengers of free radicals. These enzymes are 
important in defending the body against free radicals as well as toxic substances by 
converting them to a form that can be readily excreted. Therefore, any changes in 
these enzymes could be potentially detrimental to the host by altering these defense 
mechanisms. Normal cellular metabolism involves the production of ROS (McCord, 
1993), low levels of ROS are vital for proper cell functioning, while excessive in vivo 
generation of these products can adversely affect cell functioning (Gregorevic et al, 
2001; Fattman et al., 2003). Malondialdehyde (MDA) is one of the final products of 
lipid peroxidation in human cells, and an increase in ROS causes over production of 
MDA, which is considered a surrogate marker of oxidative stress (Nielsen et al, 
1997; Draper et al, 1990). Increased MDA production in erythrocytes is known to 
cause a decrease in the membrane fluidity of the membrane lipid bilayer and 
increased osmotic stability of cells (Raccah et al, 1996). The major intracellular 
antioxidant enzyme, SOD, specifically converts superoxide radicals to hydrogen 
peroxide, (Andersen et al, 1997) and CAT as well as Gpx detoxifies hydrogen 
peroxide to water (Inoue et al, 1994). Glutathione peroxidase protects against free 
radical injury by reducing the peroxide concentration via a glutathione dependent 
reduction process, thereby reducing the amount of peroxides available to produce 
cellular damage. Reduced glutathione is a major intracellular non-protein sulfhydryl 
compound. It has many biological functions, including maintenance of membrane 
protein and lipoprotein SH groups in the reduced form, the oxidation of which can 
otherwise cause altered cellular structure and function. Glutathione cycle operates in 
the erythrocytes for the disposal of H2O2 generated in the cell supplementing the 
function of CAT. Reduced glutathione and H2O2 are twin substrates for Gpx. Reduced 
glutathione is formed from its oxidized form, GSSG by the enzyme Gred, which 
requires NADPH as a cofactor (Meister and Anderson, 1983; Meister, 1992) 
therefore, as the balance between ROS production and antioxidant defenses is lost, the 
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resultant oxidative stress through a series of events deregulates the cellular functions 
leading to various pathological conditions. An antioxidant compound might contribute 
partial or total alleviation of such damage. Our results demonstrate a significantly 
higher CAT and SOD activities in erythrocytes from placebo treated smokers, which 
is consistent with the findings of McCuster et al. (1990) showing an increase in CAT 
and SOD activities in erythrocytes of smokers. On the other hand, the activities of 
Gred and Gpx were significantly decreased. A similar decrease in Gpx activity in 
smokers has been reported elsewhere (Kocyigit et al., 2001). Treatment of young 
smokers with dietary tocotrienols for 8 weeks significantly improved the integrity of 
erythrocytes membrane as shown by improved protection against lipid peroxidation as 
well as reversal of SOD, CAT, Gpx and Gred activities to near normal levels. Similar 
to our results, a reversal in the erythrocytes SOD and GPx activities has previously 
been reported in healthy male current smokers (25-45 years; >5 smoking years) 
supplemented with 200 mg of TRF for 8 weeks (Ismail et al, 2002). 
As mentioned earlier on page 13t, that since certain experiments such as 
mechanism(s) of lipid lowering action of tocotrienols and the extent of their protective 
effect on enzymatic and nonenzymatic antioxidant defense system including lipid 
peroxidation in various tissues etc. are unavailable from young smokers, male albino 
rats, exposed to cigarette smoke daily for 30 min for 4 weeks, have been used as an 
experimental model. In this animal model we investigated the hypolipidemic and 
antioxidant properties of Tocomin and compared its efficiency with Lovastatin. Our 
study demonstrate that average body weight gain of 18 % in 4-week cigarette smoke 
exposed (S-C) rats was significantly lower than a gain of 31 % in normal (N-C) rats. 
This reduction in growth rate in S-C rats did not fully correlate with the reduction in 
the amount of average food consumption per day (- 3 % vs. + 4 % in N-C). Therefore, 
reduced average weight gain in the S-C group may be due to overall adverse effect of 
massive amount of free radicals and toxic compounds present in the cigarette smoke. 
These results are consistent with a the previous report showing a lower body weight 
gain in rats after 3 weeks of cigarette smoke exposure (Maida and Hewlett, 1990). 
Administration of S-C rats with either 6.0 mg Tocomin or 0.50 mg Lovastatin/rat/day 
for 4 weeks was associated with a body weight gain of 49 % and 22 %, as compared 
to their respective entry point values. Similarly, in Tocomin treated (S-T3T) rats food 
consumption per day was increased by 17 %, as compared to an increase of only 6 % 
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in Lovastatin treated group (S-LT). A significantly lower (2.2- to 2.8-fold) gain in 
body weight and food consumption in S-LT group then S-T3T rats, was apparently 
due to host of toxic effects known to be exerted by Lovastatin (Assmann et al, 1998; 
Haffner et al., 1998 ). In contrast, dietary tocotrienols are naturally occurring 
analogous of tocopherol (vitamin E) isomers and have no toxicity. 
It is interesting to mention that in general, the results obtained from the 
cigarette smoke exposed hyperlipidemic rats treated with dietary tocotrienols 
exhibited great similarities with the results in young smokers supplemented with 
Tocomin for 8 weeks. In addition, in this rat model, the hypolipidemic and 
antioxidative properties of Lovastatin are also comparable to Tocomin, used in both 
animal and human models. First, we have summarized the similarities between the 
common parameters investigated in both the models. On the other hand, we will point 
out the dissimilarities between the results from two models, and discuss in detail the 
new data, which is available only from rat model. Consistent with the results from 
young smokers (Table 4), rats exposed to cigarette smoke for 4 weeks also exhibited a 
significant increase in blood nicotine and carboxyhemoglobin. Both Tocomin and 
Lovastatin were equally effective in reducing (26-30 %) the carboxyhemoglobin, 
while Tocomin was more efficient in reducing (70 %) the blood nicotine level than 
Lovastatin (50 %), indicating a strong protective effect of these agents. The results 
demonstrate that a 4-week cigarette smoke exposure induced a severe hyperlipidemia 
in S-C rats as compared to dyslipidemic young smokers. A much higher increase in 
plasma TG (102 % vs. 13 % in smokers) and atherogenic non-HDL-C (109 % vs. 46 
%) levels contributed to the increased degree of hyperlipidemia in S-C rats. On the 
other hand, in S-C rats, atherogenic HDL-C was decreased by only 11 %, in 
comparison to a decline of 51 % in smokers, indicating a very mild dyslipidemia in S-
C rats. This markedly lower degree of dyslipidemia in S-C rats, versus young 
smokers, is apparently due to species difference, which is consistent with the known 
fact that rats are highly resistant to the initiation and development of atherosclerosis. 
These results in S-C rats are further supported by a 34 % reduction in cholesterol 
content of large, light, cholesteryl ester rich HDL2, which is considered to be a strong 
predictor of presence and extent of CAD (Drexel et al, 1992). In addition, cholesterol 
content of small, dense, lipid poor HDL3, which exerts potent protection of 
atherogenic LDL against oxidative stress, was reduced by only 5 % in S-C rats vs. N-
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C value, while in young smokers it was significantly reduced by 41 %. Together, 
these results suggest that dyslipidemic smokers may be more susceptible to 
atherogenesis than a 4-week cigarette smoke exposed animals. Highly increased 
plasma TG, TC, VLDL-C, LDL-C and atherogenic non-HDL-C concentrations in S-C 
rats were significantly reduced to a level close to their counterparts in N-C rats, after 4 
weeks of Tocomin or Lovastatin treatment, while similar reversal in the above 
parameters was seen in Tocomin supplemented young smokers. In complete contrast 
to young smokers, Tocomin treatment not only blocked the minimal decline of 11 % 
seen in HDL-C level of S-C rats but increased it to a level, 58 % higher than normal 
control value. Similarly, the decrease of 34 % in HDL2-C of S-C rats was blocked by 
Tocomin and increased to a level 98 % higher than HDL2-C value in N-C. Lovastatin 
treatment of S-C rats also increased the HDL-C (36 %) and HDL2-C (49 %) 
concentrations, but to a lesser extent than Tocomin. On the other hand, after 4 weeks 
of Tocomin or Lovastatin treatment, the cholesterol content of more antioxidative 
small, dense HDL3 was increased, from a reduced value of only 5 % in S-C rats, to 39 
% and 31 % higher than normal control HDL3 value. These result are in agreement 
with published evidence indicating that Lovastatin treatment of hyperlipidemic 
subjects and animals was associated with a significant increase in HDL-C (Helve and 
Tikkanen, 1988; El-Swefy et al, 2000), while TRP has been shown to mediate an 
increase in HDL-C levels of hyperlipidemic rats as well as in a type II familial 
hypercholesterolemic subject (Minhajuddin et al, 1999; Beg et al, 1997; 
Minhajuddin et al, 2005). These results demonstrate that both dietary tocotrienols and 
Lovastatin exert a potent effect in normalizing the high levels of TG as well as 
atherogenic non-HDL-C in cigarette smoke-induced hyperlipidemia in rats. In 
addition, these agents exhibited a potent antiatherogenic effect by substantially 
increasing the concentrations of atheroprotective HDL. 
As discussed previously on page \2B, Hirano et al. (2004) have shown that 
relative to large buoyant (lb-) LDL, the concentration of more atherogenic small 
dense (sd-) LDL was significantly increased in healthy subjects with various types of 
hyperlipidemia, hyperlipidemia with CHD, and in type 2 diabetic-hyperlipidemic 
subjects with CHD. A 2- to 3-fold increase in CHD risk among patients with a 
predominance of sd-LDL particles, which is a strong and independent predictor of 
CHD, has been reported (Austin et al, 1988; Austin et al, 1990; Austin et al, 1994; 
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St-Pierre et al., 2005). In addition, it has been reported that progression of CHD was 
closely lini<ed not to the LDL particle size, but to the concentration of sd-LDL (Koba 
et al., 2006). Consistent with these reports, in response to proatherogenic action of 
cigarette smoke, our results show a substantial increase of 292 % in sd-LDL and 82 % 
in sd-LDL-apoB of S-C rats, as compared to respective normal control values. Thus, 
>84 % of LDl-C and >58 % of LDL-apoB were recognized in sd-LDL subpopulation. 
In contrast to sd-LDL, percent share of cholesterol and apoB content of LDL was 
significantly reduced by 36 % and 27 % in Ib-LDL, indicating a preferential shift of 
less atherogenic Ib-LDL to more atherogenic sd-LDL subspecies in hyperiipidemic 
rats. Tocomin or Lovastatin treatment significantly normalized (93-99 %) both the 
cholesterol and apoB concentrations of sd-LDL and Ib-LDL, as well as their percent 
share of LDL, similar to their counterparts in N-C. 
The comparison of the above results in cigarette smoke exposed rats versus 
young smokers, revealed that because of severe hyperlipidemia, coupled with a 
minimal decline in HDL-C (- 11 %) in S-C rats, there was a marked increase in 
plasma TG (+ 102 %), VLDL-C (+ 105 %) and LDL-C (+112 %). As a result, a 
substantial shift of cholesterol and apoB from less atherogenic Ib-LDL to more 
atherogenic sd-LDL had occurred, which significantly increased the sd-LDL-C (+ 292 
% vs. N-C value) and its percent share of LDL-C (85 % vs. 29 % in N-C). On the 
other hand, in dyslipidemic young smokers with mild hyperlipidemia, HDL-C levels 
was significantly reduced (-51 %), while there was a modest increase in TG (+ 14 %), 
VLDL-C (+ 33 %) and LDL-C (+ 49 %); as a consequence of which, there was a 
proportional increase in sd-LDL-C (75 % vs. control value) and its percent share of 
LDL-C (37 % vs. 32 % in control). It is interesting to mention that sd-LDL subspecies 
is known to be a generated from large TG rich VLDLl (Packard and Shepherd, 1997; 
Tribble et al., 2001), production of which is substantially enhanced in rats exposed to 
heavy dose of cigarette smoke containing massive amount of free radicals, thus 
resulting in a much higher concentrations of sd-LDL subpopulation, in comparison to 
young smokers. Both dietary Tocomin and Lovastatin effectively reduced and fully 
normalized the circulating TG, VLDL-C, LDL-C and more atherogenic sd-LDL-C, 
while cholesterol levels of antiatherogenic HDL were increased to a level 
significantly higher than N-C value. Consistent with these findings, LDL-C/HDL-C, 
HDL-C/TC, sd-LDL-C/HDL-C and Ib-LDL-C/HDL-C ratios were markedly altered 
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(+ 125 %, - 48 %, + 314 % and + 44 %, respectively, vs. corresponding ratio values in 
N-C), in S-C rats, while treatment with Tocomin or Lovastatin fully normalized these 
altered ratios to a level, 15 % to 26 % better than their counterparts in N-C, indicating 
an excellent normalization of highly atherogenic sd-LDL-C and LDL-C levels. These 
results from Tocomin or Lovastatin treated S-C rats or Tocomin supplemented young 
smokers are consistent with a recent report (Tokuno et al, 2007), where 1 mg of 
pitavastatin supplementation of type 2 diabetic patients for 3 months significantly 
reduced both LDL and sd-LDL. The efficient and preferential removal of sd-LDL, 
relative to Ib-LDL, by Tocomin and Lovastatin in S-C rats may involve similar 
mechanism(s) as described for pitavastatin (Saito et al., 2001, Sone et al., 2002) and 
fibrate (Milosavljevic etal., 2001). 
Consistent with the increase in plasma TG, FFA and TC levels of S-C rats, 
significant increases in these lipids of liver, lung and kidney were also observed. 
While, Tocomin or Lovastatin treatment of S-C rats for 4 weeks was associated with a 
significant decreases in TG, FFA and TC of each tissue. These results demonstrate 
that sustained oxidative stress in S-C rats is also able to induce hyperlipidemia in the 
above tissues with a maximum increase in hepatic TC, while both Tocomin and 
Lovastatin effectively blocked these increases and restored the TG, FFA and TC 
levels of liver, lung and kidney close to corresponding normal control values. The 
significant increase in plasma, liver, lung and kidney lipid levels is consistent with a 
significant increase (54 %) in liver HMG-CoA reductase activity of S-C rats (Table 
23). Our results are in agreement with earlier reports suggesting that chromic cigarette 
smoke exposed to rats for 90 days could enhance the cholesterol formation by 
inducing an increase in the enzymatic activity of HMG-CoA reductase (Chitra et al., 
2000; Helen and Vijayammal, 1996). Treatment of S-C rats with dietary Tocomin or 
Lovastatin was associated with a significant decrease in hepatic HMG-CoA reductase 
activity, which was restored to 84 % and 62 % of N-C value, thus, providing a 
mechanism for the reduction of plasma and tissue lipids. These results indicate that 
both tocotrienols and Lovastatin may exert their hypocholesterolemic effect in 
hyperlipidemic rats and dyslipidemic young smokers (see page no.) in a similar 
manner as previously reported for hyperlipidemic animals (Minhajuddin et al., 1999; 
Beg et al., 2000b; Minhajuddin et al., 2005; Endo et al, 1979; Tanaka et al., 1982) 
and humans (Qureshi et al, 1991; Qureshi et al, 1997; Qureshi et al, 1995). 
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Mechanism wise, as previously shown in HepG2 cells, as well as in normolipidemic 
and hyperlipidemic rats, tocotrienols reduce cholesterol synthesis by suppressing 
HMG-CoA reductase activity, which in turn is reduced by a decline in its protein 
mass (Minhajuddin e/a/., 1999; Parker e/a/., 1993). 
In response to oxidative stress, evoked in cigarette smoke-induced 
hyperlipidemic rats, our data show a significant increase in lipid/lipoprotein 
peroxidation products. Conjugated diene, lipid hydroperoxide and MDA in plasma, 
liver, lung and kidney were significantly increased in S-C rats. A similar increase in 
hepatic conjugated diene, lipid hydroperoxide and MDA has been reported in rats 
exposed to cigarette smoke for 90 days (Helen and Vijayammal, 1997), Similarly, an 
increase in liver, lung, kidney and heart conjugated diene, lipid hydroperoxide and 
MDA was reported in rats exposed to cigarette smoke for 30 days (Bindu and 
Annamalai, 2004). However, protective effect of a hypolipidemic agent with 
antioxidant property on the formation of three lipid peroxidation products in plasma 
and above tissues as well as MDA content or its release in erythrocytes of S-C rats has 
not been reported. The increase in plasma lipid peroxidation products is closely 
associated with a significant decline in total antioxidants of plasma. The increase in 
lipid peroxidation products in plasma, liver, lung and kidney and decrease in plasma 
total antioxidants is consistent with the well known prooxidant effect of cigarette 
smoke in rats. Treatment of S-C rats with either 6.0 mg Tocomin or 0.50 mg 
Lovastatin/rat/day for 4 weeks was associated with a significant decline in lipid 
peroxidation products of plasma, liver, lung and kidney and a significant increase in 
plasma total antioxidants, indicating a potent antioxidant effect of Tocomin and 
Lovastatin. Similar to plasma and other tissues, MDA content of erythrocytes in 
cigarette smoke stressed rats were significantly increased (93 %). The intact 
erythrocytes isolated from S-C rats exhibited a further increase (>4-fold) in 
susceptibility to hydrogen peroxide induced lipid peroxidation and MDA release, as 
compared to the basal MDA content in erythrocytes. Tocomin or Lovastatin 
significantly blocked the in vivo as well as in vitro susceptibility of erythrocytes to 
lipid peroxidation and MDA release. Tocomin mediated normalization of MDA was 
88-97 % of N-C value, while Lovastatin treatment caused a lesser degree of MDA 
reversal (60-73 %), indicating a more potent antioxidative property of Tocomin. 
These results indicate that due to massive and sustained load of free radicals and 
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elevated levels of lipid peroxidation products formed in hyperlipidemic S-C rats may 
further aggravate the tissue oxidant/antioxidant imbalance and damage the antioxidant 
defense systems, which may lead to disruption of cellular functions and oxidative 
damage to membranes of erythrocytes and other tissues. In addition, treatment of 
hyperlipidemic S-C rats with two potent hypolipidemic agents with strong antioxidant 
activity may mediate a reduction in both lipid levels as well as lipid peroxidation 
products by scavenging cellular free radicals, thus improving overall 
oxidant/antioxidant balance as well as possibly protecting the oxidative damage to 
membranes and tissues. It is interesting to note that the changes observed in plasma 
total antioxidants, conjugated diene, hydroperoxide and MDA as well as erythrocytes 
MDA content and its release during in vitro H2O2 induced peroxidation from S-C rats 
is qualitatively similar to the changes seen in the young smokers (Table 9 and 10). 
However, MDA release in intact erythrocytes from S-C rats was substantially higher, 
that is, >4-fold vs. >2-fold in young smokers, in comparison to their respective ex vivo 
basal MDA content in erythrocytes, indicating a massive oxidative stress in rats 
exposed to cigarette smoke , daily for 30 min, for 4 weeks. In addition, consistent 
with significantly higher free radical scavenging property of dietary tocotrienols than 
a-tocopherol (Fig. 3.1), Tocomin offered much better protection against both in vivo 
and in vitro H2O2 induced lipid peroxidation in erythrocytes from S-C rats, than 
Lovastatin. 
As discussed earlier on page 123, severe hyperlipidemia in S-C rats was 
associated with an increase in LDL and appearance of high concentrations of sd-LDL 
subpopulation, which is shown to be more prone to oxidation than Ib-LDL or LDL 
and hence more proatherogenic (De Graaf er al., 1991; Tribble et al, 1992; Dejager et 
al., 1993; Chait et al, 1993; Tribble et al, 1994; Tribble et al., 1995). Our results 
demonstrate that in normal rats, relative to Ib-LDL, in vivo oxidizability of sd-LDL, 
measured as ex vivo base line diene conjugation (BDC), was increased (29 %), while 
lag phase of its Cu"^-induced oxidation was reduced to 16.4 min, in comparison to a 
lag phase value of 54.0 min for Ib-LDL and 95.0 min for LDL, indicating a 3.2- to 
5.8-fold shortening in the lag phase of sd-LDL. This marked difference in the 
oxidizability between sd-LDL and Ib-LDL of normal rats is in agreement with 
previous reports indicating an inherently reduced concentration of antioxidants, and 
free cholesterol, increased amount of more oxidizable polyunsaturated fatty acids 
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including preformed hydroperoxides in sd-LDL (De Graaf e/ al., 1991; Thomas et al, 
1994; Sevanian et al, 1996; Tribble et al, 2001). During 4 weeks of sustained 
oxidative stress and depletion of endogenous antioxidants in hyperlipidemic S-C rats, 
the in vivo oxidizaibility of sd-LDL was further increased, resulting in a ~2-fold 
increase in ex vivo BDC level, in comparison to Ib-LDL, while there was no 
significant difference in the percent decline in lag phase values of sd-LDL (-27 %) 
and Ib-LDL (-24 %) in S-C, when compared to their values in N-C group. Both 
Tocomin and Lovastatin feeding significantly blocked the in vivo and in vitro 
oxidation of LDL density subfractions, as seen by a decrease in ex vivo BDC levels 
and an increase in their lag phase values. In Tocomin fed rats, the lag phase values of 
LDL, sd-LDL and Ib-LDL were restored to 87 %, 98 % and 93 % of their 
corresponding normal control values, while in Lovastatin treated rats, their lag time 
values were restored to 75 %, 85 % and 83 % of N-C values, indicating a better 
antioxidative effect of dietary tocotrienols than Lovastatin. Conceptually, the 
differential in vivo and in vitro oxidizaibility of sd-LDL and Ib-LDL observed in 
hyperlipidemic S-C rats is consistent with the results obtained from dyslipidemic 
young smokers (Table 12). 
As discussed on page 135, increasing evidence support an antioxidant role of 
serum HDL-complexed paraoxonase (PON) or arylesterase enzyme in the protection 
of LDL as well as HDL from oxidative modification. In addition, depletion of PON 
results in the loss of the antioxidant function of HDL, and addition of PON to HDL 
restores the protective function of HDL (Castellani et al, 1997). In the first part of the 
present study, we have demonstrated in dyslipidemic young smokers, significantly 
reduced content of cholesterol, protein, and arylesterase activity in HDL, HDL2 and 
HDL3 subfractions and a significantly impaired capacity of HDL2 and HDL3 to 
prevent in vitro LDL oxidation (Table 6, 14 and 15). In addition, supplementation of 
young smokers with dietary tocotrienols mediated a significant normalization of the 
above parameters, thus improving the antioxidative function of HDL subfractions 
(Table 6, 14 and 15). In contrast to young smokers, in cigarette smoke exposed rats 
with severe hyperlipidemia, there was a little decline in cholesterol content of HDL (-
11 %) and its subfractions, HDL2 and HDL3 (Table 19), and hence a decrease of only 
13 % to 17 % in plasma, HDL, HDL2 and HDLs-associated arylesterase activity 
(Table 29). Similarly, in contrast to dyslipidemic smokers, treatment of S-C rats with 
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Tocomin or Lovastatin was associated with a substantial increase in antiatherogenic 
HDL, HDL2 and HDL3, to a level, 31 %-98 % higher than corresponding values in 
normal control rats (Table 19) and almost full normalization (90 % to 97 %) of 
arylesterase activity in S-T3T and S-LT rats (Table 28). Together, above results 
suggest that induction of dyslipidemia, as seen in young smokers, is closely associated 
with the decline of both antiatherogenic HDLs and arylesterase enzyme, which is 
consistent with a very mild dyslipidemia in S-C rats, and hence only a marginal 
decline was seen in both HDL associated cholesterol content (-11 %) as well as 
arylesterase activity (-16 %). 
Xanthine oxidase (XO) and xanthine dehydrogenase (XD) are interconvertible 
forms of the same enzyme, known as xanthine oxidoreductase (XOR) (Borges et al., 
2002). In purine catabolism, XOR catalyzes the oxidative hydroxylation of 
hypoxanthine to xanthine and subsequently of xanthine to uric acid. Uric acid acts as 
a potent antioxidant and free radical scavenger. XOR has, therefore, important 
functions as a cellular defense enzyme against oxidative stress. With both XO and XD 
forms, but particularly with the XO form, numerous ROS and RNS are synthesized 
(Vorbach et al., 2003). Thus, the synthesis of both an antioxidant (uric acid) and 
numerous free radicals (ROS and RNS) makes XOR an important protective regulator 
of the cellular redox potential. XO generates O2' by catalyzing hypoxanthine and 
xanthine to uric acid. Under pathophysiologic conditions, this is another major source 
of vascular oxidative stress (Droge, 2002). XO exists in plasma, liver, kidney and 
endothelial cells but not in smooth muscle cells (Harrison et al., 2003). There is 
overwhelming evidence that serum XO levels are significantly increased in various 
pathological states (Borges, et al, 2002). The role of XO in the vascular dysfunction 
that occurs in the atherosclerosis was reported by White et al. (1996). Based on the 
above information, it may be possible that the inhibition of this enzymatic pathway by 
compounds that have both antiradical as well as XO inhibitory properties could 
provide additional therapeutic benefit. It has been reported that some flavonoids and 
structurally related antioxidants inhibit XO activity (Nagao et al., 1999; Khan and 
Sultana, 2004). Serum xanthine oxidase activity is known to be increased in various 
pathological disorders, such as carcinogenesis, hepatitis, inflammatory diseases, 
aging, hyperlipidemia and diabetes and that free radicals generated in the enzymatic 
processes are involved in the oxidative damage. Recently, increased XO activity in 
plasma of young smokers vs. age matched nonsmokers has been reported (Bloomer et 
aL, 2008). Our results show a significant increase in plasma, liver, lung and kidney 
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XO activity of cigarette smoke exposed rats. Tocomin or Lovastatin administration 
significantly blociced this increase in XO activity and reduced it to a level close to 
corresponding normal control values. These results show that dietary tocotrienols and 
Lovastatin, in addition to their potent hypolipidemic and antioxidant activity, has the 
ability to reduce XO activity in plasma, liver, lung and kidney, indicating an 
additional therapeutic benefit in the prevention and treatment of cigarette smoke 
induced dyslipidemia/hyperlipidemia and atherosclerosis. 
It is well known that cigarette smoking is associated with a substantial 
increase in oxidative stress, which is mainly based on the evidence of increased lipid 
peroxidation or by indirect evidence of reduced antioxidant reserve. During the course 
of oxidative stress, oxygen-derived free radicals such as superoxide anion (O2) are 
known to be generated in the cells. This 02' forms H2O2 by dismutation, which finally 
undergoes an iron-catalyzed reaction to from cytotoxic OH' . The breakdown of 
membrane phospholipids and lipid peroxidation, demonstrated in many diseases, is 
known to be mediated by fi-ee radicals. In addition, unsaturated fatty acids released 
from membrane phospholipids may affect membrane fluidity (Bagchi et ai, 1993). In 
the present study, the increased concentrations of FFA in liver, lung and kidney 
(Table 22) of rats exposed to cigarette smoke may be due to the enhanced oxidative 
degradation of membrane phospholipids, and these FFA may be used as substrate for 
lipid peroxidation. The significantly increased concentrations of conjugated diene, 
lipid hydroperoxide and MDA in liver, lung and kidney (Table 26) is apparently due 
to enhanced lipid peroxidation in cigarette smoke stressed rats. These results are 
consistent with earlier reports indicating increased lipid peroxidation products in 
tissues of rats exposed to cigarette smoke either for 30 days (Bindu and Annamalai, 
2004) or 90 days (Helen and Vijayammal, 1997). Cigarette smoke-induced oxidative 
stress is associated with an impairment of the antioxidant defense system along with 
an increase in the generation of lipid peroxidation products. This finding provides a 
perfect correlation between lipid peroxidation products and decreased activities of 
CAT and SOD, which play an important role in scavenging the toxic intermediate 
products of incomplete lipid peroxidation. A decrease in the activity of these 
enzymes, as seen in liver, lung and kidney of S-C rats (Table 30), can lead to the 
excessive availability of superoxides and peroxyl radicals, which in turn generate 
hydroxyl radicals, resulting in the initiation and propagation of more lipid 
peroxidation products (Sacks et ai, 1978). A similar decrease in hepatic CAT and 
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SOD activities, in rats exposed to cigarette smoke for 90 days, has previously been 
reported (Helen and Vijayammal, 1997). Tocomin or Lovastatin feeding of S-C rats 
significantly reduced the FFA and lipid peroxidation products, and increased the CAT 
and SOD activities in liver, lung and kidney, and reversed these parameters to near 
normal levels. These results indicate a potent free radical scavenging property of both 
dietary tocotrienols and Lovastatin. 
It is well known that glutathione (GSH) acts as a reducing agent and plays a 
vital role in detoxification. It provides antioxidant protection in the aqueous phase of 
cellular systems (Rana et al, 2002); its antioxidant activity is through the thiol group 
of its cysteine residue. Like ascorbic acid, another important water soluble 
antioxidant, GSH can directly reduce a number of ROS and is oxidized to GSSG in 
the process. Liver is viewed as a glutathione-generating site, which supplies the 
kidney and intestine with other constituents for glutathione resynthesis (Rana et al., 
2002). Intrahepatic glutathione is reported to afford protection against liver 
dysfunction by at least two ways: (i) as a substrate for glutathione peroxidase (Gpx), 
GSH serves to reduce large variety of hydroperoxides before they attack unsaturated 
lipids or convert already formed lipid hydroperoxide to the corresponding hydroxy! 
compounds; (ii) As a substrate of glutathione-S-transferase (GST), it enables the liver 
to detoxify foreign compounds or other metabolites and to excrete the products, 
preferably in to bile. Our results show a decline in GSH (Table 31), Gred and GST 
activities and an increased GPx activity in liver, lung and kidney of S-C rats (Table 
32). The decrease in tissue GSH levels in cigarette smoke stressed rats may be due to 
the effect of declined Gred activity and possibily reduced NADPH supply (Meister 
and Anderson, 1983; Meister, 1992). In addition, since GSH also acts as substrate and 
co-substrate in essential enzymatic reactions of Gpx and GST, reduction of GST 
activity may also be due to decreased levels of GSH in tissues. Gpx is also a 
scavenging enzyme, but an increase in its activity in tissues of S-C rats may further 
reduce the GSH content. In addition, an increased Gpx activity represents a 
compensatory mechanism to degrade H2O2. Thus, during oxidative stress, depletion of 
GSH, which is of clinical importance in tissue injury, mediated a significant impact 
on the antioxidant poise of liver cells. Our results are in agreement with an earlier 
report showing a reduction in Gred activity but an increase in Gpx activity in liver of 
cigarette smoke exposed rats for 90 days (Helen and Vijayammal, 1997). However, in 
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their study hepatic GSH content was significantly increased, in smoke exposed rats, 
which is in contradiction to our results. Treatment of cigarette smoke stressed 
hyperlipidemic rats with Tocomin or Lovastatin for 4 weeks, significantly restored the 
altered tissue activities of SOD, catalase, Gpx, Gred and GST including total, free and 
protein bound-SH contents of glutathione, to near normal control values, indicating an 
almost total alleviation of oxidative damage by these antioxidants. Elevated lipid 
peroxidation products formed by cigarette smoke exposure may generate a tissue 
antioxidant/oxidant imbalance that could represent a crucial link between cigarette 
smoke and atherosclerosis. Administration of either 6.0 mg dietary Tocomin or 0.50 
mg Lovastatin/rat/day to S-C rats significantly rectifies this imbalance, even though 
the exact mechanism(s) remain obscure. Both Tocomin and Lovastatin mediated a 
near normalization of peroxide levels and scavenging enzyme activities as well as 
GSH in liver, lung and kidney of cigarette smoke exposed rats, indicating a strong 
antilipid/lipoprotein peroxidative effect of these hypolipidemic agents. Based on these 
results in cigarette smoke induced hyperlipidemic rats in conjunction with the data in 
young smokers showing that supplementation of Tocomin for 8 weeks significantly 
improved the integrity of erythrocytes membrane as seen by improved protection 
against lipid peroxidation as well as reversal of enzymatic activities of catalase, 
SOD, Gpx and Gred to near normal levels (Table 10 and 11), it is likely, that a similar 
Tocomin and Lovastatin mediated amelioration of overall antioxidant defense system, 
as seen in different tissues of S-C rats, may be operative in young smokers. Thus, it is 
possible, that supplementation of young dyslipidemic smokers with dietary 
tocotrienols for 8 weeks would have been equally effective in the protection of 
cigarette smoke induced oxidative damage in hepatic, pulmonary and renal tissues. 
The combined results in dyslipidemic young smokers and cigarette smoke 
exposed hyperlipidemic rats, which represent an initial study, demonstrate that strong 
hypolipidemic impact of dietary tocotrienols and Lovastatin coupled with their potent 
antioxidative property can provide additional benefit in the suppression of oxidative 
stress, particularly in the oxidative resistance of highly atherogenic sd-LDL and LDL, 
and hence in the prevention and treatment of cigarette smoke induced 
dyslipidemia/hyperlipidemia and atherosclerosis. Although multiple atheroprotective 
effects of Tocomin and Lovastatin observed in cigarette smoke exposed rats were 
qualitatively comparable, but in view of the several toxic effects known to be 
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exhibited by statins including Lovastatin in humans (Haffner et ai, 1998; Assmann et 
al, 1998), use of dietary tocotrienols, which are vitamin E and have no toxicity, 
should be preferred. Taken together, daily intake of tocotrienols, by current young 
smokers as well as passive smokers, may be useful in the prevention and treatment of 
dyslipidemia/hyperlipidemia and atherosclerosis. 
Based on an earlier initial study in young smokers. Fuller et al. (2000) 
recommended that the only way for young smokers to reduce oxidative damage to the 
vasculature by tobacco is to quit smoking rather than to take antioxidant vitamin E (d-
a-tocopheryl acetate, 400 lU/day) or vitamin C (1000 mg/day) or combination of 
vitamins E & C supplements. Similarly, in another initial report, Bloomer, (2007) has 
demonstrated that young, novice cigarette smokers have lower blood antioxidant 
capacity and higher lipid peroxidation levels compared to nonsmokers, despite having 
similar dietary intake. Based on these results. Bloomer emphasized the importance of 
smoking abstinence to young, novice cigarette smokers. These reports clearly indicate 
that daily intake of routine dietary antioxidants by young, novice smokers, or heavy 
dose of antioxidant vitamin supplements by young smokers will not sufficiently 
alleviate the enormous in vivo oxidative stress/damage induced by cigarette smoke. 
However, since, dietary tocotrienols, because of their potent 
hypolipidemic/antiatherogenic and antioxidant actions, were able to substantially 
ameliorate/normalize all the altered parameters including atheroprotective function of 
HDL described in the thesis, we initially recommend daily supplementation of young 
smokers with dietary tocotrienols (Tocomin) . In conclusion, based on Tocomin 
mediated multiple therapeutic benefits, described in the present study, daily intake of 
tocotrienols as a dietary supplement by novice/young/old moderate or heavy smokers 
as well as chronic smokers including passive smokers may be useful in the prevention 
and treatment of tobacco-induced dyslipidemia/hyperlipidemia and atherosclerosis. In 
addition, daily use of dietary tocotrienols will be efficacious, cost effective, and a 
good source of vitamin E. 
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Summary 
Several epidemiologic studies have established a strong and consistent link 
between cigarette smoking and increased cardiac morbidity and mortality. Other 
studies show that in addition to substantial increase in oxidative stress, certain other 
compounds of cigarette smoke, such as nicotine and carbon monoxide play a role in 
atherogenesis. Our results show that due to sustained free radical (>10'^ free radicals 
per puff) load during 4.6-4.9 years of cigarette smoking, young smokers (aged 23-25 
years) exhibited several proatherogenic actions, including a significant increase in 
atherogenic non-HDL-C, with a concomitant decline in the cholesterol concentrations 
of antiatherogenic HDL and its subfractions, HDL2 and HDL3. The data indicate a 
3.1-fold increase in blood nicotine and 2.3-fold increase in carboxyhemoglobin in 
young smokers. Eight-week Tocomin (150mg/day) treatment of smokers resulted in a 
significant reduction in nicotine and carboxyhemoglobin levels, which were reversed 
to 82 % and 50 % of respective control values of age-matched nonsmokers. These 
results indicate a strong protective effect of dietary tocotrienols, which may help 
lower risk of myocardial infarction in smokers. Our results show that in comparison 
to nonsmokers, a modest and significant increase in plasma total lipid (+42 %), TG 
(+15 %), FFA (+17 %), TC (+17 %), VLDL-C (+32 %), LDL-C (+52 %) and 
atherogenic non-HDL-C (+40 %) levels in smokers, which were significantly 
reversed to 89 - 101 % of nonsmokers value after 8 weeks of Tocomin 
supplementation. While antiatherogenic HDL and its subfractions HDL2 and HDL3 
were significantly lower (41-74 %) in smokers as compared to nonsmokers. Tocomin 
significantly blocked the reduction in HDL-C and HDL2-C levels and restored to 65 
% and 75 % of respective values in nonsmokers. However, cholesterol content of 
more antioxidative HDL3 was not affected during 8 weeks of Tocomin treatment. 
This may be due to markedly increased production of oxidants and significantly 
diminished anfioxidant defense including a decline in total plasma antioxidants. 
Consistent with published reports that relative to Ib-LDL, the concentration of 
sd-LDL was substantially increased in patients with hyperLDLcholesterolemia, 
hypertriglyceridemia, combined hyperlipidemia, and hyperlipidemia with CHD; our 
results show a significantly greater increase in sd-LDL-C (75 %) than LDL-C (49 %) 
or Ib-LDL-C (36 %) of smokers as compared to nonsmokers. Thus, in smokers, >37 
% of LDL-C was recovered in sd-LDL subpopulation, which is >18 % higher than its 
percent share of total LDL-C in nonsmokers. On the other hand, although Ib-LDL-C 
in smokers was significantly increased (36 %), but its percent share of total LDL-C 
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was not increased, instead decreased (9 %), indicating a preferential shift of LDL-C 
to more atherogenic sd-LDL subspecies due to oxidative stress induced 
hyperLDLcholesterolemia in smolders. Treatment of smokers with Tocomin 
significantly reduced both the cholesterol and apoB content of sd-LDL as well as 
their percent share of LDL close to corresponding control values in nonsmokers, 
indicating a shift from atherogenic sd-LDL to less atherogenic Ib-LDL and hence a 
strong antiatherogenic effect of Tocomin. It is interesting to mention that Tocomin 
mediated reduction in sd-LDL-C (39 %) was better than that of LDL-C (29 %). Since 
it has been established that LDL-C/HDL-C and HDL-C/TC ratios are good predictors 
for the presence and severity of CAD, intake of Tocomin by young smokers resulted 
in a normalization of these ratios. Consistent with the above results, we have initially 
included sd-LDL-C/HDL-C ratio, which was substantially increased from a ratio 
value of 0.576 in nonsmokers to 2.21 in placebo treated smokers. This sd-LDL-
C/HDL-C ratio was significantly reduced to 0.985 after Tocomin treatment. These 
results, which represent an initial demonstration, indicate that supplementation of 
young smokers with dietary tocotrienols for 8 weeks effectively ameliorated all the 
lipid parameters including highly atherogenic sd-LDL. 
The increase in plasma and lipoprotein lipid levels in young smokers is 
consistent with a significant increase of 54 % in hepatic HMG-CoA reductase activity 
of rats exposed to cigarette smoke for 4 weeks. Treatment of smoke exposed rats with 
dietary tocotrienols significantly blocked the increase in hepatic HMG-CoA reductase 
activity and reversed it to 84 % of normal control value, which may provide a 
mechanism for the reduction of plasma and lipoprotein lipids in smokers treated with 
Tocomin. Based on these results, it can be concluded that cholesterol lowering 
property of Tocomin in smoke exposed rats is due to the suppression of enzymatic 
activity of HMG-CoA reductase, the rate limiting enzyme in the biosynthetic pathway 
of cholesterol. 
In response to oxidative stress, evoked in dyslipidemic young smokers, 
plasma lipid peroxidation products, namely, conjugated diene, lipid hydroperoxide 
and malondialdehyde (MDA) were significantly increased, while plasma total 
antioxidants was significantly depleted. Tocomin administration significantly 
decreased the above plasma lipid peroxidation products with a concomitant and 
significant increase in plasma total antioxidants after 8 weeks of treatment. Similar to 
plasma, MDA content of erythrocytes in placebo treated smokers was significantly 
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increased by 135 %. The intact erytlirocytes isolated from smokers exhibited a further 
increase (>2-fold) in susceptibility to hydrogen peroxide induced MDA release, as 
compared to the basal MDA content in erythrocytes. The treatment of smokers with 
Tocomin effectively blocked the in vivo as well as in vitro susceptibility of 
erythrocytes to lipid peroxidation and significantly reduced MDA levels. However, 
this Tocomin mediated reversal of erythrocytes MDA content was only 68 % of 
nonsmokers MDA value, while reversal of MDA release during H2O2 induced lipid 
peroxidation was complete (>100 %). Based on these results, its seems plausible that 
oxygen radicals formed over and above the detoxifying capacity of erythrocytes can 
cause peroxidative breakdown of phospholipid fatty acids and accumulation of MDA 
and hence membrane damage. In addition, our study suggests that due to constant 
availability of antioxidants, tocotrienols, in the plasma of treated smokers, the 
integrity of erythrocytes membrane is significantly improved as shown by substantial 
protection against in vivo as well as in vitro H2O2 induced lipid peroxidation. 
As discussed above, besides increase in the circulating levels of LDL-C 
during smoking, there is an appearance of high concentrations of sd-LDL 
subpopulation which is shown to be more atherogenic than LDL. An enhanced 
susceptibility to oxidative modification could contribute to the greater atherogenicity 
of sd-LDL. Our results show that in smokers, LDL, sd-LDL and Ib-LDL 
susceptibility to in vivo oxidation, measured as ex vivo base line diene conjugation 
(BDC), was significantly increased as compared to nonsmokers. However, the 
increase in ex vivo BDC level was greater in sd-LDL than LDL or Ib-LDL, indicating 
an enhanced in vivo oxidizability of sd-LDL in smokers. In nonsmokers, in 
comparison to a lag phase value of 80 min for both LDL and Ib-LDL, the lag time of 
sd-LDL was markedly reduced to 10 min, indicating an 8-fold shortening in the lag 
phase of Cu'*^-catalyzed sd-LDL oxidation. Consistent with these results, maximal 
conjugated diene as well as MDA formation in LDL and Ib-LDL was achieved after 
12 h of oxidation, while sd-LDL required only 30 min of Cu'^ ^-catalyzed oxidation, 
indicating a substantially enhanced oxidative susceptibility of sd-LDL as compared to 
Ib-LDL or LDL. Tocomin supplementation of young smokers partially blocked the in 
vivo and in vitro LDL, sd-LDL and Ib-LDL oxidizability as seen by a decrease in ex 
vivo BDC levels and an increase in their lag phase values, which were restored to >80 
% lag phase values of nonsmokers. Similarly, ex vivo basal and Cu'*~^ -induced 
maximal formation of MDA were markedly increased in circulating LDL, sd-LDL 
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and Ib-LDL from smokers. Tocomin treatment of smokers caused a significant 
decrease and near normalization of both basal and maximal levels of MDA in LDL, 
sd-LDL and Ib-LDL. Relative to Ib-LDL, a markedly increased oxidizability of sd-
LDL subpopulation in smokers suggests that it may be more prone to further 
oxidation in the vessel wall of humans during smoking, as reported for sd-LDL 
phenotype. 
Several mechanisms could contribute to increased oxidative modification of LDL, sd-
LDL and Ib-LDL during smoking. Paraoxonase (PON) or arylesterase is a HDL-
associated enzyme that protects LDL as well as HDL fi-om oxidative stress. Smoking 
may be related to impaired PON 1/arylesterase activity, thereby compromising 
antioxidant defense mechanisms. In the present study, we have demonstrated a 
significant decrease in the enzymatic activity of arylesterase in plasma (-41 %), HDL 
fraction (-56 %), HDL2 (-57 %) and HDL3 (-60 %) subfractions of placebo treated 
young smokers with respect to nonsmokers. Similarly, LDL-C/arylesterase activity 
ratio was substantially increased (160 %) in smokers vs. nonsmokers. Tocomin 
treatment significantly prevented the decrease in arylesterase activity in plasma (+18 
%), HDL (+23 %), HDL2 (+42 %) and HDL3 (+16 %) and partially restored these 
activity levels to 31 %, 54 %, 62 % and 46 % of corresponding values in nonsmokers. 
In addition, Tocomin supplementation was associated with a significant decline (40 
%) in LDL-C/arylesterase activity ratio and reversed it to 56 % of ratio value in 
nonsmokers. As PONl activity is thought to play an essential role in the prevention of 
LDL oxidation, depletion of the HDL-associated arylesterase activity, as seen above, 
may contribute to increased oxidizability of HDL, HDL2, HDL3, total LDL and 
highly atherogenic sd-LDL subfraction in smokers. Our results indicating an 
enhanced in vivo as well as in vitro oxidizability of LDL and more atherogenic sd-
LDL and less atherogenic Ib-LDL in conjunction with decreased plasma, HDL, HDL2 
and HDL3 linked arylesterase activity and substantially increased LDL-C/arylesterase 
ratio in young smokers is likely to be a potential mechanism for the increased 
oxidation of circulating LDL density subfi-actions. 
The present results have shown that plasma derived small dense, lipid poor 
HDL3 particles possess the more potent capacity than large, light, cholesteryl ester 
rich HDL2 to protect LDL from Cu'^-catalyzed oxidation in normolipidemic 
nonsmokers. On the other hand, these results demonstrate that greater the reduction in 
HDL2-C or HDL3-C levels in dyslipidemic smokers, lower is their antioxidative 
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activity as compared to their counterparts from normolipidemic nonsmokers. Thus, in 
smokers, a 74 % reduction in large, light HDL2-C was apparently responsible for a 
significantly lower antioxidative activity (19-23 %), while a reduction of only 41 % in 
small, dense HDL3-C showed a lower decrease (4-8 %) in the protection of LDL 
against oxidation. Consistent with the relationship between differential reductions in 
HDL2-C and HDL3-C and impairment of their antioxidative activity in dyslipidemic 
smokers, total protein content associated with HDL2 and HDL3 was also 
proportionally reduced by 64 % and 34 %. Our combined data clearly indicate that 
impairment of the antioxidative activity of HDL subtractions, particularly small, 
dense HDL3 in dyslipidemic smokers involving low antiatherogenic HDL-C levels, 
low HDL linked arylesterase activity, low HDL associated proteins, and high 
atherogenic non-HDL-C levels are intimately associated with elevated oxidative 
stress- a newly recognized CVD risk factor, and may therefore contribute to enhanced 
atherogenesis. On the other hand, supplementation of young smokers with dietary 
tocotrienols mediated a significant therapeutic normalization of all the above 
parameters. In addition, Tocomin mediated a restoration of HDL2-C and HDL3-C 
levels by 75 % and 42 % of control value in nonsmokers, while arylesterase activity 
was increased by 62 % and 46 % in HDL2 and HDL3 particles, respectively. As a 
result, both HDL2 and HDL3 from Tocomin treated smokers were able to further 
reduce the maximal conjugated diene formation to a common level, 21 % lower than 
their normal counterparts in normolipidemic nonsmokers; thus exceeding the 
protection afforded against Cu'^ -induced oxidation of LDL alone from Tocomin 
supplemented smokers. The combined results provide evidence that small, dense 
HDL3, relative to large, light HDL2, afford better potent protection of LDL against 
oxidative stress. Therapeutic normalization of HDL function, coupled with a strong 
hypolipidemic and antioxidant actions of dietary tocotrienols may therefore represent 
a novel therapeutic approach to attenuate dyslipidemia in young smokers as well as 
atherosclerosis in dyslipidemic chronic smokers. 
As indicated above, oxidative stress may be increased in smokers due to a 
higher production of reactive oxygen species (ROS), such as superoxide radical, 
hydroxyl radical, hydrogen peroxide and/or deficiency in the antioxidant defense 
systems. Therefore, as the balance between ROS production and antioxidant defenses 
is lost, the resultant oxidative stress through a series of events deregulates the cellular 
functions leading to various pathological conditions. An antioxidant compound might 
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contribute partial or total alleviation of such damage. Our results show a significant 
increase of 45 % and 15 % in the erythrocytes activities of CAT and SOD of smokers, 
while Gpx and Gred activities were significantly decreased by 39 % and 35 %. 
Supplementation of Tocomin for 8 weeks vvere found to be therapeutically quite 
effective in reversing/normalizing the altered enzymatic antioxidant defense system 
in erythrocytes of young smokers. 
Since certain experiments such as mechanism (s) of lipid lowering action of 
tocotrienols and the extent of their protective effect on enzymatic and noenzymatic 
antioxidant defense systems including lipid peroxidation in various tissues etc. are 
unavailable from young smokers, male albino rats, exposed to cigarette smoke daily 
for 30 min for 4 weeks, have been used as an experimental model. In this animal 
model we investigated the efficacy of antioxidant and hypolipidemic agents Tocomin 
and Lovastatin by analyzing all the parameters in plasma and erythrocytes, including 
blood nicotine and carboxyhemoglobin; plasma and lipoprotein lipids, erythrocytes 
lipid peroxides, arylesterase enzyme activity and differential in vivo and in vitro 
oxidizability of highly atherogenic sd-LDL, less atherogenic Ib-LDL as well as LDL, 
as investigated in young smokers treated with and without Tocomin. It is interesting 
to mention that in general, the results obtained from the cigarette smoke exposed 
hyperlipidemic rats treated with dietary tocotrienols exhibited great similarities with 
the results in young smokers supplemented with Tocomin for 8 weeks. In addition, in 
this rat model, the hypolipidemic and antioxidative properties of Lovastatin are also 
comparable to Tocomin, used in both animal and human models. Here, we have 
summarized the dissimilarities between the results from two models. The results 
demonstrate that a 4-week cigarette smoke exposure induced a severe hyperlipidemia 
in S-C rats as compared to dyslipidemic young smokers. A much higher increase in 
plasma TG (102 % vs. 13 % in smokers) and atherogenic non-HDL-C (109 % vs. 46 
% in smokers) levels contributed to the increased degree of hyperlipidemia in S-C 
rats. On the other hand, in S-C rats, atherogenic HDL-C was decreased by only 11 %, 
in comparison to a decline of 51 % in smokers, indicating a very mild dyslipidemia in 
S-C rats. This markedly lower degree of dyslipidemia in S-C rats, versus young 
smokers, is apparently due to species difference, which is consistent with the known 
fact that rats are highly resistant to the initiation and development of atherosclerosis. 
These resuHs in S-C rats are further supported by a 34 % reduction in cholesterol 
content of large, light, cholesteryl ester rich HDL2, which is considered to be a strong 
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predictor of presence and extent of CAD. In addition, cholesterol content of small, 
dense, lipid poor HDL3, which exerts potent protection of atherogenic LDL against 
oxidative stress, was reduced by only 5 % in S-C rats vs. N-C value, while in young 
smokers it was significantly reduced by 41 %. Together, these results suggest that 
dyslipidemic smokers may be more susceptible to atherogenesis than a 4-week 
cigarette smoke exposed animals. Highly increased plasma TG, TC, VLDL-C, LDL-
C and atherogenic non-HDL-C concentrations in S-C rats were significantly reduced 
to a level close to their counterparts in N-C rats, after 4 weeks of Tocomin or 
Lovastatin treatment, while similar reversal in the above parameters was seen in 
Tocomin supplemented young smokers. In complete contrast to young smokers, 
Tocomin treatment not only blocked the minimal decline of 11 % seen in HDL-C 
level of S-C rats but increased it to a level, 58 % higher than normal control value. 
Similarly, the decrease of 34 % in HDL2-C of S-C rats was blocked by Tocomin and 
increased to a level 98 % higher than HDL2-C value in N-C. Lx)vastatin treatment of 
S-C rats also increased the HDL-C (36 %) and HDL2-C (49 %) concentrations, but to 
a lesser extent than Tocomin. On the other hand, after 4 weeks of Tocomin or 
Lovastatin treatment, the cholesterol content of more antioxidative small, dense HDL3 
was increased, from a reduced value of only 5 % in S-C rats, to 39 % and 31 % higher 
than normal control HDL3 value. These results are in agreement with published 
evidence indicating that Lovastatin treatment of hyperlipidemic subjects and animals 
was associated with a significant increase in HDL-C, while TRF has been shown to 
mediate an increase in HDL-C levels of hyperlipidemic rats as well as in a type II 
familial hypercholesterolemic subject. These results demonstrate that both dietary 
tocotrienols and Lovastatin exert a potent effect in normalizing the high levels of TG 
as well as atherogenic non-HDL-C in cigarette smoke-induced hyperlipidemia in rats. 
In addition, these agents exhibited a potent antiatherogenic effect by substantially 
increasing the concentrations of atheroprotective HDL. 
The comparison of the above results in cigarette smoke exposed rats versus 
young smokers, revealed that because of severe hyperlipidemia, coupled with a 
minimal decline in HDL-C (- 11 %) in S-C rats, there was a marked increase in 
plasma TG (+ 102 %), VLDL-C (+ 105 %) and LDL-C (+112 %). As a result, a 
substantial shift of cholesterol and apoB from less atherogenic Ib-LDL to more 
atherogenic sd-LDL had occurred, which significantly increased the sd-LDL-C (+ 
292 % vs. N-C value) and its percent share of LDL-C (85 % vs. 29 % in N-C). On the 
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other hand, in dyslipidemic young smokers with mild hyperlipidemia, HDL-C level 
was significantly reduced (-51 %), while there was a modest increase in TG (+ 14 %), 
VLDL-C (+ 33 %) and LDL-C (+ 49 %); as a consequence of which, there was a 
proportional increase in sd-LDL-C (75 % vs. control value) and its percent share of 
LDL-C (37 % vs. 32 % in control). Both dietary Tocomin and Lovastatin effectively 
reduced and fully normalized the circulating TG, VLDL-C, LDL-C and more 
atherogenic sd-LDL-C, while cholesterol levels of antiatherogenic HDL were 
increased to a level significantly higher than N-C value. Consistent with these 
findings, LDL-C/HDL-C, HDL-CA'C, sd-LDL-C/HDL-C and Ib-LDL-C/HDL-C 
ratios were markedly altered (+ 125 %, - 48 %, + 314 % and + 44 %, respectively, vs. 
corresponding ratio values in N-C), in S-C rats, while treatment with Tocomin or 
Lovastatin fully normalized these altered ratios to a level, 15 % to 26 % better than 
their counterparts in N-C, indicating an excellent normalization of highly atherogenic 
sd-LDL-C and LDL-C levels. 
Consistent with the increase in plasma TG, FFA and TC levels of S-C rats, a 
significant increase in these lipids of liver, lung and kidney were also observed. 
While, Tocomin or Lovastatin treatment of S-C rats for 4 weeks was associated with 
a significant decreases in TG, FFA and TC of each tissue. These results demonstrate 
that sustained oxidative stress in S-C rats is also able to induce hyperlipidemia in the 
above tissues with a maximum increase in hepatic TC, while both Tocomin and 
Lovastatin effectively blocked these increases and restored the TG, FFA and TC 
levels of liver, lung and kidney close to corresponding normal control values. The 
significant increase in plasma, liver, lung and kidney lipid levels is consistent with a 
significant increase (54 %) in liver HMG-CoA reductase activity of S-C rats. 
Treatment of S-C rats with dietary Tocomin or Lovastatin was associated with a 
significant decrease in plasma and tissue lipid levels as well as hepatic HMG-CoA 
reductase activity, which was restored to 84 % and 62 % of N-C value, which may 
provide a mechanism for the reduction of plasma and tissue lipids. These results 
indicate that both tocotrienols and Lovastatin may exert their hypocholesterolemic 
effect in hyperlipidemic rats and dyslipidemic young smokers in a similar manner as 
previously reported for hyperlipidemic animals and humans 
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In response to oxidative stress, evoked in cigarette smolce-induced 
hyperlipidemic rats, our data show a significant increase in lipid/lipoprotein 
peroxidation products. Conjugated diene, lipid hydroperoxide and MDA in plasma, 
liver, lung and kidney were significantly increased in S-C rats. The increase in plasma 
lipid peroxidation products is closely associated with a significant decline in total 
antioxidant capacity of plasma. The increase in lipid peroxidation products in plasma, 
liver, lung and kidney and decrease in plasma total antioxidants is consistent with the 
well known prooxidant effect of cigarette smoke in rats. Treatment of S-C rats with 
either 6.0 mg Tocomin or 0.50 mg Lovastatin/rat/day for 4 weeks was associated with 
a significant decline in lipid peroxidation products of plasma, liver, lung and kidney 
and a significant increase in plasma total antioxidants, indicating a potent antioxidant 
effect of Tocomin and Lovastatin. It is interesting to note that the changes observed in 
plasma total antioxidants, conjugated diene, hydroperoxide and MDA as well as 
erythrocytes MDA content and its release during in vitro H2O2 induced peroxidation 
from S-C rats is qualitatively similar to the changes seen in the young smokers. 
However, MDA release in intact erythrocytes from S-C rats was substantially higher, 
that is, >4-fold vs. >2-fold in young smokers, in comparison to their respective ex 
vivo basal MDA content in erythrocytes, indicating a massive oxidative stress in rats 
exposed to cigarette smoke , daily for 30 min, for 4 weeks. In addition, consistent 
with significantly higher free radical scavenging property of dietary tocotrienols than 
a-tocopherol, Tocomin offered much better protection against both in vivo and in 
vitro H2O2 induced lipid peroxidation in erythrocytes from S-C rats, than Lovastatin. 
As indicated earlier, severe hyperlipidemia in S-C rats was associated with an 
increase in LDL and appearance of high concentrations of sd-LDL subpopulation, 
which is shown to be more prone to oxidation than Ib-LDL or LDL and hence more 
proatherogenic. Conceptually, the differential in vivo and in vitro oxidizaibility of sd-
LDL and Ib-LDL observed in hyperlipidemic S-C rats is consistent with the results 
obtained from dyslipidemic young smokers. 
Xanthine oxidase (XO) is a physiological source of superoxide anions in 
eukaryotic cells. Serum xanthine oxidase activity is known to be increased in various 
pathological disorders, such as carcinogenesis, hepatitis, inflammatory diseases, 
aging, hyperlipidemia and diabetes and that free radicals generated in the enzymatic 
processes are involved in the oxidative damage. Our results demonstrate that 
increased XO activity in plasma, liver, lung and kidney of cigarette smoke exposed 
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rats was significantly bloclced by Tocomin or Lovastatin and reduced to a level close 
to corresponding normal control values. These results show that dietary tocotrienols 
and Lovastatin, in addition to their potent hypolipidemic and antioxidant activity, has 
the ability to reduce XO activity in plasma, liver, lung and kidney, indicating an 
additional therapeutic benefit in the prevention and treatment of cigarette smoke 
induced dyslipidemia/hyperlipidemia and atherosclerosis. 
It is well known that cigarette smoking is associated with a substantial 
increase in oxidative stress, oxidant stress may be increased owing to a higher 
production of ROS, which are controlled by antioxidant enzymes, SOD, catalase, 
Gpx, Gred and GSH. An impaired radical scavenger function has been linked to 
decreased/increased activity of enzymatic and nonenzymatic antioxidants. Our results 
show a significant decrease in the activities of antiperoxidative enzymes, CAT, SOD, 
Gred, GST as well as GSH, in liver, lung and kidney of smoke exposed rats, except 
Gpx activity which was significantly increased. Treatment of cigarette smoke stressed 
hyperlipidemic rats with Tocomin or Lovastatin for 4 weeks, significantly 
reversed/restored the altered tissue activities of SOD, catalase, Gpx, Gred and GST 
including total, free and protein bound-SH contents of glutathione, to near normal 
control values, indicating an almost total alleviation of oxidative damage by these 
antioxidants. Both Tocomin and Lovastatin mediated a near normalization of 
peroxide levels and scavenging enzyme activities as well as GSH in liver, lung and 
kidney of cigarette smoke exposed rats, indicating a strong antilipid/lipoprotein 
peroxidative effect of these hypolipidemic agents. Based on these results in cigarette 
smoke induced hyperlipidemic rats in conjunction with the data in young smokers 
showing that supplementation of Tocomin for 8 weeks significantly improved the 
integrity of erythrocytes membrane as seen by improved protection against lipid 
peroxidation as well as reversal of enzymatic activities of CAT, SOD, Gpx and Gred 
to near normal levels, it is likely, that a similar Tocomin and Lovastatin mediated 
amelioration of overall antioxidant defense systems, as seen in different tissues of S-
C rats, may be operative in young smokers. Thus, it is possible, that supplementation 
of young dyslipidemic smokers with dietary tocotrienols for 8 weeks would have 
been equally effective in the protection of cigarette smoke induced oxidative damage 
in hepatic, pulmonary and renal tissues. 
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The combined results in dyslipidemic young smokers and cigarette smoke 
exposed hyperlipidemic rats, which represent an initial study, demonstrate that strong 
hypolipidemic impact of dietary tocotrienols and Lovastatin coupled with their potent 
antioxidative property can provide additional benefit in the suppression of oxidative 
stress, particularly in the oxidative resistance of highly atherogenic sd-LDL and LDL, 
and hence in the prevention and treatment of cigarette smoke induced 
dyslipidemia/hyperlipidemia and atherosclerosis. Although multiple atheroprotective 
effects of Tocomin and Lovastatin observed in cigarette smoke exposed rats were 
qualitatively comparable, but in view of the several toxic effects known to be 
exhibited by statins including Lovastatin in humans, use of dietary tocotrienols, 
which are vitamin E and have no toxicity, should be preferred. Taken together, daily 
intake of tocotrienols, by current young smokers as well as passive smokers, may be 
useful in the prevention and treatment of dyslipidemia/hyperlipidemia and 
atherosclerosis. Previously published reports clearly indicate that daily intake of 
routine dietary antioxidants by young, novice smokers, or heavy dose of antioxidant 
vitamin supplements by young smokers will not sufficiently alleviate the enormous in 
vivo oxidative stress/damage induced by cigarette smoke. However, since, dietary 
tocotrienols, because of their potent hypolipidemic/antiatherogenic and antioxidant 
actions, were able to substantially ameliorate/normalize all the altered parameters 
including atheroprotective function of HDL described in the thesis, we initially 
recommend daily supplementation of young smokers with dietary tocotrienols 
(Tocomin). In conclusion, based on Tocomin mediated multiple therapeutic benefits, 
described in the present study, daily intake of tocotrienols as a dietary supplement by 
novice/young/old moderate or heavy smokers as well as chronic smokers including 
passive smokers may be useful in the prevention and treatment of tobacco-induced 
dyslipidemia/hyperlipidemia and atherosclerosis. In addition, daily use of dietary 
tocotrienols will be efficacious, cost effective, and a good source of vitamin E. 
165 

Bibliography 
• Aaron, J. 1983. Biochemical links between cigarette smoking and pulmonary 
emphysema. J. Appl. Physiol. 55: 285-293. 
• Abbott, C. A., Mackness, M. I., Kumar, S., Boulton, A. J. and Durrington, P. N. 
1995. Serum paraoxonase activity, concentration, and phenotype distribution in 
diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. 
Thromb. Vase. Biol. 15: 1812-1818. 
• Abbott, R. D., Yin, Y., Reed, D. M. and Yano, K. 1986. Risk of stroke in male 
cigarette smokers. N. Engl. J. Med. 315: 717-720. 
• Abou-Seif, M. A. 1996. Blood antioxidant status and urine sulfate and thiocyanate 
levels in smokers. J. Biochem. Toxicol. 11: 133-138. 
• Abuja, P. M. and Esterbauer, H. 1995. Stimulation of lipid peroxidation in low-
density lipoprotein by a basic skeleton of reactions. Chem. Res. Toxicol. 8: 753-
763. 
• Albers, J. J., Bergelin, R. O., Adolphson, J. L. et al. 1982. Population-based 
reference values for lecithin-cholesterol acyltransferase (LCAT). Atherosclerosis. 
43: 369-379. 
• Alexandrie, A. K., Sundberg, M. I., Seidegard, J., Tomling, G. and Rannug, A. 
1994. Genetic susceptibility to lung cancer with special emphasis on CYPl Al and 
GSTMl: A study on host factors in relation to age at onset, gender and 
histological cancer types. Carcinogenesis 15: 1785-1790. 
• Ali, W. 2007. Protective impacts of tocotrienols and Lovastatin on hyperglycemia, 
cholesterol dynamics, lipid peroxidation, erythrocyte and hepatic antioxidant 
enzymes in diabetic-hyperlipidemic rats. Ph.D. Thesis. 
• Allred, E. N., Bleecker, E. R., Chaitman, B. R. et al. 1989. Short-term effects of 
carbon monoxide exposure on the exercise performance of subjects with coronary 
artery disease. N Engl J Med. 321:1426-1432. 
• Al-Turk, W. A., Stohs, S. J., El-Rashidy, F. H. and Othman, S. 1987. Changes in 
glutathione and its metabolizing enzymes in human erythrocytes and lymphocytes 
with age. J. Pharm. Pharmacol. 39:13-16. 
• Ambrose, J. A. and Barua, R. S. 2004. The pathophysiology of cigarette smoking 
and cardiovascular disease: an update. J Am Coll Cardiol. 43:1731-1737. 
• Andersen, H. R., Nielsen, J. B., Nielsen, F. and Grandjean, P. 1997. Antioxidative 
enzyme activities in human erythrocytes. Clin Chem. 43: 562-8. 
166 
Bibliography 
• Annino, J.S. and Giese, R.W. 1976. In Clinical Chemistry. Principles and 
Procedures, IV Ed. Little, Brown and Company, Boston. 33: 268-275. 
• Arebalo, R. E., Hardgrave, J. E. and Scallen, T. J. 1981. The in vivo regulation of 
rat liver 3-hydroxy-3-methylglutaryl coenzyme A reductase. Phosphorylation of 
the enzyme as an early regulatory response following cholesterol feeding. J. Biol. 
Chem. 256: 571-581. 
• Ashakumary, L. and Vijayamma, P. L. 1997. Effect of nicotine on lipoprotein 
metabolism in rats. Lipids. 32: 311-315. 
• Assmann, G., Antonio, M. and Gotto, J. 2004. HDL cholesterol and protective 
factors in atherosclerosis. Circulation. 109 (supp III): III-8-III-14. 
• Assmann, G., Cullen, P., Jossa, P., Lewis, B. and Mancini, M. 1998. International 
atherosclerosis society and international task force for prevention of coronary 
heart disease. Nutr. Metabol. Cardiovasc. Dis. 8:212-260. 
• Ashby, D. T., Rye, K. A., Clay, M. A., Vadas, M. A., Gamble, J. R. and Barter, P. 
J. 1998. Factors influencing the ability of HDL to inhibit expression of vascular 
cell adhesion molecule-1 in endothelial cells. Arterioscler. Thromb. Vase. Biol. 
18: 1450-1455. 
• Austin, M. A., Breslow, J. L., Hennekens, C. H. et al. 1988. Low-density 
lipoprotein subclass and risk of myocardial infarction. JAMA. 260: 1917-1922. 
• Austin, M. A., hokanson, J. E. and Brunzell, J. D. 1994. Characterization of low-
density lipoprotein subclass: methodologic approaches and clinical relevance. 
Curr. Opin. Lipidol. 5: 395-403. 
• Austin, M. A., King, M. C, Vranizan, K. M. and Krauss, R. M. 1990. Atherogenic 
lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. 
Circulation. 82: 495-506. 
• Austin, M. A., Mykkanen, L., Kuusisto, J., Edwards, K. L., Nelson, C, Haffner, S. 
M., Pyorala, K. and Laakso, M. 1995. Prospective study of small dense LDLs as a 
risk factor for non-insulin dependent diabetes mellitus in elderly men and women. 
Circulation. 92: 1770-1778. 
• Aviram, M., Rosenblat, M., Bisgaier, C. L. et al. 1998. Paraoxonase inhibits 
highdensity lipoprotein oxidation and preserves its functions: a possible 
peroxidative role for paraoxonase. J Clin Invest. 101: 1581-1590. 
167 
Bibliography 
Ayub, A., Mackness, M. I., Arrol, S., Mackness, B., Patel, J. and Durrington, P. N. 
1999. Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vase. 
Biol. 19: 330-335. 
Babior, B. M. 1999. NADPH-oxidase: an update. Blood. 93: 1464-1476. 
Baliarsingh, S., Beg, Z. H. and Ahmad, J. 2005. The therapeutic impacts of 
tocotrienols in type 2 diabetic patients with hyperlipidemia. Atherosclerosis. 182: 
367-374. 
Bagchi, M., Mukherjee, S. and Base, M. K. 1993 Lipid peroxidation in hepatic 
microsomal membrane isolated from mice in health and in experimental 
Leishmaniasis. Indian J. Biochem. Biophys. 30: 277-281. 
Bamoya, J. and Glantz, S. A. 2005. Cardiovascular effects of secondhand smoke: 
nearly as large as smoking. Circulation. I l l: 2684-2698. 
Barter, P. J., Baker, P. W. and Rye, K. A. 2002. Effect of high-density 
lipoproteins on the expression of adhesion molecules in endothelial cells. Curr. 
Opin. Lipidol. 13: 285-288. 
Becker, B.F. 1993. Towards the physiological function of uric acid. Free Radic 
Biol Med.l4: 615-31. 
Beg Z. H., Brewer, H. B., Jr, Horecker, B. L. and Stadtman, E. R. (eds.). 1981. 
Current topics in Cellular Regulation, Orlando, F. L., Academic. 20: 139. 
Beg, Z. H. and Brewer, H. B., Jr. 1982. Modulation of rat liver 3-hydroxy-3-
methylglutaryl-CoA reductase activity by reversible phosphorylation. Fed. Proc. 
41:2634-2638. 
Beg, Z. H. and Zainuddin, M. 2003. Impacts of tocotrienols on cholesterol 
dynamics and in the protection of accelerated aortic atherosclerosis induced by 
oxidized cholesterol in cholesterol-fed rabbits. Proceedings of the 16th annual 
conference of Indian Society of Athersclerosis research and international seminar 
on recent developments in atherosclerosis research Banaras Hindu University, 
Varanasi. p. 59-60. 
Beg, Z. H., Iqbal, J. and Minhajuddin, M. 2000b. Tocotrienols (vitamin E): 
anticholesterol impacts on plasma lipids and apo lipoproteins via reduction in the 
enzymatic activity and protein mass of HMG-CoA reductase in normal and 
hyperlipidemic rats. Proc. Oils and fats International Congress 2000, Kuala 
Lumpur, Malaysia. 4-12. 
168 
Bibliography 
• Beg, Z. H., Khan, S. Z. and Khan, A. S. 1995. Impacts of rice bran oil on 
cholesterol dynamics in hyperlipidemic humans. Symposium on atherosclerosis: 
etiology and prevention. Fed. Proc, USA. A-9. 
• Beg, Z. H., Stonik, J. A. and Brewer, H. B., Jr. 1978. Solubilization of 3-hydroxy-
3-me.thylglutaryl coenzyme A reductase from rat and chicken liver microsomes 
Anal. Biochem. 86: 531-535. 
• Beg, Z. H., Stonik, J. A. and Brewer, H. B., Jr. 1979. Characterization and 
regulation of reductase kinase, a protein kinase that modulates the enzymic 
activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proc. Natl. Acad. 
Sci., USA. 76: 4375-4379. 
• Beg, Z. H., Stonik, J. A. and Brewer, H. B., Jr. 1982. Isolation and immunological 
characterization of 3-hydroxy-3-methylglutaryl coenzyme A reductase from 
human liver Biochem. Biophys. Res. Commun. 107: 1013. 
• Beg, Z. H., Stonik, J. A. and Brewer, H. B., Jr. 1984b. In vivo modulation of rat 
liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase, reductase kinase, and 
reductase kinase by mevalonolactone. Proc. Natl. Acad. Sci., USA. 81: 7293-
7297. 
• Beg, Z. H., Stonik, J. A. and Brewer, H. B., Jr. 1984a. Human hepatic 3-hydroxy-
3-methylglutaryi coenzyme a reductase: Evidence for the regulation of enzymic 
activity by a bicyclic phosphorylation cascade. Biochem. Biophys. Res. Commun. 
119: 488-498. 
• Beg, Z. H., Stonik, J. A. and Brewer, H. B., Jr. 1985. Phosphorylation of hepatic 
3-hydroxy-3-methylglutaryl coenzyme A reductase and modulation of its enzymic 
activity by calcium-activated and phospholipid-dependent protein kinase. J. Biol. 
Chem.260: 1682-1687. 
• Beg, Z. H., Stonik, J. A. and Brewer, H. B., Jr. 1987. Modulation of the enzymic 
activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase 
systems involving reversible phosphorylationss: a review. Metabolism 36(9): 900-
917. 
• Beg, Z. H., Timani, K. A. and Khan, S.Z. 1996. Impacts of dietary rice bran oil on 
cholesterol dynamics in normolipidemic, hyperlipidemic humans and 
hyperlipidemic rats. The FASEB J. 10: A187. 
169 
Bibliography 
Beg, Z. H., Timani, K. A., Iqbal, J. and Minhajuddin, M. 1997. Tocotrienols 
(vitamin E): Hypolipidemic impacts on cholesterol dynamics of a type II familial 
hypercholesterolemic patient with severe xanthomas. The FASEB J. 11: A1266. 
Bell, A. D., Taylor, J. A., Paulson, D.F., Robertson, C. N., Mohler, J. L. and 
Lucier, G. W. 1993. Genetic risk and carcinogen exposure: A common inherited 
defect of the carcinogen-metabolism gene glutathione S-transferase Ml (GSTMl) 
that increases susceptibility to bladder cancer. J. Natl. Cancer Inst. 85: 1159-1164. 
Bennet, C.A. and Franklin, N.L. 1967. In: Statistical Analysis in Chemistry and 
Chemical Industry. John-Wiley and Sons Inc., New York, p. 133. 
Benowitz, N. L. 2003. Cigarette smoking and cardiovascular disease: 
Pathophysiology and implications for treatment. Progress in Cardiovascular 
Diseases. 46:91-111. 
Benzie, I. F. F. and Strain, J. J. 1996. The ferric reducing ability of plasma 
(FRAP) as a measure of "antioxidant power": The FRAP assay. Analytical 
Biochem. 239: 70-76. 
Berliner, J. A. and Heinecke, J. W. 1996. The role of oxidized lipoproteins in 
atherogenesis. Free Radic. Biol. Med. 20: 707-727. 
Berg, K., Dahlen, G. and Frick, M. H. 1974. Lp(a) lipoprotein and pre-betal-
lipoprotein in patients with coronary heart disease. Clin. Genet. 6: 230-235. 
Bindu, M. P. and Annamalai, P. T. 2004. Combined effect of alcohol and cigarette 
smoke on lipid peroxidation and antioxidant status in rats. Indian journal of 
biochemistry & biophysics. 41:40-44. 
Bjomheded, T., Babyi, A., Bodjers, G. and Wilkund, O. 1996. Accumulation of 
lipoprotein fraction and subfractions in the arterial wall, determined in an in vitro 
perfusion system. Atherosclerosis. 123: 43-56. 
Blatter, M. C, James, R. W., Messmer, S. et at. 1993. Identification of a distinct 
human high-density lipoprotein subspecies defined by a lipoproteinassociated 
protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem. 211: 871-879. 
Bloomer, R. 2007. Decreased blood antioxidant capacity and increased lipid 
peroxidation in young cigarette smokers compared to nonsmokers impact of 
dietary intake. Nutrition Journal. 6: 1-6. 
170 
Bibliography] 
• Bloomer, R., Solis, j . Adrienne, D., H Fisher-Wellman and smith, Wabb A. 2008. 
Postprandial oxidative stress is exacerbated in cigarette smokers.British journal of 
nutrition. 99: 1055-1060. 
• Boemi, M., Leviev, 1., Sirolla, C, Fieri, C, Marra, M. and James, R. W. 2001. 
Serum paraoxonase is reduced in type 1 diabetic patients compared to non-
diabetic, first-degree relatives; influence on the ability of HDL to protect LDL 
from oxidation. Atherosclerosis. 155: 229-235. 
• Boisfer, E., Stengel, D., Pastier, D., Laplaud, P. M., Dousset, N., Ninio, E. and 
Kalopissis, A. D. 2002. Antioxidant properties of HDL in transgenic mice 
overexpressing human apolipoprotein A-II. J Lipid Res. 43: 732-741. 
• Borges, F., Femandes, E. and Roleira, F. 2002. Progress towards the discovery of 
xanthine oxidase inhibitors. Curr. Med. Chem. 9: 195-217. 
• Bradford, M.M. 1976. A rapid and sensitive method for the quantification of 
microgram quantities of protein utilizing the principle of protein-dye binding. 
Anal. Biochem. 72: 248-254. 
• Brewer, H. B. Jr, Gregg, R. E., Hoeg, J. M. and Fojo, S. S. 1988. Apolipoproteins 
and lipoproteins in human plasma: an overview. Clin.Chem. 34: 4-8. 
• Bridges, R. B., Chow, C. K. and Rehm, S. R. 1990. Micronutrient status and 
immune function in smokers. Ann NY Acad Sci. 587: 218-231. 
• Brischetto, C. S., Connor, W. E., Connor, S. L. and Matarazzo, J. D. 1983. Plasma 
lipid and lipoprotein profiles of cigarette smokers from randomly selected familiar 
enhancement of hyperlipidemia and depression of high density lipoprotein. 
American J of Cardiology. 52: 675-680. 
• Briviba, K., Klotz, L. O. and Sies, H. 1999. Defenses against peroxynitrite. 
Methods Enzymol. 301: 301-11. 
• Brown, M. S. and Goldstein, J. L.1986. A receptor-mediated pathway for 
cholesterol homeostasis. Science. 232:34-47. 
• Brown, M. S. and Goldstein, J. L. 1979. Receptor-Mediated Endocytosis: Insights 
from the Lipoprotein Receptor System. Proc. Natl. Acad. Sci., USA. 76: 3330. 
• Brown, M. S. and Goldstein, J. L. 1980. Multivalent feedback regulation of HMG 
CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell 
growth. J. Lipid. Res. 21: 505-517. 
171 
Bibliography 
• Brown, M. S. and Goldstein, J. L. 1983. Lipoprotein metabolism in the 
macrophage: implications for cholesterol deposition in atherosclerosis. Ann. Rev. 
Biochem. 52: 223. 
• Burton, G. W., Joyce, A. and Ingold, A. U. 1983. Is vitamine the only lipid 
soluble chain breaking antioxidant in human blood plasma and erythrocytes 
membrane? Arch. Biochem. Biophys. 221: 281-290. 
• Cabana, V. G., Reardon, C. A., Feng, N., Neath, S., Lukens, J. and Getz, G. S. 
2003. Serum paraoxonase: effect of the apolipoprotein composition of HDL and 
the acute phase response. J. Lipid Res. 44: 780-792. 
• Cadenas, E. and Sies, H. 1998. The lag phase. Free. Radic. Res. 28: 601-609. 
• Cantin, A. M., North, S. L., Hubbard, R. C. and Crystal, R. G. 1987. Normal 
alveolar epithelial lining fluid contains high levels of glutathione. J. Appl. Physiol. 
63: 152-157. 
• Caralis, D. G., Deligonul, U., Kern, M. J. and Cohen, J. D. 1992. Smoking is a 
risk factor for coronary spasm in young women. Circulation. 85: 905-909. 
• Cariqui, M. H., Cowan, L. D., Heiss, G., Haskell, W. L., Laskarazewaski, P. M. 
and Chambless, L. E. 1986. Frequency and clustering of nonlipid coronary risk 
factors in dyslipoproteinemia. The lipid research clinics program prevalence 
study. Circulation. 73 (1, Part 2): 1-40, 1-50. 
• Carlberg, L and Mannervik, E. B. 1975. Glutathione level in rat brain. J. Biol. 
Chem. 250: 4475-4480. 
• Carr, A., McCall, M. R. and Frei, B. 2000. Oxidation of LDL by myeloperoxidase 
and reactive nitrogen species-reaction pathways and antioxidant protection. 
Arterioscl. Thromb. Vase. Biol. 20: 1716-1723. 
• Castellani, L. W., Navab, M., Van Lenten, B. J., Hedrick, C. C, Hama, S. Y., 
Goto, A. M., Fogelman, A. M. and Lusis, A. J. 1997. Overexpression of 
apolipoprotein All in transgenic mice converts high density lipoproteins to 
proinflammatory particles. J. Clin. Invest. 100: 464-474. 
• Castro, G. R. and Fielding, C. J. 1988. Early incorporation of cell-derived 
cholesterol into pre-beta-migrating high-density lipoprotein. Biochem. 27: 25-29. 
• Cayatte, A. J., Palacino, J. J., Horten, K. and Cohen, R. A. 1994. Chronic 
inhibition of nitric oxide production accelerates neointima formation and impairs 
172 
Bibliography 
endothelial function in hypercholesterolemic rabbits. Arterioscl. Thromb. 14: 753-
759. 
Chapman, M. J., Guerin, M. and Bruckert, E. 1998. Atherogenic, dense low-
density lipoproteins: pathophysiology and new therapeutic approaches. Eur. Heart. 
J. 19 (suppl A): A24-A30. 
Chancharme, L., Therond, P., Nigon et al. 1999. Cholesteryl ester hydroperoxide 
liabilities key feautrue of the oxidative susceptibility of small dense LDL. 
Arterioscler. Thromb. Vase. Biol. 19: 810-820. 
Chait, A., Brazg, R. L., Tribble, D. L. and Krauss, R. M. 1993. Susceptibility of 
small, dense, low-density lipoproteins to oxidative modification in subjects with 
the atherogenic lipoprotein phenotype, pattern B. Am. J. Med. 94: 350-356. 
Chaudiere, J. and Ferrari-Iliou, R. 1999. Intracellular Antioxidants: from 
Chemical to Biochemical Mechanisms. Food and Chemical Toxicology. 37: 949-
962 
Chen, C. and Loo, G. 1995. Cigarette smoke extract inhibits oxidative 
modification of low density lipoprotein. Atherosclerosis. 112: 177-185. 
Chen, N., Liu, Y., Greiner, C. D. and Holtzman, J. L. 2000. Physiologic 
concentrations of homocysteine inhibit the human plasma GSH peroxidase that 
reduces organic hydroperoxides. J. Lab. Clin. Med. 136: 58-65. 
Chen, L., Haught, W. H., Yang, B., Saldeen, T. G., Parathasarathy, S. and Mehta, 
J. L. 1997. Preservation of endogenous antioxidant activity and inhibition of lipid 
peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, 
lovastatin and amlodipine. J. Am. Coll. Cardiol. 30: 569-575. 
Chin-San, L. and Yau-Huei, Wei. 1999. 18-24 Age-Associated Alteration of 
Blood Thiol-Group-Related Antioxidants in Smokers. Environmental Research 
Section. 80: 18-24. 
Chitra, S., Semmalar, R. and Shyamala Devi, C. S. 2000. Effect of fish oil on 
cigarette smoking induced dyslipidemia in rats. Ind. J. Pharmacol. 32: 114-119. 
Christison, J. K., Rye, K. A. and Stocker R. 1995. Exchange of oxidized 
cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer 
protein. J. Lipid Res. 36: 2017-2026. 
Church, D. and Pryor, W. A. 1985. Free radical chemistry of cigarette smoke and 
its toxicological implications. Environ. Health Perspect. 64: 111-126. 
173 
Bibliography 
• Clarke, C. F., Edwards, P. A. and Lan, S. F., Tanaka, R. D, Fogelman, A. M. 
1983. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA 
levels in rat liver. Proc. Natl. Acad.Sci. USA. 80: 3305-3308. 
• Clarke, C. F., Fogelman, A. M. and Edwards, P. A. 1984. Diurnal rhythm of rat 
liver mRNAs encoding 3-hydroxy-3-methylglutaryl coenzyme A reductase. 
Correlation of functional and total mRNA levels with enzyme activity and protein 
J. Biol.Chem. 259: 10439. 
• Choen, J. D. and Bartsch, G. E. 1980. A comparison between carboxyhemoglobin 
and serum thiocyanate determination as indicators of cigarette smoking. American 
J for Public Health. 70: 283-286. 
• Cohen, R. A. 1995. The role of nitric oxide and other endothelium-derived 
vasoactive substances in vascular disease. Prog. Cardiovasc. Dis. 38: 105-128. 
• Costet, P., Luo, Y., Wang, N. and Tall, A. R. 2000. Sterol-dependent 
transactivation of the ABCl promoter by the liver X receptor/retinoid X receptor. 
J. Biol. Chem. 275: 28240-28245. 
• Cynamon, H. A., Isenberg, J. N. and Nguyen, C. H. 1985. Erythrocyte 
malondialdehyde release in vitro: a functional measure of vitamin E status. Clin. 
Chem. Acta. 151: 169-176. 
• Dalle-Donne, I., Rossi, R., Colombo, R., Giustarini, D. and Milzani, A. 2006. 
Biomarkers of oxidative damage in human disease. Clin. Chem. 52: 601-623. 
• De Graaf, J., Hak-Lemmers, H. L. M., Hectors, M. P. C, et al. 1991. Enhanced 
susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction 
in healthy subjects. Arterioscler. Thromb. 11: 298-306. 
• Dejager, S., Bruckert, E. and Chapman, M. J. 1993. Dense low density lipoprotein 
subspecies with diminished oxidative resistance predominate in combined 
hyperlipidemia. J Lipid Res. 34: 295-308. 
• Dhalla, N. S., Temsah, R. M. and Netticadan, T. 2000. Role of oxidative stress in 
cardiovascular diseases. J. Hypertens. 18: 655-673 
• Diaz, M. N., Frei, B., Vita, J. A. and Keaney, J. F. 1997. Antioxidants and 
Atherosclerotic Heart Disease. 337: 408-416. 
• Dirican, M., Sarandol, E., Ulukaya, E. et al. 1999. Effects of smoking on serum 
lipid and lipoprotein concentrations and lecithin: cholesterol acyltransferase 
activity. J Med Invest. 46: 169-172. 
174 
Bibliography 
Draper, H. H. and Hadley, M. 1990. Malondialdehyde determination as index of 
lipid peroxidation. Methods Enzymol. 186: 421-31 
Drexel, H., Franz, W., Amann, R. K., Neuenschwander, C, Luethy, A., Khan, S. 
and Follath, F. 1992. Relation of the level of high-density lipoprotein subfractions 
to the presence and extent of coronary artery disease. Am. J. Cardiol. 70: 436-440. 
Droge, W. 2002. Free radicals in the physiological control of cell function. 
Physiol. Rev. 82: 47-95. 
Dullaart, R. P. F., Hoogenberg, K., Dikkeschei, B. D. et al. 1994. Higher plasma 
lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-
smoking men. Arterioscler Thromb. 14: 1581-1585. 
Duncombe, W. G. 1963. The colorimetric micro-determination of long-chain fatty 
acids. Biochem J. 88: 7-10. 
Durrington, P. N., Mackness, B. and Mackness, M. I. 2001. Paraoxonase and 
atherosclerosis. Arterioscler. Thromb. Vase. Biol. 21: 473-480. 
Duthie, G. G., Arthur, J. R. and James, W. P. T. 1990. Effects of smoking and 
vitamin E on blood antioxidant status. Am J Clin Nutr. 42: 273-87. 
Edwards, P. A., Lan, S. F. and Fogelman, A. M. 1983b. Alterations in the rates of 
synthesis and degradation of rat liver 3- hydroxy-3-methylglutaryl coenzyme A 
reductase produced by cholestyramine and mevinolin. J. Biol. Chem. 258: 10219-
10222. 
Edwards, P. A., Lan, S. F. and Tanaka, R. D. 1983a. Mevalonolactone inhibits the 
rate of synthesis and enhances the rate of degradation of 3-hydroxy-3-
methylglutaryl coenzyme A reductase in rat hepatocytes. J. Biol.Chem. 258: 7272-
7275. 
Edwards, P. A., Lemongetto, D. and Fogelman, A. M. 1979. Improved methods 
for the solubilization and assay of hepatic 3-hydroxy-3-methylglutaryl coenzyme 
A reductase. J. Lipid Res. 20: 40-46. 
Endo, A., Tsujita, Y., kuroda, M. and Tanzawa, K. 1979. Effects of ML-236B on 
cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in 
normal animals. Biochem. Biophys. Acta. 575: 266-276. 
Eisenberg, S. and Levy, R. I. 1975. Lipoprotein metabolism. Adv. Lipid. Res. 13: 
1-89. 
175 
Bibliography 
• Eiserich, J. P., van der Vliet, A., Handelman, G. J., Halliwell, B. and Cross, C. E. 
1995. Dietary antioxidants and cigarette smoke-induced biomolecuiar damage: a 
complex interaction. Am. J. Clin. Nutr. 62: 1490S-1500S. 
• Ellis, N. I., Lloyd, B., Lloyd, R. S. and Clayton, B. E. 1984. Seleniumand vitamin 
E in relation to risk factors for coronary heart disease. J Clin Pathol. 37: 200-206. 
• Ellman, G. L. 1959. Tissue sulfhydryl groups. Principles. Biochem. Biophys 82: 
70-77. 
• El-Swefy S, Schaefer EJ, Seman LJ, et al. 2000. The effect of vitamin E, 
probucol, and lovastatin on oxidative status and aortic fatty lesions in 
hyperlipidemic-diabetic hamsters. Atherosclerosis; 149: 277-286. 
• Esterbauer, H., Gebicki, J., Puhl, H. and Jugens G. 1992. The role of lipid 
peroxidation and antioxidants in oxidative modification of LDL. Free Radic. Bio. 
Med. 13: 341-390. 
• Esterbauer, H., Striegel, G., Puhl, H., Oberreither, S., Rotheneder, M., El Saadani, 
M. and Jurgens, G. 1989. The role of vitamin E and carotenoids in preventing 
oxidation of low-density lipoproteins. Ann. N. Y. Acad. Sci. 570: 254-267. 
• Ezzati, M., Henley, S. J., Thun, M. J. and Lopez, A. D. 2005. Role of smoking in 
global and regional cardiovascular mortality. Circulation. 112: 489-497. 
• Fattman, C. L., Schaefer, L. M. and Oury, T. D. 2003. Extracellular superoxide 
dismutase in biology and medicine. Free Radic Biol Med. 35: 236-56. 
• Feingold, K. R., Judy, K., Shigenaga, Lisa, G., Chui, Moser, A., Khovidhunkit, 
W. and Grunfeld, C. 2008. Infection and inflammation decrease apolipoprotein M 
expression. Atherosclerosis.199: 19-26. 
• Fish III, J. H. and Bartholomew, J. R. 2007. Cigarette Smoking and 
Cardiovascular Disease Current Cardiovascular Risk Reports. 1: 384-390. 
• Folch, J., Lees, N. and Stanley, S.G. H. 1957. A simple method for the isolation 
and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509. 
• Franceschini, G., Madema, P. and Sirtori, C. R. 1991. Reverse cholesterol 
transport: physiology and pharmacology. Atherosclerosis. 88: 99-107. 
• Francis, G. A. 2000. High-density lipoprotein oxidation: in vitro susceptibility and 
potential invivo consequences. Biochim. Biophys. Acta. 1483: 217-235. 
176 
Bibliography 
• Freeman, D. J., Griffin, B. A., Murray, E. et al. 1993. Smoking and plasma 
lipoproteins in man: Effects on low density lipoprotein cholesterol levels and high 
density lipoprotein subtraction distribution. Eur J Clin Invest. 23: 630-640. 
• Frei, B. 1995. Cardiovascular disease and nutrient antioxidants: role of low-
density lipoprotein oxidation. Crit. Rev. Food Sci. Nutr. 35: 83-98. 
• Friedwald, W. T., Levy, R. 1., Fredrickson, D. S. 1972. Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma without use of 
preparative ultracentrifugation. Clin. Chem. 18: 499-502. 
• Fuller, C. J. and Jialal, I. 1997. Antioxidants and LDL oxidation. In Garewal HS 
(ed): "Antioxidants and Disease Prevention." Boca Raton, FL: CRC Press. 115-
130. 
• Fuller, C. J., May, M. A. and Martin, K. J. 2000. The Effect of Vitamin E and 
Vitamin C Supplementation on LDL Oxidizability and Neutrophil Respiratory 
Burst in Young Smokers. Journal of the American College of Nutrition. 19: 361-
369. 
• Fuster, V., Gotto, A. M., Libby, P. et al. 1996. 27th Bethesda Conference: 
matching the intensity of risk factor management with the hazard for coronary 
disease events. Task Force I. Pathogenesis of coronary disease: the biologic role 
of risk factors. J Am Coll Cardiol. 27: 964-976. 
• Gajalakshmi, C. K., Ravichandran, K. and Shanta, V. 1996. Tobacco-related 
cancers in Madras, India. Eur J Cane er Prev. 5: 63-8. 
• Gajalakshmi, V., Peto, R., Kanaka, S. and Balasubramanian, S. 2002. Verbal 
autopsy of 48 000 adult deaths attributed to medical causes in Chennai (formerly 
Madras), India. BMC Public Health. 2: 7. 
• Gajalakshmi, V., Peto, R., Kanaka, T. S. and Jha, P. 2003. Smoking and mortality 
from tuberculosis and other diseases in India: retrospective study of 43 000 adult 
male deaths and 35 000 controls. Lancet. 362: 507-15. 
• Gardner, C. D., Fortmann, S. P. and Krauss, R. M. 1996. Association of small 
low-density lipoprotein particles with the incidence of coronary artery disease in 
men and women. JAMA. 276: 875-81. 
• Gaut, J. P. and Heinecke, J. W. 2001. Mechanisms for oxidizing low-density 
lipoprotein: insights from patterns of oxidation products in the artery wall and 
from mouse models of atherosclerosis. Trends Cardiovasc Med. 11: 103-112. 
177 
Bibliography 
Ghafourifar, P. and Cadenas, E. 2005. Mitochondrial nitric oxide synthase. Trends 
Pharmacol. Sci. 26: 190-195. 
Gibson, D. M. 1985. Reversible phosphorylation of hepatic HMG-CoA reductase 
in endocrine and feedback control of cholesterol biosynthesis. In Regulation of 
HMG-CoA Reductase. B. Preiss, editor. Academic Press Inc., Orlando, FL. 
Chapter. 3: 79-132. 
Gibson, D. M. and Parker, R. A. 1987. In: Enzymes: Enzyme control by 
phosphorylation. (Krebs, E.G. ed.) Orlando, F.L, Academic. 18: 179-215. 
Glomset, J. A. and Norum, K. R. 1973. The metabolic role of lecithin: cholesterol 
acyltransferase: perspectives from pathology. Adv. Lipid Res. 11: 1-65. 
Glomset, J. A. 1968. The plasma lecithin: cholesterol acyltransferase reaction. J. 
Lipid. Res. 9: 155-167. 
Gofman, J. W., deLalla, O. and Glazier, F., Freeman, N. K., Lindgren, F. T., 
Nichols, A. v., Strisower, E. H., Tamplin, A. R. 1954. The serum lipoprotein 
transport system in healthy persons metabolic disorders, atherosclerosis, and 
coronary artery disease. Plasma. 2: 413-416. 
Gordon, D. J. and Rifkind, B. M. 1989. High-density lipoprotein: the clinical 
implications of recent studies. N. Engl. J. Med. 321: 1311-1316. 
Gouaze, V., Dousset, N. and Dousset, J. C. 1998. Effect of nicotine and cotinine 
on the susceptibility to in vitro oxidation of LDL in healthy nonsmokers and 
smokers. Clin Chim Acta. 277: 25-37. 
Gowri, M. S., Van der Westhuyzen, D. R., Bridges, S. R. and Anderson, J. W. 
1999. Decreased protection by HDL from poorly controlled type 2 diabetic 
subjects against LDL oxidation may be due to the abnormal composition of HDL. 
Arterioscler Thromb Vase Biol. 19: 2226-2233. 
Goyal, J., Wang, K., Liu, M. and Subbaiah, P. V. 1997. Novel function of lecithin-
cholesterol acyltransferase. J. Biol. Chem. 272: 16231-16239. 
Gregorevic, P., Lynch, G. S. and Williams, D. A. 2001. Hyperbaric oxygen 
modulates antioxidant enzyme activity in rat skeletal muscles. Eur J Appl Physiol. 
86: 24-7. 
Griffin, B. A., Freeman, D. J., Tait, G. W., Thomson, J., Caslake, M. J., Packard, 
C. J. and Shepherd, J. 1994. Role of plasma triglyceride in the regulation of 
178 
Bibliography 
plasma low density lipoprotein (LDL) subfractions: relative contribution of small, 
dense LDL to coronary heart disease risk. Atherosclerosis. 106: 241-253. 
Grinberg-Funes, R. A., Singh, V. N., Perera, F. P., Bell, D. A., Young, T. L., 
Dickey, C, Wang, L. W. and Santella, R. M. 1994. PoJycyclic aromatic 
hydrocarbon-DNA adducts in smokers and their relationship to micronutrient 
levels and the glutathione S-transferase Ml genotype. Carcinogenesis. 15: 2449-
2454. 
Gupta, P. C. 1996. Survey of sociodemographic characteristics of tobacco use 
among 99,598 individuals in Bombay, India using handheld computers. Tob 
Control. 5: 114-20. 
Gupta, P. C. and Mehta, H. C. 2000. Cohort study of all-cause mortality among 
tobacco users in Mumbai, India. Bull World Health Organ. 78: 877-83. 
Guthikonda, S., Sinkey, C, Barenz, T. and Haynes, W. G. 2003. Xanthine oxidase 
inhibition reverses endothelial dysfunction in heavy smokers. Circulation. 107: 
416-421. 
Guthikonda, S., Woods, K., Sinkey, C. A. and Haynes, W. G. 2004. Role of 
xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers. 
Am J Cardiol. 93: 664-668. 
Haberland, M. E., Fong, D. and Cheng, L. 1988. Malondialdehyde-altered protein 
occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science. 241: 
215-218. 
Habig, W. H., Pabst, M. J. and Jakoby, W. B. 1974. Glutathione-S-transferases in 
mercapturic acid fo rmation. J. Biol. Chem. 249: 7130-7139. 
Hafeman, D. G., Sunde, R. A. and Hoekstra, W. G. 1974. Effect of dietary 
selenium on erythrocyte and liver glutathione peroxidase in the rat. J. Nutr. 104: 
580-587. 
Hafiher, S. M., Applebaum-Bowden, D. and Wahl, P. W. 1985. Epidemiological 
correlates of high density lipoprotein subfractions, apolipoproteins A-I, A-II, and 
D, and lecithin cholesterol acyltransferase: Effects of smoking, alcohol, and 
adiposity. Arteriosclerosis. 5: 169-177. 
Hafiher, S. M. 1998. Technical review: management of dyslipidemia in adults 
with diabetes. Diabetes Care. 21: 160-178. 
179 
Bibliography 
• Hahn, M. and Subbiah, M. T. 1994. Significant association of lipid peroxidation 
products with high-density lipoproteins. Biochem. Mol. Bio). Int. 33: 699-704. 
• Halliwell, B. and Gutteridge, J. M. C. 1999. Free radicals in biology and 
medicine. Oxford University Press (3rd ed.). 
• Hammond, E.G., Garfinkel, L., Seidmen, H. and Law, E.A. 1976. "Tar" and 
nicotine content of cigarette smoke in relation to death rats. Environ. Res., 12: 
263-274. 
• Handelman, G. J., Packer, L. and Cross, C. E. 1996. Destruction of tocopherols, 
carotenoids, and retinol in human plasma by cigarette smoke. Am J Clin Nutr. 63: 
559-565. 
• Hansel, B., Giral, P., Nobecourt, E., Chantepie, S., Bruckert, E., Chapman, M. J. 
and Kontush, A. 2004. Metabolic syndrome is associated with elevated oxidative 
stress and dysfiinctional dense high-density lipoprotein particles displaying 
impaired antioxidative activity. J Clin Endocrinol Metab. 89: 4963-4971. 
• Harats, D., Ben-Naim, M., Dabach, Y., Hollander, G., Havivi, E., Stein, O. and 
Stein, Y. 1990. Effect of vitamin C and E supplementation on susceptibility of 
plasma lipoproteins to peroxidation induced by acute smoking. Atherosclerosis. 
85: 47-54. 
• Harrison, D., Griendling, K. K., Landmesser, U., Homig, B. and Drexler, H. 2003. 
Role of oxidative stress in atherosclerosis. Am. J. Cardiol. 91: 7 A-11 A. 
• Hawkins, R. 1.1972. Smoking, platelets and thrombosis. Nature. 236: 450-2. 
• Hayes, J. D., Flanagan, J. U. and Jowsey, I. R. 2005. Glutathione transferases. 
Annu Rev Pharmacol Toxicol. 45: 51-88. 
• He, J., Vupputuri, S., Allen, K., Prerost, M. R., Hughes, J. and Whelton, P. K. 
1999. Passive smoking and the risk of coronary heart disease.a meta-analysis of 
epidemiologic studies. New England Journal of Medicine. 340: 920-6. 
• Heitzer, T., Just, H. and Munzel, T. 1996. Anioxident vitamin C improves 
endothelial disfunction in chronic smokers. Circulation. 94: 6-9. 
• Helen, A. and Vijayammal, P. L. 1996. Vitamin C diminishes cigarette smoke 
induced hyperlipidemia in rats. J. Eco. Biol. 8: 83-89. 
• Helen, A. and Vijayammal, P. L. 1997. Vitamin C supplementation on hepatic 
oxidative stress induced by cigarette smoke journal of applied toxicology. 17: 
289-295. 
180 
Bibliography 
• Hertz, J., Hamann, U., Rogne, S., Myklebost, D., Gausepohl, G. and Stanley, K. 
K. 1988. Surface location and high affinity for calcium of a 500-kd liver 
membrane protein closely related to the LDL-receptor suggest a physiological role 
as lipoprotein receptor. EMBO. J. 7: 4119-4127. 
• Helve, E. and Tikkanen, M. J. 1988. Comparison of lovastatin and probucol in 
treatment of familial and non-familial hypercholesterolemia: different effects on 
lipoprotein profiles. Atherosclerosis. 72: 189-197. 
• Hill, P. Wynder, E.L., Hoffrnan, D. and Gori, G. B. 1975. Nicotine: an eteological 
factor for coronary heart diseases. In: eds. Proceedings of the 3'"^ world conference 
on smoking and health. New York. Washington DC. Government printing office. 
1:313-9. 
• Hirano, T., Ito, Y., Koba, S., Toyoda, M., Ikejiri, A., Saegusa, H., Yamazaki, J. 
and Yoshino, G. 2004. Clinical significance of small dense low-density 
lipoprotein cholesterol levels determined by the simple precipitation method. 
Arterioscler. Thromb. Vase. Biol. 24: 558-563. 
• Howard, G. and Thun, M. J. 1999. Why is environmental tobacco smoke more 
strongly associated with coronary heart disease than expected? A review of 
potential biases and experimental data. Environmental Health Perspectives. 107: 
853 
• Huang, J. M., Huang, Z. X. and Zhu, W. 1998. Mechanism of high-density 
lipoprotein subfractions inhibiting copper-catalyzed oxidation of low-density 
lipoprotein. Clinical Biochemistry. 31: 537-543. 
• Hurt-Camejo, E., Camejo, G., Rosengren, B., Lopez, F., Wiklund, O. and 
Bondjers, G. 1990. Differential uptake of proteoglycan-selected subfractions of 
low density lipoprotein by human macrophages. J. Lipid Res. 31:1387-98. 
• Imamura, H., Teshima, K., Miyamoto N. and Shirota, T. 2002. Cigarette smoking, 
high-density lipoprotein cholesterol subfractions and lecithin: Cholesterol 
acyltransferase in young women. Metabolism. 51: 1313-1316. 
• Ingebritson, T. S. and Gibson, D. M. 1980. In: Cohen, P. (ed): Recently 
Discovered Systems of Enzyme Regulation by Reversible Phosphorylation North 
Holland, Elsevier. 1: 63. 
• Inoue, M. 1994. Protective mechanisms against reactive oxygen species. In: 
Arias, I. M., Boyer, J. L., Fausto, N., Jakoby, W. B., Schachter, D. A., Shafritz, D. 
181 
Bibliography 
A., editors. The liver: biology and pathobiology. Raven Press: New York, USA. 
443-59. 
Ismail, N. M., Harun, A., Yusof, A. A., Zaiton, Z. and Marzuki, A. 2002. Role of 
vitamin E on oxidative stress in smokers. Malaysian Journal of Medical Sciences. 
9: 34-42. 
Ito, T., Nishiwaki, M. and Ishikawa, T. et al. 1995. CETP and LCAT activities are 
unrelated to smoking and moderate alcohol consumption in healthy 
normolipidemic men. Jpn Circ J. 59: 541-546. 
Jaleel, A., Jaleel, F., Majeed R. and Alam, E. 2007. Leptin and blood lipid levels 
in smokers and ex smokers. World Applied Sciences Journal. 2: 348-352. 
James, R. W., Leviev, I. and Righetti, A. 2000. Smoking is associated with 
reduced serum paraoxonase activity and concentration in patients with coronary 
artery disease. Circulation. 101: 2252-2257. 
Jarvis, M. J., Tunstall-Pedoe, H. et al. 1987. Comparison of tests used to 
distinguish smokers from smokers. American J for Public Health. 77: 1435-1438. 
Jenner, P. 2003. Oxidative stress in Parkinson's disease. Ann. Neurol. 53: S26-
S36. 
Jha, P., Gajalakshmi, V. and Gupta, P. C. et al. 2006. Prospective study of one 
million deaths in India: rationale, design, and validation results. PLoS Med. 3: 
el8. 
Jha, P., Jacob, B., Gajalakshmi, V., Gupta, P. C , Dhingra, N., Kumar, R., Sinha, 
D. N.., Dikshit, R. P.., Parida, D. K.., Kamadod, R., Boreham, J. and Peto, R., for 
the RGI-CGHR Investigators. 2008. A Nationally Representative Case-Control 
Study of Smoking and Death in India. N Engl J Med. 358: 1137-47. 
Jollow, D. J., Mitchell, J. R., Zampaglione, N. and Gillette, J. R. 1974. 
Bromobenzene induced liver necrosis: protective role of glutathione and evidence 
for 3, 4-bomobenzene oxide as the hepatotoxic metabolite. Pharmacology. 11: 
151. 
Joshi, R., Cardona, M., Iyengar, S. et al. 2006. Chronic diseases now a leading 
cause of death in rural India mortality data from the Andhra Pradesh Rural Health 
Initiative. Int J Epidemiol. 35: 1522-9. 
182 
Bibliography 
• Joshi, U. M., Kodavanti, P. R. S. and Mehendale, H. M. 1988. Glutathione 
metabolism and utilization of external thiols by cigarette smoke-challenged 
isolated rat and rabbit lungs. Toxicol. Appl. Pharmacol. 96: 324-335. 
• Kagota, S., Yamaguchi, Y., Shinozuka, K., Kwon, Y. M. and Kunitomo, M. 
1996. Cigarette smoke-modified low density lipoprotein impairs endothelium-
dependent relaxation in isolated rabbit arteries. Gen Pharmcol. 27: 477-81. 
• Kakkar, P., Das, B. and Viswanathan, P. N. 1984. A modified spectrophotometric 
assay of superoxide dismutase (SOD). Indian J. Biochem. Biophys. 21: 130-132. 
• Kamat, J. P. and Devasagayan, T. P. A. 1995. Tocotrienols fi"om palm oil as 
potent inhibitors of lipid peroxidation and protein oxidation in rat brain 
mitochondria. Neurosci. Lett. 195: 179-182. 
• Kamat, J. P., Sarma, H. D., Devasagayam, T. P. A., Nesaretnam, K. and Basiron, 
Y. 1997. Tocotrienols from palm oil as effective inhibitors of protein oxidation 
and lipid peroxidation in rat liver microsome. Molecular and Cellular 
Biochemistry. 170: 131-138. 
• Kane, J. P. 1983. Apolipoprotein B: structural and metabolic heterogeneity. Ann. 
Rev. Physiol. 45: 637-650. 
• Kane, J. P., Hardman, D. A. and Paulus, H. E. 1980. Heterogeneity of 
apolipoprotein B: isolation of a new species from human chylomicrons. Proc. 
Natl. Acad. Sci. USA. 77: 2465-2469. 
• Kaufman, D. W., Helmrich, S. P., Rosenberg, L., Miettinen, O. S. and Shapiro, S. 
1983. Nicotine and carbon monoxide content of cigarette smoke and the risk of 
myocardial infarcfion in young men N Engl J Med. 308: 409-13. 
• Kvietys, P. R., Inauen, W., Bacon, B. R. and Grisham, M. B. 1989. Xanthine 
oxidase-induced injury to endothelium: role of intracellular iron and hydroxyl 
radical. Am. J. Physiol. 257: H1640-H1646. 
• KeJso, G. J., Stuart, W. D., Richter, R. J., Furlong, C. E., Jordan-Starck, T. C. and 
Harmony, J. A. 1994. Apolipoprotein J is associated with paraoxonase in human 
plasma. Biochemistry. 33: 832-839. 
• Khan, N. and Sultana, S. 2004. Abrogation of potassium bromate-induced renal 
oxidative strtss and subsequent cell proliferation response by soy isoflavones in 
Wistar rats. Toxicology. 201: 173-184. 
183 
Bibliography 
• Khanduja, K. L. and Bhardwaj, A. 2003. Stable free radical scavenging and 
antiperoxidative properties of resveratrol compared in vitro with some other 
bioflavonoids. Ind. J. Biochem. Biophys. 40: 416-422. 
• Kita, T., Nagano, Y., Yokode, M., Ishii, K., Kume, N., Ooshima, A., Yoshida, H., 
and Kawai, C. 1987. Probucol prevents the progression of atherosclerosis in 
Watanabe heritable hyperlipidemic rabbit, an animal model for familial 
hypercholesterolemia. Proc. Natl. Acad. Sci. 84: 5928-5931. 
• Koba, S., Hirano, T., Ito Y., Tsunoda, F., Yokota, Y., Ban, Y., Iso, Y., Suzuki, H., 
and Katagiri, T. 2006. Significance of small low-density lipoprotein-cholesterol 
concentration in relation to the severity of coronary heart disease. Athersclerosis. 
189:206-214. 
• Kocyigit, A., Erel, O. and Gur, S. 2001. Effects of tobacco smoking on plasma 
selenium, zinc, copper, and iron concentrations and related antioxidative enzyme 
activities. Clin Biochem. 34: 629-33. 
• Kontush, A. and Chapman, J. 2006. Functionally defective high-density 
lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, 
inflammation, and atherosclerosis. Pharmacol Rev. 58: 342-374. 
• Kontush, A., Chancharme, L., Escargueil-Blanc, I., Therond, P., Salvayre, R., 
Negre-Salvayre, A. and Chapman, M. J. 2003. Mildly oxidized LDL particle 
subspecies are distinct in their capacity to induce apoptosis in endothelial cells: 
role of lipid hydroperoxides. FASEB. J. 17: 88-90. 
• Kontush, A., Chantepie, S., Chapman, M. J. 2003. Small, dense HDL particles 
exert potent protection of atherogenic LDL against oxidative stress. Arterioscler 
Thromb Vase Biol. 23: 1881-1888. 
• Kontush, A., de Faria, E. C, Chantepie, S. and Chapman, M. J. 2005. A 
normotriglyceridemic, low HDL-cholesterol phenotype is characterised by 
elevated oxidative stress and HDL particles with attenuated antioxidative activity. 
Atherosclerosis. 182: 277-285. 
• Kumar, R., Thakur, J., Rao, B. T., Singh, M. M. and Bhatia, S. P. 2006. Validity 
of verbal autopsy in determining causes of adult deaths. Indian J Public Health. 
50: 90-4. 
184 
Bibliography 
Kunitake, S. T., Jarvis, M. R., Hamilton, R. L. and Kane, J. P. 1992. Binding of 
transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition 
of oxidation of low density lipoproteins. Proc. Natl. Acad. Sci. USA. 89: 6993-7. 
Kwiterovich, P. O. jr. 2000. The metabolic pathways of high-density lipoprotein, 
low-density lipoprotein, and triglycerides: A Current Review. Am J Cardiol. 86: 
5L-10L. 
La Du, B. N. and Eckerson, H. W. 1984. The polymorphic paraoxonase/ 
arylesterase isozymes of human serum. Fed. Proc. 43: 2338-2341. 
Lakier, J. B. 1992. Smoking and cardiovascular disease. Am. J. Med. 93: 8S-12S. 
Lakshmi, S. and Rajagopal, G. 1998. Reduced glutathione level and catalase 
activity in erythrocytes in patients with diabetes mellitus. Biomedicines. 18: 37-
39. 
Lamarche, B., Rashid, S. and Lewis, G. F. 1999. HDL metabolism in 
hypertriglyceridemic states: an overview. Clin. Chim. Acta. 286: 145-161. 
Lamarche, B., Tchemof, A., Moorjani, S., et al. 1997. Small, dense low-density 
lipoprotein particles as a predictor of the risk of ischemic heart disease in men. 
Circulation. 95: 69-75. 
Law, M. R. and Wald, N. J. 2003. Environmental tobacco smoke and ischemic 
heart disease. Progress in Cardiovascular Diseases. 46: 31-8. 
Leeder, S., Raymond, S., Greenberg, H., Liu, H. and Esson, K. 2004. A race 
against time. The challenge of cardiovascular disease in developing economies. 
New York: Columbia University. 
Liscum, L., Cummings, R. D. Andersson, R. G. W., DeMartino, G. N., Goldstein, 
J. L. and Brown, M. S. 1983a. 3-Hydroxy-3-methylglutaryl-CoA reductase: A 
transmembrane glycoprotein of the endoplasmic reticulum with N-linked "high-
mannose" oligosaccharides. Proc. Natl. Acad. Sci., USA. 80: 7165-7169. 
Liu, T. Z., Chin, N., Kiser, M. D. and Bigler, W. N. 1982. Specific 
spectrophotometry of ascorbic acid in serum or plasma by use of ascorbate 
oxidase. Clinical Chemistry. 28: 2225-2228. 
Liu, L., Bortnick, A. E., Nickel, M., Dhanasekaran, P., Subbaiah, P. V., Lund-
Katz, S., Rothblat, G. H. and Phillips, M. C 2003. Effects of apolipoprotein A-I 
on ATP-binding cassette transporter A1-mediated efflux of macrophage 
185 
Bibliography 
phospholipid and cholesterol: formation of nascent high-density lipoprotein 
particles. J. Biol. Chem. 278: 42976-42984. 
Lykkesfeldt, J. 2007. Malondialdehyde as biomarker of oxidative damage to lipids 
caused by smoking. Clinica Chimica Acta. 380: 50-58. 
Mackness, B., Davies, G. K., Turkic, W. et al. 2001. Paraoxonase status in 
coronary heart disease. Are activity and concentration more important than 
genotype. Arterioscler Thromb Vase Biol. 21: 1451-1457. 
Mackness, M. I., Arrol, S. and Durrington, P. N. 1991. Paraoxonase prevents 
accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-
154. 
Mackness, M. I., Mackness, B., Durrington, P. N., Connelly, P. W. and Hegele, R. 
A. 1996. Paraoxonase: biochemistry, genetics and relationship to plasma 
lipoproteins. Curr. Opin. Lipidol. 7: 69-76. 
Maida, V. and Howlett, G. J. 1990. Effects of cigarette smoking and dietary lipids 
on rat lipoprotein metabolism. Atherosclerosis. 80: 209-216. 
Malerod, L., Juvet, L. K., Hanssen-Bauer, A., Eskild, W. and Berg, T. 2002. 
Oxysterol-activated LXRa/RXR induces hSR-BI-promoter activity in hepatoma 
cells and preadipocytes. Biochem. Biophys. Res. Comm. 299: 916-923. 
Marangon, K., Herbeth, B., Artur, Y., Esterbauer, H. and Siest, G. 1997. Low and 
very low density lipoprotein composition and resistance to copper-induced 
oxidation are not notably modified in smokers. Clinica Chimica Acta. 265: 1-12. 
Maron, D. J., Fazio, S. and Linton, M. F. 2000. Current perspectives on statins. 
Circulation. 101: 207. 
McCord, J. M. 1993. Human disease, free radicals, and the oxidant antioxidant 
balance. Clin. Biochem. 26:351-7. 
McCord, J. M., Keele, B. and Fridovich, \. 1971. An enzyme based theory of 
obligate anaerobiosis: the physiological function of SOD. Proc. Natl. Acad. Sci. 
USA. 68: 1024-1027. 
McCord, J. M. 1985. Oxygen-derived free radicals in postischemic tissue injury. 
NEnglJ Med. 312:159-63. 
McCuster, K. and Hoidal, J. 1990. Selective increase of antioxidant enzyme 
activity in the alveolar macrophages from cigarette smokers and smoke-exposed 
hamsters. American Reviews of Respiratory Disease. 141: 678-82. 
186 
Bibliography 
• Meisinger, C, Baumert, J., Khuseyinova, N., Loewel, H. and Koenig, W. 2005. 
Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary 
heart disease events in apparently healthy, middle-aged men from the general 
population. Circulation. 112: 651-657. 
• Meister, A. 1989. Metabolism and function of glutathione, in: "glutathione: 
chemical, biochemical, and medical aspects" (D. Dolphin, R. Poulson and O. 
Avramovic, Eds.), Wiley, New York. Part A. 367-474. 
• Meister, A. and Anderson, M. E. 1983. Glutathione. Annu Rev Biochem. 52: 711-
60. 
• Meister, A. 1992. On the antioxidant effects of ascorbic acid and glutathione. 
Biochem. Pharmacol. 44: 1905-1915. 
• Mero, N., Eliasson, B., Smith, U. and Taskinen, M. R. 1995. Insulin resistance 
and increased prevalence of small dense Idl-particles in smokers. Atherosclerosis. 
115: 3-42. 
• Michelet, F., Gueguen, R., Leroy, P., Wellman, M., Nicolas, A. and Siest, G. 
1995. Blood and plasma glutathione measured in healthy subjects by HPLC: 
Relation to sex, aging, biological variables, and life habits. Gen. Clin. Chem. 41: 
1509-1517. 
• Miller, D. M., Buettner, G. R. and Aust, S. D. 1990. Transition metals as catalysts 
of "autoxidation" reactions. Free Radic. Biol. Med. 8: 95-108. 
• Mills, G. C. 1959. The purification and properties of glutathione peroxidase of 
erythrocytes. J. Biol. Chem. 234: 502-505. 
• Milosavljevic, D., Griglio, S., Le, Naour. G. and Chapman, M. J. 2001. 
Preferential reduction of very low density lipoprotein-1 particle number by 
fenofibrate in type II B hyperlipide-mia: consequences for lipid accumulation in 
human mono-cyte-derived macrophages. Atherosclerosis. 155: 251-260. 
• Minhajuddin, M., Iqbal, J. and Beg, Z. H. 1999. Tocotrienols (vitamin E): 
anticholesterol impacts on plasma lipids and apoprotein via reduction in HMG-
CoA reductase activity and protein mass in normal and hyperlipidemic rats. 
Current Adv. Atheroscler. Res. (S. Dwivedi, ed.) 2: 120-128. 
• Minhajuddin, M., Iqbal, J. and Beg, Z. H. 2005. Hypolipidemic and antioxidant 
properties of tocotrienol rich fraction isolated from rice bran oil in experimentally 
induced hyperlipidemic rats. Food and chemical Toxicology. 43: 747-753. 
187 
Bibliography 
• Miyata, M. and Smith, J. D. 1996. Apolipoprotein E allele-specific antioxidant 
activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. 
Nat Genet. 14:55-61. 
• Morel, D. W. 1994. Reduced cholesterol efflux to mildly oxidized high-density 
lipoprotein. Biochem. Biophys. Res. Commun. 200: 408-416. 
• Moriguchi, E. H., Fusegawa, Y., Tamachi, H. et al. 1990. Effects of smoking on 
HDL subfractions in myocardial infarction patients: effects on lecithin-cholesterol 
acyltransferase and hepatic lipase. Clin Chim Acta. 195: 139-144. 
• Moss, A. J., Goldstein, S. and Greene, W. 1971. Precursors of ventricular 
arrhythmias during early pre-hospital phase of acute myocardial infarction. 
Circulation. 43 and 44: suppi 2:11-44 abstract. 
• Murray, C. J. L. and Lopez, A. D. 1996. Global burden of disease and injury 
series.Global burden of disease, Harvard School of Public Health. Boston.Vol.l. 
• Murat Ka9maz, H. OztUrk, S., ^ete, Servet., Mustafa, Kavutcu. and Liker, D. 
1997. The effects of smoking on antioxidant defence system and m.mbrane free 
fatty acid content of erythrocytes and plasma lipid parameters: Protective role of 
antioxidant vitamins. Nutrition Research. 17: 931-940. 
• Nagano, Y., Arai, H. and Kita, T. 1991. High-density lipoprotein loses its effect to 
stimulate efflux of cholesterol from foam cells after oxidative modification. Proc. 
Natl. Acad. Sci. USA. 88: 6457-6461. 
• Nagao, A., Seki, M. and Kobayashi, H. 1999. Inhibition of xanthine oxidase by 
flavonoids. Biosci. Biotechnol. Biochem. 63: 1787-1790. 
• Nagy, J., Demaster, E. G., Wittmann, I., Shultz, P. and Raij, L. 1997. Induction of 
endothelial cell injury by cigarette smoke. Endothelium. 5: 251-263. 
• Naruse, K., Shimizu, K. and Muramatsu, M. 1994. Long-term inhibition of NO 
synthesis promotes atherosclerosis in hypercholesterolemic rabbit thoracic aorta. 
PGH2 does not contribute to impaired endothelium-dependent relaxation. 
Arterioscl. Thromb. 14: 746-752. 
• Naurooz-Zadeh, J., Tajaddini-sramadi, J., Eddie Ling, K. L. and Wolf, S. 1996. 
Low-density lipoprotein is the major carrier of lipid hydropeoxides in plasma: 
relevance to determination of total plasma lipid hydroperoxide concentrations. 
Biochem. J. 313: 781-786. 
188 
Bibliography 
• Navab, M., Berliner, J. A., Watson, A. D., Hama, S. Y., Territo, M. C, Lusis, A. 
J., Shih, D. M., Van Lenten, B. J., Frank, J. S., Demer, L. L. et al. 1996. The Yin 
and Yang of oxidation in the development of the fatty streak. A review based on 
the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vase. Biol 
16:831-842. 
• Navab, M., Hama, S. Y., Anantharamaiah, G. M., Hassan, K., Hough, G. P., 
Watson, A. D., Reddy, S. T., Sevanian, A., Fonarow, G. C. and Fogelman, A. M. 
2000. Normal high-density lipoprotein inhibits three steps in the formation of 
mildly oxidized low-density lipoprotein: steps 2 and 3. J. Lipid. Res. 41: 1495-
508. 
• Navab, M., Hama, S. Y., Hough, G. P., et al. 1998. High density associated 
enzymes: their role in vascular biology. Curr. Opin. Lipidol. 9: 449-56. 
• Neki, N. S. 2002. Lipid Profile in Chronic Smokers-A Clinical Study. Journal, 
Indian Academy of Clinical Medicine. 3: 51-4. 
• Neunteufl, T., Heher, S., Kostner, K. et al. 2002. Contribution of nicotine to acute 
endothelial dysfunction in long-term smokers. J Am Coll Cardiol. 39: 251-256. 
• Nielsen, F., Mikkelsen, B. B., Nielsen, J. B., Andersen, H. R. and Grandjean, P. 
1997. Plasma malondialdehyde as biomarker for oxidative stress: reference 
interval and effects of life style factors. Clin Chem. 43: 1209-14 
• Niehaus WG, Samuelsson B. 1968. Formation of malondialdehyde from 
phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 
6:126-130. 
• Nishio, E. and Watanabe, Y. 1997. Cigarette smoke extract inhibits plasma 
paraoxonase activity by modification of the enzyme's free thiols. Biochemical and 
Biophysical Research Communications. 236: 289-293. 
• Nigon, F., Lesnik, P., Rouis, M. and Chapman, M. J. 1991. Discrete subspecies of 
human low density lipoproteins are heterogeneous in their interaction with the 
cellular LDL receptor. J. Lipid Res. 32:1741-53. 
• Nobecourt, E., Jacqueminet, S., Hansel, B., Chantepie, S., Grimaldi, A., Chapman, 
M. J. and Kontush, A. 2005. Defective antioxidative activity of small, dense HDL 
particles in type 2 diabetes: relationship to elevated oxidative stress and 
hyperglycemia. Diabetologia 48: 529-538. 
189 
Bibliography 
• Nofer, J. R., Levkau, B., Wolinska, I. et al. 2001. Suppression of endothelial cell 
apoptosis by high-density lipoproteins (HDL) and HDL-associated 
lysosphingolipids. J. Biol. Chem. 276: 34480-34485. 
• Nourooz -Zadeh, J., Tajaddini-sramadi, J., Eddie Ling, K. L. and Wolf, S. 1996. 
Low-density lipoprotein is the major carrier of lipid hydropeoxides in plasma: 
relevance to determination of total plasma lipid hydroperoxide concentrations. 
Biochem. J. 313: 781-786. 
• Noro, T., Oda, Y., Taxhio, M., Ueno, A. and Fuku Shima, S. 1983. Inhibitors of 
xanthine oxidase from the flowers and buds of Daphne genkwa. Chem. Pharm. 
Bull. 31: 3984-3987. 
• Oda, M. N., Bielicki, J. K., Ho, T. T., Berger, T., Rubin, E. M. and Forte, T. M. 
2002. Paraoxonase 1 overexpression in mice and its effect on high-density 
lipoproteins. Biochem Biophys Res Commun. 290: 921-927. 
• Ohkawa, H., Ohishi, N. and Yagi, k. 1979. Assay of lipid peroxides in animal 
tissues by thiobarbituric acid reaction Analyt. Biochem. 95: 351-358. 
• Oliver, M. F. and Yates, P. A. 1971. Induction of ventricular arrhythmias by 
elevation of arterial free fatty acids in experimental myocardial infarction. 
Cardiology. 56: 359-64. 
• Oram, J. F. and Lawn, R. M. 2001. ABCAl: the gatekeeper for eliminating excess 
tissue cholesterol. J. Lipid. Res. 42: 1173-1179. 
• Ostos, M. A., Conconi, M., Vergnes, L., Baroukh, N., Ribalta, J., Girona, J., 
Caillaud, J. M., Ochoa, A. and Zakin, M. M. 2001. Antioxidative and 
antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-
deficient mice. Arterioscler Thromb Vase Biol. 21: 1023-1028. 
• Ozguner, F., Koyu, A. and Cesur, G. 2005. Active smoking causes oxidative stress 
and decreases blood melatonin levels. Toxicol Ind Health. 21(1-2): 21-6. 
• Packer, L. 1995. Nutrition and biochemistry of the lipophilic antioxidants, vitamin 
E and carotenoids. In: Nutrition, lipids, health, and disease; Ong, A. S. H., Niki, 
E., Packer, L. Eds; American Oil Chemical Society: champaign, I L. 8-35. 
• Packard, C. J. and Shepherd, J. 1997. Lipoprotein heterogeneity and 
apolipoprotein B metabolism. Arterioscler. Thromb. Vase. Biol. 17: 3542-3556. 
• Palinski, W., Rosenfeld, M. E., Yla-Herttuala, S., Gurtner, G. C, Socher, S. S., 
Butler, S. W., Parthasarathy, S., Carew, T. E, Steinberg, D. and Witztum, J. L. 
190 
Bibliography 
1989. Low-density lipoprotein undergoes oxidative modification invivo. Proc. 
Natl. Acad. Sci. USA. 86: 1372-1376. 
Park, E. M., Park, Y. M. and Gwak, Y. S. 1998. Oxidative damage in tissues of 
rats exposed to cigarette smoke. Free Radic. Biol. Med. 25: 79-86. 
Parker, R. A., Pearce, B. C, Clark, R. W., Godan, D. A. and Wright, J. J. K. 1993. 
Tocotrienols regulate cholesterol production in mammalian cells by 
posttransalational suppression of 3-hydroxy-3-methylglutarylcoenzyme A 
reductase. J. Biol. Che. 268: 11230-11238. 
Pastor, N., Weinstein, H., Jamison, E. and Brenowitz, M. 2000. A detailed 
interpretation ofOHradical footprints in a TBPDNAcomplex reveals the role of 
dynamics in the mechanism of sequencespecific binding. J. Mol. Biol. 304: 55-68. 
Patsch, W, Brown, S. A., Morrisett, J. D., Gotto, Jr., A. M. and Patsch, J. R. 1989. 
A dual-precipitation method evaluated for measurement of cholesterol in high-
density lipoprotein subfractions HDL2 and HDL3 in human plasma. Clin. Chem. 
35:265-270. 
Pearce, B. C, Parker, R. A., Deason, M. E., Qureshi, A. A. and Wright, J. J. K. 
1992. Hypocholesterolemic activity of synthetic and natural tocotrienols. J. Med. 
Chem. 95: 3595. 
Pednekar, M. S. and Gupta, P. C. 2007. Prospective study of smoking and 
tuberculosis in India. Prev Med. 44: 496-8. 
Pompella, A., Visvikis, A., Paolicchi, A., de Tata, V. and Casini, A. F. 2003. The 
changing faces of glutathione, a cellular protagonist. Biochem Pharmacol. 66: 
1499-503. 
Population Division of the Department of Economics and social affairs of the 
United Nation Secretariat. 2004. World population prospects: the 2004 revision 
and world urbanization prospects. Population Division of the Department of 
Economics and social affairs of the United Nation Secretariat. 
Porkka, K. V. K. and Ehnholm, C. 1996. Smoking, alcohol and lipoprotein 
metabolism. Curr Opin Lipidol. 7: 162-166. 
Princen, H. M. G., van Poppel, G., Vogelezang, C, Buytenhek, R. and Kok, F. J. 
1992. Supplementation with Vitamin E but Not 6 -Carotene Invivo Protects Low 
Density Lipoprotein From Lipid Peroxidation In vitro Effect of Cigarette 
Smoking. (Arteriosclerosis and Thrombosis.l2: 554-562. 
191 
Bibliography 
Pugalendi, K. V. and Ramakrishnan, S. 1991. Blood cholesterol and HDL 
cholesterol in cigarette smokers. Indian J. Phys. Pharm. 35: 138-140. 
Qureshi, A. A., Bradlow, B. A., Brace, L., Manganello, J., Peterson, D. M., 
Pearce, B. C, Wright, J. J. K., Gapor, A. and Elson, C. E. 1995. Response of 
hypercholesterolemic subjects to administration of tocotrienols. Lipids. 30: 11 Ti-
ll 77. 
Qureshi, A. A., Bradlow, B. A., Salser, W. A. and Brace, L. D. 1997. Novel 
tocotrienols of rice bran modulate cardiovascular disease risk parameters of 
hypercholesterolemic humans. Nutritional Biochem. 8: 290-298. 
Qureshi, A. A., Burger, W. C, Prentice, N., Bird, H. R. and Sunde, M. L.* 1980c. 
Suppression of cholesterol and stimulation of fatty acid biosynthesis in chicken 
livers by dietary cereals supplemented with culture filtrate of Trichoderma viride. 
J.Nutr. 110: 1014-1022. 
Qureshi, A. A., Mo, H., Packer, L. and Peterson, D. M. 2000. Isolation and 
identification of novel tocotrienols from rice bran with hypocholesterolemic, 
antioxidant, and antitumor properties J. Agri. and food chem. 48: 3130-3140. 
Qureshi, A. A., Peterson, D. M., Hasler-Rapacz, J. O. and Rapacz, J. 2001b. Novel 
tocotrienols of rice bran suppress cholesterogenesis in hereditary 
hypercholesterolemic swine. J. Nutr. 131: 223-230. 
Qureshi, A. A., Qureshi, N., Wright, J. J. K. et al. 1991. Lowering of serum 
cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am J 
Clin Nutr. 53: 1021S-6S. 
Qureshi, A. A., Qureshi, N., Hasler-Rapacz, J.O., Weber, F. £., Chaudhary, V., 
Crenshaw, T.D., Gapor, A., Ong, A.S.H., Chong, Y.H. and Peterson, D. 1991c. 
Dietary tocotrienols reduce concentrations of plasma cholesterol, apolipoprotein 
B, thromboxane B2, and platelet factor 4 in pigs with inherited hyperlipidemias. 
Am. J. Clin. Nutr. 53: 1042S-1046S. 
Qureshi, A. A., Qureshi, N., Wright, J. J. K., Shen, Z., Kramer, G., Gapor, A., 
Chong, Y. H., Dewitt, G., Ong, A. S. H. and Peterson, D. M. 1991,. Lowering of 
serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). 
Am. J. Clin. Nutr. 53: 1021S-1026S. 
192 
Bibliography 
• Qureshi, A. A., Sami, S. A., Salser, W. A. and Khan, F. A. 2001,. Synergistic 
effect of tocotrienol-rich fraction (TRF25) of rice bran and lovastatin on lipid 
parameters in hypercholesterolemic humans. J. Nutr. Biochem. 12: 318-329. 
• Qureshi, A. A., Sami, S. A., Salser, W. A. and Khan, F. A. 2002. Dose-dependent 
suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran 
in hypercholesterolemic humans. Atherosclerosis. 161: 199-207. 
• Qureshi, N. and Qureshi, A. A. 1993. Tocotrienols, novel hypocholesterolemic 
agents with antioxidant properties. In: Vitam. E health and disease; Packer, L., 
Fuchs, J. Eds; Marcel decker: New York. 247-267. 
• Raccah, D., Fabreguets, C , Azulay, J. P. and Vague, P. 1996. Erythrocyte Na""-
K*-ATPase activity, metabolic control, and neuropathy in IDDM patients. 
Diabetes Care. 19: 564-568. 
• Raederstroff, D., Elste, V., Aebischer, C. and Weber, P. 2002. Effect of either 
gamma-tocotrienol or a tocotrienol mixture on the plasma lipid profile in 
hamsters. Ann. Nutr. Metab. 46: 17-23. 
• Rani, M., Bonu, S., Jha, P., Nguyen, S. N. and Jamjoum, L. 2003. Tobacco use in 
India: prevalence and predictors of smoking and chewing in a national cross 
sectional household survey. Tob Control. 12: e4. 
• Ramesh, T. and Begum, V. M. H. 2006. Hypolipidemic effect of Sesbania 
grandiflora on cigarette smoke exposed rats. Pharmacologyonline. 3: 309-323. 
• Rana, S. V. S., Allen, T. and Singh, R. 2002. Inevitable glutathione, then and now. 
Ind.J. Exp. Biol. 40: 706-716. 
• Rao, A. V. and Ramakrishnan, S, 1975. Indirect assessment of 
hydroxymethylglutaryl-CoA reductase (NADPH) activity in liver tissue. Clin. 
Chem.21: 1523-1525. 
• Reddy, K. S. 2004. Cardiovascular disease in non-western countries. N. Engl. J. 
Med. 350: 2438-2440. 
• Reddy, K. S. and Yusuf S. 1998. Emerging epidemic of cardiovascular disease in 
developing countries. Circulation. 97: 596-601. 
• Richert, L., Castagna, M. and Beck, J. P., Rong, S., luu, B. and Ourisson, G. 1984. 
Growth-rate-related and hydroxysterol-induced changes in membrane fluidity of 
cultured hepatoma cells: Correlation with 3-hydroxy-3-methyl glutaryl CoA 
reductase activity Biochem. Biophys. Res. Commun. 120: 192-198. 
193 
Bibliography 
Remaley, A. T., Stonik, J. A., Demosky, S. J., Neufeld, E. B., Bocharov, A.V., 
Vishnyakova, T. G., Eggerman, T. L., Patterson, A. P., Duverger, N. J., 
Santamarina-Fojo, S. and Brewer, H. B., Jr. 2001. Apolipoprotein specificity for 
lipid efflux by the human ABCAl transporter. Biochem. Biophys. Res. Commun. 
280:818-823. 
Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C, 
Schaefer, E. J., McNamara, J. R., Kashyap, M. L, Hershman, J. M., Wexler, L. F. 
and Rubins, H. B. 2001. Relation of gemfibrozil treatment and lipid levels with 
major coronary events: VA-HIT. A randomized controlled trial. JAMA. 285: 
1585-1591. 
Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G. and Clift, S. M. 
1991. Inhibition of early atherogenesis in transgenic mice by human 
apolipoprotein AI. Nature. 353: 265-267. 
Russel, D. W., Yamamoto, P. and Schneider, W. J., Brown, M. S. and Goldstein, 
J. L. 1983. cDNA cloning of the bovine low-density lipoprotein receptor: 
feedback regulation of a receptor mRNA. Proc. Natl. Acad. Sci. USA. 80: 7501. 
Sacks, T., Moldow, F., Craddock, P. R., Bowes, T. K. and Jacob, H. S. 1978. 
Oxygen radical mediate endothelial cell damage by complement stimulated 
granulocytes. An in vitro model of immune-vascular damage. J. Clin. Invest. 61: 
1161-1167. 
Sanderson, K. J., Van Rij, A. M., Wade, C. R. and Sutherland, W. H. 1995. Lipid 
peroxidation of circulating low-density lipoproteins with age, smoking and in 
peripheral vascular disease. Atherosclerosis. 118: 45-51. 
Santanam, N., Sanchez, R., Hendler, S. and Parthasarathy, S. 1997. Aqueous 
extracts of cigarette smoke promote the oxidation of low density lipoprotein by 
peroxidases. FEBS Lett. 414: 549-551. 
Saito, Y., Teramoto, T., Yamada, N., Itakura, H., Hata, Y., et al. 2001. Clinical 
efficacy of NK-104 (Pitavastatin), a new synthetic HMG-CoA reductase inhibitor, 
in the doswe fmd-ing, double blind, three-group comparative study. Rishou lyaku. 
17: 829-855. 
Sayre, L. M., Smith, M. A. and and Perry, G. 2001. Chemistry and biochemistry 
of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 8: 721-738. 
194 
Bibliography 
• Schectman, G., Byrd, J. C. and Gruchow, H. W. 1989. The influence of smoking 
on Vitamin C status in adults. Am. J. Public Health. 79: 158-162. 
• Scheffler, E., Huber, L., Fruhbis, J., Schulz, I., Ziegler, R. and Dresel, H. A. 1990. 
Alteration of plasma low density lipoprotein from smokers. Atherosclerosis. 82: 
261-265. 
• Schonbaum, G. R. and Chance, B. 1976. Catalase. In The Enzymes, ed. P. D. 
Boyer, 2nd edn. New York Academy. 13: 363-408. 
• Schwedhelm, E., Bartling, A., Lenzen, H., Tsikas, D., Maas, R., Brummer, J., 
Gutzki, F. M., Berger, J., Frolich, J. C. and Boger, R. H. 2004. Urinary 8-iso-
prostaglandin F2 as a risk marker in patients with coronary heart disease: a 
matched case-control study. Circulation. 109: 843-848. 
• Schwartz, K., Lawn, R. M. and Wade, D. P. 2000. ABCl gene expression and 
apoA-I-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. 
Res. Commun. 274: 794-802. 
• Sedlack J. and Lindsay R. H. 1968. Estimations of total protein bound and non-
protein bound sulfhydryl groups in tissues with EUman's reagent. Anal. Biochem. 
25: 192-205. 
• Seetharamaiah, G. S. and Chandrasekhara, N. 1989. Studies on 
hypocholesterolemic activity of rice bran oil. Atherosclerosis. 78: 219-223. 
• Seppo, L., Lahteenmaki, T. et al. 2005. Effect of vitamin E on the toxicity of 
oxidized LDL on edotheliial cells in vitro in smokers vs nonsmokers on diets rich 
in fish. European J of Clinical Nutrition. 59: 1282-1290. 
• Serbinova, E., Kagan, V., Han, D. and Packer, L. 1991. Free radical recycling and 
intramembrane mobility in the antioxidant properties of alpha-tocopherol and 
alpha-tocotrienol. Free Radic. Biol. Med. 10: 263-275. 
• Sevanian, A., Hwang, J., Hodis, H., et al. 1996. Contribution of an invivo oxidized 
LDL to LDL oxidation and its association with dense LDL subpopulations. 
Arterioscler. Thromb. Vase. Biol. 16: 784-793. 
• Sharma, R. D. and Rukmini, C. 1986. Rice bran oil and hypocholesterolemia in 
rats. Lipids. 21: 715-717. 
• Sharma, R. D. and Rukmini, C. 1987. Hypocholesterolemic activity of 
unsaponifiable matter of rice bran oil. Int. J. Med. Res. 85: 278-281. 
195 
Bibliography 
• Shennan, N. M., Seed, M. and Wynn, V. 1985. Variation in serum lipid and 
lipoprotein levels associated with changes in smoking behaviour in non-obese 
Caucasian males. Atherosclerosis. 58: 17-25. 
• Shih, D. M., Gu, L., Xia, Y. R. et al. 1998. Mice lacking serum paraoxonase are 
susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287. 
• Siekmeier, R., Wulfroth, P. Wieland, H., Grob, W. and Marz, W. 1996. 
Lowdensity lipoprotein susceptibility to in vitro oxidation in healthy smokers and 
nonsmokers. Clin Chem. 42: 524-530. 
• Siems, W. G., Grune, T. and Esterbauer, H. 1995. 4-Hydroxynonenal formation 
during ischemia and reperfusion of rat small-intestine. Life Sci. 57: 785-789. 
• Silverberg, E. 1984. Cancer statistics. Cancer. 34: 7-23. 
• Sinha, A. K. 1972. Colorimetric assay of catalase. Anal. Biochem. 47: 389-394. 
• Singh, R. B., Singh, N. K., Rastogi, S. S., Wander, G. S., Aslam, M., Onouchi, Z. 
Kummerow, F. A., and Nangia, S. 1997. Antioxidant effects of lovastatin and 
vitamin E on experimental atherosclerosis in rabbits. Cardiovascul. Drug. Therap. 
11:575-590. 
• Siptal, A. B. and Sabine, J. R. 1981. Membrane-mediated controlof hepetic beta-
hydroxy-beta-methylglutary-coenzyme A reductase. Biochem. J. 194: 889. 
• Smith, F. B., Lowe, G. D. O., Fowkes, F. G. R., Rumley, A., Rumley, A. G., 
Donnan, P. T. and Housley, E. 1993. Smoking, haemostatic factors and lipid 
peroxides in a population case control study of peripheral arterial disease. 
Atherosclerosis. 102: 155-162. 
• Sohn, H. O., Lim, H. B., Lee, Y. G. et al. 1993. Effect of subchronic adminstrtion 
of antioxidants against cigarette smoke exposure in rats. Archives of Toxicology. 
67: 667-73. 
• Solak, Z. A., Kabaroglu, C, Cok, G., Parildar, Z., Bayindir, U., Ozmen, D. and 
Bayindir, O. 2005. Effect of different levels of cigarette smoking on lipid 
peroxidation, glutathione enzymes and paraoxonase 1 activity in healthy people. 
Clin Exp Med. 5:99-105. 
• Sone, H., Takahashi, A., Shimano, H., Ishibashi, S., Yoshino, G., Morisaki, N., et 
al. 2002. HMG-CoA reductase inhibitor decreases small dense low-density 
lipoprotein and remnant-like particle cho-lesterol in patients with type-2 diabetes. 
Life Sci. 71: 2403-2412. 
196 
Bibliography 
Spiteller, G. 2001. Lipid peroxidation in aging and age-dependent disease. Exp. 
Gerontol. 36: 1425-1457. 
Srikantaiah, M. V., Tormanen, C. D., Redd, W. L., Hardgrave, J. E. and Scaiien, 
T. J. 1977. Purification of 3-hydroxy-3-methylglutaryl coenzyme A reductase by 
affinity chromatography on blue dextran/Sepharose 4B. Comparison of enzyme 
purified from normal rats and from rats treated with cholestyramine. J. Biol. 
Chem. 252: 6145. 
Stampfer, M. J., Krauss, R. M., Ma, J. et al. 1996. A prospective study of 
triglyceride level, low-density lipoprotein particle diameter, and risk of 
myocardial infarction. J. Am. Med. Assoc. 276: 882-888. 
Steinberg, D. 1997. Low density lipoprotein oxidation and its pathobiological 
significance. J Biol Chem. 272: 20963-20966. 
Steinberg, D., Parthasarthy, S., Carew, T. E., Khoo, J. C. and Witztum, J. L. 1989. 
Beyond cholesterol: modification of low-density lipoprotein that increase its 
atherogenicity. N. Engl. J. Med. 320:915-24. 
Steinberg, D. and Lewis, A. 1997. Oxidative modification of LDL and 
atherogenesis. Circulation. 95: 1062-1071. 
Stephens, S. G., Parsons, A., Schofield, P. M., Kelly, F., Cheeseman, K., 
Mitchinson, M. J. and Brown, M. J. 1996. Randomized controlled trial of vitamin 
E in patients with coronary disease: Cambridge Heart Antioxidant Study 
(CHAOS). Lancet. 347: 781. 
Stief, T. W. 2000. The blood fibrinolysis/deep-sea analogy: a hypothesis on the 
cell signals singlet oxygen/photons as natural antithrombotics. Thromb. Res. 99: 
1-20. 
Stocks, J. and Dormandy, T. L. 1971. The autooxidation of human red cell lipids 
induced by hydrogen peroxide. Br. J. Hematology. 20: 95-111. 
St-Pierre, A. C, Cantin, B., Dagenais, G. R. et al. 2005. Low-density lipoprotein 
subfractions and the long-term risk of ischemic heart diseases in men: 13-year 
follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vase 
Biol. 25: 553-9. 
Strain, J. J., Carville, D. G. M., Barker, M. E. et al. 1989. Smoking and blood 
antioxidant enzyme activities Biochem Sot Tram. 17: 497-S. 
197 
Bibliography 
Stuehr, D. J., Kwon, N. S. and Nathan, C. F. 1990. FAD and GSH participate in 
macrophage synthesis of nitric oxide. Biochem. Biophys. Res. Comm. 168: 558-
565. 
Suama, C, Dean, R. T., Stocicer, R et al. 1995. Human atherosclerotic plaque 
contains both oxidized lipids and relatively larg amount of a-tocopheroi and 
ascorbet. Arterioscler Thromb Vase Biol. 15: 1616-1624. 
Sulochana, K. N., Punitham, R. and Ramakrishnan, S. 2002. Effect of cigarette 
Smoking on cataract: Antioxidant enzymes and constituent minerals in the lens 
and blood of humans. Indian Journal of Pharmacology. 34: 428-431. 
Suzuki, N., Fidge, N., Nestel, P. and Yin, J. 1983. Interaction of serum 
lipoproteins with the intestine. Evidence for specific high-density lipoprotein-
binding sites on isolated rat intestinal mucosal cells J. Lipid Res. 24: 253. 
Takahashi, Y. and Smith, J. D. 1999. Cholesterol efflux to apolipoprotein AI 
involves endocytosis and resecretion in a calcium-dependent pathway. Proc. Natl. 
Acad. Sci. USA. 96: 11358-11363. 
Tan, D. T. S., Khor, H. T., Low, W. H. S., Ali, A. and Gapor, A. 1991. Effect of a 
palm-oil vitamin E concentrate on the serum and lipoprotein lipids in humans. 
Am. J. Clin. Nutr. 53: 1027S-1030S. 
Tanaka, R. D., Edwards, P. A., Lans, S. F., Knoppel, E. M. and fogelman, A. M. 
1982. The effect of cholestyramine and Mevinolin on the diurnal cycle of rat 
hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Lipid. Research. 
23:10261-1031. 
Teoh, M. K., Chong, J. M., Mohamed, J. and Phang, K. S. 1994. Protection by 
tocotriemols against hypercholesterolaemia and atheroma. Med. J. Malaysia. 49: 
255-262. 
Theriault, A., Chao, J.T., Wang, Q., Gapor, A. and Adeli, K. 1999b. Tocotrienol a 
review of its therapeutic potential. Clin. Biochem. 32: 309-319. 
Theriault, A., Wang, Q., Gapor, A. and Adeli, K. 1999,. Effects of y-tocotrienol 
on apoB synthesis, degradation and secretion in HepG2 cells, Arterioscler. 
Thromb. Vase. Biol. 19: 704-712. 
Thomas, C. E., Jackson, R. L., Ohiweiler, D. F. and Ku, G. 1994. Multiple lipid 
oxidation products in low-density lipoproteins induce interleukin-1 beta release 
from human blood mononuclear cells. J. Lipid Res. 35: 417-427. 
198 
Bibliography 
• Tomeo, A. C, Geller, M., Watkins, T. R., Gapor, A. and Bierenbaum, M. L. 1995. 
Antioxidant effects of tocotrienols in patients witli hyperlipidemia and carotid 
stenosis. Lipids. 30: 1179-1183. 
• Toth, K. M., Berger, E. M., Beehler, C. J. and Repine, J. E. 1986. Erythrocytes 
from cigarette smokers contain more glutathione and catalase and protect 
endothelial cells from hydrogen peroxide better than do erythrocytes from 
nonsmokers. Am. Rev. Respir. Dis. 134: 281-284. 
• Tokuno, A., Hirano, T., Hayashi, T., Mori, Y., et al. 2007. The Effects of Statin 
and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic 
Patients with Type 2 Diabetes. J. Ather. Thromb. 14: 128-132. 
• Travis, J. 1987. Oxidants and antioxidants in the lung. Am. Rev. Respir. Dis. 135: 
773-774. 
• Tribble, D. L, Thiel, P. M, van den Berg, J. J. M. and Krauss, R. M. 1995. 
Differing tocopherol oxidative lability and ascorbic acid sparing effects in buoyant 
and dense LDL. Arterioscler. Thromb. 15: 2025-2031. 
• Tribble, D. L., Holl, L. G., Wood, P. D. and Krauss, R. M. 1992. Variations in 
oxidative susceptibility among six low-density lipoprotein subfractions of varying 
size and density. Atherosclerosis. 93: 189-199. 
• Tribble, D. L., Rizzo, M., Chait, A., Diane, M. L., Blanche, P. J. and Krauss, R. 
M. 2001. Enhanced oxidative susceptibility and reduced antioxidant content of 
metabolic precursor of small, dense low-density lipoproteins. Am. J. Med. 110: 
103-110. 
• Tribble, D. L. 1999. Antioxidant consumption and risk of coronary heart disease: 
emphasis on vitamin C, vitamin E and beta-carotene. Circulation. 99: 591-595. 
• Tribble, D. L., van den Berg, J. J., Motchnik, P. A., Ames, B. N., Lewis, D. M., 
Chait, A. and Krauss, R. M. 1994. Oxidative susceptibility of low-density 
lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol 
content. Proc. Natl. Acad. Sci. USA. 94: 1183-1187. 
• Trinder, P. 1969. Determination of glucose in blood using glucose oxidase with an 
alternative oxygen receptor. Ann. Clin. Biochem. 6: 24-27. 
• Tselepis, A. D. and Chapman, M. J. 2002. Inflammation, bioactive lipids and 
atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, 
platelet activating factor-acetylhydrolase. Atherosclerosis. (Suppl 3): 57-68. 
199 
Bibliography 
US Department of Health and Human Services. 2006. The health consequences of 
involuntary exposure to tobacco smoke: a report of the surgeon general, atlanta, 
ga: us dept of health and human services, centers for disease control and 
prevention, coordinating center for health promotion, national center for chronic 
disease prevention and health promotion, office on smoking and health. 
Valko, M., Izakovic, M., Mazur, M., Rhodes, C. J. and Telser, J. 2004. Role of 
oxygen radicals in DNA damage and cancer incidence. Mol. Cell. Biochem. 266: 
37-56. 
Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T. D., Mazur, M. and Telser, J. 
2007. Free radicals and antioxidants in normal physiological functions and human 
disease. The international Journal of Biochemistry & Cell Biology. 39 : 44-84 
Valko, M., Morris, H. and Cronin, M. T. D. 2005. Metals, toxicity and oxidative 
stress. Curr. Med. Chem. 12: 1161-1208. 
Valko, M., Rhodes, C. J., Moncol, J., Izakovic, M. and Mazur, M. 2006. Free 
radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. 
Interact. 160: 1-40. 
Valabhji, J., McColl, A. J., Schachter, M., Dhanjil, S., Richmonds, W. and 
Elkeles, R. S. 2001. High-densitylipoprotein composition and Paraoxonase 
activity in type 1 diabetes. Clinical Science. 101: 659-670. 
Van Kampen, E. L. and Zijistra, W. G. 1961. Standardization of 
hemoglobinometry. II. The hemiglobincyanide method. Clin. Chem. Acta. 6: 538-
544. 
Van Lenten, B. J., Navab, M., Shih, D., Fogelman, A. M. and Lusis, A. J. 2001. 
The role of high-density lipoproteins in oxidation and inflammation. Trends. 
Cardiovasc. Med. 11: 155-161. 
Yancey, P. G., Bortnick, A. £., Kellner-Weibel, G., De la Llera-Moya, M., 
Phillips, M. C. and Rothblat, G. H. 2003. Importance of different pathways of 
cellular cholesterol efflux. Arterioscler. Thromb. Vase. Boil. 23: 712-719. 
Van, R., Filesi, C. and Giovannini, C. 2005. Novel mechanisms of natural 
antioxidant compounds in biological systems: involvement of glutathione and 
glutathione-related enzymes. Journal of Nutritional Biochemistry. 16: 577-586. 
Varley, H. and Goueenlock, A. H. 1976. Practical clinical biochemistry. 5th ed. 
Heinmaun Medical, New york, Interscience Books. 1: 24-26. 
200 
Bibliography 
• Vaughan, C. J., Gotto, A. M. J., Shih. R. and Basson, C. T. 2000. The evolving 
role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. 35: 1-
10. 
• Vella, J. C, Linaje, M. J. and Perez-Iniguez, B. 1994. Serum concentration of 
lipoprotein (a) and cholesterol in HDL subfractions in relation to cigarette 
consumption. Rev. Soc. Esp. Quim. Clin. 13: 50-253. 
• Venkateswaran, A., Laffitte, B. A., Joseph, S. B., Mak, P. A., Wilpitz, D. C, 
Edwards, P. A. and Tontonoz, P. 2000. Control of cellular cholesterol efflux by 
the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA. 97: 12097-
12102. 
• Von Eckardstein, A., Noter, J. R. and Assmann, G. 2000. Acceleration of reverse 
cholesterol transport. Curr. Opin. Cardiol. 15: 348-354. 
• Vorbach, C, Harrison, R. and Capecchi, M. R. 2003. Xanthine oxidoreductase is 
central to the evolution and function of the innate immune system. Trends 
Immunol. 24: 512-517. 
• Watkins, T., Lenz, P., Gapor, A., Struck, M., Tomeo, A. and Bierenbaun, M. 
1993. Y-tocotrienol as a hypocholesterolemic and antioxidant agent in rats fed 
atherogenic diets. Lipids. 28: 1113-1118. 
• Watson, A. D., Berliner, J. A., Hama, S. Y. et al. 1995. Protective effect of high 
density lipoprotein associated paraoxonase: inhibition of the biological activity of 
minimally oxidised low density lipoprotein. J Clin Invest. 96: 2882-2891. 
• WHO, the World Health Report. Geneva, Switzerland. 2006. 
• WHO, the World Health Report. Geneva, Switzerland. 2007. 
• Wieland, H. and Seidel, D. 1989. A simple method for precipitation of low-
density lipoproteins. Journal of Lipid Research. 24: 904-909. 
• Winniford, M. D. 1990. Smoking and cardiovascular function. J. Hypertens. 9: 
S17-S23. 
• Williams, D. L., Connelly, M. A., Temel, R. E., Swamakar, S., Phillips, M.C., De 
la Llera-Moya, M. and Rothbiat, G. H. 1999. Scavenger receptorBl and 
cholesterol trafficking. Curr. Opin. Lipidiol. 10: 329-339. 
• Witztum, J. L. and Steinberg, D. 2001. The oxidative modification hypothesis of 
atherosclerosis: does it hold for humans? Trends. Cardiovasc. Med. 11: 93-102. 
201 
Bibliography 
• White, C. R., Darley-Ushmar, V., Berrington, W. R., McAdams, M., Gore, J. Z., 
Thompson, J. A., Parks, D. S., Tarpey, M. M. and Freeman, B. A. 1996. 
Circulating plasma xanthine oxidase cotributes to a vascular dysfunction in 
hyperchlolesterolemic rabbits. Proc. Natl. Acad. Sci. USA. 93: 8745-8749. 
• Xu, X. P., Meisel, S. R., Ong, J. M. et al. 1999. Oxidized low-density lipoprotein 
regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-
derived macrophages. Circulation. 99: 993-998. 
• Yen, G. C. and Duh, P. D. 1994. Scavenging effect of methanolic extract of 
peanut hulls on free radical and active-oxygen species. J. Agric. Food Chem. 42: 
629-632. 
• Yamaguchi, Y., Kagota, S., Haginaka, J. and Kunitomo, M. 2000. Evidence of 
modified LDL in the plasma of hypercholesterolemic WHHL rabbits injected with 
aqueous extracts of cigarette smoke. Environ. Toxicol Pharmacol. 8: 255-260. 
• Yamaguchi, Y., Kagota, S., Haginaka, J. and Kunitomo, M. 2000. 
Peroxynitritegenerating species: good candidate oxidants in aqueous extracts of 
cigarette smoke. Jpn J Pharmacol. 82: 78-81. 
• Yamaguchi, Y., Matsuno, S., Kagota, S, Haginaka, J. and Kunitomo, M. 2004. 
Peroxynitrite-mediated oxidative modification of low-density lipoprotein by 
aqueous extracts of cigarette smoke and the preventive effect of fluvastatin. 
Atherosclerosis. 172: 259-265. 
• Yamaguchi, Y., Matsuno, S., Kagota, S., Haginaka, J. and Kunitomo, M. 2001. 
Oxidants in cigarette smoke extract modify low-density lipoprotein in the plasma 
and facilitate atherogenesis in the aorta of Watanabe heritable hyperlipidemic 
rabbits. Atherosclerosis. 156: 109-17. 
• Yamaguchi, Y., Kagota, S., Haginaka, J. and Kunitomo, M. 2002 Participation of 
peroxynitrite in oxidative modification of LDL by aqueous extracts of cigarette 
smoke. FEBS Lett. 512: 218-22. 
• Yamaoka, M. and Carrillo, M. J. H. 1990. Effects of tocopherols and tocotrienols 
on the physicochemical property of the liposomal membrane in relation to their 
antioxidant activity. Chem. Phys. Lipids. 55: 295-300. 
• Yagi, K. 1987. Lipid peroxides and human diseases Chem. Phys. of Lipids 45: 
337-351. 
202 
Bibliography 
• Yasue, H., Hirai, N., Mizuno, Y., Harada, E., Itoh, T., Yoshimura, M., Kugiyama, 
K. and Ogawa, H. 2006. Low-grade inflammation, tlirombogenicity, and 
atherogenic lipid profile in cigarette smokers. Circ J. 70: 8-13. 
• Yla'Herttuala, S., Palinski, W., Rosenfeld, M. E., Parthasarathy, S., Carew, T. E., 
Butler, S., Witztum, J. L. and Steinberg, D. 1989. Evidence for the presence of 
oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit 
and man. J Clin Invest. 84: 1086-1095. 
• Yokode, M., Kita, T., Arai, H., Kawai, C, Narumiya, S. and Fujiwara, M. 1988. 
Cholesteryl ester accumulation in macrophages incubated with low density 
lipoprotein pretreated with cigarette smoke extract. Proc Natl Acad Sci. 85: 2344-
2348. 
• Yokus, B., Mete, N., Cakir, U.D. and Toprak, G. 2005. Effects of Active and 
Passive Smoking on Antioxidant Enzymes and Antioxidant Micronutrients. 
Biotechnol. & Biotechnol. 3: 19. 
• Yoshikawa, M., Sakuma, N., Hibino, T., Sato, T. and Fujinami, T. 1997. HDL3 
exerts more powerful anti-oxidative, protective effects against copper-catalyzed 
LDLoxidatKMithanHDLz Clinical Biochemistry. 30: 221-225. 
• Yusuf, S., Dagenais, G., Pogue, J. et al. 2000. Vitamin E supplementation and 
cardiovascular events in high-risk patients, the Heart Outcomes prevention 
Evaluation study Investigators. N. Engl. J. Med. 342: 154-160. 
• Zainuddin, M. 2004. Impact of tocotrienols on cholesterol dynamics and in the 
protection of accelerated aortic atherosclerosis induced by oxidized cholesterol in 
rabbits. Ph.D. Thesis. 
• Zainuddin, M., AH, W. and Beg, Z. H. 2006. The protective impacts of 
tocotrienols on LDL oxidizability and accelerated atherosclerosis induced by 
oxidized cholesterol in cholesterol fed rabbits." XIV international symposium on 
atherosclerosis, Rome, Italy. Atherosclerosis Supplements. 7: 529. 
• Zweier, J. L., Broderick, R., Kuppusamy, P., Thompson-Gorman, S. and Lutty, G. 
A. 1994. Determination of the mechanism of free radical generation in human 
aortic endothelial cells exposed to anoxia and reoxygenation. J Biol Chem. 269: 
24156-24162. 
203 
